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Abstract
In view of the evidence that CD8+ T-cells are involved in mediating immunity
against Theileria parva, the antigens recognised by these cells are obvious candidates
for inclusion in a subunit vaccine. Results from previous studies have inferred that
the CD8+ T-cell response to T. parva is focused on a limited number of
immunodominant antigens that exhibit polymorphism between different parasite
strains. This could pose a major challenge to the design of a broadly effective subunit
vaccine. The recent identification ofCTL target antigens has provided the
opportunity to characterise immunodominance within the T. parva system.
The objective of this study was to quantitatively assess immunodominance in the
CD8+ T-cell response to T. parva and to characterise the clonal composition and
TCRp repertoires of the epitope-specific T-cell populations. The results from four
animals presented in this study have demonstrated that the CDS T-cell response
restricted by two MHC class I haplotypes is reproducibly dominated by single
polymorphic epitopes. Using a suite ofmolecular tools developed during this study it
was determined that the T-cell populations specific for both these epitopes were
polyclonal but dominated by a limited number of large clonal expansions and the
TCRP repertoires expressed by these populations was diverse.
During the course of this work several novel bovine TCRp genes were identified.
Further examination ofTCRp cDNA transcripts and the bovine genome assembly
substantially expanded the known bovine TCRP repertoire, which is now the largest
characterised for any species. Notably several VP subfamilies, especially Vpi and 13
have undergone extensive duplication and contain large numbers of genes. By
annotating the available genomic data it has been shown that the bovine TCRB locus
has a highly conserved synteny with the human TCRB locus. Furthermore, this
annotation has demonstrated that prodigious duplication of a cassette containing a
Vpi and Vpi3 gene has contributed to the large membership of these two
subfamilies and that there are three D-J-Cp clusters in the bovine TCRB locus rather
than the two seen in the other mammalian TCRB loci described.
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Definitions
The following definitions related to Theileria parva materials used in this study are
derived from Irvin et cil. (1983)
Isolate - viable organisms isolated on a single occasion from a field sample.
Stabilate - a sample of organisms preserved alive (usually in replicate) on a single
occasion. In the context of this work sporozoite stabilates have been used.
Strain - a population of homogenous organisms possessing a set of defined
characteristics. In the context of this work this term is used to refer to a population of
organisms that have identical genetic material. Unambiguous characterisation of a
strain can only be assured if the population of organisms was initiated from a parasite
clone.
xvii
1 Chapter 1 - General introduction
1.1 Theileria parva
The obligate intra-cellular protozoan parasite Theileria parva is a member of the
class Sporozoa, sub-phylum Apicomplexa, which includes several pathogens of
medical and veterinary importance such as Plasmodium and Toxoplasma. It is the
cause of an acute and usually fatal lymphoproliferative disease of cattle called East
Coast Fever (ECF), which is prevalent in a large area of eastern, southern and central
Africa (Figure l. I). The predominant vector for T. parva transmission is the three
host ixodid tick Rhipicephalus appendicidatis (Brown ear tick), although in its
southern range the related species R. zambeziensis (Lawrence et al., 1983) and R.






Congo / i j Malawi
J ... k \Y / R
Zimbabwe
Mozambique
Figure 1.1 Geographical distribution of Theileria parva in Africa. Reproduced from the Annual
Report of the International Laboratory of Research on Animal Diseases (ILRAD) 1990.
The disease is widely recognised as one of the major constraints on the livestock
industries in the affected region. Firstly because of the financial cost of the disease
and the measures taken to control it, estimated to be approximately US$ 168 million
per year (Mukhebi et al., 1992) and secondly because the more productive Bos
1
taurus breeds (european breeds such as Friesian) and their crosses with the
indigenous Bos indicus breeds (e.g. Zebu) are more susceptible to ECF, and so
increasing production through genetic improvement of the local livestock has been
impeded.
1.1.1 Lifecycle of T. parva and pathogenesis of ECF
The lifecycle of T. parva is illustrated in Figure 1.2. Ticks become infected following
ingestion of the intra-erythrocytic stage (piroplasms) whilst feeding on an infected
animal. Within the tick gut, piroplasms rapidly differentiate (probably during the
final stages of repletion) into micro- and macro-gametes which undergo syngamy to
form spherical zygotes that invade the epithelial cells of the gut wall (Schein et al.,
1977). During the brief diploid phase of the lifecycle following syngamy there is an
opportunity for sexual recombination (McKeever, 2006), which can facilitate the
exchange within heterogenous T. parva populations of genes containing
immunologically important determinants (section 1.1.3.3). Development from
zygotes to motile kinetes and their subsequent migration through the haemocoel to
the salivary glands appears to be synchronised with tick moulting (Young and Leitch,
1980, 1981), which may facilitate invasion of the salivary gland acinar cells by the
kinetes (Mehlhorn and Schein, 1984). The kinetes have a strong tropism for the 'E'
cells of type 3 acini (Fawcett et al., 1982b; Young et al., 1983), although other acini
and cell types have been reported to contain kinetes (Mehlhorn and Schein, 1984;
Shaw and Young, 1995). Within the salivary gland the kinetes transform into
multinucleate, syncitial sporoblasts (Fawcett et al., 1982a). Commencement of the
next tick feed initiates sporogony, during which the sporoblasts rapidly develop and
expand, until, after approximately 3-4 days of feeding, a terminal episode of
cytoplasmic fission releases uni-nucleate sporozoites (Fawcett et al., 1982a; Young
et al., 1983). Up to 50,000 sporozoites may be released from a single infected
salivary gland (Fawcett et al., 1982a), but this emission is gradual, so that inoculation
of the sporozoites into the host occurs as a prolonged 'trickle' (Shaw and Young,
1995).
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Following inoculation into the host, the parasite is not readily detectable for several
days, thus events during this stage of the lifecycle have not been studied in detail in
vivo. However, in vitro studies show that sporozoites rapidly enter (in as little as 3
minutes) into lymphocytes of all lineages - CD4+, CD8+ and y8 T-cells and B-cells
(Baldwin et al., 1988) by a process of receptor-mediated endocytosis (Fawcett et al.,
1982c; Webster et al., 1985).
Figure 1.2 Lifecycle of Theileria parva. Reproduced from the Annual Report of the
International Laboratory of Research on Animal Diseases (ILRAD) 1990.
The sporozoite rapidly penetrates the enclosing host-cell membrane, so that within
15 minutes it lies free within the cytoplasm, surrounded by a network of
microtubules (Shaw, 2003; Shaw et al., 1991). Within 3 days the sporozoite
differentiates into a multi-nuclear schizont (Stagg et al., 1981), a process that induces
the infected cell to transform to a proliferating lymphoblast. The mechanisms
3
underlying this transformation are an active area of research and have been reviewed
in several recent articles (Dessauge et al., 2005; Dobbelaere and Kuenzi, 2004;
Dobbelaere and Rottenberg, 2003). The schizont divides synchronously with the host
cell (Hulliger et al., 1964; Irvin et al., 1982) and by close association with its mitotic
spindle during division ensures schizont infection of both daughter cells and hence
exponential clonal expansion of the parasite.
In experimental in vivo infections, schizonts are first detected in the draining lymph
node 5-7 days after needle inoculation of sporozoites (Emery, 1981b; Morrison et al.,
1981; Shatry et al., 1981), concurrent with the onset of pyrexia and localised
lymphomegaly. Within 2-3 days schizonts disseminate throughout the lymphoid
system and can be detected in distant lymph nodes (Emery, 1981b; Morrison et al.,
1981; Shatry et al., 1981), causing a generalised lymphomegaly. The schizont-
infected cells also metastasize in large numbers to non-lymphoid tissues including
the gut and lungs and the subsequent tissue damage accounts for clinical symptoms
of ECF such as diarrhoea and respiratory distress (a comprehensive clinical
description of ECF is given in Irvin and Mwamachi, 1983). In the later stages of
disease there is a severe leucopaenia (Morrison et al., 1981; Shatry et al., 1981),
which is probably a consequence of both non-specific lympholysis (DeMartini and
Moulton, 1973; Emery, 1981b; Emery et al., 1981) and invasion of bone marrow
tissue by schizont-infected cells (Morrison et al., 1981; Wilde, 1966). Susceptible
animals generally die within 3 weeks of infection, with death usually attributed to
respiratory failure due to extensive pulmonary infiltration by parasitized cells and
pulmonary oedema (Irvin and Mwamachi, 1983).
A proportion of schizonts eventually undergo merogony. The uni-nucleate
merozoites produced are released by rupture of infected lymphocytes, invade
erythrocytes and differentiate to piroplasms, which are usually evident from
approximately day 12 post-infection (Shatry et al., 1981). There is a limited but
insignificant multiplication of piroplasms (Conrad et al., 1986; Fawcett et al., 1987)
which constitute the infective stage for the tick vector.
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1.1.2 Parasite Diversity
There exists a high level of genetic diversity within field populations of T. parva. In
a recent study of 104 field isolates (Abbreviations and Definitions) of T. parva taken
from 3 sites in Uganda, 84 distinct genotypes were identified (Oura et al., 2005).
Several in vitro methods have been developed to analyse genotypic polymorphisms
among T. parva strains (Abbreviations and Definitions), including pulsed-field gel
electrophoresis (Morzaria et al., 1990), restriction fragment length polymorphism
(RFLP) analysis using repetitive DNA, ribosomal or telomeric probes (Allsopp and
Allsopp, 1988; Bishop et al., 1993; Bishop etal., 1996; Conrad et al., 1987a),
polymerase chain reaction (PCR) ofTprl repetitive DNA sequence (Allsopp et al.,
1989), PCR-RFLP (Bishop et al., 2001) and most recently, a panel of micro- and
mini-satellite markers (Oura et al., 2003). Application of these techniques has
permitted investigation of T. parva population structure and epidemiology in natural
field situations (Bishop et al., 1994; Oura et al., 2005) and the epidemiological
consequences of immunization interventions (Geysen et al., 1999; Oura et al., 2004).
Currently, molecular genotyping is also being used to study sexual recombination
between T. parva strains (F. Katzer, paper in process).
Evidence of in vivo immunological heterogeneity between T. parva strains was
demonstrated over thirty years ago in cross-immunity trials of animals immunised by
the infection and treatment (I & T) protocol (whereby animals are immunised by
infection with a sporozoite stabilate (Abbreviations and Definitions) and concurrent
treatment with oxytetracycline). Animals immunised using the I & T protocol were
protected against homologous but not necessarily heterologous T. parva-strain
challenge (Radley et al., 1975c). Subsequently, in vitro recognition of T. parva
schizont-infected cells by monoclonal antibodies (Conrad et al., 1987b; Minami et
al., 1983) and CD8+(Goddeeris etal., 1986; Goddeeris etal., 1990) and CD4'
(Brown et al., 1989) T-cells has revealed antigenic polymorphism between strains.
The existence of immunological heterogeneity has obvious implications for the
future development of vaccines (section 1.1.5).
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1.1.3 Protective Immunity to T. parva
Animals naturally recovered from infection with T. parva or immunized by the I & T
protocol develop immunity to homologous challenge that persists for at least 3.5
years (Burridge et al., 1972; Radley et al., 1975a). The ability to generate protective
immunity by immunizing animals with autologous schizont-infected cells (Emery et
al., 1982), and the transient appearance of schizont parasitosis in immune animals
undergoing challenge (Morrison et al., 1987) indicate that the protective immune
response is directed against schizont-infected lymphocytes rather than sporozoites.
The failure to transfer immunity with serum or y-globulins from immunised animals
(Muhammed et al., 1975), or demonstrate in vivo or in vitro protective function of
anti-schizont antibody (Creemers, 1982; Wagner et al., 1974) suggests that
protection is not mediated by antibody.
Demonstration that transfer of thoracic duct lymphocytes from immune to non¬
immune chimaeric twins was capable of transferring immunity (Emery, 1981 a),
identified the protective response as cell-mediated. In vitro and ex vivo studies
identified a cell-mediated cytotoxicity directed against schizont-infected cells present
in peripheral blood mononuclear cells (PBMC) of immune, but not naive, animals
(Eugui and Emery, 1981; Pearson et al., 1979). The appearance and activity of these
cytotoxic cells in immunised animals undergoing challenge is chronologically linked
to clearance of the parasite (Emery et al., 1981; Eugui and Emery, 1981; Morrison et
al., 1987). The cytotoxic effector cells were characterised as being CD8+ T-cells
(Goddeeris et al., 1986; Morrison et al., 1987), and a subsequent study involving
adoptive transfer of lymphocytes from immune to non-immune monozygotic twins
undergoing challenge showed that transfer of CD8+ T-cells was protective
(McKeever et al., 1994).
The frequency of cytotoxic T-cell precursors (CTLp) in immune animals can be very
high. CTLp frequencies of 1:625 to 1:1005 PBMC can be found three weeks post-
immunisation and levels of between 1:3084 and 1:3903 PBMC are maintained for a
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period of up to 6 months (Taracha et al., 1992). In immunised animals undergoing
challenge, CTLp can constitute about 2.5% of the efferent lymph lymphocytes (ELL)
draining from the regional lymph node by day 7 of challenge, and in the PBMC
CTLp frequency peaks at approximately 0.1% on days 9-10 post-challenge
(McKeever et al., 1994).
1.1.3.1 T. parva-specific cytotoxic lymphocytes show parasite strain-
specificity and major histocompatability class I restriction
The lack of absolute cross-protection offered by I & T immunization indicates that
the protective immune response exhibits a degree of parasite strain-specificity
(Radley et al., 1975c). Study of ex vivo and in vitro responses have demonstrated that
T. parva-specific cytotoxic lymphocytes (CTLs) display parasite strain-specificity
(Goddeeris etal., 1986; Goddeeris et al., 1990; Morrison et al., 1987; Taracha et al.,
1995a; Taracha et al., 1995b). Results from a detailed in vitro analysis of CTL clones
derived from T. parva (Muguga)-immunised animals indicate that CTLs are
generally able to recognise some, but not all heterologous strains (Goddeeris et al.,
1990).
In a study of 22 animals that were immunized by the I & T protocol with either T.
parva (Muguga) or T. parva (Marikebuni 3219) strains and then challenged with the
reciprocal parasite, Taracha et al. (1995a) demonstrated a correlation between T.
parva-strain specificity ofCTLs in vitro and cross-immunity protection in vivo.
Immunization in 9 of the animals generated cross-protection and these animals
developed CTL capable of recognising both T. parva (Muguga) and T. parva
(Marikebuni 3219). The remaining 13 animals did not generate cross-immunity,
suffering severe disease following heterologous parasite strain challenge, and
analysis revealed that their CTL recognised the immunizing but not the challenge
parasite strain.
As would be anticipated for CD8+ T-cells, T. parva-specific CTLs are subject to
restriction by major histocompatability class I (MHCI - Morrison et al., 1987). A
notable feature of the MHCI restriction of T. parva-specific CTL responses in
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MHCI heterozygous animals is that the response is usually preferentially biased
towards one of the MHCI haplotypes (Morrison et al., 1987; Taracha et al., 1995b)
and furthermore, in haplotypes expressing more than one MHCI product they are
frequently biased towards a single MHCI gene product (Morrison et al., 1987;
Taracha etal., 1995b).
1.1.3.2 Immunodominance
The strain-specificity of T.parva-specific CTL responses and the finding that they are
often restricted by a single MHCI product implies that the CD8+ T-cell response in
individual animals is focused on a limited numbers of immunogenic epitopes that
display polymorphism between strains.
Moreover, the presence of an apparent hierarchy in MHCI haplotypes, with respect
to their capacity to preferentially restrict T. parva-specific CTL, suggests that these
epitopes exist in an immunodominance hierarchy (section 1.3), whereby certain
epitopes are capable of dominating the elicitation of T-cell responses (Morrison,
1996a; Morrison et al., 1987).
Further evidence of immunodominance in the CD8+ T-cell response to T. parva is
provided by the results from a study of monozygotic twins homozygous for the
bovine MHCI haplotype A10 (expressing the two MHCI products A10 and KN104).
In this study one twin was immunised using T. parva (Muguga) and the other with T.
parva (Marikebuni 3219). The T. parva (Marikebuni 3219)-immunised twin
generated cross-reactive KN104-restricted CTLs and was protected from challenge
with T. parva (Muguga), whereas the T. parva (Muguga)-immunised twin generated
KN104 restricted T. parva (Muguga)-specific CTLs and suffered severe clinical
reaction to subsequent T. parva (Marikebuni 3219) challenge (Taracha et al., 1995b).
However, following recovery this twin developed cross-reactive KN104-restricted
CTL. These results indicate that in the context ofKN104-restriction, although an
epitope common to both strains is capable of eliciting a CD8+ T-cell response, there
is an immunodominant T. parva (Muguga)-specific epitope (Taracha et al., 1995b),
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the presence of which inhibits the CTL response against the common epitope
(section 1.3.2.4).
1.1.3.3 The mosaic model
In vitro analysis of the cross-reactivity of a panel of 31 CTL clones derived from T.
parva (Muguga)-immunised animals of various MHCI haplotypes demonstrated that
the strain-specificity of CD8+ T-cells is profoundly influenced by their MHCI-
restriction (Goddeeris et al., 1990). Clones restricted by the same MHCI element
displayed identical strain-specificity, whereas CTL of disparate MHCI-restriction
exhibited different parasite-strain recognition patterns. Based on these data it has
been proposed that CTL epitopes are distributed amongst the different T .parva
strains according to a mosaic model (McKeever and Morrison, 1998; Morrison,
1996a).
A simplified form of the mosaic model in presented in Figure 1.3. Six parasite strains
(A-F) each express 2 or 3 potentially immunogenic epitopes restricted by the MHCI
haplotypes 1 (Figure 1.3a) and 2 (Figurel .3b). Each epitope is present in only some
of the strains and the epitopes are more or less randomly distributed amongst the
strains. This is consistent with the location of polymorphic epitopes in different
parasite proteins, the genes of which have the potential to segregate during sexual
recombination (section 1.1.1), which the model assumes is a frequent event between
heterologous parasite strains co-present in infected ticks. As the epitopes presented
by MHCI haplotype 1 (1-1 to 1-6) and haplotype 2 (2-1 to 2-6) may be located in
different proteins their distribution amongst the strains differs. The model assumes
that immunized animals generate CTL against only the most immunodominant
epitope present in the immunising strain.
Applying the model allows the prediction of the cross-reactivity of the CTL induced
by immunisation with each strain in the two MHCI haplotypes. For example,
immunization with strain F will generate CTL capable of also recognising strain C in
haplotype 1 animals and CTL capable of recognising strains A + D in haplotype 2
animals; whereas immunisation of haplotype 1 and 2 animals with strain E will
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Figure 1.3 Schematic representation of the mosaic model. The epitopes expressed by each
parasite strain (A-F) are represented by the coloured boxes. Figure 1.3a and Figure 1.3b show
the distribution of epitopes restricted by MHCI haplotype 1 (1-1 to 1-6) and MHCI haplotype 2
(2-1 to 2-6) respectively. The CTL response following immunisation is assumed to be directed
only to the most immunodominant epitope expressed in the immunizing strain with the
immunodominance hierarchy of epitopes as follows; 1 -1 >2-1 >1 -2>2-2>l -3>2-3>l -4>2-4>l-5>2-
5>l-6>2-6. Blue and red boxes indicate the epitopes against which CTL responses are directed
following immunization with strains E and F respectively.
generate CTL that will cross-react with strains B + D and strains B + C respectively.
Thus, in agreement with experimental observations, the model shows that both the
immunising parasite strain and the MHCI phenotype of an animal will influence the
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cross-reactivity of the resulting CTL response and therefore its ability to protect
against heterologous challenge (Goddeeris et al., 1990; Taracha et al., 1995b). The
model also facilitates consideration ofMHCI heterozygous animals - in the
illustrated example immunization of a MHCI 1/2 animal with strains E and F will
induce CTL cross-reactive with strains B + C and A + D respectively - and replicates
the dominance of certain MHCI haplotypes in restricting the CTL response to
particular parasite strains (Morrison et al., 1987; Taracha et al., 1995b).
According to the mosaic model no strain is anticipated to generate inherently broad
cross-reactive CTL. In agreement with observations from experimental (Dolan et al.,
1980; Morzaria et al., 1987; Radley et al., 1975b) and field data, the model predicts
that certain combinations of two or more immunising parasite strains can provide
substantially wider coverage - if it is assumed that the immunodominant epitope
from each strain is capable of eliciting CTL as a consequence of presentation by
different antigen-presenting cells (APCs) permitting subversion of
immunodominance (section 1.3.2.4). For example, immunization with a
combination of strains E and F would protect MHCI haplotype 2 animals against all
heterologous strain challenge and haplotype 2 animals against challenge with all but
strain A.
1.1.4 Other components of the immune response
The majority of published work has focused on studying the protective CD8+ T-cell
response to T. parva. However, some studies have provided insight into the
responses of other components of the immune system.
A strong proliferative CD4+ T-cell response is seen in vitro following stimulation of
PBMC from immunised cattle with autologous T. purra-infected cells (Baldwin et
al., 1987). Although some T. parva-specific CD4+ T-cells have cytolytic activity
(Baldwin et al., 1992) it is thought their main function is to provide help to the
activation of T. parva-specific CD8+ T-cells. Evidence from a study conducted by
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Taracha et al. (1997) suggests that CD4+ T-cell help is required for the activation of
both naive and memory T. parva-specific CD8+ T-cells in vitro; whilst production of
soluble factors (most likely to be cytokines such as IL-2) by CD4 T-cells appears
sufficient to activate memory CD8+ T-cells, naive cells seem to require direct
physical contact with parasite-specific CD4+ T-cells. These results are consistent
with the need for CD4+ T-cell help seen in many CD8+ T-cell responses (Bevan,
2004). Results from cell-transfer experiments with enriched T. parva-specific CD4+
T-cells suggest that they are not able to confer protection in the absence of other
effectors (unpublished observations reported in McKeever et al., 1999).
It has also been established that y8 T-cell populations expand in vivo during the
course of infection and in vitro when stimulated with autologous T. parva-infected
cells; a proportion of these yS T-cells show cytotoxic activity which is neither MHC-
restricted nor strain-specific (Daubenberger et al., 1999). There is some evidence that
natural killer-like (NK-like) cells may also contribute to the immune response to T.
parva (Goddeeris et al., 1991); however the significance of the yS T-cell and NK-like
cell responses against T. parva have not been evaluated.
Although humoral responses do not appear to play a significant role in immunity
induced by a single immunisation with T. parva (Muhammed et al., 1975), animals
that receive multiple challenges develop antibodies capable of neutralising the
infectivity of sporozoites in vitro (Musoke et al., 1982). In vitro studies have
demonstrated the ability of these antibodies to neutralise sporozoites of different
parasite strains (Dobbelaere et al., 1984; Musoke et al., 1984) and subsequent work
has shown these antibodies recognise a major 67 KDa surface coat protein of
sporozoites (p67) encoded by a single copy gene that exhibits sequence conservation
across different T. parva strains (Neneetal., 1992; Nene etal., 1996).
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1.1.5 Control of T. parva
The current control strategy for controlling T. pcirva is based principally on the
elimination of the tick vector by the use of acaricides. Although effective if
rigorously applied, the requirement for the continuous use of the acaricides combined
with their high cost and often poor availability in rural areas, the emergence of
acaricide resistance in tick populations and concerns regarding the contamination of
the environment, make continued reliance on intensive application of acaricides for
the control of theileriosis unsustainable. Therefore, the search for alternative and
more sustainable control measures is a necessity.
1.1.5.1 Immunization by the infection and treatment protocol
The use of the I & T protocol for immunisation using either a 'cocktail' of mixed
parasite strains (e.g. the 'Muguga cocktail' used by Radley et al. (1975b) which
comprises 3 T. parva strains - Muguga, Serengeti-transformed and Kiambu 5) or a
parasite isolate that is known to contain heterologous strains (e.g. Tparva
(Marikebuni) used by Morazaria et al. (1988)) has been shown to be both
economical and effective across a spectrum of different farming systems under 'in¬
field' conditions (Minjauw et al., 1999; Morzaria et al., 1988; Nyangito et al., 1994;
Pegram et al., 1996; Young et al., 1992). The successful use of sporozoite strains in
areas geographically distant from where they were first isolated indicates that the
antigenic composition of T. parva strains is not significantly different across its
geographical distribution (Mutugi et al., 1989; Oura et al., 2004).
Although applied extensively in some areas, for example Eastern Zambia, where
>150,000 calves were immunized by the I & T protocol between 1987 and 2002
(Marcotty et al., 2002), I & T immunization has not attained widespread use due to a
variety of drawbacks. Prominent amongst these are the lack of local infrastructure for
the production and quality-control of sporozoites and the cold-chain on which
distribution of viable sporozoites for immunisation is reliant. Additionally, because it
gives rise to a carrier status (Kariuki et al., 1995; Maritim et al., 1989), there is also a
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perceived risk of introducing foreign immunisation strains into native tick
populations previously free of them (Geysen et ah, 1999).
1.1.5.2 Subunit vaccines
The development of a subunit vaccine is generally considered to offer the best long
term solution to the control of ECF (McKeever and Morrison, 1998; Morrison,
1996b).
Since 1992 various forms of a neutralizing subunit vaccine based on recombinant
p67 sporozoite surface antigen have been developed and assessed under laboratory
conditions (Bishop et ah, 2003; Heussler et al., 1998; Kaba et ah, 2005; Musoke et
ah, 1992; Nene et ah, 1995) with the results indicating that ~70% of vaccinates are
protected against severe disease after experimental challenge with an LD7o dose of
sporozoites. However, only a small proportion of immunised animals achieve
complete neutralisation of infection, with the remainder developing schizont
parasitosis of varying severity upon challenge. As all vaccinates develop high titres
of neutralizing antibody, it is inferred that the variation in protection afforded by p67
vaccination may be attributable to other immune mechanisms which have not been
quantified in the trials (Bishop et ah, 2003; Musoke et ah, 1992). Recent results from
the first field trial of a p67 subunit vaccine reported that the efficacy of vaccination
averaged only -50% for a group of 97 animals located at 3 different sites in Kenya
that were exposed to field challenge for a period of up to 4 months following
vaccination (Musoke et ah, 2005).
Given the protective role of CD81 T-cells in response to T. parva, CTL epitopes are
obvious candidates for inclusion in subunit vaccines. By immuno-screening APCs
transiently transfected with T. parva (Muguga) schizont cDNA clones, using CTL
derived from I & T immunised animals of diverse MHCI haplotypes, 6 antigens
(Tpl, Tp2, Tp4, Tp5, Tp7 and Tp8) containing CTL epitopes have been identified
(Graham et ah, 2006). Tpl and 2 have been annotated as hypothetical proteins,
whereas Tp4, 5, 7 and 8 were predicted to encode the s-subunit of T complex protein
1, elongation translation factor 1A, heat-shock protein 90 and cysteine protease,
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respectively (Gardner et al., 2005). These antigens were used to vaccinate two
groups of 12 cattle employing either plasmid DNA/ modified vaccinia virus Ankara
strain (MVA) or canary pox/MVA primer/boost vaccination regimes. (Graham et al.,
2006). As there were no significant differences between the two vaccination regimes
the authors presented the results as a single group. Although 19 out of the 24
vaccinated cattle (79%) developed antigen-specific CD8+ T-cell IFN-y responses (as
measured by an ELISpot assay), only 7 of these animals produced a CTL response.
On subsequent challenge with a lethal dose of homologous sporozoite only these 7,
and an additional 3 vaccinates (-40% of the vaccinated animals) survived (Graham et
al., 2006). Moreover, all of the vaccinates developed clinical disease when
challenged. This disappointing result may reflect the failure of the antigen-delivery
strategies to elicit antigen-specific CD8 ' T-cells with appropriate function for
protection and/or the failure of the vaccination protocols to induce adequate CD44 T-
cell responses in vaccinates (Graham et al., 2006). As discussed above, there is
evidence that the latter are required to provide help for the activation ofCTL (section
1.4.4).
In the future, generation of a multi-component subunit vaccine against T. parva
incorporating p67, CTL and CD4+ epitopes able to provoke the relevant effective
responses would present the ideal solution. However, as in humans, the major
challenge for subunit vaccination in cattle remains the development of appropriate
antigen-delivery systems that reproducibly evoke potent CTL responses (Graham et
al., 2006; McKeever et al., 1999).
1.1.5.3 Immunodominance and subunit vaccination
A major issue that will need to be addressed in the use of CD8' T-cell antigens in T.
parva subunit vaccines is the effect of immunodominance. If subunit vaccination
does not achieve subversion of the immunodominance hierarchy then the immunity
induced will remain focused on a limited number of polymorphic immunodominant
epitopes and as such display limited parasite strain cross-reactivity. In some murine
and primate systems subject to immunodominance, subunit vaccination has been
shown to be capable of concurrently eliciting CTL to both immunodominant and
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subdominant epitopes (Chen et al., 1998; Fu et al., 1997; Santra et al., 2002), and
thereby induce potentially increased breadth of protection. However, evidence from
other immunodominance models suggests that it may be necessary for the
immunodominant and subdominant epitopes in the subunit vaccine to be delivered
separately to ensure presentation by different APCs in order to subvert
immunodominance (section 1.3.2.4 - Kedl et al., 2000; Pion etcil., 1999; Wolpert et
al., 1998) and generate more cross-protective responses.
An alternative strategy may be to identify more broadly conserved subdominant
epitopes to include in a subunit vaccine (Altfeld and Allen, 2006). It is known that
CTLs specific for subdominant epitopes have a role in controlling viral infections,
such as HIV, where there is immunodominance amongst the CTL epitopes (Frahm et
al., 2006); and subunit vaccination using subdominant epitopes has proven to afford
protection against SIV in rhesus monkeys (Santra et al., 2002) and influenza in mice
(Oukka et al., 1996).
Identification of T. parva antigens recognised by CD8+ T-cells on defined MHC
backgrounds (Graham et al., 2006) provides for the first time the opportunity to
quantitatively assess immunodominance in the Tpurra-specific CD8+ T-cell
response. As clonal diversity and the TCR repertoire of T-cells responding to
antigens has been shown in other systems to be an important factor in both the
efficacy of CD8+ T-cell responses and their ability to recognise antigenic variants
(section 1.2.6.1) it was also of interest in this project to examine these features of the
T. purwi-specific CD8+ T-cell response. Therefore, in the remainder of the
introduction, background infonnation on TCR (in particular the TCRP chain) and
immunodominance is discussed.
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1.2 The ap T-cell receptor
An essential feature of the adaptive immune system ofjawed vertebrates is its ability
to discriminate between the vast array of antigens it encounters and then mount
appropriate antigen-specific responses. This is achieved by the expression of diverse
repertoires of clonally distributed antigen-specific receptors (AgRs) on lymphocytes:
immunoglobulin (Ig) on B-cells and aP and yS T-cell receptors (TCR) on ap and y§
T-cells respectively. Ig and TCRs share many characteristics, including genomic
organisation of TCR and Ig genes and tertiary protein structure (Chothia et al., 1988;
Davis and Bjorkman, 1988), and are thought to have evolved from a common
ancestor, although the exact Ig/TCR evolutionary history remains unresolved
(Glusman et al., 2001; Richards and Nelson, 2000).
The apTCR is a disulphide-linked heterodimer composed of an a and p polypeptide
chain, each of which consist of (i) a short cytoplasmic tail, (ii) a hydrophobic
transmembrane domain, (iii) a short hinge region containing a cysteine residue that
forms the inter-chain disulphide bond, (iv) a membrane-proximal constant (C)
domain and (v) a membrane-distal variable (V) domain. On the cell surface TCRs are
associated with invariant accessory chains of the CD3 complex, which function in
signal transduction following TCR ligation.
apTCRs recognise antigen in the form of short processed peptides presented in
association with MHC molecules on the surface of APCs. apT-cells are categorised
into two major classes on the basis of effector function and expression of either
CD4+ or CD8+ MHC binding co-receptors. The ligands for apTCRs ofCD8'
'cytotoxic' T-cells are peptide-MHCI complexes (pMHCI) and the ligands for
apTCRs ofCD4+ 'helper' T-cells are pMHCII. MHCI molecules generally bind
peptides derived from degraded intra-cytosolic proteins whilst MHCII molecules
bind peptides derived from exogenous proteins that have been degraded in the
lysosomal pathway.
17
1.2.1 Somatic recombination in antigen-specific receptors
A distinguishing characteristic of AgRs is that exons encoding the variable domains
of the component polypeptide a, (3, y, 5 TCR chains and IgH (heavy) and IgK/X,
(Funkhouser et al.) immunoglobulin chains are not present in the germline but are
formed during lymphocyte development by somatic recombination of variable (V),
diversity (D - (3, 5 and IgH only) and joining (J) gene segments (Tonegawa, 1983).
The chromosomal loci for each of the chains (TCRB for TCRp chain, TCRG for
TCRy chain, TCRA/D for TCRa and 8 chains, IGH for IgH, IGK for IgK and IGL for
Ig/t) contain multiple copies of these genes; the different permutations ofV(D)J
combination that can be achieved for individual lymphocytes provides an integral
source of diversity for AgR repertoires (section 1.2.4).
Recombination signal sequences (RSS), which are composed of a conserved
heptamer and nonamer sequence separated by a spacer of either 12bp (12-RSS) or
23bp (23-RSS), are found at the 3'end ofV segments, 5'end of J segments and both
the 3'end and 5' end of D segments (Hesse et al., 1989; Max et al., 1979; Ramsden
et al., 1994; Sakano et al., 1979). These RSS are recognised by lymphocyte-specific
recombination activating protein 1 (RAG1) and RAG2, which initiate somatic
recombination by creating double stranded breaks that cleave the RSS from gene
segments undergoing recombination (McBlane et al., 1995). The gene segments are
then recombined through the action of ubiquitously expressed DNA repair machinery
(Weaver, 1995). Recombination is restricted by the 12/23 rule; by which
recombination can only occur between a gene segment flanked by a 12-RSS and one
flanked by a 23-RSS (Tonegawa, 1983). The 12/23 rule is sufficient to guarantee
correct recombination of V(D)J elements, except for TCRp and 8 chains, where
direct V gene (12-RSS) to J gene (23-RSS) recombination is avoided by mechanisms
'beyond the 12/23 rule' which ensure the interposition of a D gene between the V
and J segments (Bassing et al., 2000; Hughes et al., 2003; Jung et al., 2003; Olaru et
al., 2005).
V(D)J recombination is tightly controlled in a lineage- and stage-specific way so that
although all Ig and TCR chain recombination uses the same generic RAG 1/2 and
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RSS system, Ig and TCR are only rearranged in B-cells and T-cells respectively and
rearrangement of loci occurs only at the correct developmental stages, e.g.
rearrangement of the TCRB locus prior to the TCRA locus in a(3 T-cells (reviewed in
Bassing et al., 2002; Schatz, 2004; Schlissel, 2003). Strict regulation of V(D)J
recombination is also essential in enforcing allelic exclusion in which all loci, except
TCRA, are limited to the production of a single functional rearrangement (reviewed
in Khor and Sleckman, 2002; Mostoslavsky et al., 2004). In contrast, the TCRA
locus is allelic inclusive and as a consequence about 30% of a(3 T-cells contain
mRNA transcripts for two functionally rearranged TCRa chains and thus can express
two distinct aP TCRs that share the same P chain (Borgulya et al., 1992; Casanova
et al., 1991; Heath and Miller, 1993; Padovan et al., 1993).
1.2.2 Nomenclature of TCR genes
Two alternative standardised systems of TCR gene nomenclature have been
established by the WHO-IUIS Nomenclature sub-committee on TCR designation
(Kazatchkine, 1995) and by the IMmunoGeneTics database (IMGT - Giudicelli and
Lefranc, 1999). The major conceptual difference between the two systems is in the
nomenclature ofV gene segments. In both systems V genes are organised into
subfamilies (WHO-IUIS)/subgroups (IMGT) whose members share over 75%
nucleotide similarity in germline configuration. In the WHO-IUIS nomenclature,
subfamilies (and members of subfamilies) are numbered arbitrarily according to their
order of discovery, whereas in the IMGT system subgroups (and members of
subgroups) are numbered based on their position in the loci starting from the 5'end.
Due to differences in (i) the order of discovery of V genes and (ii) evolution of the
loci in mouse and human, orthologous murine and human V genes rarely have
corresponding subfamily/subgroup names in either system. Tables that detail the
correspondence between the two nomenclature systems for V genes are available
through the IMGT website (http://imgt.cines.fr) and the table for the human TCRpV
genes has been reproduced in Appendix A. In both the IMGT and WHO-IUIS
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systems it is convention that V genes of other species are designated subfamily
numbers corresponding to the human V gene with which they share highest
nucleotide similarity (Baron et al., 2001; Butler et al., 2005; Houston and Morrison,
1999; Isono et al., 1994; Schrenzel et al., 1994). Following its approval by the
Human genome organisation (HUGO) nomenclature committee, the IMGT system is
considered official and is widely used, but the WHO-IUIS nomenclature is still cited
in many current publications (e.g. Gillespie et al., 2006; Trautmann et al., 2005) and
will be used in this study to provide continuity with previously published work on
bovine TCR genes (Buitkamp et al., 1993; Houston et al., 1999; Tanaka et al., 1990)
The notation used in the WHO-IUIS system is predominantly self explanatory.
Following the TCR prefix, initials are used to described the locus (A,B,G,D) and
gene segment type (V,D,J,C). For V genes the succeeding number identifies the
subfamily, whereas for the D, J and C genes this number identifies, if appropriate,
the DJC cluster in which the genes are located (section 1.2.3). The subsequent S
number is used in V genes to enumerate and distinguish subfamily members; for
example, TCRBV5s4 refers to T-cell receptor gene ofTCRB locus, variable gene
subfamily 5, member 4, which can be further abbreviated to V(35s4. In J gene
nomenclature the S number is used to delineate the genes within a cluster, which are
numbered according to genomic order proceeding from the 5'end.
1.2.3 The human and murine TCRB loci and TCRp genes
1.2.3.1 The TCRB locus
The genomic sequences of all TCR loci in human and mouse are now available
(GenBank accession numbers are given in Appendix B) and have provided an
important resource for studying various aspects ofTCR gene biology. The TCR loci
are large, incorporating hundreds of kilobases (Kb), ranging from nearly 200Kb for
the human TCRG locus to over 1.7Mb (Megabases) for the murine TCRA/D locus.
Within each TCR locus there is an array ofV gene segments at the 5'end and a
region containing the (D)-J-C elements at the 3' end. The TCRB locus is located on
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chromosome 7q34 in humans and chromosome 6A-C in mice (Barker et al., 1984;
Caccia et al., 1984; Isobe et al., 1985) and is approximately 650Kb in length in both
species (Rowen et al., 1996, GenBank accession numbers AE000663-665).
Schematic representations of the human and murine TCRB loci are given in Figure
1.4. The TCRB locus has three distinctive characteristics:
(i) The duplication of the entire DJC region, leading to the presence of two
tandemly located DJC clusters, each consisting of a single 5' D(3 gene, six to seven
jp genes and a single 3' CP gene. The jp genes are approximately 50bp in size and
are flanked at their 5' end by a 12-RSS. The Dp genes are very short, 9-16bp, and
flanked by 12-RSS and 23-RSS on their 5' and 3' ends respectively. The Cp genes
are present as four exons which have a combined length of ~550bp.
(ii) The presence of a solitary VP gene (Vp20sl in humans and VP 14s 1 in mice)
that is located 3' to the DJC clusters and lies in the reverse transcriptional orientation
to the other TCRP genes. It has been hypothesized that the anomalous location and
orientation of this gene is due to its exclusion from an ancient inversion event that
incorporated the rest of the TCRB locus (Glusman et al 2001) and
(iii) The interposition of trypsinogen genes 5' and 3' to the Vp gene array. This
association is ancient (>300 million years), as demonstrated by its conservation in
the chicken (Glusman et al., 2001).
1.2.3.2 Germline human and murine Vp repertoire
The human TCRB locus contains 65 Vp genes distributed amongst 30 subfamilies,
and the murine locus 35 Vp genes distributed amongst 31 subfamilies. Each VP gene
is composed of two exons; a leader (L) exon, generally ~49bp long, separated by an
intron of ~80-250bp from a variable (V) exon of ~300bp which is immediately
flanked at its 3'end by a 23-RSS (Siu et al., 1984).
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V(3 genes follow a "birth and death' model of evolution whereby new genes are
created by duplication and some are maintained in the genome whilst others are
deleted or become non-functional (Clark et al., 1995; Su and Nei, 2001).
Phylogenetic trees of human and murine Vp genes exhibit branching patterns (Arden
et al., 1995a, b), indicating that VP gene duplications have occurred continuously
over a prolonged period of time. Extensive intermingling of human and murine VP
sequences in phylogenetic trees (Clark et al., 1995; Su and Nei, 2001) reflect the
occurrence ofmany Vp duplications prior to rodent/primate divergence 80-110
million years ago (Kumar and Hedges, 1998; Li et al., 1990).
Figure 1.4 Schematic representation of the human and murine TCRB loci (overleaf). The
human (upper) and murine (Lopes et al.) loci are shown in parallel in three segments running
from the 5'end (upper panel) to the 3'end (lower panel). Genes within the loci are shown
according to the legend below. VP genes represented by two coloured boxes have allelic forms of
different functional status. Vp gene names in red type are examples of genes within duplicated
cassettes (section 1.2.3.2). Red lines indicate orthologous human and murine Vp genes as
documented in the literature (section 1.2.3.3 - Bosc and Lefranc, 2000; Clark et at., 1995;
Glusman et at., 2001; Lai et at., 1988). The arrows adjacent to human Vp20sl and murine
Vpi4sl indicate the opposite transcriptional orientation of these genes compared to the other
TCRp genes in the TCRB loci. The boxes representing genes, and the distances between the
genes are not shown to scale. Exons are not shown. The format of the figure follows that of the
IMGT database (http://imgt.cines.fr).
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The disparity in the number of VP genes in the human and murine germline
repertoire testifies to more extensive duplication in the human; nine of the
subfamilies have multiple members, with the largest subfamilies being V(15 (8
members), V(313 (9 members) and V(36 (9 members). In contrast only two of the
murine subfamilies have multiple members - Vp5 and Vp8, which have three
members each. The exact mechanisms leading to duplication are unknown, but
unequal cross-over, possibly facilitated by genomic repeats in the loci (such as
retroviral or LINE repeats) has been suggested as a potential mechanism (Glusman et
al., 2001). Much of the expansion of the human VP gene repertoire has occurred
through the duplication of cassettes containing multiple Vp genes; the most
prominent example being the five repeats of a 20Kb region ofDNA that includes a
VP5, 13 and 6 gene (Figure 1.4 - Rowen et al., 1996; Su and Nei, 2001). Similarly
the expansion of murine VP5 and 8 appears to have occurred following duplication
of a cassette containing the ancestral genes of these two subfamilies - leading to three
adjacently located pairs of tandemly organised VP5/VP8 in the middle of the locus
(Figure 1.4 - GenBank accession numbers AE000663-665).
1.2.3.3 VP pseudogenes and the functional Vp repertoire
The germline VP repertoires of humans and mice include numerous pseudogenes.
Nineteen of the human Vp genes (-30%) in the TCRB locus, and fourteen of the
murine VP genes (-40%) are non-functional. Some of these pseudogenes lack an
open-reading frame (either due to frame-shifts or substitutions creating premature
stop codons), whilst others maintain an open-reading frame (ORF pseudogenes) but
are non-functional due to defects in splice sites, defects in their RSS that prohibit
somatic recombination or nucleotide substitutions that cause the loss of structurally
important amino acids (Rowen et al., 1996, GenBank accession numbers AE000663-
665). Due to the presence of pseudogenes, not all of the Vp subfamilies in humans
and mice contain functional genes. In humans the functional VP repertoire comprises
46 genes in 23 subfamilies and the functional murine VP repertoire consists of 21
genes in 19 subfamilies (Bosc and Lefranc, 2000; Folch and Lefranc, 2000b).
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In addition to the VP genes in the TCRB locus, in humans duplication and inter-
chromosomal translocation has generated a cluster of seven VP genes present on
chromosome 9 (Robinson et al., 1993; Rowen et al., 1996). Because no Dp, jp or CP
genes were incorporated in the translocation, these genes are unable to form TCRp
chains and are therefore termed 'orphan' pseudogenes.
1.2.3.4 Orthology between human and murine VP genes
Various criteria have been used to describe orthology between human and murine VP
genes, including (i) >65% nucleotide sequence identity (Lai et al., 1988), (ii) >60%
amino acid sequence identity (Clark et al., 1995), (iii) proximity on phylogenetic
trees (Clark et al., 1995; Su and Nei, 2001) and (iv) sharing of distinctive features,
e.g. human Vp23 and murine Vp5 have L exons of 79bp, rather than the typical
~50bp (Glusman et al., 2001). However, due to complexities introduced into the
human and murine TCRB loci by deletion, duplication, mutation and gene
conversion events subsequent to human/murine divergence, identification of
orthologues amongst the VP genes is not always straightforward. For example in
some instances, a single subfamily in one species appears to have several orthologues
in the other species (e.g. human Vpl9 could be an orthologue of either murine Vp20,
17 or 3), presumably as a result of gene duplication in the ancestral locus and
subsequent deletion of genes in one of the species, or alternatively duplication of an
ancestral gene in the other species subsequent to divergence (Clark et al., 1995;
Glusman et al., 2001).
Such complications and the application of different criteria have led to different
researchers producing discordant results when describing human/murine VP
orthologues. Thus, Clark et al. (1995) identified 14 subfamily orthologies, whereas
Bosc and LeFranc (2000) identified only 11. Orthologous relationships between
murine and human TCRp genes that have been described in the literature are shown
in Figure 1.4, and demonstrates the conservation of order of orthologous VP genes
between the human and murine TCRB loci (Lai et al., 1988).
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1.2.4 Diversity in the a(3TCR repertoire
1.2.4.1 Mechanisms of generating apTCR diversity
A diverse apTCR repertoire is integral to the ability of T-cells to mount efficient
antigen-specific responses (reviewed in Goldrath and Bevan, 1999; Nikolich-Zugich
et al., 2004). Diversity of the aPTCR repertoire is generated during assemblage of
TCRs in thymocytes (developing T-cells) by two mechanisms; combinatorial
diversity and junctional diversity (Davis and Bjorkman, 1988).
Combinatorial diversity occurs at two levels: (i) different permutations of V(D)J
genes in re-arrangements used to form a and p chains and (ii) different combinations
of rearranged a and P chains in apTCRs. The amount of diversity that can be
produced is a function of the number of functional Va, Ja, VP, Dp and jp genes
available for recombination - in humans combinatorial diversity theoretically could
produce ~3 x 105 unique apTCRs.
Junctional diversity dramatically amplifies this diversity by editing the nucleotide
sequence of the V(D)J junction through the activities of exonuclease and terminal
deoxynucleotide transferase (Tdt), which respectively remove and insert bases to the
5'end of V, the 5' and 3' ends of D and the 3'end of J gene segments undergoing
somatic recombination. The accumulation of combinatorial and junctional diversity
can theoretically produce a potential repertoire of 1 x 1015 unique apTCRs (Davis
and Bjorkman, 1988), which is several orders of magnitude greater than the ~l-2 x
108 and 1012 T-cells present in mice and human respectively (Arstila et al., 1999;
Casrouge et al., 2000). As a consequence of the mechanisms used, much of the
diversity represented in this repertoire is focused within the V(D)J regions (also
known as the CDR3 regions - section 1.2.5) of the a and P chains.
1.2.4.2 Diversity of the naive apTCR repertoire
Estimates of the actual diversity of the peripheral apTCR repertoire present in
individual mice and humans have been obtained by extrapolation of direct molecular
measurements (Arstila et al., 1999; Casrouge et al., 2000). The results suggest that
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the naive human and murine repertoires comprise in the order of 2 x 106 and 2.5 x
107 unique aPTCRs respectively; thus the apTCR repertoire expressed by individuals
represents a fraction of the potential repertoire that can be generated. Various factors
have been demonstrated to influence which aPTCRs will constitute an individuals
repertoire, the most significant of which are (i) thymic selection, (ii) non-random
rearrangement and (iii) germline polymorphisms of the TCRB locus.
1, Thymic selection
Once aPTCRs are expressed in the thymus, thymocytes undergo positive and
negative selection before emigrating to join the mature peripheral pool (reviewed in
Starr et al., 2003; von Boehmer et al., 2003). The affinity of apTCRs for pMHC
expressed on thymic epithelial and dendritic cells determines the fate of individual
thymocytes during these selection processes. In positive selection, thymocytes
bearing apTCR with low but appreciable affinity for self pMHC are rescued from
'death by neglect', which is the fate of thymocytes bearing aPTCRs with no
appreciable affinity for self pMHC. Negative selection subsequently deletes
thymocytes bearing aPTCR with high affinity for pMHC from the repertoire. Thus
the combined effect of positive and negative selection is to produce mature T-cells
with a repertoire of aPTCRs that are capable of interacting with self-MHC molecules
but are not auto-reactive. Less than 5% of thymocytes survive selection, dramatically
reducing the diversity of apTCR expressed by T-cells exported from the thymus
(Correia-Neves et al., 2001; Nikolich-Zugich et al., 2004; Sant'Angelo et al., 1997).
As MHC proteins are highly polymorphic, for example, in man more than 800 alleles
ofMHCI and more than 600 alleles ofMHCII proteins are known (Robinson et al.,
2003), the MHC ligands that participate in thymic selection differ between
individuals and result in variation in the o^TCRs that survive thymic selection.
Human cohort studies have demonstrated that individuals sharing MHC haplotypes
have more similar peripheral apTCR repertoires than individuals with different MHC
haplotypes (Akolkar et al., 1993; Gulwani-Akolkar et al., 1991; Mizushima et al.,
1997); and in MHC disparate mice strains, the apTCR repertoires also show
markedly different frequencies of expression of certain VP subfamilies (Bill et al.,
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1988). Similarly, the thymic selection of CD4+ and CD8" T-cells against MHCI and
MHCII proteins respectively has been observed to generate significant differences in
the frequency at which these T-cell subsets express certain VP genes (Hawes et al.,
1993; Liao et al., 1990). Evidence from several studies has shown that the influence
ofMHC phenotype on apTCR repertoire is mediated through both positive (Benoist
and Mathis, 1989; Blackman et al., 1989; Liao et al., 1989; MacDonald et al., 1988a)
and negative selection (Bill et al., 1989; Kappler et al., 1987; Liao et al., 1990).
Another factor that can influence the apTCR repertoire surviving thymic selection is
the presence of endogenous super-antigens (eSAGs). eSAGs are molecules encoded
by retroviruses integrated into the genome that can bind to MHCII molecules outside
of the peptide binding groove to form a ligand for apTCR expressing certain Vp
genes (Herman et al., 1991). eSAG interaction with immature thymocytes leads to
clonal deletion of all cells bearing apTCRs expressing the relevant VP genes
(Kappler et al., 1988; MacDonald et al., 1988b; Meylan et al., 2005; Nelson et al.,
2004; Pullen et al., 1988); for example, expression of the eSAG Minor Lymphocyte
Stimulating antigen la (Mls-la) in some strains ofmice causes clonal deletion of
Vp8sl+ and Vp6+ T-cells (Kappler et al., 1988; MacDonald et al., 1988b).
2, Non-random rearrangement
Thymocyte populations that have not undergone thymic selection demonstrate biased
expression patterns of VP and jp genes (Ema et al., 1997; Jores and Meo, 1993;
Manfras et al., 1999; Nanki et al., 1998) due to preferential usage of certain TCRp
genes in somatic recombination. These biases are maintained in post-selection
repertoires (Ema et al., 1997; Nanki et al., 1998; Rosenberg et al., 1992) and
therefore have substantial impact on mature peripheral apTCR repertoires.
Although the RSS associated with different VP genes is generally conserved, there is
variation in the sequences of the heptamer, nonamer and spacer components of RSS
(Glusman et al., 2001; Ramsden et al., 1994). Extensive analysis of Ig recombination
has shown that RSS sequence variation can determine the frequency with which V
genes are used (Feeney et al., 2004; Montalbano et al., 2003; Nadel et al., 1998a;
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Nadel et al., 1998b). Similarly, ex vivo and in vitro studies have demonstrated that
the frequency with which certain TCRP genes are used in rearrangement is also
influenced by the RSS (Livak et al., 2000; Wu et al., 2003) and it has been
postulated that use of certain orthologous V|3 genes at strikingly similar frequencies
in humans and mice may reflect conservation of their RSS sequences (Livak, 2003,
2004)
As each V(3 gene is under the control of its own promoter and there are substantial
sequence differences between individual V[3 gene promoters (Halle et al., 1997),
disparity in promoter activity has also been cited as a possible explanation for
preferential use of specific V(3 genes (Chen et al., 2001a; Ryu et al., 2004; Sieh and
Chen, 2001). Unlike biased use of Ig V genes, biases in the usage of VP genes is not
dependent on their proximity to the DJC region (Sieh and Chen, 2001; Wilson et al.,
2001).
3, Germline polymorphisms in the TCRB locus
Various murine TCRB locus germline deletions have been described in laboratory
mouse strains and in wild mice (Behlke et al., 1986; Haqqi et al., 1989; Jouvin-
Marche etal., 1989;Kotzin etal., 1985; Noonan et al., 1986; Pullen etal., 1990). A
8.8Kb deletion described in New Zealand White mice incorporates the Cpi, Dp2
genes and the jp2 cluster of genes (Kotzin et al., 1985; Noonan et al., 1986) whilst
the other deletions reported involve loss of various VP elements which can involve
>50% of the entire VP germline repertoire (Haqqi et al., 1989). Two
insertion/deletion-related polymorphisms (IDRPs) have been reported in the human
TCRB locus (Seboun et al., 1989), one of which involves three VP genes (Zhao et
al., 1994).
Some of the human and murine VP genes have allelic variants (Bosc and Lefranc,
2000; Folch and Lefranc, 2000b). For some, e.g. human Vp20sl and murine Vpi7sl,
there are non-functional as well as functional alleles (Charmley et al., 1993; Wade et
al., 1988). For other VP genes, alleles are found to be expressed at different levels in
the apTCR repertoire due to polymorphic differences in the coding region (Vissinga
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et al., 1994), the promoter region (Kay et al., 1994), the RSS sequence (Posnett et
al., 1994) or interactions with super-antigens (Cazenave et al., 1990).
The loss of functional TCRp genes either by gerinline deletion or presence of non¬
functional allelic forms and the existence of alleles that are expressed at different
frequencies will obviously impact on the level of expression of genes within the
naive aJ3TCR repertoire.
4, Stochastic selection
Despite the constraints placed on an individual's a[3TCR repertoire by germline
polymorphisms, non-random rearrangements and thymic selection, evidence from
two murine studies suggests that a large redundancy of diversity is maintained. In
one study, analysis of the naive repertoire of two genetically identical mice revealed
that only 20-25% of the TCRp chains expressed were shared (Bousso et al., 1998);
whilst in another study, the reconstituted TCR repertoires of several alymphoid mice
that received spleen cells from the same donor, were found to be highly divergent,
with up to 80% of the TCR sequences being unique to individual recipients
(Maryanski et al., 2001). Thus, it would appear that the naive repertoire of an
individual is also influenced by the stochastic expression of apTCR from an
enormous available repertoire.
1.2.5 apTCR interaction with pMHC ligands
Over the last decade high resolution analyses of 24 apTCRs bound to pMHC
antigens have provided detailed structural information of how aPTCRs interact with
their ligands (reviewed in Garcia and Adams, 2005; Hennecke and Wiley, 2001;
Housset and Malissen, 2003; Rudolph et al., 2006). As predicted from comparison to
immunoglobulins (Chothia et al., 1988; Davis and Bjorkman, 1988) the apTCR
antigen-binding surface is composed of 6 loops, called complementarity determining
regions (CDRs), that are brought together at the membrane distal end of the receptor
as shown in Figure 1.5 (Garboczi et al., 1996; Garcia et al., 1996). The a and P
chains each contribute 3 loops (CDRa 1-3 and CDRp 1-3 respectively). The CDRls
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and CDR2s are encoded within the germline V genes and the CDR3s are encoded by
the V(D)J junctional region. Consequently, as most of the nucleotide diversity of the
TCRa and p chains is focused within the V(D)J region, the CDR3 regions display a
much greater level of variability than the CDR1 and CDR2 regions (section 1.2.4.1).
In all of the apTCR/pMHC structures described there is a conserved diagonal
positioning of the apTCR across the pMHC ligand which maximises TCR/pMHC
interaction (Garcia and Adams, 2005; Rudolph et al., 2006).This orientation places
the germline encoded CDR1 and 2 loops predominantly in contact with the
conserved a-helices of the presenting MHC molecules, whilst the highly variable
CDR3 loops primarily interact with the peptide, as shown in Figure 1.5. However,
there is considerable variation within this generalised orientation of TCR/pMHC
structures; the angle at which the TCR lies on the pMHC can vary by up to ±45°
(Rudolph et al., 2006; Teng et al., 1998) and the tilt of the TCR on the pMHC also
displays variability, such that in some complexes the CDRpi and 2 loops make
minimal contact with the MHC (Marrack et al., 2001; Teng et al., 1998).
Consequently the contribution made by the different CDR loops to the binding
energy varies between individual TCR/pMHC complexes (Borg et al., 2005;
Manning et al., 1998).
1.2.6 Antigen-specific TCR repertoires
Each pMHC ligand is recognised by a repertoire of antigen-specific apTCRs selected
from within the naive repertoire. Experimental evidence that TCRp chain transgenic
mice, in which the diversity of the naive TCR repertoire is markedly decreased, can
mount normal responses against a panel of antigens indicates that there is a large
redundancy of TCRs available for recognising specific epitopes (Listman et al.,
1996). However, identification of'holes' (i.e. pMHC for which there are no cognate
TCR) in the TCR repertoire subsequent to loss of certain TCR genes in other studies
shows there are limits to this redundancy (Kumar and Sercarz, 1994; Nanda et al.,
1991).
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Figure 1.5 TCR interaction with pMHC ligand. (A) Lateral view of a typical TCR/pMHC
complex. TCR on top (a chain in pink, p chain in light blue), pMHC on bottom (MHCI heavy
chain - al, a2 and «3 helices in light green and p2 microglobulin (P2M) in dark green, peptide in
yellow with amino acid positions 1, 4 and 8 (PI, P4 and P8) indicated). TCR binding surface is
formed by six complementarity determining regions (CDRs). CDRla magenta, CDR2a purple,
CDR3a yellow, CDRip cyan, CDR2p navy blue and CDR3p green (Garcia et al., 1998). (B) CDR
placement over the composite peptide-MHC ligand in a typical TCR/pMHC complex. MHC
helices shown as white ribbons, peptide in yellow with the NH2- (N) and COOH- (C) termini
indicated, TCRa chain CDRs in red and TCRp chain CDRs in blue (adapted from Hennecke
and Wiley 2001).
The available naive a(3TCR repertoire obviously has a significant impact on the
composition of antigen-specific repertoires (Attuil et al., 2000; Bousso et al., 1998).
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Germline deletion of TCR genes (Brawand et al., 1999; Wallace et al., 2000),
expression of allelic variants of TCR genes (Gahm et al., 1991) and negative
selection against co-expressed MHC products (Belz et al., 2000; Burrows et al.,
1995) have all been documented as altering antigen-specific TCR repertoires.
However, the stochastic selection of apTCRs from within the available naive
repertoire also plays a role in moulding the shape of antigen-specific repertoires
(Attuil et al., 2000; Bousso et al., 1999; Kedzierska et al., 2004).
1.2.6.1 Diverse and restricted TCR usage in antigen-specific TCR
repertoires
Some antigen-specific repertoires are extremely diverse (Campos-Lima et al., 1997;
Casanova etal., 1991;Horwitz etal., 1994; Taylor et al., 1990; Utz et al., 1996), but
for many pMHC the specific repertoire is restricted, showing use of particular Va
and/or V[3 genes (and hence conserved CDR1 and 2 sequence) in combination with
conservation of the hypervariable CDR3 sequence (Argaet et al., 1994; Cose et al.,
1995; Gillespie et al., 2006; Lehner et al., 1995; Moss et al., 1991).
Various factors have been identified as influencing the diversity of antigen-specific
TCR repertoires, (i) Maryanski and colleagues proposed that epitopes that bear close
homology to self-peptides have restricted repertoires due to limitations in the
diversity of cognate ocpTCR that survive negative selection (Casanova et al., 1992;
Casanova and Maryanski, 1993; Maryanski et al., 1997). (ii) Evidence from
experimental models suggest that the stability of pMHC complexes is correlated with
the ability to elicit clonal expansion of both high and low avidity T-cells and that
therefore stable pMHC are able to generate a more diverse antigen-specific TCR
repertoire than unstable pMHC (Busch and Pamer, 1998; Campos-Lima et al., 1997).
(iii) Results from two recent structural studies indicate that the topology of the
composite pMHC ligand may influence the antigen-specific TCR repertoire, with
featureless or super-bulged pMHC complexes inducing limited diversity, whilst
pMHC with prominent features selected a diverse TCR repertoire (Miles et al., 2005;
Turner et al., 2005). (iv) The diversity of an antigen-specific repertoire can also be
restricted by the presence of a dominant TCR clonotype that exhibits optimal binding
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to the pMHC ligand (Kjer-Nielsen et al., 2002; Stewart-Jones et al., 2003). For
example, in the case of the influenza peptide FLRGRAYGL presented by HLA-B8,
the dominant TCR clonotype is cross-reactive with the alloantigen HLA-B*4402 and
therefore deleted in HLA-B8+/HLA-B*4402+ individuals - in these individuals the
FLRGRAYGL/HLA-B8 antigen-specific repertoire is diverse compared to that seen
in HLA-B8+/HLA-B*4402~ individuals (Burrows et al., 1995).
Diversity of antigen-specific TCR repertoires in CD8T T-cells responses has been
associated with enhanced anti-viral protection in both human and mouse models
(Lopes et al., 2003; Messaoudi et al., 2002). This has been attributed to greater TCR
diversity allowing, (i) selection of the most efficient CD8+ effector T-cells
(Messaoudi et al., 2002) and (ii) enhanced ability to recognise epitope variants
through the presence ofmultiple 'fine specificities' within a diverse antigen-specific
TCR repertoire, and therefore control of'escape mutants' in viral pathogens such as
HIV (Douek etal., 2002; Lopes et al., 2003; Pantaleo etal., 1997).
1.2.6.2 Stability of antigen-specific TCR repertoires
Once established antigen-specific repertoires are not fixed, and although some clones
may persist for up to 57 months (Levitsky et al., 1998; Maini et al., 2000) other
clones does not display such stability and are lost from the repertoire whilst novel
clones become incorporated into it (Annels et al., 2000; Chen et al., 2001c).
Repeated exposure to antigen can significantly alter the TCR repertoire through the
process of 'immuno-focusing' - the narrowing ofTCR diversity (Kedzierska et al.,
2004; Maryanski et al., 1999; McHeyzer-Williams and Davis, 1995). Analysis of
immuno-focusing in several bacterial and viral models indicate that this narrowing is
the result ofpreferential selection of T cells with high affinity TCR (Busch and
Pamer, 1999; Savage et al., 1999; Trautmann et al., 2005; Zhong and Reinherz,
2004). Based on results from in vivo studies Kedl et al. (2002) have proposed that
this selection of high affinity TCR is mediated by the ability of T-cells bearing such
TCR to out-compete T-cells with low affinity TCR for pMHC presented by APC.
Consequently, T-cells expressing high affinity TCR are preferentially expanded
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during antigenic challenge and more likely to contribute to the memory cell pool that
responds in subsequent exposures.
1.2.6.3 Characteristics of CD8+ T-cell responses
As will be discussed in section 1.3 many CD8+ T-cell responses to complex antigens
are focused on a limited number of immunodominant epitopes. Studies using
tetrameric pMHCI complexes have demonstrated that in vivo CD8+ T-cell responses
to the immunodominant epitopes of viruses can be massive. During the primary
response to Epstein-Barr virus (EBV) infection, 44% of CD8+ T-cells in one
individual were specific for a single dominant epitope (Callan et al., 1998) and even
in individuals that have recovered from EBV infection >5% of the circulating CD8+
T-cell population are specific for the dominant epitope (Callan et al., 1998; Tan et
al., 1999). Similarly large expansions of antigen-specific CD8+ T-cells have been
demonstrated in the response to LCMV infection in mice (Butz and Bevan, 1998).
Adoption of techniques that permit characterisation of the apTCR of large numbers
of antigen-specific T-cells has shown that the antigen-specific repertoire of CD8+
responses are frequently polyclonal but dominated by a small number of large oligo-
clonal expansions (Chen et al., 2001c; Maryanski et al., 1996; Naumov et al., 1998;
Peggs et al., 2002). Another feature of some CD8+ antigen-specific TCR repertoires
is the occurrence of 'public' TCRs, i.e. identical antigen-specific TCRs present in
different individuals sharing the same MHC haplotype (Argaet et al., 1994; Levraud
et al., 1996; Quinn et al., 2006; Zhong and Reinherz, 2004). Structural studies have
demonstrated that two such 'public' TCRs of humans exhibit optimal binding to their
pMHC ligands, mainly attributable to a combination of features unique to these
particular clonotypes (Kjer-Nielsen et al., 2002; Kjer-Nielsen et al., 2003; Stewart-
Jones et al., 2003). The high affinity that 'public' TCRs have for their ligands is
thought to account for their recurring preferential selection from the naive a(3TCR
repertoire of unrelated individuals (Kedzierska et al., 2004; Kjer-Nielsen et al., 2002;
Stewart-Jones et al., 2003; Trautmann et al., 2005).
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1.3 Immunodominance
Despite the presence of enormous numbers of potentially immunogenic peptides in
viruses, bacteria, tumours and tissue grafts, the bulk of the responding CD8" T-cell
population is typically focused on a limited number of peptides by a phenomenon
known as immunodominance (Yewdell and Bennink, 1999). These epitopes are
generally categorised into hierarchies of'immunodominant' and 'subdominant'
epitopes, according to the magnitude of the T-cell response they elicit. Within
immunodominant CD8+ T-cell responses, the hierarchy of epitopes is usually
reproducible in individuals sharing the same MHCI haplotype.
Immunodominance poses a major hurdle to the development of vaccines that aim to
induce CD8 T-cell responses (Yewdell and Del Val, 2004). The focusing of the
response against a limited number of epitopes favours the emergence of'escape
mutants' in viruses such as HIV/SIV (Allen et al., 2000; Barouch et al., 2002;
Goulder et al., 1997) and limits the breadth of protection afforded against pathogens
where the protective CD8+ T-cell response is focused on a limited number of
immunodominant epitopes that vary between pathogen strains (e.g. T. par\>a -
sections 1.1.3.2 and 1.1.5.2). Consequently, vaccination strategies must aim to
modify or circumvent immunodominance to enable the induction of CD8+ T-cell
responses to either a diversity of epitopes or broadly conserved epitopes, so that the
immunity generated will, where relevant, cover a wide range of pathogen strains and
limit the emergence of viral 'escape mutants' (Altfeld and Allen, 2006; Liu et al.,
2006; Walker and Korber, 2001).
1.3.1 The MHCI-CD8+ T-cell antigen-presentation pathway
Immunodominance results from the interplay of a multitude of interdependent factors
that exert influence at the various stages of the MHCI-CD8f T-cell immuno-
surveillance system (Yewdell and Bennink, 1999; Yewdell and Del Val, 2004).
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Peptides presented by MHCI molecules to CD8" T-cells are predominantly derived
from cytosolic proteins degraded by the proteasome, a multi-catalytic protease
complex in the cytosol (reviewed in Rock et al., 2002). The proteasome exists in two
forms; the constitutive proteasome, which is expressed in most cells, and a modified
form known as the immunoproteasome, which is expressed in dendritic cells and
cells exposed to IFNy (Groettrup et al., 1995; Morel et al., 2000). Substitution of the
catalytic subunits Y, Z and MB 1 in the constitutive proteasome for their counterparts
LMP-2, LMP-7 and MECL-1 in the immunoproteasome results in different cleavage
site preferences and therefore generation of different peptide pools by the two forms
of proteasome (Eleuteri et al., 1997; Tenzer et al., 2004; Toes et al., 2001).
Peptides generated by the proteasome are subsequently conveyed to the endoplasmic
reticulum (ER) by the transporter associated with antigen processing (TAP), a
heterodimeric membrane-spanning protein (Monaco et al., 1990; Neeljes et al.,
1993; Spies and DeMars, 1991). Although proteasomal cleavage dictates the C
terminus of antigenic peptides, the N terminus may be extended by several amino
acid and require trimming by amino-peptidases (Craiu et al., 1997; Mo et al., 1999);
both cytosolic and ER-localised amino-peptidases that trim MHCI epitopes have
recently been identified (Rock et al., 2004; Saric et al., 2002; Serwold et al., 2001;
Serwold et al., 2002; Stoltze et al., 2000; York et al., 2002). In the ER, the processed
peptides are loaded into nascent MHCI molecules and then exported to the cell
surface for interaction with CD8f T-cells.
1.3.2 Factors influencing immunodominance
The mechanisms underlying immunodominance have been the subject of intensive
investigation and numerous contributory factors have been identified. These can be
categorised broadly into factors that influence (i) abundance of epitope generated, (ii)
efficiency of epitope presentation by MHC, (iii) the available T-cell population
bearing cognate TCR and (iv) competition between CD8+ T-cells for APCs. As
immunodominance is the product of the summation of these factors, it cannot be
37
definitively attributed to any single factor. Furthermore, the relative importance of
the different factors in determining immunodominance varies between different
epitopes and systems (Chen et al., 2000; Deng et al., 1997; Pion et al., 1999;
Sandberg et al., 1998).
1.3.2.1 Epitope abundance
A correlation between the quantity of epitope generated from its parent protein and
its ability to elicit a CD8+ T-cell response has been demonstrated in many models
(Del Val et al., 1991; Eisenlohr et al., 1992; Ossendorp et al., 1996; Shastri et al.,
1995). However, epitope abundance is not correlated to immunodominance in other
models, presumably due to the more significant counter-influence of other factors
(Anton et al., 1997; Crotzer et al., 2000).
The sequence flanking an epitope can dramatically alter its liberation from the parent
protein (Del Val et al., 1991; Eggers et al., 1995) and consequently its
immunogenicity (Moudgil et al., 1998; Vijh et al., 1998). Several recent studies have
demonstrated the contribution that the flanking sequences of epitopes can make to
immunodominance hierarchies. By exchanging the flanking sequences of an
immunodominant and subdominant epitope from ovalbumin, Mo et al. (2000)
demonstrated that the relative hierarchy of the these epitopes was correlated to the
flanking sequences, whilst in another study Zhu et al. (2005) demonstrated that the
crypticity (i.e. failure to elicit a detectable CD8+ T-cell response) of some epitopes
was directly attributed to their flanking sequences. Altered flanking sequences have
also been revealed to cause loss of immunogenic epitopes, thus causing a change in
immunodominance hierarchies (Beekman et al., 2000; Milicic et al., 2005).
Similarly, the proteolytic activities of the proteasome and amino-peptidases have
been shown to affect epitope abundance (Gileadi et al., 1999; Schwarz et al., 2000;
York et al., 2002). The efficient generation of some epitopes requires expression of
the immunoproteasome (Schultz et al., 2002; Sewell et al., 1999; Sijts et al., 2000),
whilst other epitopes are more efficiently generated by the constitutive proteasome
(Morel et al., 2000); thus the differential expression of the two proteasomal forms
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has the ability to influence immunodominance hierarchies (Basler et al., 2004; Chen
et al., 2001b). A recent study using a mutant mouse lacking one of the amino-
peptidases that trims MHCI epitopes (endoplasmic reticulum aminopeptidase 1 -
ERAP1) demonstrated that absence of this enzyme drastically alters
immunodominance hierarchies, thereby indicating the role it has in mediating
immunodominance (York et al., 2006).
1.3.2.2 Epitope presentation by MHCI
The crucial influence that peptide affinity for the presenting MHC molecule has on
immunodominance has been well documented (Chen et al., 1994; Sette et al., 1994;
van der Most et al., 1996). However, in subsequent studies it was appreciated that the
immunogenicity of an epitope was more accurately reflected by its ability to form
stable pMHC complexes (Levitsky et al., 1996; van der Burg et al., 1996). In all
studies in which pMHC stability has been assessed it has been found to correlate
with immundominance (Brooks et al., 1998; Bullock et al., 2000; Busch and Pamer,
1998; Gallimore et al., 1998). This has been related to the formation of stable
immunological synapses between APCs and CD8+ T-cells, which may have to be
maintained for >10hr to achieve full T-cell activation (Davis et al., 2003; Yoshimura
et al., 2004). The extended pMHC/TCR dwell time facilitated by stable pMHC
complexes may enable maintenance of the immunological synapse for the required
period, whereas unstable pMHC may not (Kalergis et al., 2001). Stable pMHC may
also contribute to immunodominance by enabling the activation of both high and low
avidity CD8+ T-cells whereas unstable pMHC are more likely to be capable of only
activating high avidity CD8+ T-cells (Busch and Pamer, 1998).
1.3.2.3 Available T-cell population bearing cognate TCR
It has been well established that the naive CD8+ T-cell precursor frequency plays an
important role in determining immunodominance in some systems (Cao et al., 1996;
Choi et al., 2002; Deng et al., 1997; Sandberg et al., 1998; Thatcher et al., 2000).
Consequently, as a dominant influence on shaping the naive CD8+ T-cell repertoire,
thymic selection can exert substantial influence over immunodominance hierarchies
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(Slifka et al., 2003) and may account for the effect that co-expressed MHC
haplotypes can have in altering them (Belz et al., 2000; Lacey et al., 2003). An
example of this is the depression of the CD8 ' T-cell response to the
immunodominant H2Db-restricted influenza polymerase224-233 peptide (DbPA224) in
mice that co-express H2Dk. This is associated with the loss of a prominent DbPA224-
specific Vp7+ T-cell response and is thought to reflect H2Dk mediated clonal deletion
of these cells during negative selection (Belz et al., 2000).
The influence of the naive TCR repertoire in moulding immunodominance has been
most strikingly demonstrated in experimental models where the immunodominant
antigen-specific repertoire is restricted to T-cells bearing specific VP genes. For
example, the immunodominant epitope ofHLA-CW3 recognised by CD8+ T-cells in
DBA/2 mice is CW3170-179, and the responding T-cells almost exclusively use a
specific allele of VplO (MacDonald et al., 1993). In DBA/2 mice that express an
alternative VplO allele, an immune response against HLA-CW3 is still generated but
the CW3]7o-i79 epitope is no longer immunodominant (Bour et al., 1999). Similar
changes in immunodominance hierarchies have been observed in other systems
where the naive TCR repertoire is manipulated by alteration of VP gene expression
(Connolly, 1994; Daly etal., 1995).
The frequency ofmemory T-cells has an equivalent influence on immunodominance
hierarchies. Expansion of the memory CD8+ T-cell pool for subdominant antigens
either by antigen-specific vaccination or previous infection with a pathogen sharing a
cross-reactive epitope can cause them to assume immunodominance (Brehm et al.,
2002; Rodriguez et al., 2002) and in the experimental influenza A model of
immunodominance in H2Db mice, memory CD8+ T-cell frequency plays a crucial
role in the assumption of immunodominance by the DhPA224 epitope in secondary
immune responses (La Grata et al., 2006).
1.3.2.4 Competition between CTLs for APCs
Enhancement of the response against subdominant epitopes in the absence of
immunodominant epitopes suggests that the T-cell responses against
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immunodominant epitopes are capable of inhibiting that against subdominant
epitopes (Chen et al., 2000; Deng et al., 1997). Demonstration in a variety of
experimental systems that the immunodominance hierarchy could be subverted by
the presentation of immunodominant and subdominant epitopes on either an excess
of APCs (Grufman et al., 1999; Palmowski et al., 2002; Sandberg et al., 1998) or by
segregation on separate APCs (Kedl et al., 2000; Pion et al., 1999; Wolpert et al.,
1998) indicated that this inhibition was due to competition at the level of the APC/T
cell interaction.
It is known that this competition is an early event under in vivo conditions (Willis et
al., 2006) but it is still uncertain what mechanism(s) are operating. Competition for
cytokines and/or co-stimulatory factors in the APC microenvironments has been
proposed (Kedl et al., 2003; Wolpert et al., 1998; Yewdell and Del Val, 2004). In a
series of adoptive transfer experiments it was shown that high affinity CD8 : T-cells
have a competitive advantage and therefore are more effective at mediating
immunodominance (Kedl et al., 2003; Kedl et al., 2002). As with other factors
associated with mediating immunodominance, there is evidence that competition for
APC may not exert a significant affect in all experimental immunodominant models
(Kedl et al., 2003; Probst et al., 2002).
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1.4 Aims of the project
In cattle immune to T. parva, there is evidence that the CD8^ T-cell response is
prominent in mediating protection. Characteristics of this response suggest that it is
focused on a limited number of immunodominant epitopes that exhibit
polymorphism between parasite strains. Immunodominance amongst polymorphic
MHCI-restricted epitopes potentially poses a major challenge to the development of
a subunit vaccine for T. parva, which will need to elicit effective CD8+ T-cell
responses capable of recognising a wide range of parasite strains. Previous studies of
the response to T. parva were conducted in the absence of any knowledge of the
antigens that are recognised by the responding CD8' T-cells, and evidence of
immunodominance was largely inferred from observations on the strain specificity of
the responses. The recent identification of target antigens now provides an
opportunity to gain a more detailed understanding of immunodominance in the
T.parva system. This information will contribute significantly to the rational design
of a T. parva subunit vaccine.
In other systems, epitope-specific CD8+ T-cells responses characterised by diversity
in clonal composition and TCR repertoire have been correlated with more effective
pathogen control due to increased efficiency and expression of multiple 'fine
specificities' permitting recognition of epitope variants. Therefore, characterisation
of these two features of epitope-specific CD8+ T-cell responses to potential T. parva
subunit vaccine candidate antigens is of particular interest.
The principal aims of this study were to; (i) quantify the CD8" T-cell response to
defined MHCI-restricted epitopes and thereby identify immunodominant epitopes
that could be candidates for inclusion in a subunit vaccine and (ii) determine the
clonal composition and TCRfl repertoire expression of the CD8+ T-cell responses to
these epitopes.
In order to address these aims, it was necessary to first develop molecular tools for
analyses of bovine TCRp gene expression. (Chapter 3). The second objective was to
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determine the proportion of the CD8+ T-cell responses of immunised animals that
were specific for defined epitopes and so provide quantitative data on their relative
immunodominance on defined MHC backgrounds (Chapter 6). The third objective
was to determine, by the application of the TCR tools developed, the clonal
composition and TCRp chain repertoire expressed by the responding epitope-specific
CD8+ T-cells (Chapter 6).
As a consequence of the TCRp chain sequencing completed in the course of this
work, the known bovine TCRP gene repertoire was substantially expanded by the
identification of new genes (Chapter 4). The development of this work also coincided
with the generation of bovine genome sequence data. Further examination of the
TCRp gene repertoire by exploration of the incomplete bovine genome revealed an
extensive expansion and permitted a partial annotation of the bovine TCRB locus
(Chapter 5).
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2 Chapter 2 - Materials and methods
2.1 Experimental animals
Animals used in this study were Friesian-Holsteins bred at the Institute for Animal
Health (IAH), Compton from parents with serologically defined MHCI phenotypes
(Davies et al., 1994). MHC phenotypes of animals 468, 592, 605, 641 and 1011 had
been determined using a panel of MHCI-specific mono-clonal antibodies (Ellis et al.,
1999); 592 and 1011 were homozygous for the A10 MHCI haplotype, 468 and 641
were homozygous for the A18 MHCI haplotype and 605 was homozygous for the
A14 MHCI haplotype.
2.2 Experimental immunization and challenge
The animals used for experimental immunizations were assumed to be naive as the
parasite does not occur in the UK. Immunization was achieved by the infection and
treatment protocol as described by Radley et al. (1975a). Briefly, animals were
infected by subcutaneous administration on the left side of the neck with a lethal
dose of cryopreserved Centre for Tropical Veterinary Medicine (CTVM), Theileria
parva (Muguga) sporozoite stabilate 71, prepared according to the method described
by Cunningham et al. (1973). Concurrently 20 mg/kg of long-acting oxytetracycline
(Terramycin LA, Pfizer, Sandwich, Kent, UK) was administered by deep intra¬
muscular injection into the gluteal muscles.
In challenge infections, a lethal dose ofCTVM Theileria parva (Muguga) sporozoite
stabilate 71 was administered, as described above (without concurrent
oxytetracycline treatment) to animals previously immunised using this stabilate.
The courses of infections were monitored by rectal temperature and assessment of
the size of the local draining (i.e. left pre-scapular) lymph node.
44
2.3 Cellular techniques
2.3.1 Isolation of peripheral blood mononuclear cells (PBMC)
Blood was obtained by jugular venupuncture and collected into an equal volume of
Alsever's solution (Appendix C.l) which served as an anti-coagulant and diluent.
PBMC were isolated as described in Goddeeris and Morrison (1988). Aliquots of 30
ml of the blood/Alsever's solution mixture were carefully overlaid onto 20 ml of
Ficoll-Paque Plus (Amersham Biosciences, Chalford St. Giles, Beds., UK) in 50 ml
polypropylene tubes and centrifuged at 900 x g for 30 min at room temperature.
PBMC were harvested from the Ficoll-Paque Plus/serum interface and mixed with an
equal volume of Alsever's solution before pelleting for 10 min at 450 x g at room
temperature. The pellet was washed three times in Alsever's solution, counted and
re-suspended in a suitable volume of the appropriate medium, according to intended
subsequent use.
2.3.1.1 Red blood cell (RBC) lysis
If necessary, RBCs contaminating the PBMC were lysed prior to the second wash by
re-suspending the pellet in 3 ml ofRBC lysis buffer (Appendix C.2) pre-heated to
37°C, and then incubating at 37°C for 1 min.
2.3.2 Antibody-directed, complement-mediated lysis
Cells were re-suspended in standard culture medium (SCM - Appendix C.3) at a final
concentration of 1 x 107 cells/ml, with 1 ml each of ILA-12 and CC15 hybridoma
culture supernatants (section 2.3.2.1) per 5 x 107 cells, and incubated on ice for 30
min. Cells were pelleted by centrifugation at 180 x g for 10 min at 4°C and washed
twice in SCM.
Cells were subsequently re-suspended in SCM at 5 x 106 cells/ml, rabbit serum
(section 2.3.2.2) added at a ratio of 1 in 5 and the mixture incubated at 37°C for 40
min to allow complement lysis to occur. The cells were pelleted and washed twice in
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SCM, re-suspended in 30 ml SCM, layered over 20 ml Ficoll-paque Plus in a 50 ml
polypropylene tube, and then centrifuged at 900 x g for 20 min at room temperature.
Live, unlysed cells were collected from the Ficoll/SCM interface, mixed with an
equal volume of SCM and pelleted at 450 x g for 10 min at room temperature. The
effectiveness of the lysis was assessed by FACS analysis of the remaining live cell
population (section 2.3.7).
2.3.2.1 Hybridoma lines
ILA-12 and CC15 (Table 2.1) hybridomas were cultured in SCM at 37°C in a
humidified atmosphere of 5% CCL until exhausted and the supernatant then
harvested. Titration experiments were completed to establish appropriate
concentrations for their use (data not shown). The results indicated that a dilution of
1:5 - 1:10 was suitable for both supernatants.
2.3.2.2 Rabbit serum
Rabbit blood was collected by intra-cardiac puncture immediately post-mortem into
plain 50 ml polypropylene tubes. The blood was allowed to clot at room temperature
for 3 h and then stored at 4°C overnight. Following fragmentation of the clot, the
blood was spun at 450 x g for 10 min and the serum harvested. Titration experiments
were completed to establish the appropriate concentration for serum use as a source
of complement (data not shown). The results indicated that a dilution of 1:5 was
suitable.
2.3.3 \n-vitro generation of T. parva-specific CD8+ T-cell enriched
cell-lines
The protocol for generation of Theileria parva-specific CD8+ T-cell enriched cell-
lines by in-vitro stimulation was adapted from that described by Goddeeris and
Morrison (1988).
46
First stimulation - PBMC were isolated and counted as described above (section
2.3.1). Autologous T. parva (Muguga) infected cells (stimulators - section 2.3.5)
were harvested, counted and exposed to 50Gy of gamma irradiation from a
137Caesium source for 20 min. Into each well of 24-well plates were placed 2 ml of
SCM containing 2 x 106 PBMC/ml and 1 x 105/ml irradiated autologous stimulators.
Plates were incubated for 7 days in a humidified atmosphere of 5% CCE at 37"C.
Second stimulation - Cells from the first stimulation were harvested, counted and re-
seeded into 24-well plates in 2 ml of SCM at a density of 2 x 106/ml together with
irradiated autologous stimulators at 1 x 105/ml. Plates were incubated for 7 days in a
humidified atmosphere of 5% CCE at 37°C.
Third stimulation - Cells from the second stimulation were harvested, counted and
the CD4' and WCl+yS T-cell populations lysed as described above (section 2.3.2).
The remaining cells were re-seeded into 24-well plates in 2 ml of SCM at a density
of 1 x 103/ml together with irradiated autologous stimulators at a density of 2 x
105/ml, irradiated autologous PBMC (fillers - irradiation as for stimulators) at a
density of 2 x 106/ml and lOOU/ml recombinant human IL-2 (Chiron Corporation,
Emeryville, CA.,USA), and incubated for 7 days in a humidified atmosphere of 5%
C02 at 37°C.
2.3.4 Cloning of T. parva-specific CD8+ T-cells
Cell lines from third stimulations were harvested and assessed for CD8+ purity by
FACS (section 2.3.7). If there was significant contamination (>10%) of the CDS '
population with either WC1+ yS T-cells and/or CD4 * T-cells, the cells were subject to
another round of antibody-directed, complement-mediated lysis (section 2.3.2), until
>90% of the population were CD8+. Cells from the third stimulation were then
counted and serially diluted in SCM to give a concentration of 40, 20, 10, 5, and 2.5
cells/ml. Aliquots of lOOpl of these suspensions were distributed into the wells of 96-
well plates to give plates containing 4-0.25 cells/well. To each well was added a 100
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pi aliquot of SCM containing 5 x 104/ml irradiated autologous stimulators, 2 x
105/ml irradiated autologous fdlers and 200U/ml of recombinant human IL-2. Plates
were incubated for 2 weeks in a humidified atmosphere of 5% CCb at 37°C. After 2
weeks plates were visually screened and wells displaying obvious growth were
selected for further expansion. Only wells from plates showing growth in <30% of
wells were selected, as they have greater than 83% probability of being truly clonal
(Henry et al, 1980).
2.3.4.1 Expansion of clones
Selected clones were transferred to individual wells in 48-well plates. To each well
was added 1ml of SCM containing 5 x 105/ml irradiated autologous stimulators, 5 x
105/ml irradiated autologous fdlers and lOOU/ml of recombinant human IL-2. Plates
were incubated in a humidified atmosphere of 5% CO? at 37"C, and clones re-
stimulated every two weeks as required.
2.3.5 Generation and maintenance of T. parva-infected cell lines
Theileria parva (Muguga) transformed (TpM) cell lines were established in vitro
from PBMC of animals 468, 641, 1011 and 592 as described in Goddeeris and
Morrison (1988). In brief, 2 xlO7 PBMC were isolated (as described in section 2.3.1),
pelleted by centrifugation at 200 x g for 5 min, re-suspended in 0.5 ml of CTVM
Theileria parva (Muguga) sporozoite stabilate 80 suspension and incubated in a
humidified atmosphere of 5% CO? at 37°C for 1.5 h with gentle mixing every 15
minutes. The cells were then washed once in 10 ml SCM, re-suspended in 10 ml of
SCM, divided into two culture flasks, incubated in a humidified atmosphere of 5%
CO2 at 37°C and visually monitored for transformation of lymphoid cells.
Once established TpM cell lines were kept incubated in a humidified atmosphere of
5% CO? at 37°C and maintained in log growth by removal of three-quarters of the
cultured cell suspensions and replacement of this volume with SCM every 2/3 days.
The phenotype of the TpM cell lines established were determined by fluorescence-
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activated cell sorting (FACS) analysis using a panel of mAb specific for CD4, CD8,
y8 T-cells, CD3 and IgM as described below (section 2.3.7). 468TpM, 641TpM and
101 lTpM had phenotypes consistent with CD4+ aP T-cells whilst the phenotype of
592TpM was that of a B-cell.
2.3.6 Cryopreservation of cellular material
Cells to be cryopreserved were pelleted, re-suspended at 2 x 106 cells/ml in 90%
heat-inactivated Foetal bovine serum (FBS)/10% dimethylsulphoxide (DMSO;
Sigma, Poole, Dorset, UK) and 1ml aliquots transferred into polypropylene cryovials
(CryoTube, Nunc, Roskilde, Denmark). These vials were placed into an isopropanol
jacketed container (Cryo 1°C Freezing Container, Nalgene, Neerijse, Belgium) and
slowly frozen at -70°C before being transferred to liquid nitrogen storage. Upon use,
cryopreserved material was rapidly thawed by incubation in a water bath at 37 °C.
2.3.7 Fluorescence-activated cell sorting (FACS) analysis
The monoclonal antibodies (mAbs) used for primary labelling in FACS analysis are
listed in Table 2.1. mAbs derived from culture supernatants were used at a dilution of
1:5 in FACS media (Appendix C.4), while those derived from ascitic fluid were used
diluted 1:1,000 in FACS medium.
Aliquots of 50 pi of 2 x 107 cells/ml suspensions were distributed in wells of 96-well
round-bottom well plates and 50 pi of the required primary labelling mAbs added.
Plates were incubated at 4°C for 30 min, washed three times in FACS medium and
then re-suspended in 50 pi of fluorescein-isothiocyanate (FITC) labelled goat
polyvalent anti-mouse immunoglobulin G,A,M antibody (Sigma-Aldrich, Poole,
Dorest, UK). Following incubation at 4°C for 30 min, the cells were washed three
times in FACS medium and then re-suspended in 200 pi FACS medium for analysis
using a FACScan fluorescence activated cell sorter (Beckton Dickinson, Mountain
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View, CA., USA.). Negative controls were incubated with FACS medium instead of
primary labelling antibody.
Anitbody Isotype Specificty Cell distribution
IL-A12" IgG2a CD4 CD4+ T-cells
IL-A105 lgG2a CD8 CD8+ T-cells, NK-T cells
IL-A51b IgGl CD8a chain CD8+ T-cells, NK-T cells
CC15C lgG2a WC1 Peripheral y8 T-Cells
GB21 Ad lgG2b y8 TCR All y8 T-cells
ILA-24C IgGl MyD-1 Monocytes/Macrophages/Dendritic cells
ILA-30f IgGl IgM B-cells
MM1 A8 IgGl CD3 T-cells
NKp46-AKSl' IgGl NKp46 NK-like cells
Table 2.1 Monoclonal antibodies used for primary labelling in FACS analysis. References
defining the specificity of mAbs: Bensaid and Hadam (1991)a, MacHugh and Sopp (1991)l>,
Morrison and Davis (1991)c, Davis et al (1996)'1, Ellis et al (1988)c, Naessens et al (1988), Davis et
al (1993)8, Davis and Splitter (1991)h, Storset et al (2004)'.
2.3.8 Cytotoxicity Assays
51Chromium (5lCr) and 11'indium ('"in) 4h-release assays were performed
essentially as described by Goddeeris and Morrison (1988).
2.3.8.1 Peptide loading of target cells
Theileria annulata-infected cell lines (TA) 592TA and 641TA were used as 'null'
target cells presenting MHCI AlO-restricted and MHCI A18-restricted epitopes from
T. parva (Muguga) respectively. Peptide for the A18-restricted epitope Tpl.l
(VGYPKVKEEML) was kindly provided by Dr. E. Taracha (ILRI, Nairobi, Kenya)
and peptides for the AlO-restricted epitopes Tp2.1 (QSLVCVLMK) and Tp2.2
(KSSHGMGKVGK) were produced by Pepscan Systems (Lelystad, Netherlands).
Immediately before labelling with radioactive isotope, target cells were re-suspended
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at 2 x 106 in cytotoxicity medium (Appendix C.5) and incubated for 15-30 min with
1 pg/ml peptide.
2.3.8.2 Radioactive labelling of target cells
5lCr and '"in (GE Healthcare Ltd., Little Chalfont, Bucks, UK) were used as the
labelling isotopes depending on their availability and the number of effector cells
available. Labelling of T. parwz-infected cells with 5lCr and 1 "in normally results in
the incorporation of 0.1-0.4 and 2-6 cpm/cell respectively (Goddeeris and Morrison,
1988). Thus, approximately 10 times fewer '' 'in-labelled target cells than MCr-
labelled target cells are needed for cytotoxicity assays and there is an equivalent
reduction in the number of effector cells required.
Target cells were re-suspended at 2 x 107 cells/ml in cytotoxicity medium. For
labelling with 3lCr, 0.1 ml of the cell suspension (i.e. 2 x 106 cells) was incubated
with 100 pCi of 5lCr for 1 h at 38°C in a 15 ml polypropylene tube; the cells were
then washed three times in 10 ml of cytotoxicity medium before being re-suspended
in 2 ml of cytotoxicity medium (i.e. 1 x 106 cells/ml). For labelling with " 'in, 50 pi
of the cell suspension (i.e. 1 x 106 cells) was incubated with 5pCi of "'in for 15 min
at 38°C in a 15 ml polypropylene tube; the cells were then washed six times in 10 ml
of cytotoxicity medium before being re-suspended in 10 ml of cytotoxicity medium
(i.e. 1 x 103 cells/ml).
2.3.8.3 51Cr and 111ln 4-h release cytotoxicity assays
CD8+ T-cell enriched cell-lines were re-suspended in cytotoxicity medium at a
concentration of 1 x 107 for5'Cr or 1 x 106 for 1" In 4 h-release assays. In duplicate,
200 pl/well of two-fold dilutions of the cell-lines were distributed into either 96-well,
flat bottom culture plates (for 3lCr release assays) or 96-well V-bottomed culture
plates (for 11 'in release assays) resulting in a range of effector cell concentration of
200 x 104 to 6.25 x 104 cell/well for 3lCr release assays and 200 x 103 to 6.25 x 103
cell/well for "'in release assays. Aliquots of 100 pi of un-quantified CD8+ T-cell
clone suspensions were used in " 'in release assays for clones derived from the cell-
lines; these assays were completed unduplicated in 96-well V-bottomed culture
plates.
To each well containing effector cells (CD8+ T-cell-enriched cell-lines or clones) 50
pi of target cell suspension (i.e. 5 x 104 5lCr or 5 x 103 1 "in labelled cells) were
added. In the CD8" T-cell-enriched cell-line assays this resulted in effector to target
cell ratios of 40:1 to 1.25:1.
In triplicate, 50 pi of target cell suspension was added to wells containing (i)
cytotoxicity medium - to allow measurement of the spontaneous release of isotope
label and (ii) 0.2% (v/v in water) Tween 20 (Sigma, Poole, Dorset, UK) - to measure
maximal release of the isotope label. In cytotoxicity assays for the CD8 T-cell-
enriched cell-lines 200 pi of cytotoxicity medium/0.2% Tween 20 was used whereas
in the CD8+ T-cell clone assays 100 pi was used.
Plates were centrifuge for 1 min at 180 x g and then incubated for 4 h at 38°C in a
humidified atmosphere of 5% CO2. Following incubation the plates were again
centrifuged for 1 min at 180 x g and then half of the volume of the supernatant
(carefully avoiding aspiration of any of the pelleted cells) from each well (125pl for
assays with CD8+ T-cell enriched cell-lines and 75pl for assays with CD8" T-cell
clones) was transferred to a sample vial and the gamma emissions measured over a
period of 1 min in a Wallac Wizard 1470 Automatic Gamma Counter (PerkinElmer,
Beaconsfield, Bucks., UK).For each sample the percentage cytotoxicity was
calculated as:
Cytotoxicity (%) = sample release - spontaneous release
maximal release - spontaneous release
For measurements taken in duplicate/triplicate the arithmetic mean average
cytotoxicity was calculated. Based on experience within the laboratory, an arbitrary
parameter of >10% cytotoxicity was used to define significant cytotoxic activity.
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2.4 Molecular Techniques
2.4.1 Isolation of RNA
Total RNA was extracted from cell pellets using Tri-Reagent (Sigma-Aldrich, Poole,
Dorset, UK) according to the manufacturer's instructions. Cells were re-suspended in
approximately 100 pi of PBS (Appendix C.6) and then lysed in Tri-reagent (1 ml per
5 -10 x 106 cells) by repeated pipetting. The homogenate was incubated for 5 min at
room temperature to allow complete dissociation of nuclear-protein complexes.
Chloroform was then added to the homogenate (0.2 ml chloroform per 1 ml of Tri-
reagent) and the mixture was vortexed vigorously for 15 s, allowed to stand at room
temperature for 2-15 min and then centrifuged at 12,000 x g for 15 min at 4°C. The
aqueous phase was transferred to a fresh eppendorf, mixed with isopropanol (0.5 ml
per 1 ml Tri-reagent), incubated for 5-10 min at room temperature and then
centrifuged at 12,000 x g for 10 min at 4°C to precipitate the RNA. The RNA pellet
was washed twice in 1 ml of 75% ethanol, air dried and then re-suspended in 25 pi of
nuclease free water. RNA was stored at -80 °C until use.
2.4.2 Quantification of nucleic acids
Absorbance of light at 260 and 280 nm wavelengths by samples of RNA/DNA
solutions diluted in nuclease free water were measured using a GeneQuant
spectrophotometer (Biochrom, Cambridge, UK). The concentration and quality of
RNA and DNA solutions was estimated based on the assumptions that (i) RNA and
DNA have an absorbance reading of 1.0 at 260 nm at concentrations of 40 pg/ml and
50 pg/ml respectively and (ii) optimal quality RNA/DNA solutions have a
260nm:280nm reading ratio >1.8 (Sambrook et al., 1989).
2.4.3 Reverse transcription - complementary DNA (cDNA)
synthesis
First strand cDNA was synthesized from RNA using the Reverse Transcription
System (Promega, Madison, WI, USA). The manufacturers protocol for priming with
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Oligo(dT)15 primer was followed with the exception of allowing 1 h instead of 15
min for 42°C incubation. Briefly, lpg (or multiples thereof) of RNA was incubated at
70°C for 10 min, micro-centrifuged briefly and place on ice until added to the
reaction mixture which consisted of 4 pi MgCB (25mM), 2 pi lOx Reverse
Transcription Buffer, 2 pi dNTP mixture (lOmM), 0.5 pi Recombinant RNAsin
Ribonuclease Inhibitor, 15u avian myeloblastoma virus reverse transcriptase (AMV-
RT), 0.5 pg Ohgo(dT)i5 primer and nuclease free water added to give a final volume
of 20 pi. The reaction mixture was incubated at 42°C for 1 h, then incubated at 95°C
for 5 min and at 0 °C for 5 min to inactivate the AMV-RT and stop it binding to the
cDNA. cDNA was stored at -20°C until use.
2.4.4 Polymerase chain reaction (PCR)
2.4.4.1 Design and synthesis of primers
All primers used (excluding BCON-4, previously designed by Dr. G. Russell and Dr.
N. MacHugh) were manually designed during the course of this work. All primers
were synthesized by MWG Biotech (Ebersberg, Germany).
(a) Bovine TCRfVfVfj subfamily-specific 5'primers
The sequences of the final panel of external (VBext) and internal (VBint) Vp
subfamily-specific primers designed are shown in Table 2.2. Sequences of VP
subfamily-specific primers that were designed but subsequently rejected are not
shown, but are available on request. The number succeeding the (*) denotes the
version of the primers adopted for the final panel - from herein, except for where
specified, VP subfamily-specific primers are described without reference to the
version being used and refer to the primers presented in Table 2.2.
(b) Bovine 'Pan- Vfl' primer
A highly degenerate 'Pan-VP' 5'primer was designed as described in section 3.3.3.










VB1 *lext TCCCCTGA(AGC)TCTGGA CAC VBl*lint GGTACCAACAGGCCCTGG
VB2*lext CTCTCGTCTCTCAGCAGC VB2*lint GATGCCACATACGAACAAGG
VB3*3ext CGTGATAGAGTGCATACAGAAC
A
VB3*lint GAT GCT GGC ACG GTT GAG




VB7*2ext CTCAGATACCAAAATACCTAGTC VB7*lint CCAGAGCTCATGTTCATCCAC








VB13*lext CACTCAGGACCCCAGATT VB13*lint ACCTGGGACACGGGCTGAG
VB14*2ext AGGCCCCCTGGA(AT)GCCGAT VB14*lint CCAAGACACCGCATCACAGA
G






VB17A*lext CCCA(CT)GGATGCTGAAATCTA VB17A*3int CTGGGCTACAGTGCCATG
VB17B*lext CCTGCTCAAAAAGGAAGG VB17B*lint CTCTCGTGAAAAGAAGCCTTT
C
VB20*lext GAACTCAGACCATCCATCAGT VB20*lint TCCAGAACTTCAAAGCTTCCA
GG
VB24*3ext CCCAAGATACCTGGTTACCG VB24*lint GAAGCCAAGCCAAGCACC
VB28*2ext GCGCAGGATCTTGGAGACTGA VB28*lint CGCCAAGATCCGGGATTTG
Table 2.2 The final panel of bovine VP subfamily-specific primers.
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(c) Bovine TCRfiC (C/3) specific 3 'primers
In all, 5 different CP-specific 3' primers were used in this study: BCext and BCint
were used in combination with VP subfamily-specific primers; PVBrevl and
PVBrev2 were used in combination with the 'Pan-VP' primer; and BCON-4 was
used in sequencing reactions. The primers were designed using publicly available
bovine TCRpC sequence data (GenBank accession numbers D90139 and D90140 -
Appendix B), their sequences are detailed in Table 2.3, and their annealing sites to
the TCRpC gene are shown in Appendix D.
Primer Sequence
BCint GGT CAG CTC CAC GTG GTC
BCext CGT GAC CTG CTT GTT CAC
BCON-4 CTC TGC TTC CGA GGG TTC
PVBrevl CAC GTG GTC (AG)GG GTA GAA
PVBrev2 GTG ACC TGC TTC CTG TTC
Table 2.3 The bovine Cp-specific primers.
2.4.4.2 General PCR protocols
All PCR reactions described below and in other sections of this thesis were
completed in PTC-100 thermal cyclers (MJR Inc., Watertown, Mass, USA).
(a) V/3 subfamily-specific semi-nested PCR
Eighteen PCR reactions, one for each VP subfamily, were completed for each cDNA
template. Each first round reaction used 10 pmol each of BCint (Table 2.3) and the
relevant VBext primer (Table 2.2), 0.5 unit BIOTAQ (5units/pl Bioline, London,
UK), 2 pi SM-0005 buffer (ABgene, Epsom, Surrey, UK - Appendix C.7), lpl
cDNA diluted 1:5-1:20 in DDW, and nuclease free water to give a final volume of 20
pi. The first round programme was as follows: 94"C for 3 min, 5 cycles of (94°C for
40 s, 60°C for 1 min, 72°C for 30 s), 5 cycles of (94°C for 20 s, 60°C for 1 min, 72°C
for 30 s) and a final extension period of 72°C for 3 min.
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Each second round reaction used the same components as the first round reaction
except that 1 pi of the first round product rather than cDNA was used as template and
the VBext primers were replaced with the corresponding VBint primers (Table 2.2).
The second round programme was as follows: 94°C for 3 min, 25 cycles of (94°C for
15 s, 60°C for 1 min, 72°C for 30 s) and a final extension period of 72°C for 3 min.
(b) Pan- Vft semi-nested PCR
First round reactions were composed of 200 pmol of the 'Pan-VP' primer (section
2.4.4.1), 10 pmol of PVBrev2 (Table 2.3), 0.5 unit BIOTAQ (5units/pl Bioline,
London, UK), 2 pi SM-0005 buffer (ABgene, Epsom, Surrey, UK - Appendix C.7),
1 pi 1:10 diluted cDNA in DDW, and nuclease free water to give a final volume of 20
pi. Second round reactions had the same constituents but used lpl of the first round
product instead of 1:10 diluted cDNA as template and used PVBrevl (Table 2.3)
instead of PVBrev2 as the 3'primer. The programme for both rounds of amplification
was as follows: 94°C for 3 min, 5 cycles of (94°C for 1 min, 57°C for 1 min, 72°C for
1 min), 25 cycles of (94°C for 30 s, 60°C for 1 min, 72°C for 1 min) and a final
extension period of 72°C for 10 min.
2.4.5 Agarose gel electrophoresis
PCR products/RE digestion products were analysed by agarose gel electrophoresis
using either a midi-gel system (Flowgen, Ashby de la Zouch, Leics., UK) or a large
gel system (Owl Separation Systems, Portsmouth, NH, USA). 10 pi aliquots of
PCR/RE digestion product were mixed with 2pl of 1 in 6 loading buffer (Appendix
C.8) and loaded into a 1.5% agarose gel (Bioline, London, UK), prepared with 1 x
TAE (Appendix C.9). Electophoresis was carried out at 120 V for 40 min in the
midi-gel system or 200 V for 1 h with the large gel system, using 1 x TAE as running
buffer. 1 pg of 1 Kb Plus DNA Ladder (Invitrogen Ltd., Paisley, UK) was used to
enable estimation of product sizes.
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Following electrophoresis gels were stained in a bath of Ethidium Bromide (0.5
pg/ml) in 1 x TAE for 30 min before visualisation and storage of gel image with the
Gel Doc 2000 system (Biorad, Hercules, CA, USA).
2.4.6 Purification of PCR products
The Wizard PCR Preps DNA Purification System (Promega, Madison, WI, USA)
was used for the direct purification of PCR products, according to the manufacturer's
instructions. Briefly, 30-300 pi of PCR reaction was added to 100 pi of Direct
Purification Buffer and vortexed briefly before addition of 1 ml DNA resin and three
further brief vortexes over a 1 min period. The DNA/resin mixture was passed
though a mini-column and the DNA/resin attached to the mini-column membrane
washed with 80% isopropanol. Following two centrifugations at 10,000 x g for 2 min
(to dry the resin), 40 pi of nuclease free water was applied to the mini-column, the
mini-column incubated at room temperature for 1 min before elution of the purified
DNA by centrifugation at 10,000 x g for 20 s. DNA not used immediately was store
at-20°C.
2.4.7 Generation of plasmid sub-clones
Purified PCR products were cloned into pGEM-T Easy vector system (Promega,
Madison, WI, USA) according to the manufacturer's guidelines. Ligation reactions
contained 5 pi 2x Rapid ligation Buffer, 1 pi pGEM-T Easy Vector, 25 ng PCR
product, 1 pi T4 DNA Ligase (3 weiss units/pl) and nuclease free water to give a
final volume of 10 pi and were incubated overnight at 4°C. The following day ligated
plasmids/PCR product were transformed into High Efficiency Competent JM109
cells (Promega, Madison, WI, USA). Briefly, 50 pi of JM109 (>108cfu/pg DNA)
were thawed on ice, added to 2 pi of ligation reaction and then incubated on ice for
20 min before heat-shocking for 45-50 s at exactly 42°C and immediately returning
to ice for 2 min. 950 pi of SOC medium (Appendix C.10) at room temperature was
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added and the cells then incubated for 1.5 h in a rotary shaking incubator at 37°C and
150 rpm. 100 pi of transformation reaction was plated onto duplicate Luria-Bertani
(LB)/ampicillin/IPTG/XGal plates (Appendix C.l 1) and incubated overnight at 37°C.
The following day transformed colonies were identified by blue/white screening.
2.4.7.1 Verifying presence of PCR product inserts in plasmid sub¬
clones
(a) Method A - PCR verification ofpresence of insert
Selected colonies were picked using a fine pipette tip, streaked onto gridded LB agar
plates containing lOOpg/ml ampicillin (Appendix C. 11) and incubated for 6
h/overnight at 37°C. Quantities of expanded colonies were harvested, added to lOpl
of nuclease free water and denatured by heating at 95 °C for 5 min. Following
centrifugation at 13,000 x g for 5 min (to sediment the cellular debris), the aqueous
phase (containing plasmid DNA) could be subjected to appropriate PCR
amplification and the product analysed by electrophoresis as described above
(section 2.4.4-2.4.5).
(b) Method B - Restriction Endonuclease (RE) verification ofpresence of insert
Selected plasmid sub-clones were expanded and DNA prepared as described in
sections 2.4.7.2 and 2.4.7.3 below. RE reaction mixtures containing 5 pi of plasmid
DNA, 20 units EcoRl (1 pi of 20,000 units/ml - New England Biolabs, Hitchin,
Herts., UK), 1 pi lOx Eco R1 buffer (England Biolabs, Hitchin, Herts., UK), and 3 pi
nuclease free water were incubated at 37°C for 1 h and the products of the RE
digestion subsequently analysed by electrophoresis as described in section 2.4.5.
Presence of a RE product of the anticipated size indicated successful insertion of
PCR product into the pGEM-T Easy vector which has EcoRl cutting sites flanking
the insertion site.
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2.4.7.2 Expansion and preparation of frozen stocks of plasmid sub¬
clones
Selected sub-clones were picked using a fine pipette tip and inoculated into 6 ml of
LB media containing ampicillin at 100 pg/ml (Appendix C. 12) in a sterile 30 ml
flask and incubated overnight in a rotary shaking incubator at 37°C and 220 rpm.
Aliquots of 750 pi of cultures were mixed with 750 pi of a 50:50 mix of LB media
and glycerol (Sigma, Poole, Dorset, UK) and stored at -70°C.
2.4.7.3 Plasmid DNA Preparation - ('Mini-preps')
(a) Method A - Alkali Lysis Method adapted from Sambrook et al (1989)
Cultures of plasmid transformed bacteria were prepared as detailed above (section
2.4.7.2). Cells from 1.5 ml of culture were pelleted by centrifugation at 10,000 x g
for 5 min, re-suspended in 150 pi of Re-suspension Buffer (Appendix C.13a) and
then lysed in 150 pi of Lysis Buffer (Appendix C.13b). Following addition of 150 pi
ofNeutralizing Buffer (Appendix C.13c) cellular debris was pelleted by centrifuging
at 15,000 x g for 30 min. The supernatant was carefully collected (to avoid
disturbance of the cellular debris), transferred to a fresh eppendorf and centrifuged at
15,000 x g for 15 min at 4°C to pellet out any contaminating cellular debris.
Supernatant was again transferred to a fresh eppendorf, mixed with 1 ml of 100%
ethanol and incubated at -20°C for 20 min. DNA was pelleted by centrifuging at
13,000 x g for 30 min at room temperature, washed once in 450 pi of 70% ethanol,
air-dried, re-suspended in 30 pi of nuclease free water and stored at -20°C until used.
(b) Method B - WizardMini-preps DNA Purification System
The Wizard Mini-preps DNA Purification System (Promega, Madison, WI, USA) is
a modified form of the alkali-lysis method, using mini-columns rather than ethanol
precipitation to isolate DNA, and was used according to manufacturer's instructions.
Cells from 1.5 ml of plasmid transformed bacterial culture were pelleted (as
described in Method A), re-suspended in 200 pi of Cell Re-suspension Solution and
then lysed in 200 pi of Cell Lysis Solution. Following addition of 200 pi of
Neutralisation Solution, cellular debris was pelleted by centrifuging at 13,000 x g for
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5 min, and the supernatant mixed with 1 ml of DNA resin before being passed
through a mini-column. After washing the column with 2 ml of Column Wash
Solution, the mini-column was centrifuged at 10,000 x g for 2 min to dry the
DNA/resin on the mini-column membrane. 30-50 pi of nuclease free water was
added to the mini-column, and following 1 min incubation at room temperature, the
mini-column was centrifuged for 20 s at 10,000 x g. Eluted DNA was collected and
stored at -20°C until used.
2.4.8 TCRp chain CDR3 heteroduplex analysis (CDR3P-HDA)
2.4.8.1 Principle of the technique
The bovine CDR3|3-HDA method developed in this study is based on that described
for humans in Bernardin et al. (2003) and is represented schematically in Figure 2.1.
Aliquots of cDNA from a sample T-cell population are PCR amplified using
5'primers specific for each VP subfamily in concert with the Cp-specific 3'primer
BCext (thus amplifying across the CDR3P region). Mono-clonal DNA 'probes' for
each subfamily are generated by PCR amplification of a representative plasmid sub¬
clone using the same VP subfamily-specific primers in concert with BCext which is
5'end labelled with the fluorophore 6-carboxy-fluorescein (FAM). The PCR products
from the sample T-cell population are mixed with an excess of the labelled probe
from the same VP-subfamily, the mixture denatured by heating to 95°C (to separate
DNA strands) and then cooled to permit re-annealing. For each subfamily,
complementarity between the CP (5'extremity) and VP (3' extremity) regions
facilitates the formation ofDNA heteroduplices between strands of the 'probe' and
the sample T-cell population amplicons.
The mixtures are then subjected to non-denaturing polyacrylamide gel
electrophoresis (ND-PAGE). The differences between the CDR3P sequences of the
'probes' and the TCRp chains present in the sample T-cell population result in
'bulges' in the heteroduplices that retard their electrophoretic migration during ND-
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Figure 2.1 Schematic representation of the CDR3P-HDA technique. (A) Aliquots of cDNA from
a sample T-cell population are PCR amplified by 5'primers specific for each Vp-subfamily in
concert with the Cp-specific 3'primer BC-ext. (B) IVIono-clonal DNA 'probes' for each
subfamily are generated by PCR amplification of a representative plasmid sub-clone using the
same VP subfamily-specific primers in concert with BCext which is 5'end labelled with the
fluorophore FAM (blue star).(C) The PCR products from the sample T-cell population are
mixed with an excess of the labelled 'probe' from the same Vp subfamily, denatured and then
re-annealed. (D) The re-annealed mixtures undergo ND-PAGE and are visualized by
fluoresence emission. Expanded T-cell clones are represented by distinct bands against the
background of a polyclonal smear. Homoduplices of the labelled probe are identified as large
bands at the bottom of the gel, whilst single strands of labelled probe DNA may be seen as bands
at the top of the gel.
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PAGE. As the heteroduplices formed between the 'probe' and the different CDR3(3
variants in the sample T-cell population will have different structures, the degree of
this retardation will vary for the different heteroduplices. Consequently, when the gel
is visualised clonal expansions present in the sampled T-cell population appear as
distinct bands against the background of a polyclonal smear. Fluorophore labelling of
only the reverse strand of the 'probes' results in each clonal expansion being
represent as a single band on visualisation by fluorescence emission. Homoduplices
of the 'probe' DNA are identified as large bands that run furthest during
electrophoresis, whilst single strands of FAM labelled 'probe' DNA may be seen as
bands that have migrated very slowly through the gel.
2.4.8.2 Protocol
In eighteen separate reactions, aliquots of cDNA from sample T-cell populations
were amplified with VP subfamily-specific 5'primers and the communal 3'primer
BCext. For subfamilies Vpi, 10, 14, 16 and 17a the VBint primers (Table 2.2) were
used and for all other subfamilies the VBext primers (Table 2.2) were used. Each
PCR reaction was composed of 50 pmol each of 5' and 3' primers, 5 pi cDNA, 10 pi
SM-0005 buffer (ABgene, Epsom, Surrey, UK - Appendix C.7), 0.5 unit BIOTAQ
(5units/pl Bioline, London, UK) and nuclease-free water to give a final volume of
100 pi. The PCR programme was as follows: 94°C for 3 min, 5 cycles of (94°C for 1
min, 60°C for 1 min, 72°C for 1 min), 25 cycles of (94°C for 30 s, 60°C for 1 min,
72°C for 1 min) and a final extension period of 72°C for 10 min.
To generate the FAM-labelled 'probes' for each subfamily aliquots of 25ng of DNA
from mono-clonal plasmid sub-clones 1.4, 2.2, 3.1, 4.1, 6.2, 7.2, 8.1, 9.1, 10.1, 13.1,
14.6, 15.1, 16.1, 17A.7, 17B.1, 20.4, 24.1, 28.3 (section 3.3.2) were PCR amplified
using the same primers and reaction conditions as for the sample cDNA but with
BCext primer 5'labelled with the fluorophore FAM.
A 10 pi aliquot of each sample PCR product was mixed with a 5 pi aliquot of the
appropriate Vp-matched labelled 'probe', the mixture incubated at 95°C for 5 min (to
denature DNA duplices) and then at 50°C for 15 min (to allow re-annealing). The
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mixtures were kept on ice until loading with 5pl loading buffer (Appendix C.14)
onto a 9% non-denaturing polyacrylamide gel (Appendix C.15) in a Biorad Protean®
II xi system (Biorad, Hercules, CA, USA). Gels were run at 8 mA for 16 h at 4°C
with 0.5 x TBE (Appendix C.16) as running buffer. Gels were visualised and images
stored using a Molecular Imager FX (Biorad, Hercules, CA, USA) with a 488 nm
laser and a 530 nm band pass emission filter.
For CDR3|3-HDA ofT-cell clones for which the subfamily of the V(3 gene had
already been determined only the relevant reactions were completed and the cDNA
used diluted at 1:5 as template for the PCR.
2.4.9 Sequencing
Some PCR products and plasmid inserts were sequenced at either the Moredun
Proteomics Facility (Moredun Research Institute, Edinburgh, UK) or DBS Genomics
(University of Durham, Durham, UK) following sample preparation by Wizard PCR
Preps DNA Purification System (section 2.4.6) or plasmid DNA preparation (2.4.7.3)
as appropriate.
However, the majority of sequencing reactions were completed within the laboratory
on a 96-well plate format using a BigDye ® Terminator v3.1 (Applied Biosystems,
Foster City, CA, USA) protocol adapted from that provided by Lynne Richardson at
the Sequencing Unit of the Department of Zoology, University of Oxford.
2.4.9.1 Sample preparation
To each well containing PCR reaction product 60 pi of 20% (w/v) Polyethylene
glycol (PEG) MW8000/2.5M NaCl (Appendix C.17) was added, the plate was gently
vortexed to ensuring mixing and then incubated at room temperature for 30 min.
Plates were centrifuged at 2250 x g for 1 h at 4°C to pellet DNA, and the supernatants
discarded by centrifuging the inverted plate at 500 x g for 1 min. As PEG
preferentially binds large DNA fragments centrifugation tends to pellet PCR
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products rather than residual primers or dNTPs, which are consequently removed
with the supernatants. Following two washes in 150 pi ice cold 70% ethanol, the
PCR products were air-dried and re-suspended in a volume of nuclease free water
equal to that of the initial PCR reaction. Presence of PCR products and reduction in
residual primers was checked by agarose gel electrophoresis as described in section
2.4.5.
2.4.9.2 Sequencing reaction and analysis
Sequencing reactions were composed of 2 pi of purified PCR product, 2.67 pmol of
the sequencing primer BCON-4 (Table 2.3), 2 pi 5 x CSA buffer (Appendix C. 18),
0.25 pi BigDye ® Terminator v3.1 and nuclease-free water added to a final volume
of lOpl. The sequencing reaction programme was 30 cycles of (96°C for 10 s, 50°C
for 5 s, 60°C for 2 min).
Sequencing products were prepared for analysis by ethanol precipitation. To each
well was added 15 pi nuclease free water, 50 pi 100% ethanol and 2 pi of 3M
NaOAc pH5.2 (Appendix C.19). Following mixing by gentle vortex and subsequent
incubation at room temperature for 45 min, sequencing products were pelleted by
centrifuging for 1 h at 2,250 x g at 4°C. The supernatants were discarded by
centrifuging the inverted plate for 1 min at 500 x g. The DNA pellets were washed
once in 150 pi ice cold 70% ethanol and air-dried. Samples were sent to the
Sequencing Unit of the Department of Zoology, University of Oxford and analysed
using a 3730x1 DNA Analyser and Sequencing Analysis software (Applied
Biosystems, Foster City, CA, USA).
Where sequencing results contained any ambiguities that could not be resolved by
analysis of the sequence chromatogram the sample was re-sequenced and if
necessary a consensus sequence formed.
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2.5 Sequence Data and Analysis
2.5.1 Nomenclature of bovine TCRp genes
To provide continuity with previously published work on bovine TCRP genes
(Buitkamp et al., 1993; Houston and Morrison, 1999; Tanaka et al., 1990) the WHO-
IUIS nomenclature system (Kazatchkine, 1995) has been used in this study. In
accordance with convention, bovine VP genes have been given subfamily names
according to the human VP gene with which they share highest nucleotide similarity
(Baron et al., 2001; Houston and Morrison, 1999; Isono et al., 1994; Schrenzel et al.,
1994).
Based on observations made on human and murine VP genes (Arden et al., 1995a, b)
it has been convention to assume (in the absence of contrary genomic data) that VP
sequences sharing >98% nucleotide sequence identity represent different allelic
variants of the same gene, whereas sequences sharing <98% identity are the products
of different gene loci. For the analysis of cDNA data and comparison of cDNA and
genomic VP sequence data this convention has been adopted in this study.
Annotation of the part of the bovine TCRB locus incorporating the Dp, jp and CP
genes (Chapter 5) has permitted the bovine jp genes to be named according to their
position within the TCRB locus, in accordance with the WHO-IUIS system, and has
been applied where appropriate.
To facilitate use of the IMGT/V-QUEST software programme (http://imgt.cines.fr -
Giudicelli et al., 2004) the IMGT unique numbering system was applied for
description of VP genes (Lefranc et al., 2003). This system defines CDR1 and CDR2
as being formed by amino acid residues 27-38 (bp 79-114) and 56-65 (bp 166-195)
of the mature VP polypeptide chain respectively. Conserved cysteine (Cys/C)
residues are located at position 23 and 104, and the tryptophan (Trp/W) at position
41 and the tyrosine (Tyr/Y) at position 42 are also conserved.
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2.5.2 Bovine TCRp gene sequence data
Bovine TCRP gene sequences deposited in the GenBank database were accessed
through the NCBI website (http://www.ncbi.nlm.nih.gov).
The following TCRpV sequences have been submitted by Tanaka et al. (1990);
D90130 (Vpisl), D9012I (Vp2sl), D90123 (Vp2s3), D90122 (Vp2s6), D90127
(Vp3sl), D90126 (Vp3sl), D90124 (Vp4sl), D90133 (Vp6sl), D90131 (Vp7sl),
D90128 (Vp 15s 1), D90129 (Vpi5s2), D90125 (Vpl7sl) and D90132 (Vp28sl):
Buitkamp et al. (1993); LI 8951 (Vp6s2): and Houston (1997); AJ006346 (Vp24s),
AJ006347 (Vp20sl), AJ006567 (Vp2s6), AJ006568 (Vpisl), AJ006569 (Vpis2),
AJ006570 (Vpis3), AJ006571 (Vpis3), AJ006572 (Vpis4), AJ006573 (Vpis5),
AJ006574 (Vpls6), AJ006575 (Vpls7), AJ006576 (Vpis9), AJ006577 (Vpl4sl),
AJ006578 (Vpi3sl), AJ006579 (VpiOsl), AJ006580 (Vp6s3), AJ006581 (Vp2sl),
AJ006582 (Vp2s3), AJ006583 (Vp2s4), AJ235264 (Vpi0s2), AJ235265 (VpiOs3),
AJ235266 (Vpl3s2), AJ235267 (Vpi3s3), AJ235268 (Vpi6sl).
Additional TCRpV gene sequences were obtained from Houston (1997) for Vpis8,
VpislO, Vplsl 1, Vp2s2, Vp2s5, Vp2s7, Vp4s2, Vp6s3, Vp7s2, Vp9sl and Vpl7s2;
and from data made available by Russell and MacHugh (unpublished) for Vp4s3,
Vp4s4, Vp8sl, VP8s2 and Vpi7s2. The nucleotide and amino acid sequences of
these VP genes are provided in Appendix E.
Two bovine TCRpC sequences have be deposited by Tanaka et al. (1990) - D90139
and D90140. Bovine TCRpj sequences were obtained from Tanaka et al. (1990) and
Houston (1997).
2.5.3 TCRp gene sequence analysis
Details ofTCRp chain cDNA transcript sequence and genomic TCRp gene sequence
analysis are provided in sections 4.2.2 and 5.2.3 respectively. DNAsis vl.O software
(Miriabio Inc., Alameda, CA) was used for completion ofmost sequence analysis.
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2.5.4 Presentation of TCR0 chain sequence data.
The sequences ofTCRP chains have been presented in the standardised format of
Chothia et al. (1988). The expressed VP and Jp gene segments are identified and the
sequences of the 3 framework codons (FR) flanking the CDR3P, as well as the
CDR3P itself, are displayed.
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3 Chapter Three - Molecular tools for analysing
clonal composition and TCRp repertoire of bovine
T-cell responses
3.1 Introduction
The specificity of apT-cells for particular pMHC ligands is determined by the
clonotypically expressed apTCR (Dembic et al., 1986; Sha et al., 1988). Following
recognition of cognate pMHC ligands by engagement of specific apTCRs, T-cells
become activated and undergo clonal expansion. Molecular analysis of TCR
expression by T-cells responding to antigenic stimulation has provided insights into
many important aspects of T-cell biology including: the clonal composition of
antigen-specific T-cell populations (Annels et al., 2000; Bousso et al., 1999; Maini et
al., 2000; Maryanski et al., 1999); the diversity of TCR repertoires expressed by
antigen-specific T-cells (Gillespie et al., 2006; Lehner et al., 1995; Naumov et al.,
1998; Quinn et al., 2006); the development and evolution of T-cell responses
(Blattman et al., 2000; Busch and Pamer, 1999; Kedzierska et al., 2004; Sourdive et
al., 1998; Zhong and Reinherz, 2004); T-cell responses induced by vaccination
(Bennett et al., 2006; Coulie et al., 2001); the relevance of TCR repertoire diversity
of responding T cell clonotypes in constraining 'escape mutant' viruses (Douek et
al., 2002; Lopes et al., 2003; Pantaleo et al., 1997; Price et al., 2004; Turnbull et al.,
2006) and the in vivo persistence of T-cell clones in the memory pool (Chen et al.,
2001c; Levitsky et al., 1998; Maini et al., 2000; Turner et al., 2003).
In human, primate and murine studies a number of molecular tools have been
developed and used to analyze the clonality and TCR repertoires of antigen-specific
T-cell responses (reviewed in Rufer, 2005). These techniques have predominantly
been developed to analyse the allelically excluded TCRp chain, although in many
studies TCRa chain expression has also been examined. Due to the enormous
diversity that is focused into the hypervariable CDR3P region, many techniques are
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based on the assumption that each T-cell clonotype expresses a unique CDR3P, and
use this as a marker of T-cell clonality.
Immunofluorescence staining of T-cells with VP subfamily-specific monoclonal
antibodies (e.g. Busch and Pamer, 1999; Coseetal., 1995; Pantaleo etal., 1994;
Trautmann et al., 2005) and semi-quantitative RT-PCR with VP subfamily-specific
primers (e.g. Lehner et al., 1995; Pantaleo et al., 1994) have been widely used to
detect alterations in the representation of VP subfamilies in responding T-cell
populations. However, the information provided by these techniques is of low
resolution as although they can be used to identify preferential VP subfamily
expression, they do not delineate the number of clonal expansions present within
expanded Vp subfamilies or provide information on either the hypervariable CDR3P
sequence or jp gene usage of expanded clones.
Higher resolution descriptions of T-cell clonality and TCR repertoires have been
achieved using various PCR based techniques. TCRp chain sequencing of antigen-
specific CD8+ T-cell clones derived by limiting dilution from antigen-stimulated T-
cell cultures has been used in several studies (Cose et al., 1995; Lehner et al., 1995;
Utz et al., 1996) and can be combined with functional analysis (Coulie et al., 2001)
but is subject to the bias that may be introduced by in vitro culture (Dietrich et al.,
1997). Modified anchored RT-PCR followed by sub-cloning and sequencing has
been used to study the clonality ofCD8 T-cell responses to HIV/SIV infections in
humans and primates (Chen et al., 2001c; Douek et al., 2002; Price et al., 2004) and
the persistence of adoptively transferred tumour-specific CD8+ T-cells (Robbins et
al., 2004; Zhou et al., 2004). This technique provides an unbiased representation of
clonality and TCR repertoire but requires a massive sequencing effort. Single-cell
RT-PCR ofMHCI-tetramer specific CD8+ T-cells has been used in direct ex vivo
analysis of the clonalify/TCR repertoire of responses to defined individual epitopes
(Kedzierska et al., 2004; Maryanski et al., 1999; Turner et al., 2003) and provides an
elegant and powerful tool for this type of work, although a considerable sequencing
effort is also required.
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Two extensively used methods that provide a rapid means of detecting expanded T-
cell clones in complex mixtures of T-cells are spectratyping (aka immunoscope -
Bousso et al., 1998; Cibotti et al., 1994; Levraud et al., 1996; Naumov et al., 1998;
Peggs et al., 2002) and TCRP chain CDR3 heteroduplex analysis (CDR3p-HDA -
Bernardin et al., 2004; Lopes et al., 2003; Maini et al., 2000; Turnbull et al., 2006).
In spectratyping, distortions of the normal Gaussian distribution of CDR3P length
within VP subfamilies are taken to reflect clonal expansions (Naumov et al., 1998;
Pannetier et al., 1993; Peggs et al., 2002). The CDR3P-HDA technique exploits the
retarded migration through non-denaturing poly-acrylamide gel of DNA
heteroduplices formed between TCR chains containing Vp genes of the same
subfamily but distinct CDR3p sequences, to identify clonal expansions (section
2.4.8.1). Modifications of this technique have introduced labelled probes that have
improved both its interpretation and sensitivity (Bernardin et al., 2003; Maini et al.,
1998). In contrast to the other methods, spectratyping and CDR3P-HDA are not
dependent on high levels ofTCRp chain sequencing to detect clonal expansions.
At present no molecular tools are available to study the clonal composition or TCR
repertoire of bovine T-cell responses. This chapter describes the development ofRT-
PCR protocols that enable the amplification and sequencing of TCRP chains of
individual bovine T-cell clones and also a CDR3P-HDA technique that is capable of
identifying clonal expansions within complex bovine apT-cells populations.
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3.2 Materials and methods
3.2.1 Sequence data and analysis
All available deposited and unpublished bovine VP gene sequences (section 2.5.2)
were admitted to an *in-house" database stored using DNAsis vl .0 software
(Miriabio Inc., Alameda, CA). Sequence data for bovine CP was derived from
sequences deposited in the GenBank database (D90129 and D90140 - section 2.4.4.1
and Appendices B and D). Details of TCRP chain sequence analysis methods are
provided in section 4.2.2. TCRP chain transcript sequences have been displayed in
the method defined by Chothiae/ al (1988) as described in section 2.5.4.
The sequence of the artefactual band was compared to bovine and human sequences
deposited in the GenBank database using the BLASTN algorithm facility available
on the NCBI website (http://www.ncbi.nlm.nih.gov/BLAST).
3.2.2 PCR
3.2.2.1 VP-subfamily-specific PCR amplification of cDNA for generation
of plasmid sub-clones
Naive PBMC from animal 605 were isolated (section 2.3.1) and cDNA generated as
described in sections 2.4.1-2.4.3. In separate reactions cDNA was amplified using
the VBext primers detailed in Table 2.2, with the exceptions noted in Table 3.1, in
combination with the common CP specific reverse primer BCext (Table 2.3).
Each PCR reaction used 30 pmol of each primer, 1.5 unit BIOTAQ (5units/pl
Bioline, London, UK), 6 pi SM-0005 buffer (ABgene, Epsom, Surrey, UK -
Appendix C.7), 3pl cDNA, and nuclease free water to give a final volume of 60 pi.
The programme used was as follows: 5 min at 94°C, 5 cycles of (1 min at 94°C, 1
min at 60°C, 1 min at 72°C), 25 cycles of (30s at 94°C, 1 min at 60°C, 1 min at







VBext primer used for generation of plamid sub-clone inserts
Name Sequence
3 VBext3*3 VBext3*2 GAT AGA GTG CAT ACA GAA CAT GG
6 VBext6*2 VBext6*l TTT GCA GGC AGG GGC CAG ACT
8 VBext8*2 VBext8*l ACA CTT CTC TGC TCA TGC TC
9 VBext9*2 VBext9*l TAG AAC ATC CTA GAA TGT GAG
14 VBextl4*l VBextl4*l TAT CTC CTG GGA GCA GGC
16 VBextl6*5 VBextl6*3 GAA TCT GAG TTG TGA CCA TAT
24 VBext24*3 VBext24*l AGG CTT CTC CTC TGT GTG GC
Table 3.1 Vp subfamily-specific 5' primers used in the generation of inserts for plasmid sub¬
clones instead of those described in Table 2.2.
3.2.2.2 Assessing specificity of Vp-subfamily specific primers
DNA from plasmid sub-clones VB1.1, 2.2, 3.1, 4.1, 6.2, 7.2, 8.1, 9.1, 10.1, 13.1,
14.6, 15.1, 16.1, 17A.6, 17B.1, 20.1, 24.1, 28.3 was prepared by the alkali lysis
method (section 2.4.7.3), quantified (section 2.4.2) and diluted in nuclease free
double distilled water to give solutions with final concentrations of~0.5ng/pl.
In individual PCR reactions each of the Vp subfamily-specific 5' primers, in
combination with the common Cp specific 3'end primer BCint, were used to amplify
each of these templates. The final set of VP subfamily-specific VBext and VBint
5'primers are detailed in Table 2.2. Each reaction contained 10 pmol of each primer,
0.5 unit BIOTAQ (5units/pl Bioline, London, UK), 2pi SM-0005 buffer (ABgene,
Epsom, Surrey, UK - Appendix C.7), 1 pi DNA, and nuclease free water to give a
final volume of 20pl. For data relating to the results presented in Figure 3.3 PCRs
were completed as described above but using BCext instead of BCint as the
3'primer. The PCR programme used was as described in 3.2.2.1 above.
3.2.2.3 Vp subfamily-specific semi-nested PCR
The optimised VP subfamily-specific semi-nested PCR protocol is detailed in section
2.4.4.2. cDNA (sections 2.4.1 - 2.4.3) from unfractionated PBMC was used undiluted
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and cDNA prepared from T-cell clones was used diluted at either 1:5 or 1:10 in
nuclease free water.
3.2.2.4 'Pan-Vp' PCR
The optimised protocol for 'Pan-VP' PCR is detailed in section 2.4.4.2.
PCR products were subject to agarose gel electrophoresis, visualised and gel images
analysed and stored as described in section 2.4.5.
3.2.3 Plasmid sub-cloning
(a) PCR amplified TCRp chain transcripts
PCR products were purified using the Wizard PCR Preps DNA Purification System
(section 2.4.6), sub-cloned into plasmid pGEM-T Easy vectors and used to transform
High Efficiency Competent JM109 cells as described in section 2.4.7. Selected
plasmid sub-clones were expanded overnight (section 2.4.7.2) and the presence of
insert verified by restriction endonuclease analysis (section 2.4.7.1) of mini-preps of
plasmid DNA (sections 2.4.7.3).
(b) Artefactual band in Vp subfamily-specific semi-nested PCR
The artefactual band was extracted from agarose gel using the GeneClean II kit
(Qbiogene, CA, USA) according to the manufacturer's instructions. Briefly, the
DNA band was excised from an ethidium bromide stained agarose gel and
transferred to a 1.5 ml centrifuge tube. The excised gel was weighed, and
approximately 3 times the gel volume (assuming 1 g = 1 ml) of sodium iodide (Nal)
was added to it; the gel/Nal was incubated at 45°C-55°C until the agarose dissolved.
10-15 pi of re-suspended Glassmilk was added to the gel/Nal and the mixture
incubated at room temperature for 5-10 min with intermittent agitation every 1 min,
before centrifugation at 10,000 x g for 5 min. The supernatant was discarded and the
pellet washed in 30 x volume ofNew Wash a total of 3 times before being air-dried
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at room temperature. The pellet was then re-suspended in 15 pi of nuclease-free
water, centrifuged at 10,000 x g for 30 s and the eluted DNA recovered in the
supernatant. The DNA was then sub-cloned into plasmid pGEM-T Easy vector and
used to transform High Efficiency Competent JM109 cells as described above.
3.2.4 CDR3P-HDA
The protocol for CDR3P-HDA is given in section 2.4.8. When DNA from plasmid
sub-clones was being utilised as the 'sample', then aliquots of 25ng DNA were used
as the template for PCR amplification. Aliquots of 10 pi of H2O were mixed with
'probes' prior to the de-naturing/re-annealing stage ofCDR3P-HDA where indicated,
to demonstrate that in the absence of other DNA the 'probes' did not generate
heteroduplices.
For generation of FAM labelled PCR amplicons from sub-clone VB20.1 and
subsequent CDR3P-HDA, the protocol for generation of VP20 'probe' was followed
using VB20.1 DNA as template.
For the dilution series clones 592.15D (Vp2+) and (B) 485.144 (Vpi3+) were serially
diluted in unfractionated PBMC from animal 605 before RNA extraction and cDNA
production (section 2.4.1-2.4.3).
3.2.5 Theileria parva-specific CD8+ T-cell-lines and clones
Theileria parva-specific, in vitro CD8T T-cell enriched cell-lines were generated
from animals 468 and 592, as described in section 2.3.3, and approximately 90
individual T-cell clones established from each them (section 2.3.4). The TCRp
chains expressed by these clones were sequenced following PCR amplification using
the VP subfamily-specific semi-nested PCR (section 3.2.2.3) and the results are
presented in Chapter 6 and Appendix L. cDNA from the cell-lines and the individual
clones were subject to CDR3P-HDA as described above (section 3.2.5)
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3.2.6 Sequencing
The sequences presented in this chapter were obtained from sequencing performed at
either the Moredun Proteomics Facility (Moredun Research Institute, Penicuik,
Scotland) or DBS genomics (Durham University, Durham, UK). Plasmid DNA and
PCR products were prepared for sequencing using the Wizard Mini-preps DNA
Purification System/alkali lysis method (section 2.4.7.3) and by the Wizard PCR
Preps DNA Purification System (section 2.4.6) respectively and quantified (section
2.4.2). Plasmid sub-clone inserts were sequenced using either the T7 and/or SP6




3.3.1 The known bovine TCRpV repertoire contains 46 genes in 17
subfamilies
Bovine TCRpV (VP) sequence data from studies using cDNA library analysis
(Tanaka et al., 1990), cross-species subfamily-specific PCR (Buitkamp et al., 1993)
and anchored PCR (Houston, 1997; Houston and Morrison 1999; Russell and
MacHugh unpublished data) was compiled to form a database. Using the IMGT/V-
QUEST software programme (Giudicelli et al., 2004) the human Vp gene to which
each bovine Vp gene shared highest nucleotide percentage identity was determined.
From this analysis it was found that the gene previously designated as bovine
Vpi2sl actually had significantly higher nucleotide identity to human Vp28sl than
to any of the Vpi2 members (80% compared to 66% at nucleotide level), and was
therefore re-named as bovine Vp28sl (section 1.2.2). Within the previously
unanalysed sequence data of Russell and MacHugh, a novel bovine subfamily, Vp8,
with two members (Vp8sl and Vp8s2) was identified, as were two new members of
the VP4 subfamily (Vp4s3 and Vp4s4). As noted previously, the two bovine Vpi7
members had less than 75% nucleotide homology to each other, but when compared
to human sequences, both showed highest nucleotide identity to Vpi7 (Houston,
1997). The accumulated data gave a bovine repertoire of 46 Vp genes distributed
over 17 subfamilies, as summarised in Table 3.2.
3.3.2 Vp-subfamily specific PCR amplification from cDNA
Using the sequence database, a set of VP subfamily-specific 5' primers were
designed. For subfamilies with multiple VP gene sequences present in the database,
the sequences were aligned using the ClustalW algorithm to identify conserved areas
to which a primer could anneal; for some subfamilies (e.g.Vpi) degeneracy had to be
introduced towards the 5'end of the primer to accommodate all of the sequences.
Due to lack of a conserved sequence of suitable length between VP 17s 1 and Vpi7s2
two primers, VB17a and VB17b were designed to be specific for Vpi7s2 and
77
VP 17s 1 respectively. Two 3' primers for the CP gene, BCint and BCext, were also
designed using sequences in the GenBank database.
vp
subfamily















1 1 1,2,3,4,5,6,7,8*,9,10*,11* 4 11
2 1,3,6 1,2*,3,4,5*,6,7* 3,5*,6,7* 7
3 1 1 1
4 1 2* 3* 4* 4
6 1 2 3* 2 3




13 1,2,3 1 3
14 1 1
15 1,2 1,2 2
16 1 1
17 1 2* 1,2* 2
20 1 1 1
24 1 1 1
28 1 1 1
Total 12 1 39 16 46
Table 3.2 The known bovine VP repertoire. The members of each Vp subfamily (column 1)
identified by Tanaka et al. (1990) - column 2, Buitkamp et al. (1993) - column 3, Houston (1997)
and Houston and Morrison (Houston and Morrison, 1999) - column 4 and Russell and
MacHugh, unpublished - column 5, are shown. Genes suffixed by * have not be deposited in
GenBank and the sequences are derived from either Houston (1997) or unpublished data
provided by Russell and MacHugh (section 2.5.2). These sequences are detailed in Appendix E.
The total number of known members belonging to each VP subfamily is shown in column 6.
The 5' VP subfamily-specific primers were used in separate reactions, with the 3'
CP-specific primer BCext, to amplify cDNA from un-fractionated bovine PBMC;
primers that failed to generate product of the anticipated size were re-designed. The
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product from each reaction was sub-cloned into pGEM-T plasmid vectors and the
sequences for two plasmid sub-clones from each reaction were determined (Table
3.3). All belonged to the anticipated V|3 subfamily. However, the VP gene sequence
in sub-clones VB1.1, VB10.2, VB13.1 and VB13.3 were sufficiently different from
previously identified members of the respective subfamilies to be considered new
members - Vpisl2, Vpl0s4, Vpi3s4 and Vpi3s5 respectively (section 2.5.1).
Descriptions of these genes are given in Chapter 4. Although the sequence of the VP
region of sub-clone VB20.1 was identifiable as Vp20sl, it was not possible to obtain
sequence for the CDR3 or Jp gene regions; later work demonstrated that this was



























































































































































































16 . 5 16sl TGTGCCAGC
CAS
AGCCGAGGTTTCGAGGAGCAG














































20.1 20sl Not able to sequence
















GCT GCC GGG ACA GTT GAC TAT











Table 3.3 (continued) Sequences of TCRp chain inserts of the panel of plasmid sub-clones
generated.
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The specificity of the Vp subfamily-specific primers was assessed using diluted
DNA from a panel of the plasmid sub-clones. Several of the primers displayed
marked cross-reactivity, amplifying genes belonging to various Vp-subfamilies and
required re-design (data not shown). Ultimately, a set of primers, all but 3 of which
only amplified Vp genes of the relevant subfamily when tested against the panel of
plasmid sub-clones (i.e. were subfamily-specific - e.g. VBextl3 - Figure 3.1a), was
acquired. Primers VB2, 10 and 16 non-specifically amplified Vp genes of other
subfamilies (e.g. VBext2 - Figure 3.1b) as detailed in Table 3.4.
To achieve improved subfamily specificity it was decided to design an additional set
ofVp subfamily-specific primers to be used in conjunction with the initial set
(henceforth referred to as VBext primers) in semi-nested PCR (snPCR). As with the
VBext primers, several of these VBint primers had to be re-designed because when
used in single-round PCR (i.e. non-nested) they either failed to generate product
from cDNA of unfractionated PBMC or displayed cross-reactivity when examined
for Vp subfamily-specificity against the panel of plasmid sub-clones. The final set of
VBint primers was subfamily-specific, with the exception of VBlint, VB13int and









VBextl6 7.2 7s 1
VBintl 6.2 6s 1
13.1 13s4
VBintl3 24.1 24s 1
VBintl4 13.1 13s4
17A.6 17s2
Table 3.4 VP subfamily-specific primers demonstrating cross-reactive
amplification of plasmid sub-clones containing VP genes from other subfamilies.
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Importantly, the pattern of cross-reactivity displayed by the two sets of 5' primers
suggested that when used in combination in snPCR, amplification should be V(3
subfamily-specific (i.e. none of the VBext/VBint primer pairs cross-reactively
amplified the same VP subfamily). Indeed, the results indicated that replacement of
VBext2, 10 and 16 with their VBint counterparts would have sufficed in creating a
VP subfamily-specific set of 5' primers. Nevertheless it was decided to develop a
snPCR protocol as the combined use the two 5'primers in snPCR would; (i) afford
more assured VP subfamily-specificity of PCR amplification and (ii) if required
could provide greater sensitivity without the compromise in specificity frequently
seen if single primer sets are used in a high number of PCR cycles.
A snPCR protocol was established that allowed the generation of a single band of the
anticipated size by each pair of VBext/VBint subfamily-specific 5'primers from
cDNA of un-fractionated PBMC (Figure3.2a). Using this protocol cDNAs from 22
T-cell clones that had been generated within the laboratory were amplified. The
majority of cDNAs were amplified by only one set of VP subfamily-specific primers
(e.g. 485.280 - Figure 3.2b), but some were amplified by 2 or more sets (e.g. 485.71 -
Figure3.2c). Direct sequencing of the products confirmed that in each case
amplification was VP subfamily-specific (Table 3.5) and that some of the T-cells
expressed 2 or more TCRp chains, presumably because they were not mono-clonal,
expressed a non-functional as well as a functional TCRp chain or lacked allelic
exclusion (Davodeau et al., 1995; Padovan et al., 1995).
Within the 24 unique TCRp chains expressed by the 22 clones, 18 of the 50
previously sequenced VP genes and 4 novel Vp genes (designated as Vp2s8, Vp4s5,
Vpi0s5 and VB17s3 - described in Chapter 4) were identified. These Vp genes were
distributed over 14 of the 17 bovine Vp subfamilies (no Vp8, Vpl5, Vpi7s2 or VP28
genes were identified), demonstrating the effectiveness of the snPCR over a wide
coverage of the Vp repertoire.
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500 500
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
500-4 500
Lane 1 2 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Lane
1 - Molecular markers 6 - plasmid VB6.2
2 - plasmid VB1.1 7 - plasmid VB7.2
3 - plasmid VB2.2 8 - plasmid VB8.1
4 - plasmid VB3.1 9 - plasmid VB9.1
11 - plasmid VB13.1
12 - plasmid VB14.6
13 - plasmid VB15.1
14 - plasmid VB16.1
16 - plasmid VB17B.1
17 - plasmid VB20.1
18 - plasmid VB24.1
19 - plasmid VB28.3
5 - plasmid VB4.1 10 - plasmid VB10.1 15 - plasmid VB17A.6 20 - Molecular markers
Figure 3.1 Specificity of VP subfamily-specific primers. PCR amplification of DNA from a
panel of plasmid sub-clones by (A) VBextl3 and (B) VBext2. VBextl3 is subfamily-specific
amplifying only DNA from plasmid sub-clone VB13.1 (lane 11) which expresses the Vpi3s4
gene. VBext2 amplifies sub-clone VB4.1 (lane 5) which expresses the Vp4s3 gene as well as sub¬
clone VB2.2 (lane 3) which expresses the Vp2s3 and therefore is not subfamily-specific.
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500- B— 500
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
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5-VB4*2ext/VB4*lin 10-VB10*2ext/VB10*lint 15-VB17A*lext/VB17A*3int 20-Molecular markers
Figure 3.2 PCR amplification using the Vp subfamily-specific snPCR protocol. (A)
Amplification of cDNA from unfractionated PBMC - showing generation of product of the
anticipated size for each subfamily (lanes 2-19). (B) Amplification by VBext2/VBint2 (lane 3) of
cDNA from T-cell clone 485.280 which expresses a Vp2+ TCRp chain - Table 3.5. (C)
Amplification by VBext2/VBint2 and VBext7/VBint7 (lanes 3 and 5) of cDNA from T-cell clone
485.71 which expresses Vp2+and Vp7+TCRp chains - Table 3.5. (D) Artefactual band of ~650bp
generated in reactions producing no Vp subfamily-specific product (lanes 3-19) in amplification



























































































































































































































Table 3.5 (continued) Sequences of TCRp chains expressed by 22 T-cell clones obtained using
the Vp subfamily-specific snPCR protocol. * Sequence is out of frame and therefore non¬
functional.
The sensitivity of the snPCR protocol has not been fully assessed for all of the primer
pairs. However, using Vp3-specific primers with cDNA derived from a Vp3+ T-cell
clone (633.49), it was demonstrated that product could be generated from the
equivalent of -300 cells (data not shown). This level of sensitivity was considered
sufficient for the purpose of identifying the TCRp chains expressed by individual T-
cell clones.
A frequent artefact of the snPCR protocol was the generation of a product of
approximately 650bp in reactions that generated no Vp subfamily-specific product
(Figure 3.2d). This band was extracted from one gel, purified and sub-cloned into a
plasmid vector for sequencing. The resulting sequence was found to have 99%
nucleotide identity with a sequence in the bovine genome database (locus
XM_595623 on scaffold NW_932240.1/Bt9_WGA1710_2 - Appendix F), which
automated annotation has predicted to encode a homologue of human nesprin-1. The
artefact displayed 87% nucleotide sequence identity with the deposited sequence of
human nesprin-1 protein (GenBank accession number AF495910 - Zhang et al., 2002
- Appendix B). Analysis of the sequence revealed an annealing site for BCint and the
reverse complement of BCint at opposing ends of the product (Appendix F). As the
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size of the artefact was significantly greater than any of the anticipated Vp-subfamily
specific products and the artefact band was generally weak, it was considered
unlikely to interfere in subsequent application of the snPCR and therefore no efforts
were made to eliminate it by adjusting the protocol.
3.3.3 Design of a 'Pan-VP' primer
None of the VP subfamily-specific primers were able to amplify cDNA from a
cloned, Theileria purvu-transformed cell line (468TpM ), which was shown by
FACS analysis to express CD3 but not the y/8 TCR and was therefore considered to
be an aP T-cell (data not shown). This suggested that 468TpM expressed a TCRP
chain containing a VP gene that was either (i) from a novel bovine VP subfamily or
(ii) a novel member of a known subfamily that lacked the conserved sequence
against which one or both of the subfamily-specific primers annealed.
Degenerate primers directed against sequences conserved between V subfamilies
have been used in rodents (Broeren et al., 1991), humans (Obata et al., 1993), dogs
(Ito et al., 1993) and pigs (Baron et al., 2001) to amplify TCR chains in which the
sequence of the V gene is unknown. It was decided to use this methodology to try to
isolate the TCRp chain of 468TpM.
Alignment of all the sequenced bovine VP genes using the ClustalW algorithm
revealed that the only universally conserved sequence was the 5 base TGGTA that
includes the codon for the conserved tryptophan at amino acid position 41 of the VP
domain. Therefore, a bovine 'Pan-Vp' 5' primer was designed with these 5 bases at
the 3'end. An additional 9 bases of the primer contained various degrees of
degeneracy based on the known bovine VP gene sequences (Table 3.6). Four
guanines were added to the 5'end of the primer to aid stabilization of annealing.
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Base 14 13 12 11 10 9 8 7 6 5 4 3 2 1
Primer
sequence
N N N V T D T H Y T G G T A
A 12 10 3 26 5 1 36 54
C 2 33 16 7 1 1 6 48
G 10 7 4 21 39 54 54
T 30 4 31 53 10 52 12 6 54 54
Table 3.6 Design of the bovine 'Pan-VP' 5' primer. All of the sequenced bovine Vp gene
sequences were aligned by the ClustalW algorithm and the frequency of all four nucleotides
(A,C,G and T) at the nine positions preceeding the conserved TGGTA at positions 100-104
(1MGT Unique Numbering System) in the known Vp genes was determined. Based on this data
the sequence of the 14 3' bases of the primer were established with degneracy introduced as
appropriate (Y=C/T; N=A/C/G/T; V=A/C/G; D=A/G/T; H=A/C/T).
Used in conjunction with the two CP-specific 3'end primers (PVBrevl and PVBrev2
- Table 2.3) in a snPCR protocol the 'Pan-Vp' primer was able to amplify cDNA
from 468TpM, which expressed a Vp gene subsequently designated as a member of a
novel bovine subfamily, Vp5 (described in Chapter 4).
3.3.4 A bovine CDR3(5 heteroduplex analysis (CDR3(5-HDA)
method
An overview of the basic principle of the CDR3P-HDA method developed in this
study is given in section 2.4.8.1 and details of the method are provided in section
2.4.8.2.
The requirement for 5'end (VP) and 3' (CP) end complementarity between TCRp
DNA strands forming a heteroduplex dictates that the CDR3P-HDA method has a
substantial degree of inherent Vp-subfamily specificity. Using the non-specifically
amplified products ofVB 13.1 and VB17A.6 generated by the VB14int 5'primer
(Figure 3.3a), it was demonstrated that this was indeed the case. Whilst a
heteroduplex could be formed between the Vpi4 'probe' (generated from VB14.6)
and the VB14int/BCext amplified product ofVB14.7 (Figure 3.3b lane 2), neither of
the products amplified from VB13.1 or VB17A.6 was able to form a heteroduplex
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with the V[314 "probe' (Figure 3.3b lanes 3 and 4). Similarly, cross-reactive products
generated by other V(3-subfamily-specific primers could not form heteroduplices
with the relevant VP subfamily probe (data not shown). Consequently it was decided
to use only a single round PCR to generate amplicons used in the CDR3P-HDA
method, as sufficient VP-subfamily specificity would be present in the system.
The ability to form CDR3P heteroduplices for each VP subfamily was verified using
products of the respective subfamily but derived from different plasmid sub-clones
than those selected for 'probe' generation (examples given in Figure 3.4a).
Importantly, for the majority of the multi-membered subfamilies the sub-clones
contained Vp genes that were different from those present in the 'probes',
demonstrating the ability to form heteroduplices between different members of the
same VP subfamily (e.g. VP2 - the Vp2 'probe' is generated from plasmid sub-clone
VB2.2 which contains Vp2s3 and the plasmid sub-clone VB2.4 contains Vp2s6).
Amplicons from plasmid sub-clone VB20.1 formed two heteroduplex bands with the
VP20 'probe' (Figure 3.4b lane 2) and furthermore were capable of forming
heteroduplices in the absence of the 'probe' (Figure 3.4b lane 3). This infers that sub¬
clone VB20.1 contains 2 clones with dissimilar CDR3P regions and explains why it
was not possible to obtain a sequence for the CDR3p/jp regions of this plasmid
(section 3.3.2).
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Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Lane
1 - Molecular markers 6 - plasmid VB6.2
2 - plasmid VB1.1 7 - plasmid VB7.2
3 - plasmid VB2.2 8 - plasmid VB8.1
4 - plasmid VB3.1 9 - plasmid VB9.1
5 - plasmid VB4.1 10 - plasmid VB10.1
11 - plasmid VB13.1 16
12 - plasmid VB14.7 17
13 - plasmid VB15.1 18
14 - plasmid VB16.1 19







Lane 1 - V(314 probe + h2o
2 - V(314 probe + PCR product from plasmid
sub-clone VB14.7
3 - V(314 probe + PCR product from plasmid
sub-clone 13.1
4 - V(314 probe + PCR product from plasmid
sub-clone 17A.6
Figure 3.3 Vp subfamily-specificity of CDR3P-HDA. (A) PCR amplification ofDNAfroma
panel of plasmid sub-clones with VB14int/BCext is not subfamily specific - as well as specific
amplification of sub-clone VB14.7 (Vpi4+- lane 12), sub-clones VB13.1 (Vp 13+- lane 11) and
VB 17A.6 (Vpi7+- lane 15) are cross-reactively amplified. (B) CDR3P-HDA has inherent VP
subfamily specificity as the Vpi4 'probe' can form a heteroduplex with the amplified product
from sub-clone VB14.7 (lane 2) but not the amplified products from sub-clones VB13.1 (lane 3)
or VB17A.6 (lane 4). Heteroduplex (red arrows), homoduplices (yellow arrows) and single-
stranded 'probe' DNA (blue arrows) have been indicated.
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Lane 1
Lane V(31 probe + H20
V(31 probe + PCR product from plasmid
sub-clone VB1.1
V£2 probe + H20
V{32 probe + PCR product from plasmid
sub-clone Vb2.4
V(33 probe + H20
V(314 probe + PCR product from plasmid
sub-clone 17A.6
6 12 3
Lane 1 - V|320 probe + H20
2 - V(51 probe + PCR product from
plasmid sub-clone VB20.1
3 - Sub-clone VB20.1 amplified
with BCext-FAM + H20
Figure 3.4 CDR3P-HDA formation. (A) Examples of heteroduplex formation between the; Vpi
'probe'/amplified PCR product from plasmid sub-clone VB1.1 (lane 2a), Vp2 'probe'/amplified
PCR product from plasmid sub-clone VB2.4 (lane 4a) and Vp3 'probe'/amplified PCR product
from plasmid subclone VB3.3 (lane 6a). When run in the absence of other DNA none of the
'probes' generate heteroduplex bands (lanes la, 3a, 5a). (B) Vp20 subfamily heteroduplex
formation. Two heteroduplices are formed between the Vp20 'probe'/amplified PCR product
from plasmid sub-clone VB20.1 (lane 2b). When run in the absence of other DNA the Vp20
'probe' only formed a homoduplex (lane lb) whereas if sub-clone VB20.1 was amplified with the
labelled BCext-FAM 3'primer and then subjected to CDR3P-HDA in the absence of any other
DNA, two heteroduplices were formed, indicating that sub-clone VB20.1 was not composed of
mono-clonal TCRp. This would explain the inability to sequence the CDR3 sequence of the
TCRp chain insert of this plasmid (section 3.3.2). Heteroduplices (red arrows), homoduplices
(yellow arrows) and single-stranded 'probe' DNA (blue arrows) have been indicated.
91
3.3.4.1 Clonal specificity and sensitivity of clonal detection by CDR3p-
HDA
A key feature of CDR3(3-HDA is that each expanded T-cell clonotype is represented
as a distinct and reproducible band that constitutes a unique •molecular footprint'
(Maini et al., 1998). This enables (i) different expanded clones to be distinguished
from each other and (ii) clones to be re-identified in multiple samples - either from
different time-points in longitudinal studies or from different T-cell populations (e.g.
comparisons between in vitro and ex vivo or local and systemic T-cell populations).
Using a small panel of Vp2+ clones/sub-clones it was possible to establish that T-
cells expressing identical TCRp chains (i.e. of the same clonotype) had a common
CDR3P-HDA 'molecular footprint', whilst those expressing TCRP chains with the
same VP subfamily but different CDR3P regions had dissimilar CDR3P-HDA
migration patterns (Figure 3.5).
Lane 1 - vp2 probe + h2o
2 - vp2 probe + 4-85.130
3 - V(32 probe + 485.182
4 - vp2 probe + 485.280
5 - V($2 probe + sub-clone
VB2.4
Lane 1
Figure 3.5 CDR3P-HDA migration patterns of Vp2+ bovine TCRp chains. Vp2+T-cell clones
485.130 (lane 2), 485.182 (lane 3) and 485.280 (lane 4) express identical TCRP chains (Table 3.5)
and have a common CDR3P-HDA 'molecular footprint' in CDR3P-HDA. The CDR3P-HDA
migration pattern of the Vp2+TCRp chain insert of plasmid sub-clone VB2.4 (lane 5) is
dissimilar to that of the three 485 T-cell clones (Table 3.3), reflecting its expression of a different
CDR3P sequence. Heteroduplices (red arrows) and homoduplices (yellow arrows) have been
indicated.
By seeding Vp2+ and Vpi3+ in vitro derived T-cell clones independently into
unfractionated PBMC it was possible to evaluate the sensitivity of the CDR3P-HDA
method. The sensitivity differed between the two clones; a distinct band representing
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the Vp2+ clone was clearly visible at a dilution of 1:10,000 (Figure 3.6a), but the





Lane 1 — Vp probe + H20
2 - Vp probe + clone at 1:100 in unfractionated PBMC
3 — V|3 probe + clone at 1:1, 000 in unfractionated PBMC
4 - V(3 probe + clone at 1:10, 000 in unfractionated PBMC
5 - VP probe + clone at 1:100,000 in unfractionated PBMC
6 - Vp probe + clone at 1:1,000,000 in unfractionated PBMC
Figure 3.6 Sensitivity of detection of T-cell clonal expansions by CDR3P-HDA. Serial ten-fold
dilution of T-cell clones (A) 592.15D (Vp2+) and (B) 485.144 (Vpt3+) in unfractionated PBMC. A
distinct heteroduplex band (red arrow) representing the TCRp chain expressed by 592.15D is
clearly visible in dilutions down to 1:10,000 (lane 4a). The heteroduplex band representing the
TCRp chain expressed by 485.144 (red arrow) is only evident at dilutions down to 1:1,000 (lane
3b). In the V p2 series it is notable that a polyclonal smear (section 2.4.8.1) becomes more
prominent as the seeded clones are diluted out (lanes 2a-6a). The homoduplices formed by the
labelled 'probes' are indicated by yellow arrows and single-stranded labelled 'probe' DNA by
blue arrows.
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3.3.4.2 Analyzing a complex T-cell population by CDRp3 -HDA
In humans CDRP3 -HDA techniques have been used principally to provide a rapid,
global analysis of the clonal composition of complex T-cell populations (Lopes et
al., 2003; Maini et al., 2000). The bovine CDRJ33-HDA method was used to examine
the clonal composition of T. parva-spec\f\c in vitro CD8^ T-cell enriched cell-lines
derived from the PBMC of two immunised animals (Figure 3.7a and b). CDRP3 -
HDA revealed that both cell-lines were highly oligoclonal, with many distinct
heteroduplex bands distributed amongst most of the VP subfamilies.
1 2 3 4 6 7 8 9 10 13 14 15 16 17a 17b 20 24 28
VP subfamilies
1 2 3 4 6 7 8 9 10 13 14 15 16 17a 17b 20 24 28
VP subfamilies
Figure 3.7 CDR3P-HDA of complex bovine T-cell populations. Analysis of T.parva-specific, in
vitro CD8+ T-cell enriched cell-line from animal (A) 592 and (B) 468. Heteroduplex bands
representing expanded clonotypes identified from TCRp chain sequence of individual T-cell
clones derived from these cell-line are shown by red arrows, with the number indicating the
number of clones out of the -90 analysed that are represented by each band. Homoduplices are
indicated by yellow asterisk.
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From each of the two cell-lines approximately 90 CD8+ T-cell clones were generated
by limiting dilution and their TCR(3 chains sequenced (Chapter 6). Sequence analysis
identified 15 TCRp chains that were expressed by multiple clones (i.e expanded
clonotypes) from animal 592 and 10 TCRP chains that were expressed by multiple
clones from animal 468. By comparing the CDR3P-HDA migration patterns of these
clones with that of the parent cell-lines it was demonstrated that each of the clonal
expansions identified amongst the clones was represented on the CDRP3-HDA of the







1 - 592 cell-line
2 - T-cell clone 592.21
3 - T-cell clone 592.27
4 - T-cell clone 592.34
5 - T-cell clone 592.90
Lane
1 - 592 cell-line
2 - Vp2 Aprobe' + H20
3 - T-cell clone 592.7
4 - T-cell clone 592.15
5 - T-cell clone 592.18
Figure 3.8 Comparison of CDR3P-HDA migration patterns of individual T-cell clones and the
parent cell-lines. (A) The heteroduplex bands present in the Vp6 subfamily CDR3P-HDA of a
T.parva-specific, in vitro CD8+ T-cell enriched cell-line from animal 592 (lane la) show co-
migration with the heteroduplex bands of the 4 Vp6+ T-cell clones derived from it (lanes 2a-5a).
Clones 592.34 and 592.90 (lanes 4a and 5a) express the same TCRp chain and co-migrate with
the most prominent heteroduplex band in the Vp6 subfamily CDR3P-HDA of the parent cell-
line, suggesting that within Vp subfamilies CDR3P-HDA is semi-quantitative. Clones 592.21
(lane 2a) and 592.27 (lane 3a) express unique Vp6+ chains that show co-migration with less
prominent heteroduplex band of the 592 cell-line. (B) Examples of the co-migration of the
heteroduplex bands present in Vp2 subfamily CDR3P-HDA of a T./wrvfl-specific, in vitro CD8+
T-cell enriched cell-line from animal 592. Heteroduplex bands are indicated by red arrows and
homoduplices by yellow asterisk.
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Many of the other heteroduplex bands present in the cell-lines co-migrated with
clones expressing unique TCRP chains and probably represent additional minor
clonal expansions (Figure 3.8a). These results indicate that by using the bovine
CDRP3-HDA it is possible to rapidly acquire an accurate global representation of the
clonal composition of complex bovine T-cell populations.
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3.4 Discussion
The ability to characterise the clonal composition and TCR repertoires of T-cell
responses in humans and mice by molecular analysis of expressed TCRs has been
crucial in addressing many important questions relating to T-cell biology. This
chapter describes the development and testing ofRT-PCR protocols for isolation and
identification of expressed bovine TCR(3 chains and a CDR3P-HDA technique that
can be used to identify clonal expansions within complex bovine T-cell populations.
Application of these molecular tools now offers the opportunity to characterise the
TCR repertoire and clonal composition of bovine T-cell responses.
Using a sequence database of 46 bovine V{3 genes belonging to 17 subfamilies, 2 sets
of essentially Vp subfamily-specific 5'primers have been designed and validated.
Combined use of these two primer sets in an optimised semi-nested PCR protocol to
amplify the TCRP chains expressed by 22 T-cell clones indicated that they were
specific for their respective Vp subfamilies. Although 14 of the 17 VP subfamilies
were represented amongst these 22 TCRp PCR products, it must be noted that
subfamily specificity has only been established on a limited number of plasmid sub¬
clones expressing partial TCRP chains and cDNAs from T-cell clones. It is therefore
possible that as yet undetected cross-reactive amplification might occur with (i)
members ofmultiple gene VP subfamilies/novel subfamilies not represented within
the panel of sub-clones/T-cell clones examined or (ii) full length TCRp transcripts of
the VP genes expressed by the sub-clones. The identification of several novel Vp
genes, including a novel subfamily (Vp5 - see below) indicates that the sequence
database used for designing the VP subfamily-specific primers does not represent the
complete bovine VP repertoire. Therefore, the VP subfamily-specific snPCR protocol
may need re-evaluation and adaptation in the future as additional Vp genes and
subfamilies are identified. The novel Vp genes identified through the work in this
chapter are presented in Chapter 4.
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Although the Vp3+-specific snPCR was shown to generate product from as few as
300 cells, a full titration was not conducted and it is therefore possible that products
could be generated from significantly fewer cells. Further evaluation of the
sensitivity of the protocol for a variety of subfamilies may be of interest, especially if
alternative techniques such as single-cell PCR of tetramer-isolated cells are to be
developed in the future (Kedzierska et al., 2004; Maryanski et al., 1999; Turner et
al., 2003).
The VP subfamily-specific snPCR protocol failed to amplify cDNA from a cloned T.
parva-transformed cell-line (468TpM ) which FACS data had implied was an apT-
cell. This suggested that 468TpM was expressing a novel VP gene that lacked
annealing sites for the VP subfamily-specific primers. Several techniques are
available for amplifying TCR transcripts expressing unknown V genes, including
inverse PCR using circularised cDNA (Uematsu, 1991), anchored-PCR (Loh et al.,
1989) and design of primers that anneal to sequence conserved across V gene
subfamilies (Obata et al., 1993). Due to the laborious template modifications that are
required in the first two techniques, it was decided to attempt to develop a 'Pan-Vp'
primer. Application of the designed primer in a snPCR protocol successfully
amplified the TCRP chain expressed by 468 TpM, which was identified as member
of a novel bovine subfamily (VP5).
The sequence of the bovine 'Pan-VP' primer designed in this study is identical to that
of the human 'Pan-VP' primer designed and validated by Obata et a.l (1993). This
primer has also been used to amplify canine TCRP chains (Ito et al., 1993),
suggesting it may be useful across a spectrum of mammalian species. Furthermore, it
has been suggested that the 'Pan-VP' primer could be used to amplify TCRa, TCRy
and TCR8 chains (in combination with Ca-, Cy- and C8-specific 3'primers) as the
target sequence pentamer (TGGTA) to which the 'Pan-VP' primer anneals is also
conserved in Va, Vy and V8 genes (Obata et al., 1993). One disadvantage of the
'Pan-VP' primer is that it does not generate sequence of the first lOObp of the VP
gene. However, in humans enough Vp sequence is obtained to permit identification
and differentiation ofmost VP genes (Obata et al., 1993) and from examination of
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the available bovine V[3 sequences it appears this also applies to bovine VP genes
(data not shown).
In subsequent work completed in this study the 'Pan-VP' primer enabled
identification of another novel VP subfamily (Vpx - section 4.3.1) and has also been
used to amplify the TCRp chains of a large number of individual T-cell clones,
encompassing the majority of the VP subfamilies (Chapter 6). However, results from
this work (Chapter 6 - data not shown) and that reported by Obata et al (1993)
revealed one disadvantage of this method, namely that it does not yield readable
TCRp chain sequences from T-cells expressing 2 or more TCRP chains following
direct sequencing of the PCR product. In these circumstances amplification by VP
subfamily-specific snPCR was required to obtain readable TCRp chain sequence.
CDR3p-HDA has been used in human and primate studies to provide rapid, global
descriptions of the clonal composition of T-cell responses to HIV/SIV (Bernardin et
al., 2004; Lopes et al., 2003; Turnbull et al., 2006), EBV (Maini et al., 2000) and
BCG vaccination (Bennett et al., 2006). In comparison to the spectratyping
technique, CDR3P-HDA has greater sensitivity in the detection of clonally expanded
T-cells (Maini et al., 1998; Shen et al., 1998). Furthermore, with spectratyping it is
not possible to identify whether disruptions of the Gaussian distribution are due to
individual expanded clones or multiple clones expressing CDR3P regions of
conserved length (Maryanski et al., 1996). As CDR3P-HDA identifies clones on the
basis ofCDR3P sequence rather than length, it has a greater capability to
differentiate between expanded clonotypes and hence provide greater resolution of
the clonal composition of complex aPT-cell populations (although there are
limitations to this, as discussed below).
The sensitivity for detection of clones by CDR3P-HDA was assessed for the V(32 and
Vpi3 subfamilies by seeding in vitro derived clones into unfractionated PBMC.
Whilst the sensitivity of detection of the Vp2+ clone was equivalent to that seen in a
human CDR3p-HDA technique (Maini et al., 1998) at 1:10,000, the sensitivity of
detection of the Vpi3+ clone was reduced by 10-fold to 1:1000 (Figure 3.6). There
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are several possible factors that may have contributed to this difference in sensitivity.
Subsequent studies described in chapters 4 and 5 demonstrated that the bovine Vf313
subfamily has undergone substantially more extensive duplication than the V(32
subfamily. There may therefore be a higher overall level of expression ofVpi3 in
unselected PBMC compared to Vp2 and consequently more competition from
polyclonal Vpi3+ chains during both PCR amplification and heteroduplex formation,
resulting in the lower sensitivity in detection of expanded Vpi3+ clones. However, in
the absence of comparative quantitative data on expression levels of VP 13 and Vp2
(e.g. by quantitative PCR), this remains speculative. The sequence of the individual
Vpl3+ and Vp2+TCRp chains expressed by the clones will also influence their
ability to form thermodynamically stable heteroduplices with the fluorochrome-
labelled 'probes' and so affect sensitivity of detection. Also, as TCR mRNA levels
vary widely between different cells (Callan et al., 1998; Maini et al., 1998), it is
possible that some of the difference in sensitivity was due to different level of
mRNA expression by the seeded Vpi3+ than Vp2+ clones. Thus, the levels of
sensitivity reported in this chapter should not be considered absolute values but
rather provide a general indication of sensitivity, which will be subject to both inter-
and intra-subfamily variation dependent on a number of variables. It should also be
noted that because TCR mRNA levels increase in activated T-cells (Callan et al.,
1998; Wotton et al., 1993) it is probable that the sensitivity thresholds identified by
use of in vitro derived clones in resting PBMC will not be directly applicable to a
complex, active T-cell response.
The bovine CDR3P-HDA was used to examine two T. parva-specific in vitro CD81
T-cell enriched cell-lines. The results indicated that both cell-lines were complex
populations, each containing numerous oligo-clonal T-cell expansions. The clonal
composition of these cell-lines as described by CDR3P-HDA was in good agreement
with that demonstrated by sequence analysis of the TCRp chains expressed by
approximately 90 clones generated by limiting dilution from each of the cell-lines.
All of the expanded clonotypes identified by sequencing of individual clones were
represented by a distinct heteroduplex band in the parent cell-lines CDR3(3-HDAs
(Figure 6.7). Furthermore, most of the clones expressing unique TCRp chains were
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also represent on the parent cell-line CDR3p-HDA (examples shown in Figure 6.8a).
Some of the heteroduplex bands did not co-migrate with the TCRp amplicons from
any of the derived clones (e.g. the two VP8 heteroduplex bands in the 468 cell-line)
and most likely reflect clonal expansions not represented within the individual clones
analysed. Direct sequencing of the bands from the gel (Bemardin et al., 2003, this
study - data not shown) could be used to confirm that they are genuine
heteroduplices. Alternatively these bands may be artefactual. Use of proof-reading
Taq polymerase for PCR amplification in a human CDR3P-HDA protocol helped in
reducing the presence of artefactual bands (Dr. A. Bennett, personal communication)
and may be something to consider using in future work with the bovine CDR3p-
HDA.
In general, the intensity of heteroduplex bands evident within subfamilies appears to
reflect the size of the clonal expansions represented (e.g. Figure 6.8a). Flowever, the
intensity of heteroduplex bands is an unreliable parameter for inter-subfamily
comparison of clone sizes. For example, although the larger Vp28+ clonotype is
represented by the most intense heteroduplex band on the 592 cell-line CDR3P-HDA
(upper heteroduplex band in final lane of Figure 3.7a), it is notable that the band
representing the Vpi7b' clonotype (comprising 6 individual clones - Figure 3.7a) is
fainter than that representing the V(38+ clonotype (comprising only 2 individual
clones - Figure 3.7a). This is unsurprising given the inter-subfamily variation in
sensitivity that, as discussed above, is inherent in the technique - but it does have
implications for the accurate interpretation of the results of CDR3P-HDA.
The ability ofCDR3p-HDA to separate and allow identification of expanded
clonotypes is a function of the expression of unique CDR3P sequences by individual
clonotypes. However, it is well documented that some clonotypes sharing the same
pMHC-specificity can express TCRs that have TCRP chains that are either identical
or show minimal differences (Annels et al., 2000; Hamrouni et al., 2003; Kedzierska
et al., 2004) and that subsequently may not be effectively segregated in CDR3P-
HDA (Cook and Beverley, 2001). Amongst the 592 clones there were two Vp28sl +
clonotypes that could be differentiated on the basis of (i) expression of different
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alleles of the V(328sl gene and (ii) co-expression in one clonotype of a non¬
functional Vpl3s6+TCRP chain (section 6.3.6.2), but which expressed identical
CDR3P sequences and consequently shared the same CDR3P-HDA migration
pattern. Therefore, in the uncloned 592 cell-line, both clonotypes were represented
by the same heteroduplex band (Figure 3.7 last lane, upper band). The ability to
segregate these two clonotypes by sequencing the TCRP chains of individual clones
was to some extent fortuitous and is a reminder that care is needed in evaluation of
clonal composition of complex T-cell populations by CDR3P-HDA (and other
techniques that employ analysis of TCRp sequence as a marker of clonality).
In summary, a suite ofmolecular tools that allow the sequencing of bovine TCRp
chains and also the accurate and rapid characterisation of the clonal composition of
complex bovine T-cell populations has been developed and validated. These generic
tools can now be applied to study the TCR repertoire and clonal composition of a
wide range of bovine T-cell responses, including those induced by T. parva.
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4 Chapter 4 - Examination of the bovine TCRp gene
repertoire
4.1 Introduction
The aPTCR repertoire is characterised by enormous diversity (Arstila et al., 1999;
Casrouge et al., 2000) which facilitates the recognition of the myriad pMHC ligands
that may be presented to T-cells. Much of this diversity is generated by somatic
recombination, whereby different permutations of individual non-contiguous variable
(V), diversity (D - in p chain only) and joining (J) gene segments, selected essentially
at random from the multiple copies available, are brought together to form the single
exons that encode the variable domains of the a and P chains. Further diversity is
created by (i) nucleotide editing at the V(D)J junctions, with terminal nucleotides
removed by exonuclease activity and non-germline nucleotides added by terminal
deoxynucleotide transferase (Tdt) and (ii) different combinations of a and P chains.
Following extensive analysis of TCRp chain transcripts during the 1980 and 1990s
(Arden et al., 1995a, b) and genomic sequencing of the TCRB loci (Rowen et al.,
1996, GenBank accession numbers AE000663-AE000665), the full repertoire of
human and murine TCRp genes is known. In other species such as cattle (Houston,
1997; Houston and Morrison, 1999; Tanaka et al., 1990), pig (Baron et al., 2001;
Butler et al., 2005), horse (Schrenzel et al., 1994), goat (Obexer-Ruff et al., 1998),
sheep (Halsey etal., 1999), rabbit (Isono etal., 1994) and rat (Smith et al., 1991)
partial information on TCRP genes, of varying levels of resolution has also been
gathered from cDNA analyses.
TCRpV (VP) genes are classified into subfamilies, the members of which share
>75% nucleotide sequence identity (Kazatchkine, 1995). Inter-species comparisons
reveal a much higher level of sequence similarity between VP gene in orthologous
subfamilies in different species than between Vp genes of different subfamilies in the
same species (Baron et al., 2001; Clark et al., 1995) reflecting establishment of some
VP subfamilies prior to mammalian radiation. However, both the number of VP
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subfamilies and the number of members within subfamilies differ between humans
and mice (section 1.2.3.2), indicating that the ancestral VP genes have been subject
to different deletion and duplication events in the 80-110 million years subsequent to
human-mouse divergence (Kumar and Hedges, 1998; Li et al., 1990). Examination
of the available data for other species also demonstrates that during speciation the
repertoires of individual species have been moulded by different duplication events.
For example, VP22 and Vpi, both single-member subfamilies in humans and mice,
have multiple members in pig and sheep respectively (Baron et al., 2001; Halsey et
al., 1999). As with the VP genes there is also a high level of inter-species sequence
conservation of the Dp, jp and CP genes (Baron et al., 2001; Schrenzel et al., 1994;
Williams et al., 1991), implying that the basic Dp, Jp and CP repertoires were also
formed early in mammalian speciation.
Characterisation of the full complement of the TCRP genes in human and mice has
allowed the development of methods to comprehensively study TCRp expression in
these species, yielding useful information on various aspects of the clonality and
TCR repertoire of antigen-specific T-cells (section 3.1) Application of such methods
to farm animal species is impeded by incomplete knowledge of the TCRp gene
repertoires. Previous studies of cattle TCRP genes have identified 46 VP genes
distributed within 17 subfamilies and 13 jp genes (Buitkamp et al., 1993, Russell and
MacHugh, unpublished; Houston, 1997; Houston and Morrison, 1999; Tanaka et al.,
1990). Two of the subfamilies, Vpi and Vp2 have been found to be extensively
duplicated, having 11 and 7 members respectively (Houston, 1997).
In the course of developing techniques to analyse bovine TCRp chain sequence
(Chapter 3) and their application to study the CD8+ T-cell response to Theileria
parva (Chapter 6), a large dataset of rearranged TCRp chain cDNA sequences has
been generated. Analysis of this dataset identified 22 novel VP genes, including
members of 3 novel subfamilies, and 4 novel jp genes. Notably, Vp4, 10 and 13
were identified as additional subfamilies that had undergone extensive duplication
and subsequent subfamily-specific cDNA analysis identified further novel genes
within these subfamilies. The results presented in this chapter contribute to a more
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thorough characterisation of the bovine TCRp gene repertoire which will be useful in
developing and refining molecular techniques to study bovine T-cell responses.
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any of the previously identified V(3 genes were, according to convention (section
2.5.1), considered to represent a novel gene and added to the database.
Using the 1MGT/V-QUEST software programme (Guidicelli et al 2004 -
http://imgt.cines.fr) the human VP gene with the highest nucleotide similarity to each
VP gene was identified and the subfamily of the bovine VP genes thus determined
(except for bovine VpX - section 4.3.1). The 1MGT/V-QUEST programme was also
used to align the bovine VP genes according to the IMGT unique numbering system
and define the complementarity determining regions (CDRs).
Sequence data for porcine VPX and murine VP2, were obtained from sequences
AY690918 and AE000663 deposited in the "NCBI nucleotide database
(http://www.ncbi.nlm.nih.gov) - Appendix B.
(ii) Analysis and nomenclature of.Jfi genes
Only sequence 5? to the CP gene up to and including that encoding the conserved
Phe-Gly-X-Gly (F-G-X-G) motif of jp genes has been considered to represent
germline jp sequence (sequence 5' to this could have been altered during somatic
recombination). TCRP transcripts were accordingly edited prior to further analysis.
Edited jp gene sequences were compared with 'in-house' databases containing the
human and known bovine Jp gene nucleotide sequences using the BLASTN
algorithm. Eluman jp sequences were derived from annotated genomic sequence of
the human TCRB locus (GenBank accession number U66061), and bovine sequences
from Tanaka et al (1990) and Houston (1997). In the WHO-1UIS system jp gene
nomenclature is determined by genomic location (Kazatchkine, 1995). Therefore, the
bovine jp genes were assigned temporary numerical names prior to the annotation of
the jp genes in the bovine TCRB locus (section 5.3.2).
Percentage nucleotide/amino acid identities were calculated using the Lasergene
software (DNAstar, Madison, WI)
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4.2.3 Subfamily-specific generation and sequencing of TCR0
chain transcripts
4.2.3.1 Subfamily-specific PCR amplification of cDNA
Naive PBMC from animals 641 and 605 were isolated (section 2.3.1) and cDNA
generated as described in sections 2.4.1-2.4.3. In separate reactions cDNA was
amplified with the VB4ext, VB7ext, VBlOext and VB13ext 5'primers (Table 2.2) in
combination with the common CP-specific 3'primer BCext (Table 2.3). Each PCR
reaction used 20 pmol of each primer, 1 unit BIOTAQ (5units/pl Bioline, London,
UK), 4 pi SM-0005 buffer (ABgene, Epsom, Surrey, UK - Appendix C.7), 2 pi
cDNA, and nuclease free water to give a final volume of 40 pi. The programme used
was as follows - 5 min at 94°C, 5 cycles of (1 min at 94°C, 1 min at 60°C, 1 min at
72°C), 25 cycles of (30 s at 94°C, 1 min at 60°C, 1 min at 72°C) and a final
extension period of 5 min at 72°C.
4.2.3.2 Cloning and sequencing of TCRp chain transcripts
Following confirmation ofPCR products of the expected size by agarose gel
electrophoresis (section 2.4.5), the products were purified using the Wizard PCR
Preps DNA Purification System (section 2.4.6), sub-cloned into plasmid pGEM-T
Easy vectors and used to transform High Efficiency Competent JM109 cells (section
2.4.7). The presence of inserts of the anticipated size in selected sub-clones was
verified by PCR as described in section 2.4.7.1. The resulting PCR products were
sequenced (section 2.4.9.1-2.4.9.2) and the sequences analysed as described in
section 4.2.2.
4.2.4 Southern blot
4.2.4.1 Culture of bovine fibroblasts
A bovine skin fibroblast line from animal 605 was cultured in supplemented D-MEM
medium (Appendix C.20) incubated at 37°C in a humidified atmosphere of 5% CCL
in air. Cells grown in culture flasks were washed once in PBS (Appendix C.6),
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incubated at 37°C for 5 - 10 min in trypsin (Trypsin EDTA (lx), Gibco, Paisley,
UK) and the harvested cells washed in foetal bovine serum (Gibco, Paisley, UK),
counted and then stored at -20°C until use.
4.2.4.2 Extraction and quantification of genomic DNA
Genomic DNA was extracted using the Wizard Genomic DNA Purification Kit
(Promega, Madison, WI, USA) according to the manufacturer's instructions. Briefly,
n
5x10 pelleted cells were washed in PBS, re-suspended and then lysed in 3 ml of
Nuclei Lysis Solution. 30 pi ofRNAse Solution was mixed into the nuclear lysate
and the mixture incubated at 37°C for 15 - 30 min. 2 ml of Protein Precipitation
Solution was added and the mixture incubated on ice for 5 min prior to centrifugation
at 13,000-16,000 x g for 4 min. The supernatant (containing the DNA) was carefully
transferred to a clean 15 ml tube, 6 ml of isopropanol added at room temperature and
the tube inverted gently until white threads ofDNA became visible. The DNA was
pelleted by centrifugation at 15,000 x g for 1 min at room temperature, washed in 6
ml of 70% ethanol, air-dried and re-hydrated by incubation in 500 pi of nuclease-free
water at 65°C for 1 h and subsequently overnight at room temperature. The re-
suspended DNA was quantified as described in section 2.4.2 and then stored at 2 -
8°C until use.
4.2.4.3 Enzyme digestion and separation of DNA fragments by agarose
gel electrophoresis
Aliquots of 20 pg of genomic DNA were incubated overnight at 37°C in 200 pi of
the respective enzyme digestion reactions containing Hincflll, Xba\ (lOU/pg DNA),
Sphl or Ssp\ (2.5U/pg DNA) in the relevant buffer and, where required, bovine
serum albumin (BSA). All enzymes, buffers and BSA were from New England
Biolabs (Hitchin, Herts. UK). To enable subsequent loading into an agarose gel, the
digested DNA samples were concentrated by ethanol precipitation; 400 pi ethanol
and 20 pi 3M sodium acetate pH 5.6 (Appendix C.19) was added to each digest
reaction. Following incubation at -20°C for 30 min, digested DNA was pelleted by
centrifuging at 12,000 x g for 15 min at 0°C. Digested DNA pellets were washed
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twice in 70% ethanol, air dried and re-suspended overnight at room-temperature in
25 pi of nuclease-free water.
Digested DNA was loaded into a 20cm x 20cm 0.8 % agarose gel (GNA 200 system,
Pharmacia Biotech AB, Uppsala, Sweden) prepared with 1 x TAE (Appendix C.9)
and run at 33 V for 16 h using 1 x TAE as running buffer. 5 pg of Lambda DNA
digested with HinclIII (Promega, Madison, WI, USA) was loaded into each gel to
provide molecular weight markers. After electrophoresis, the gels were stained in
ethidium bromide and visualised as described in section 2.4.5.
4.2.4.4 Transfer of DNA from agarose gels to nylon membranes
DNA was transferred from the agarose gel to a nylon membrane (Hybond-N+,
Amersham Biosciences, Chalfont St. Giles, UK) by capillary transfer as described in
(Sambrook et al., 1989). To facilitate the transfer, the DNA first had to be
depurinated and denatured. DNA was depurinated by agitating the gel for
approximately 30 min whilst submerged in 0.125M HC1 (Appendix C.21), the gel
was washed in distilled water and then the DNA denatured by agitating the gel for
approximately 45 min whilst submerged in 1.5M NaCl, 0.5M NaOH (Appendix
C.22). After a further wash, the gel was neutralised by agitating for approximately 30
min whilst submerged in 1M Tris (pH7.4) containing 1.5M NaCl (Appendix C.23).
Following a further wash, the gel was placed in a capillary blot for 16 h, with 20 x
SSC (Appendix C.24) used as the transfer buffer. Following transfer, the DNA was
fixed to the membrane by incubating for 2 h at 80°C whilst enclosed in dry 3MM
Whatman paper.
4.2.4.5 Probe generation
PCR amplification of the VP regions of plasmid clones VB1.1, VB2.2, VB13.1 and
VB14.6 (Table 3.3) provided DNA to generate Vpi, 2, 13 and 14 subfamily-specific
probes. Individual 100 pi reactions contained 50 pmol of each of the relevant 5' and
3'primers (Table 4.1), 2.5 units BIOTAQ (5units/pl Bioline, London, UK), 10 pi
SM-0005 buffer (ABgene, Epsom, Surrey, UK - Appendix C.7), 5 pi plasmid DNA
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(lOng/ml) and nuclease free water to give a final volume of 100 pi. Reactions were
completed using the following programme - 3 min at 94°C, 30 cycles of (94°C for 1
min, 54°C for 1 min and 72°C for 1 min) and a final extension period of 3 min at
72°C. Analysis of PCR products by electrophoresis (section 2.4.5) confirmed
generation of products of the anticipated size. PCR products were purified using
Wizard PCR Preps DNA Purification System (section 2.4.6) and quantified (section
2.4.2).
Primer Sequence
VBl*lfor CCC CAA ATA (CT)(CT)T GAT CAA ATC AAG
VBl*lrev GCT GGC ACA GAG ATA CAC G
VB2*lfor CTC TCG TCT CTC AGC AGC
VB2*2rev GCT GTC TGC AGG ATC CAC
VB13*lfor CAC TCA GGA CCC CAG ATT
VB13*lrev AGT ACA CAG ATG TCT GGG AG
VB14*2for AGG CCC CCT GGA (AT)GC CGA T
VB14*lrev GGC CAA CTC CAA GGT CAG
Table 4.1 Forward and reverse primers used for generation of Vpi, 2, 13
and 14 subfamily specific DNA probes.
Each DNA was labelled with 32P-dCTP using the Random Primed DNA Labelling
Kit (Roche Applied Science, Penzberg, Germany) according to the manufacturer's
instructions. Briefly, nuclease-free water was added to 25 ng aliquots of each PCR
product to give a final volume of 9 pi. The DNA was denatured by heating for 10
min at 95°C (and then immediately placed on ice to prevent re-naturing) and the
following added - 1 pi each of dATP, dGTP, dTTP (all at 0.5 mM), 2 pi Reaction
Mixture (hexanucleotide mixture in lOx reaction buffer), 2 units Klenow Enzyme (2
U/pl) and 50 pCi (a-32P) dCTP 3000Ci/mmol (GE Healthcare Ltd., Little Chalfont,
Bucks, UK). The reaction was mixed and briefly centrifuged before incubation at
37°C for 30 min. The reaction was stopped by the addition of 2 pi 0.2M EDTA
(pH8.0) and heating to 65°C for 10 min. Immediately before hybridization probes
were denatured by heating at 95 - 100°C for 2-5 min and incubated on ice until
used.
Ill
4.2.4.6 Hybridization and visualisation
Blots were pre-hybridised by complete submersion in pre-warmed Rapid-Hyb buffer
(Roche, Applied Science, Penzberg, Germany) for 15 min at 65°C before the probes
were added to give a final concentration of approximately 2 ng of probe DNA per ml
of Rapid-Hyb buffer. Hybridisation was completed at 65°C for 2 h with continuous
rotation. After hybridisation, blots were given three stringency washes; the first in 2
x SSC, 0.1%(w/v) SDS for 20 min at room temperature, the second in 0.5 x SSC,
0.1%(w/v) SDS for 15 min at 65°C and the third in 0.1 x SSC, 0.1%(w/v) SDS for
15 min at 65 °C. The blots were moistened in 0.1 x SSC, 0. l%(w/v) SDS, wrapped in
Saran wrap and exposed to x-ray film (Biomax MS Film, Kodak, Hemel Hempstead,
Herts, UK) whilst incubated at -70 °C. Exposures for different times ranging from 1
hour to 16 hours were made.
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4.3 Results
4.3.1 Analysis of rearranged bovine I CRp chains identifies 22
novel Vp genes and 3 new vp subfamilies.
Within the dataset of approximately 450 bovine TCRp chain sequences generated
during the completion of the work described in Chapters 3 and 6, 173 unique TCR(3
chain rearrangements were identified. The currently known repertoire of 46 bovine
VP genes has been established from the analysis of a combined total of-150 TCRp
chain sequences in several studies (Buitkamp et al., 1993, Russell and MacHugh,
unpublished; Houston, 1997; Houston and Morrison, 1999; Tanaka et al., 1990). The
availability of 173 new bovine TCRp chain sequence thus offered a significant
opportunity to re-evaluate the repertoire of bovine Vp genes.
Amongst the 173 rearranged TCRP transcripts, 57 VP genes distributed within 20
subfamilies were identified. This included 35 of the 46 VP genes identified in
previous studies including 6 that had been represented by a single sequence result
(Vpisl 1, 4s3, 7s2, 8s2, 9sl, 16s 1). All previously identified subfamilies were
represented within the dataset; the 11 previously identified genes not represented
were all members of multi-member subfamilies (Vpis2, ls4, 1 s 10, 2s 1, 2s2, 2s5,
4sl, 4s2, 4s4, lOsl and 10s2).
The other 22 Vp sequences identified represented novel VP genes. Eighteen of these
genes were new members of already established Vp subfamilies, including 2 new
members each for subfamilies Vpi (1 s 12, 1 s 13 - Figure 4.1), Vp2 (2s8, 2s9 - Figure
4.2) and Vp4 (4s5, 4s6 - Figure 4.3) and a single new Vpl7 gene (17s3 - Figure 4.4).
More notably, numerous novel genes were found in subfamilies VpiO (10s4, 10s5,
10s6, 10s7 - Figure 4.5) and Vp 13 (13s4, 13s5, 13s6, 13s7. 13s8, 13s9, 13s 10 -
Figure 4.6), which respectively more than double and triple the number of identified
members of these 2 subfamilies and expands them to sizes comparable with
subfamilies Vpi and Vp2. As would be anticipated, each of these novel subfamily
members had >75% nucleotide sequence identity with other members of their
respective subfamilies (Figures 4.1c- 4.6c). From the partial cDNA sequences
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obtained 2 of the Vp genes (Vpi0s6 and Vpi3s6) would be predicted to encode non¬
functional VP polypeptides. Vpi0s6 is predicted to be a pseudo-gene due to a
frameshift in the reading frame and Vpi3s6 is predicted to be an open reading frame
(ORF) pseudo-gene due to loss of the codon for the conserved cysteine residue at
position 104 which is essential for the correct protein folding of the VP
immunoglobulin domain.
The four remaining genes were members of novel bovine Vp subfamilies. The genes
designated as bovine VP5sl, VP 12s 1 and Vpl2s2 were classified as such because
they showed highest nucleotide sequence identity to human Vp5s3 (73.6%) and
human VP12s 1 (74.6% for both Vp 12s 1 and 12s2) respectively (sections 1.2.2 and
2.5.1). However, both Vpi2 genes have nearly as high nucleotide identity with
members of the human Vpi3 subfamily (Vpi2sl has 74.2% nucleotide identity with
human Vp 13s 1 and VP 12s 1 has 73.8% nucleotide identity with human Vpi3s5), and
show sufficiently high homology (>75%) to all bovine Vpi3 subfamily members,
that if considered without reference to human sequence comparison, both VP 12
genes would be incorporated within the Vp 13 subfamily (Figure 4.6c). Furthermore,
both Vpl2 genes were identified following amplification with Vpi3 subfamily-
specific primers. Similarly, Vp5sl shows higher nucleotide identity to human Vpl
(70.4%) than some human Vp5 subfamily members (e.g. 67.4% identity with human
Vp5sl) and displays >75% nucleotide homology to 7 out of the 13 members of the
bovine Vpi subfamily (Figure 4.1c). The ambiguity in defining bovine genes as
members ofVpi or 5 and Vp 12 or 13 reflects the situation in humans where
members of these subfamilies frequently share >75% homology (Arden et al.,
1995a). The nucleotide and amino acid sequences of Vp5sl are shown aligned with
the novel Vpi subfamily genes in Figure 4.1 and those of Vp 12s 1 and 12s2are
shown in Figure 4.6 with the novel Vpl3 sequences.
The final novel gene identified had no human orthologue (<30% nucleotide identity
with any human VP gene) but shared 76.2% nucleotide identity with murine Vp2. A
Sus scrofa (porcine) VP gene identified by Baron et al (2001) in a miniature pig
showed similar phylogenetic characteristics (GenBank accession number AY690918)
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and was subsequently given the subfamily designation VpX by Butler et al. (2005).
The bovine gene has 80.3% nucleotide identity with the porcine VpX gene, and was
given the corresponding name - VpXsl. The nucleotide and amino acid sequences of
bovine VpXsl are given in Figure 4.7.
4.3.2 Further examination of large multi-member subfamilies
Nearly 40% of the VP genes identified in the above analysis (22/57) were novel, with
all but 2 (Vpi7s3 and VpXsl) belonging to one of five large subfamilies - Vpl, Vp2,
Vp4, VpiO and Vpl3 or the 'associated' VP5 and Vpi2 subfamilies. The high
frequency with which novel genes were identified in the large subfamilies, especially
in VpiO and Vpi3, suggested that the complement of known genes belonging to
these subfamilies was still incomplete.
The ability to amplify TCRp chains by PCR using VP subfamily-specific primers
offered the opportunity to analyze the membership of selected subfamilies. In
separate reactions cDNA from unfractionated PBMC was amplified using the
VBlOext and VB13ext 5'primers in combination with the CP-specific 3'primer
BCext and the products sub-cloned into plasmid vectors. Analysis of the resulting
partial TCRp chain transcripts revealed 74 unique VpiO TCRp chain rearrangements
(derived from animal 641) and 161 unique VP 13 TCRp chain rearrangements (77
derived from animal 605 and 84 from animal 641). These sequences included four
novel VP 10 genes (Vpi0s8, 10s9, 10s 10 and 10s 11 - Figure 4.5) and nine novel
Vpl3 genes (Vpl3sll, 13sl2, 13sl3, 13sl4. 13sl5, 13sl6, 13sl 7, 13sl8, 13sl9-
Figure 4.6). By including the previously identified sequences, this takes the total
membership of subfamily VpiO to 11 genes and VP 13 to 19 genes. However, (i) not
all of the previously identified VpiO and Vpl3 genes were present in this set of
sequences (Vpi0s5, 10s6, 13s3, 13s7 and 13s9 were absent), (ii) there were marked
differences in the representation of different VP 13 members in the sub-clones
derived from animals 641 and 605 (Figure 4.8), with some members only present in
the sub-clones from one animal (e.g. "VP 13sl6 in animal 641), and (iii) several genes
115
Figure 4.1 A) Nucleotide sequence and B) amino acid sequence of novel Vpi and V05 genes.
Sequences are aligned and CDR1 and CDR2 (shaded regions) defined according to the IMGT
unique numbering system. Identity is shown as dashes and gaps by dots. C) Percentage
nucleotide (top-right) and amino acid (bottom-left) sequence identity of the V|S1 and Vp5 genes.
Shaded boxes indicate >75% nucleotide identity between Vp5sl and Vpi subfamily members -
the value conventionally used to define members of the same subfamily.
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61 71 81 91 101 111




121 131 141 151 161 171
VBlsl2 TGGTACCAAC AGGCCCTGGG CCAGAGCCCC GAGTTCCTCA CTCAGTATTA CAGGCAGGAA
VBlsl3 G C T- T T-ATGG-A—
VB5sl A-A- T G C A—T T-G T TGAAACTCTG
181 191 201 211 22 1 231
VBlsl2 GTT AGGGG AGAAGCACAG CTCCCG. . . G ATCGATTCTC AGGAAAACAG
VB1S13 GAG -AT-A GA G-A-C A-G--A...- TG
VB5sl CAA —A-C TA G-A-C T-TT—...A G T --C
241 251 261 271 281 291
VB 1 s 12 TTT . . . AGTG ACTTTCACTC TGAGCTGAAC TTGAGCTCCT TGGAGCTGAC GGACTCAGCC
VB 1 s 13 --C... C-AG -C--A C A T
VB5sl --C...CCT- AG--- G A C--A-- T---
VB1S12 GTGTATCTCT GT





11 21 31 41 51
VBlsl2 T LGCSPVSGHL S .VS WYQQALGQSP EFLTQYYRQE
VBlsl3 G -Q—I NGK
VB5sl QS-G- Q-IFEF-ETL
61 81 91
VBlsl2 V....RGEAQ LP.DRFSGKQ F.SDFHSELN LSSLELTDSA VYLC
VBlsl3 E....NEKGN M-. E- -.--SS-QM-
VB5sl Q....-AKGN FS.N—LA— -.P—S VN—D L
c
Nucleotide sequence identity (%)
ox
lsl ls2 ls3 ls4 ls5 ls6 ls7 ls8 ls9 lslO lsll lsl2 lsl3 5sl
lsl 95. 6 80.2 81.7 87.6 80.2 83.5 84.5 80.3 81.0 80. 6 93.1 80.5 73.8
ls2 90.1 80. 6 80.6 88.4 79.1 84.6 83.8 80.0 80.2 80. 1 96.3 80.6 72 . 6
ls3 65. 9 68.1 85.3 84.2 87.2 90.5 85.3 88.2 89.2 93.0 80.3 87.0 74 . 8
ls4 70.3 70.3 79.1 85.0 92.6 89.4 86.3 88.5 86.0 86. 9 79.8 92.9 74.3
ls5 78.7 80. 1 75.2 77.3 84.2 86.9 87 . 3 83.9 82.3 85 . 7 87.2 83.4 75.7
ls6 67.0 67 . 0 81.3 89.0 74 . 2 93. 8 82 . 8 86.7 87.9 89.2 78 . 9 97.0 75.2
1S7 72.5 78.0 86.8 83.5 79.8 89.0 87.5 88 . 9 88.3 91.2 85 . 9 93.5 76.7
ls8 76.7 74.4 74.4 78.9 78.7 72.2 80. 0 84 . 5 82.7 86.1 82 . 6 83.4 74.3
ls9 70.0 71.1 84 . 4 80.0 75.2 74 . 4 82.2 77.8 84 . 8 86.5 78 . 4 87.0 75.1
lslO 64.9 66.2 83. 1 77. 9 72.7 80.5 80.5 70.1 76.6 94 . 8 80.7 87.6 75 .7
lsll 64.0 67 . 4 88 . 4 79.1 75.6 82.6 87.2 73.2 79.0 87 . 5 81.7 88 .2 76.3
lsl2 87 . 5 95. 8 65. 3 70.4 79.2 65.3 77 . 5 73.6 69.4 68 . 0 66.7 79.8 72.7
lsl3 64.2 69. 6 80. 3 87 . 5 73.2 94.6 91.1 73.2 71.4 80.3 82 .1 67 . 8 75.3
5sl 53. 6 53.5 55.4 51.7 53. 6 53. 6 58 . 9 55.4 53.4 58 . 9 58 . 9 51. 8 53.6
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Figure 4.2 A) Nucleotide sequence and B) amino acid sequence of novel Vp2 genes. Sequences
are aligned and CDR1 and CDR2 (shaded regions) defined according to the IMGT unique
numbering system. Identity is shown as dashes and gaps by dots. C) Percentage nucleotide (top-
right) and amino acid (bottom-left) sequence identity of the V02 genes.
VB2s8 CCCACAGG GCTTTCAGTA AGAGTGGAGC CTCTGTGACC
VB2S9 G G- -
CDR1
VB2s8 ATCGAGTGCC GTGCAGTGGA CTTTCAAGCC TCAAGT ATGTTC
VB2s9 C T A C- T
CDR2
1 71
VB2S8 TGGTACCGTC AGTTCCCAAA ACGAGGCCTC GTGCTGATGG CAACTTCTAA TGTGGGCACT
VB2s9 G- - —C
VB2s8 AATGCC ACATA CGAACAAGGT TATACCAAGG ACAAGTTTCC CATCAGTCAT
VB2s9 — A C







11 21 31 41 51
VB2s8 HR AFSKSGASVT IECRAVDFQA SS......MF WYRQFPKRGL VLMATSNVGT
VB2s9 R- L TT V- A—
61 71 81 91 101
VB2s8 NA...TYEQ GYTKDKFPIS HP.DLTFSSLM VTNVDPADSG LYFC
c
Nucleotide sequence identity (%)
2s1 2s2 2s3 2s4 2s5 2s6 2s7 2s8 2s9
2sl 95.3 96. 4 95 . 3 96.4 94 . 3 96.5 91. 9 93.8
2s2 89.4 97 .1 94 . 6 96. 8 91.2 96.1 96. 9 95 . 0
2s3 93. 6 91.5 93.8 96.8 96.4 95.3 93.8 92.7
2s4 92 . 4 90.0 oCO00 96.0 96.7 95.6 93.5 95 . 4
2s5 92.5 90. 4 90 . 4 94 . 6 97.2 96. 8 94.2 95.4
2s6 87.2 91.5 89.4 95.6 91.4 95.4 95 . 4 94 . 6
2s7 94.5 92 . 5 90 . 4 95 . 6 94.7 90 . 4 93 . 8 96.5
2s8 82 . 6 94.2 84.9 86.0 86.0 88 . 4 87.0 95 . 8
2s9 87.2 89.5 82 . 6 91.8 90.7 87.2 91. 9 90 . 7
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Figure 4.3 A) Nucleotide sequence and B) amino acid sequence of novel Vp4 genes. Sequences
are aligned and CDR1 and CDR2 (shaded regions) defined according to the IMGT unique
numbering system. Identity is shown as dashes and gaps by dots. C) Percentage nucleotide (top-
right) and amino acid (bottom-left) sequence identity of the Vp4 genes.
A
1 11 21 31 41 51





61 71 81 91 101 111
VB4 s5 ATCGAGTGTC GTCAGGTTGA TAGCCAGCTC ACCGCG ATGTAC
VB4s6 ---A ...-A--C— T TG- . . i t.
VB4 s7 GTC AT-
VB4S8 ... C— G- —TTT-
CDR2
121 131 141 151 161 171




18 1 191 201 211 221 23 1
VB4s5 AAGGCT ACTTA CGAGAGTGGG TTTACTGACA ACAAATTTCC CATTAGCCGC
VB4s6 T GG G GA
VB4s7 ......... C- -GG G GA
VB4s8 GG G GA
VB4S5 CCG...GTCC TTGCGTTCTC AACTCTGACT GTGAGCAACG CGAGCTCCGA AGACAGCAGC
VB4S6 ...AAA- -G-A C T
VB4S7 ...AAA- -G-A T- T--T









1 11 21 31 41 51
VB4s5 R AICQRGTSVM IECRQVDSQL TA MY WYRQLPGQSL VLMATANQGS
VB4 s 6 MT -K-.— -W —
VB4 s7 R -M — ;
VB4 s8 . V NF. —
61 71 81 91 101
VB4s5 KA...TYESG FTDNKFPIS RP.VLAFSTLT VSNASSEDSS SYFC
VB4s6 —... —ED D —.K-E
VB4 s7 —... —ED D —.K-E
VB4s8 —ED D —.K-EI T
c
Nucleotide sequence identity (%)
4sl 4s2 4s3 4s4 4s5 4s6 4s7 4s8
4sl 90 . 3 96. 4 90.8 92 . 9 90.1 91.0 95.2
4s2 83.5 93.2 89.2 88.7 95.3 92 . 5 93.7
4s3 92 . 9 89. 9 92 . 9 92.2 93.7 92 . 9 97.2
4s4 87 .2 82.5 90. 6 92 . 6 90. 6 96.1 91.8
4s5 91.7 83.7 89.4 89.4 90.2 93.3 91.0
4s6 85.7 93.6 91.7 89.4 88.2 92.9 94 .1
4s7 87.0 88 . 7 90. 6 91.8 91.8 92 . 9 94 .1
4s8 90.5 89. 9 94.0 87.0 87 . 0 90.5 91.8
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Figure 4.4 A) Nucleotide seq uence and B) amino acid sequence of the novel Vpi7 gene.
Sequences are aligned and CDR1 and CDR2 (shaded regions) defined according to the IMGT
unique numbering system. Dots identify gaps. C) Percentage nucleotide (top-right) and amino
acid (bottom-left) sequence identity of the Vpi7 genes.
VB17S3 CGG AGCTGTGACC
CDR1
61 71 81 91 101 111
VB17s3 CTGGAATGTG AACAGGATTT TGATTACGAC TCA ATGTAC
CDR2
1 71
VB17S3 TGGTACCGAC AGGACCCAGG TCTAGGACTG AGGCGGATCT TCTTCTCACA ATTTGTAAAC
VB17s3 ACT. .GTTCA GAAAGAAGAC ATAGCT... A AAGGCTACAG CGCCTCTCGT





VB17S3 GAVT LECEQDFDYD S MY WYRQDPGLGL RRIFFSQFVN
































Figure 4.5 A) Nucleotide sequence and B) amino acid sequence of novel V p 10 genes. Sequences
are aligned and CDR1 and CDR2 (shaded regions) defined according to the IMGT unique
numbering system. Identity is shown as dashes and gaps by dots. C) Percentage nucleotide (top-
right) and amino acid (bottom-left) sequence identity of the VpiOgenes. Shaded boxes show that

















VB10S4 ATGGATTGTG TCCCCATTAA AGGACACGCT TCT GTTTAC
VB 10 s 5 AA— T— -A-
VBlOsS T— T-T- CA-
VB10s7 T— AT- AA-
VB10s8 A— TAT- AA-
VB10S9 A-G TAT- AA-
VBlOslO A— TAT- AA-
VBlOsll A:— T-T- AA-
CDR2
VB10S4 TGGTATCTCA AGAAGCTGGA AT CATTT GAGTTTTTGG TTTATTTGCG GAATGGAAAA
VB10 S 5 G- - G - GAAG A C--A-A -G A
VBlOsS A- - --CA-- -GAAG T :
VB10S7 G- - --CA-- -GGAG - -A C C—AAA CA-G-C
VB10s8 G- - G -GAAG--C-C C--A- C—T-A GCA-G-C
VB10S9 G- - G -GAAG--C-C c C—T-A GCA-G-C
VBlOslO G- - G -GAAG c C—T-A GCA-G-C









.ACAGA AGATACAGCC ATGTTCAAAC AGCGATTTTC AGCTGAGTGC
|-T - -T
| t
.GTG-- AA-G-A--TC T G CC G
. GTG- - --GC AA G G
. GTGA- - -GC AA G G
124
VBlOslO — T
VBlOsll — GTG- - --GC AA G G G---
CCC
-G-






VB10 S 5 --
VB10S6 --
VB10S7 C
VB 10 S 8 --













61 71 81 91 101
VB10 s 4 I. . ..TEDTA MFKQRFSAEC P.QNSPCSLE INSTEAADSA LYFC
VB10 s 5 I. . . . I V--
VB10 s 6 V. . . . -D
VB10S7 I.. . .V E V-Q L-PW
VB 10 s 8 I.. . .V- G E V--E R. V-A-
VB10s9 I.. ..VKG-E V--E A-
VBlOslO I.. ..VKG-E V--E V











VKGKDQKAK MDCVPIKGHA S .VY WYLKKLE.SF
L R- K S i.. -- - -RR EAL
V SS- VH.......-- --H--P-GA-
G 1 N --R--P-GA-
G-R- IN...,.,.,-- - -RR EAL
E R R—I N.......-- - -RR EAL




Nucleotide sequence identity (%)
lOsl 10S2 10s3 10s4 10s5 10s6 10s7 10s8 10s9 lOslO lOsll 25sl
10sl 93.7 87 . 4 93.4 88.5 95. 6 86.0 83.9 83.9 85.6 86.0 67.5
10s2 91.1 90.3 95.5 90.5 94.7 84 . 4 83.9 84 .8 85.5 86.0 67.1
10s3 80.0 83.3 88.5 90.9 85.2 86.0 87 .7 86.8 88 . 5 88 . 8 67.1
10s4 91.3 92.5 80.2 90.1 90.1 83.9 84.3 83 . 9 86.0 86.4 66.3
10s5 80.2 81.5 82.7 81.5 95.6 85.2 87.2 86.4 87.6 88.5 71.0
10s6 96. 0 85.5 76.3 86.8 77 . 6 83. 9 82 . 6 81.7 83.4 83.9 65.3
10s7 80.2 76.5 74.1 77.8 71.6 76.3 87 . 6 87 . 6 89.3 89.7 65.9
10s8 71. 6 71.6 77.8 72.8 77 . 8 68.4 77 . 8 95.8 96.7 95.4 68.7
10s9 71. 6 74.1 76.5 72.8 75.3 68.4 76.5 91.3 95.9 95.5 68.3
lOslO 74 . 0 74.1 77.8 75.3 75.3 71.0 80.2 92 . 6 91. 4 97 .1 69.8
lOsll 77 . 8 76.5 80.2 77.8 77.8 73.7 81.5 90.1 88.8 92.6 68.3
25sl
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Figure 4.6 A) Nucleotide sequence and B) amino acid sequence of novel Vpi3 and Vpi2 genes.
Sequences are aligned and CDR1 and CDR2 (shaded regions) defined according to the IMGT
unique numbering system. Identity is shown as dashes and gaps by dots. C) Percentage
nucleotide (top-right) and amino acid (bottom-left) sequence identity of the Vpi3 and Vpi2
genes. Shaded boxes indicate >75% nucleotide identity of Vpi2sl and Vpi2s2 with Vpi3
subfamily members - the value conventionally used to define members of the same subfamily.
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61 71 81 91 101 111
VB13S4 CTGAGATGCA CTCAGGATCT GAACCACAAT TAT ATGTAC
VB 13 S 5 A T- T G—
VB13s6 -A G— G—................. . ...
VB13s7 C T- -GGT—TG-C -C-
VB13S8 C T- -GGT--TG-- -GC ■...
VB 13 S 9
VB 13 s 10 G GT-
VB13s 11 A T- -GGT--TG-C CGC....... ....
VB13s 12 T- -T G-C AG.......
VB13s 13 T---C T- -C -GGT—T—C -GC
VB 13s 14 C T- -G-T—T—C -GC..
VB13s 15 T C T- -C -GGT—T—C -GC
VB13S16 C T- —G-TTT-GC
VB13S17 G—
VB13S18 TT -GGT—T—C -TC. . . . C-
VB13s 19 C T- T -GGT—TG-C -C- G




121 131 141 151 161 171
VB13 s 4 TGGTACCGAC AAGACCTGGG ACGCGGGCTG AGGCTGATCC ATTACTCAAA TGGCCCTCCC
VB13S5 --A —GC TGTG-GT
VB 13 s6 - -A —GT -AT T
VB13s8 T --AT —GT -—TG T
VB13s9 T A CA- T C— A—T G
VB13S10 T |
VB13S11 - -A T GC -—TGTG-GT
VB13S12 A-- --T-A T- G T TC -TT-A—GA-
VB13S13 T --AA —GC GTG-GT
VB13S14 T --AA —GT CTG
VB13S15 T --AA :—-GT - -CTG T
VB13S16 CA- - --AT GT -AT
VB 13 s 18 - -A G- TG-G-G-
VB13S19 - -A T ff—GC G
181 191 2 01 211 221 231
VB1 3s4 AAC ACAGA GAACGGAGAT GTGCCC . . . G AGAGCTACAG CGTCTCCAGA
VB13s5 -GC - - -CCA ...- -CG-G
VB13s6 GC- - -G- A CC ...- --G
VB 13 s 7 -C- --G-T A ...- --G
VB 13S8 G—............--G-T T--A CA-A ...- --G-T
VB13s9 T— AG - - G T...- --G
VB13S10 T— ..... ...- - -G
VB13S11 TCT....... -GC-- -CCA T...- -CGAG
VB13S12 T— .--GT- C--A CA T...- -TG
VB13sl3 TCT....... GC - -CCA T...- -CG-G
VB13sl4 ....... --G-T T--A T A-A ...- --G-T
VB13sl5 G— --G-T T--A C A-A--T...- --G-T
VB13S16 TC- - -G- - --GA CC ...- - -G
VB 13 S17 ...- - -G T
VB 13S18 -CT -GA-- -CCA C ...A -TG-G T T-A-
VB13sl9 -C-. -TG-T A C T...- -CG-G G- T
VB12sl T—............ G T...- - -G
VB12s2 ...- -CG
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241 251 261 271 281 291
VB13S4 CCA. . .AGCA CAGAGGACTT TCCTCTCACA CTGGAGTCTG CCAACCGCTC CCAGACATCT
VB13 s 5 T--... A A -G G C- AG-- C
VB13 S 6 ... G
VB 13 S 7 ... A-A C G A A
VB13S8 ... -A C G
VB13S9 ... C
VB13S10 ... C G---
VB13S11 T--... A A -T A G C- AG-- C
VB13S12 T--... A C G
VB13S13 T--. . . A A G G C- AG-- C
VB13S14 ... -A C--- C G A---
VB13S15 ...---- - -A C-T G A---
VB 13 s 16 ... T A C G-
VB13S17 ... C
VB 13S18 T— ... -A- - A A -G-A G
VB 13S19 T--... A-A-CC T C- A A C
VB12sl ... - C







VB 13 S 9 --
VB 13 S10 --
VB13S11 - -T -T
VB13S12 --




VB 13 S17 --
VB 13 S18 --
VB 13 S19 -T





1 11 21 31 41 51
VB13S4 QVIRSGQKPT LRCTQDLNHN Y
VB13S5 --V-R--NA- -K D -
VB13S6 --V-R-LNA- -T -SFS n
VB13S7 --V-K-LNV- -T -G-D R.
VB13S8 --V-T--NT- -T -G-D c.,
VB13S9 - -V V- -
VB13S10 - -V
VB13Sll --V-R--SA- -K -G-D R.
VB13S12 --VKT--NV- -Y-D R
VB13S13 --VRT--KA- -T -G— r.
VB13S14 - - V-T A- -T -D— r.
VB13 S15 --V-R-LNT- -T -SFS -
VB13S16 --V-T--NM- D -
VB13S17 --M-T--NV- S— -G— F
VB13S18 --M-T--NV- S— -G— F
VB13S19 --V-T--NA- -T--L- -G-D R
VB12S1 - - V V-














61 71 81 91 101
VB13S4 N. . ..TENGD VP.ESYSVSR P . STEDFPLT LESANRSQTS VYFC
VB13s5 S. . ..S-P-- --.DG S.-K-N-A-- Q
VB13s6 A. . ..--K-A --.-Q -- _ _ s
VB13s7 T. . ..-VK-- --.-G -- -,-KK -K H
VB13s8 D. . ..-VK-- I-.-G -- - . - -K
VB13S9 Y. . . .RG .-G
VB13sl0 Y. . . . --.-G -- __ p
VB13sll S. . ..S-P-- --.DE -- S.-K-N-AH- Q
VB13sl2 T. . ..-YK-- M-.DG -- S. N
VB13sl3 S. . ..S-P-- --.DG D.-K-N-A-- Q
VB13sl4 ..-VK-- I-.-G -- -.--KA H
VB13sl5 S. . ..--R-A --.-G -- -,-I-N
VB13sl6 --.-G
VB13sl7 T. . . . A- P- - --.NG -K S.NK-N-A--
VB13sl8 T. . ..S-P-- - -.NG -K S.NK-N-A--
VB13sl9 T. . ..MVK-- --.DG-G- -- S.-KNH H













































































































































































































































































































































































































































Figure 4.7 A) Nucleotide sequence and B) amino acid sequence of VpXsl, aligned and CDR1
and CDR2 (shaded regions) defined, according to the IMGT unique numbering system.
A
1 11 21 31 41 51
VBXsl C CTCGCAGACA GGCTGAAACC
CDRX
61 71 81 91 101 111
VBXsl CTGCGGTGCA TCCTGAAGGA TTCCCAGTAC CCCTGG ATGAGC
CDR2
121 131 141 151 161 171
VBXsl TGGTACCAGC AGGATCTCCG GGGGCAACTA CAGGTGCTGG CCAGTCTGCG GCGTACCGGG
18 1 191 201 211 221 23 1
VBXsl GAT AAGGA AGTCATAAAC CTCCCTGGAG CGAATTACCG GGCCACGCGG
241 2 51 261 271 281 291





1 11 21 31 41 51
VBXsl PRRQAET LRCILKDSQY PW MS WYQQDLRGQL QVLASLRRTG
61 71 81 91 101
VBXsl D. ...KEVIN LPGANYRATR V.SESELSLH VANVT. . QGR TLFC
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were represented by only one transcript (e.g. VP 13s 12). This would indicate that
although this strategy enabled a rapid and focused examination of a large number of
unique TCRP transcripts bearing VP genes of specific subfamilies and the
identification of several new members, comprehensive characterisation of the
membership of these subfamilies had probably still not been achieved. A similar but
smaller scale experiment examined 32 VP4 clones derived from animal 641 and
identified 2 novel genes - Vp4s7 and Vp4s8 (Figure 4.3).
35%
I L ■ ■ 11
T— CM CO LO CO
(/)(/>(/}(/>(/)(/)
CO CO CO CO CO CO CO CO CO
Subfamily members
Figure 4.8 Percentage of TC'Rp transcript sub-clones generated from animals 605 (blue) and
641 (maroon) using the 5'primer VB13ext, that expressed the different Vpi3 and 12 subfamily
members.
4.3.3 Additional VP genes amplified by VpiO and Vp13 subfamily-
specific primers
In addition to Vpi3 genes, both Vp12sl and Vpi2s2 genes were amplified from the
cDNA of animal 641 by the 5'primer VBl3ext (Figure 4.8). As stated before (section
4.3.1), both Vpi2 members were initially identified following amplification with
VP13 subfamily-specific primers and so this was not unexpected. A single TCRP
chain transcript amplified by VBlOext was found to have highest nucleotide
sequence identity to human Vp25sl (77.9%, compared to 68.0% nucleotide identity
with human VpiOsl) and had <75% nucleotide homology with all of the bovine
VpiO genes (Figure 4.5c); accordingly the gene was named Vp25sl. The nucleotide
and amino acid sequence data for Vp25sl is given in Figure 4.9.
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Figure 4.9 A) Nucleotide sequence and B) amino acid sequence of V(525sl, aligned and CDR1
and CDR2 (shaded regions) defined, according to the IMGT unique numbering system.
A
1 11 21 31 41 51
VB25S1 GTTCAAG GGAAAGGACT GGAAGTGAAA
CDR1
61 71 81 91 101 111
VB25S1 ATGTATTGTG TTCCCAAAAA AGGACATATT TAT.. GTGTTC
CDR2
121 131 141 151 161 171
VB25S1 TGGTATCAGC AGATCCTGAC CAAAGAGTTC AAGTTCTTGA TTTCCTTCCA AAATGATAAA
1 81 191 201 211 221 2 31
VB25sl GTC TTGGA TGATAAAGAG ATGCCC. . .A AGAGATTTTC AGCTGAGTGC
241 251 261 271 281 291
VB25S1 CCC...TCAA ACTCACCTTG TAGTCTGAAG ATCCAGCCTA CGGAGCCGCA GGACTCAGCT
301 311
VB2 5S1 ATGTATTTCT GT
B
CDRl CDR2
1 11 21 31 41 51
VB25S1 VQGKGLEVK MYCVPKKGHT: Y.......VF WYQQILTKEF KFLISFQNDK
61 71 81 91 101
VB25sl V....LDDKE MP.KRFSAEC P.SNSPCSLK IQPTEPQDSA MYFC
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4.3.4 Demonstration of Vpi, Vf32, and VP13 subfamily expansion
in genomic DNA
An alternative approach to examining the extent of membership of bovine Vp
subfamilies was to examine un-rearranged genomic DNA using Southern blot
analysis with subfamily-specific probes.
Genomic DNA from a primary fibroblast cell-line was digested with four enzymes
{HindiII, Sspl, Xbal and Sphl), selected on the basis that identified VP genes
belonging to the subfamilies being examined did not have the respective restriction
sites. 32P-labelled probes specific for Vpi, Vp2, VP13 and Vpi4 (representing a
putative single member subfamily) were generated; due to the high nucleotide
similarity between members of the Vpi and 5 subfamilies and the Vpi2 and 13
subfamilies (Figure 4.1c and Figure 4.6c) it was assumed that the Vpi probe would
bind to both Vpi and VP5 genes and the Vpi3 probe would bind both Vpi2 and
Vpi3 genes.
Hybridization with the Vpi4 probe revealed a single band (5.0-7.9kb in size) in
preparations of DNA digested with Hindlll, Sspl and Sphl (Figure 4.10a) - consistent
with Vpi4 being a single member subfamily. The results of hybridisation with the
VP2 probe were dependent on the enzyme that had been employed for digestion. In
the Xbal digested-DNA at least eight bands of varying intensity, ranging in size from
3.0 - 10.0 Kb, were discernible (Figure 4.10b, lane 3), whilst in the Hindlll digested-
DNA only two bands of 4.1 and 4.4 Kb were detected (Figure 4.10b lane 1) and in
each of the Sspl and Sphl digested preparations there were 4 bands (Figure 4.10b,
lanes 2 and 4). The marked variation in the intensity of bands detected with the Vp2
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Both the V|31 and Vpi3 probes gave a highly complex banding pattern (Figure 4.10c
and d), with a minimum of 15 bands ranging in size from 1.0 - 14.0Kb detected with
three out of the four enzymes (Hindlll, Sspl and A7>al). Again variation in intensity
of the bands suggested that some of the bands represented superimposed genes.
Notably, there was a high degree of similarity in the banding pattern of the vpi and
VP 13 probes (Figure 4.10e), suggesting that some ofthe Vpi and Vpi3 genes may
be located on the same DNA fragments.
Thus, the results of the southern blots corroborate the cDNA data, demonstrating that
several bovine TCRpV subfamilies contain large numbers ofmembers. However, (i)
potential superimposition of multiple DNA fragments sharing restriction sites in
some bands, (ii) the possibility that some of the larger bands may represent DNA
fragments containing multiple VP genes belonging to the same subfamily and (iii)
likely cross-reactivity of subfamily specific probes prevents precise enumeration of
the membership of these subfamilies.
4.3.5 Analysis of bovine jp genes from rearranged TCRp chain
transcripts.
Analysis of the initial dataset of 173 unique TCRP chains revealed the existence of
16 different jp gene sequences, including all 13 that had been described in previous
studies (Houston, 1997; Tanaka et al., 1990); no additional jp genes were identified
in the TCRP transcripts subsequently generated. All of the jp gene sequences
identified were present in more than one unique TCRp rearrangement, and thus
sequence variation is assumed to represent genuine germline sequence variation
rather than experimental error due to mis-incorporation of nucleotides. As Jp
nomenclature is based on genomic position, which was unavailable at the time of
analysis, the jp genes were given a temporary numeric nomenclature (J 1-16), with
the three novel jp genes identified being J14-16.
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Each of the bovine Jp sequences shared high nucleotide (70-93%) and amino acid
(60-100%) sequence identity to human orthologues (Table 4.2). There appeared to be
two bovine orthologues to each of four human jp genes in the second genomic
cluster (jp2sl, 2s2, 2s5 and 2s7). The two bovine orthologues of human Jp2s5 (J6
and J8) differed from each other by a single nucleotide substitution and similarly J7
and J15, both orthologues of human jp2sl, differed by only two base pairs; therefore
these pairs of sequences may represent allelic variants of the same jp gene.
However, the two bovine orthologues of human Jp2s2 - J1 and J10 - demonstrated
significant sequence divergence (12/30bp difference - only 60% nucleotide identity),
as did the two bovine orthologues of human jp2s7 - J3 and J13 - (6/30bp difference
- only 80% nucleotide identity); suggesting that these J genes are products of
different gene loci rather than allelic variants.
The frequencies with which the jp genes were expressed were highly variable, with
one of the novel genes, J16, being only identified in two of the approximately 400
unique TCRp rearrangements analysed, whilst others such as J2 were utilized in
-20% of TCRP transcripts. However, this skewed frequency of jp usage may reflect
the biased nature in which the majority of these transcripts were generated (i.e. from
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73 80
312 2s6 TTCGGGGCCGGCAGCTGGCTGACGGTGGTG





314 lsl TTTGGAAAAGGCACCAGGCTCACGGTTGTA 90 90






Table 4.2 The 16 bovine Jp genes identified from TCRP chain transcripts. The human
orthologue for each gene (column 2) was assumed to be that showing highest nucleotide (column
4) and amino acid (column 5) sequence identity. Nucleotide alignment of the bovine jp genes
(upper) with their human orthologues (Lopes et al.) is shown in column 3, with identical base
pairs shown as dashes. The three novel bovine jp genes identified in this study are J14-16.
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4.4 Discussion
The results of analysing over 400 unique bovine TCRp chain rearrangements
presented in this chapter constitute a significant advance towards the complete
characterisation of the bovine TCRp gene repertoire. Analysis of-150 bovine TCRp
rearrangements in previous studies had established a repertoire of 46 VP genes in 17
subfamilies and 13 Jp genes (Buitkamp et al., 1993 Russell and MacHugh,
unpublished; Housset et al., 1997; Houston, 1997; Tanaka et al., 1990). In this study
an additional 38 novel bovine VP genes, including members of 4 novel subfamilies
(VP5, 12, 25 and X), and 3 novel jp genes were identified, bringing the currently
known bovine TCRP gene repertoire to 84 VP genes distributed over 21 subfamilies,
and 16 jp genes.
In the absence of VP gene germline sequence data, a major challenge to VP gene
classification is the difficulty in defining sequences sharing high nucleotide identity
as allelic variants or products of unique but closely related subfamily members.
Based on observations made by Arden et al. (1995a,b) on human and murine VP
sequences, it has been convention to assume that sequences differing by less than 5
nucleotides (or sharing >98% nucleotide identity) are allelic variants. However, there
are demonstrable exceptions to this convention - for example, human Vp8sl and
Vp8s2 differ by only 5 nucleotides (Siu et al., 1986) whereas the two alleles of
murine VpiOsl differ by 9 nucleotides (Smith et al., 1990). For the analysis
completed in this study the convention was strictly adhered to. Some of the novel VP
genes displayed levels of nucleotide identity with other subfamily members
approaching 98%, but such high levels of nucleotide identity between different
members was not atypical for previously identified genes within these subfamilies
(Figures 4.1-4.6 parts c). This may reflect recent VP duplication events with minimal
subsequent divergence, or gene conversion such as that seen with human Vpi3s2a
and Vpl3s2b (Glusman et al., 2001). Until the full genomic sequence of the bovine
TCRB locus is known classification of closely related Vp sequences will retain an
element of uncertainty.
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Analysis of VP sequences derived from amplified TCRP chain mRNA transcripts is
further complicated because sequence variation may reflect artefacts generated by (i)
modification of the 3' end nucleotide sequence of Vp genes during somatic
recombination or (ii) mis-incorporation of nucleotides during PCR, replication of
plasmid sub-clones or sequencing. In this study the sequence 3' to the conserved
cysteine at position 104 was excluded from analysis, removing somatic
recombination as a potential source of non-germline sequence variation. Although it
is not possible to eliminate sequence variation from mis-incorporation of nucleotides,
most of the novel Vp genes identified (27 out of 38) were present in multiple
transcripts, suggesting they reflect genuine germline sequence variation rather than
technical artefacts. Of the 11 novel VP genes identified from single transcripts,
matching sequences for 5 (VP 1 s 12, Vpi0s5, Vpl0s6, Vpl3sl2 and Vp25sl) were
later identified in the available bovine genome data (see Chapter 5), and it is
anticipated that future studies will produce evidence corroborating the sequences of
the remaining 6 (Vp2s8, Vp2s9, Vp4s7, Vp4s8, Vpl3sl 1, Vpl3sl3).
By convention Vp genes of non-human/non-murine species have been designated
subfamily numbers corresponding to the human VP with which they display highest
nucleotide identity (Baron et al., 2001; Li et al., 1990; Schrenzel et al., 1994; Tanaka
et al., 1990). Adherence to this convention resulted in 3 genes being ascribed to the
novel bovine subfamilies VP5 and Vpl2 (section 4.3.1). However, by the criterion of
members of the same VP subfamily sharing >75% nucleotide identity (Arden et al.,
1995a; Kazatchkine, 1995) both Vpi2 genes could be considered to be members of
the bovine Vpi3 subfamily (Figure 4.6c) and similarly the single VP5 gene shares
>75% nucleotide identity with 7 out of the 13 bovine Vpi members (Figure 4. lc). As
such, the utilisation of this convention may be artificially sub-dividing bovine
subfamilies and demonstrates the difficulties that can be encountered by
extrapolating conventions concerning TCR gene nomenclature across species.
The number of genes constituting the known bovine VP repertoire (84 VP genes)
now exceeds that of humans (65 Vp genes - Rowen et al., 1996), making it the
largest VP repertoire characterised to date. The bovine VP repertoire demonstrates a
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substantial level of gene duplication, with 11 of the 21 bovine VP subfamilies
identified containing multiple members (Table 4.3). More strikingly, results from this
study have added VP4, 10 and 13 to Vpl and 2 as bovine subfamilies which have
undergone extensive duplication, each having >8 members. Sixty of the 84 genes
(over 70%) in the VP repertoire belong to one of these 5 subfamilies. Despite
intensive sequencing of a large number ofVpi0+ and Vpi3+ TCRP transcripts,
results suggest that this analysis has not been exhaustive and further members of
these subfamilies remain to be identified (section 4.3.2). The use of subfamily-
specific primers to generate VP sequences for analysis will have undoubtedly
favoured identification ofmultiple members of the selected subfamilies. It is possible
that similar investigations of other subfamilies would extend the known membership
of some of them, although an analysis of 32 Vp7 transcripts amplified using the
subfamily-specific primer failed to identify any new members of this subfamily (data
not shown).
The large membership of the Vpi, 2 and 13 subfamilies was evident in analysis of
restriction enzyme digested genomic DNA by southern blot, where subfamily-
specific probes hybridised with multiple bands. Marked variation in the intensity of
the bands was notable in several of the lanes in Figure 4.10 (e.g. Figure 4.10b lane
3), suggestive that some of the bands represented superimposed copies of subfamily
members. This most likely reflects the fact that recently duplicated VP genes in the
same subfamily typically have conserved flanking non-coding sequence and
therefore retain some of the same restriction sites (Glusman et al., 2001). Such a
phenomenon has been observed for some murine TCRaV genes (Clark et al., 1995)
and may also account for a previous underestimate of the number of bovine Vp2
genes made from southern blot data ofPstI digested genomic DNA (Tanaka et al.,
1990).
Comparisons of VP sequences from different mammalian species provide convincing
evidence that ancient duplications of an ancestral VP gene predating mammalian
radiation established many of the different Vp subfamilies
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V|3 subfamily Bovine Human Porcine Ovine Caprine
1 13 1 Yes 5 Yes
2 9 1 Yes 1 Yes
3 1 1 1 Yes
4 8 1 Yes 1 Yes
5 1 8 Yes
6 3 9 Multigenic 1 Yes
7 2 3 Multigenic 1 Yes
8 2 5 Yes 1 Yes
9 1 2 Yes Yes
10 11 1 Yes 1 Yes
11 1 Yes
12 2 3 Yes
13 19 9 Yes 2 Yes
14 1 1 Yes
15 2 1 1 Yes
16 1 1
17 3 1 Yes 1 Yes
18 1
19 1




24 1 1 Yes 1 Yes
25 1 1 Yes
26 1
27 1




Total 84 65 18
Table 4.3 The bovine, human, porcine, ovine and caprine Vp gene repertoires. Details
of the number of members in porcine and caprine subfamilies is limited and so YES is
used to indicate subfamilies in which Vp genes have been identified. Porcine subfamilies
VP6, 7 and 22 are known to be multigenic (Baron et al. 2001; Butler etal. 2005).
(Baron et al., 2001; Clark et al., 1995; Houston and Morrison, 1999). Consistent with
this view ofVP evolution, all of the 21 bovine subfamilies now identified have >70%
nucleotide sequence identity to human orthologues, with the exception of VPX,
which is an orthologue ofmurine Vp2. The human orthologue of this gene appears to
have been deleted (Glusman et al., 2001), but an orthologue has been identified in
the pig (Baron et al., 2001) which, like cattle, is an artiodactyl (even-toed ungulate)
species. Given the conservation of V(3 subfamilies across the mammalian spectrum it
is possible that bovine orthologues to at least some of the other 10 human VP
subfamilies will be found with further investigation.
Due to duplications and deletions of the TCRB locus that have occurred subsequent
to mammalian radiation there is variation in the germline VP gene repertoires of
individual species (Table 4.3 - Baron et al., 2001; Bosc and Lefranc, 2000; Folch and
Lefranc, 2000b; Halsey et al., 1999). As the retention of duplications in particular VP
subfamilies indicates that they are likely to convey an evolutionary advantage for the
survival of a species, similarities and differences in which subfamilies have
undergone duplication in various species are of interest. In contrast to the mouse, in
which only 2 of the 31 subfamilies have multiple members, 9 of the 30 human
subfamilies are multi-membered (section 1.2.3.2) as are 11 of the 21 bovine
subfamilies so far identified. Some of the expanded subfamilies are common to
human and cattle (e.g. VP6, Vp7 and Vp8) whereas others differ (e.g.Vp2, VP4 and
VP 10 are duplicated in cattle but not human).
It is intriguing to note that in both human and cattle the VP 13 subfamily has been
subjected to extensive amplification, as have the VP5 subfamily in humans and Vpl
subfamily in cattle. As commented on above, phylogeny of human Vpi and 5 genes
(Arden et al., 1995a), and nucleotide sequence identity of bovine Vpi and 5 genes
(section 4.3.1) demonstrate that these two subfamilies are intimately related. In
humans, expansion of the VP5 and Vpi3 subfamilies is largely due to multiple
duplication of a cassette containing Vp5 and Vpi3 elements (Rowen et al., 1996; Su
and Nei, 2001). Substantial similarity in the banding patterns produced by the Vpl
and Vp 13 probes in southern blots of digested bovine genomic DNA (Figure 4.10e)
144
suggests that in cattle there also may have been extensive duplication of a cassette
containing a Vpl and Vpi3 gene. As it has been estimated that the human cassette
containing the Vp5 and VP 13 genes underwent duplication in only the last 32 million
years (Su and Nei, 2001), which is after human/bovine divergence 65-80 MYA (Li et
al., 1990), the expansion of human Vp5 and 13 and bovine Vpi and 13 subfamilies
may represent equivalent but distinct evolutionary developments (see also section
5.4).
Data on the VP repertoires of three other artiodactyl species - sheep, goat and pig -
have been published. The pig is the only other artiodactyl species whose Vp
repertoire has been subject to extensive analysis (Baron et al., 2001; Butler et al.,
2005). Members of 19 subfamilies have been identified, including 3 subfamilies that
are absent from the bovine repertoire (Vpl 1, Vp21 and Vp22). Baron et al. (2001)
identified 2 members in both Vp6 and VP22 subfamilies and Butler et al. (2005)
described several different VP7 sequences. However, comprehensive details of the
numbers ofVp genes in the different porcine subfamilies are awaiting publication
(Butler et al., 2005). A limited study in sheep, based on analysis of 34 TCRp
sequences, identified 18 VP genes in 13 subfamilies (Halsey et al., 1999) and in
goats, analysis of 55 sequences identified members of 19 subfamilies (Obexer-Ruff
et al., 1998). With the exception of caprine subfamily Vp30, all of the subfamilies
identified in these two ruminant species are represented in the bovine repertoire.
Notably, the only subfamilies identified in sheep as having duplications were Vpl
andvpi3 (Halsey et al., 1999).
Sixteen bovine jp sequences have been identified, which again exceeds the number
of jp genes identified in any other species to date. All of the jp genes shared >70% to
human orthologues, which is similar to the levels of homology identified between
orthologous human and porcine Jp genes (Baron et al., 2001).
Sequencing of the region including the full repertoire of Dp. jp and CP genes has
been achieved for the human (Rowen et al., 1996), murine (GenBank accession
number AE000665), rat (Williams et al., 1991) and porcine (GenBank accession
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number AB079894) TCRB loci. In all cases the Dp, jp and CP genes are located in
tandemly duplicated DJC clusters, each containing a single Dp gene, several (six or
seven) jp genes and a single constant (CP) gene and there is a high level of inter¬
species conservation of the Dp and jp genes in both sequence and organisation
(Baron etal., 2001; Schrenzel etal., 1994; Williams etal., 1991).
Intriguingly, several of the human Jp genes in the second DJC cluster appear to have
two bovine orthologues. The orthologues of human Jp2s5 and Jp2sl show minimal
sequence variation and may represent allelic variants of the same gene, but the
orthologues of Jp2s2 and jp2s7 display significant sequence divergence and are
likely to represent different gene loci. Based on recent preliminary analysis of
genomic sequence data, it has been suggested that the bovine TCRB locus contains a
third constant region gene (Conrad et al., 2002). A duplication event incorporating
the jp2 cluster and a CP gene could account for both the identification of two bovine
orthologues for several jp2 genes and the presence of a third CP gene. In the sheep,
10 jp genes have been identified, including a jp2s2 orthologue and a jp gene which
was unclassified but the amino acid sequence of which is identical to bovine J10,
also an orthologue of Jp2s2 (Halsey et al., 1999). The existence of two Jp2s2
orthologues in the sheep is suggestive that this extra duplication event occurred prior
to ovine/bovine divergence 22 MYA (Hassanin and Douzery, 2003) and may be a
feature of other ruminant species.
In conclusion, the results presented in this study have expanded the known repertoire
of bovine TCRp genes, which appears to be characterised by a high level of
duplication of both VP and jp genes. Notably, several subfamilies, Vpi, 2, 4, 10 and
13, have undergone prodigious duplication. Identification of these new bovine TCRP
genes will be helpful in the development and refinement of methods to study T-cell
responses in cattle. However, it is likely that additional bovine TCRP genes remain
to be identified.
Part of the southern blot data presented in this chapter contributed to the publication
Houston et al. (2005) which has been reproduced at the end of this thesis.
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5 Chapter 5 - The Bovine TCRB locus
5.1 Introduction
T-cells can be segregated into two distinct lineages that express either an apTCR
(a(3T-cells) or a ySTCR (y8T-cells). The a,(3,y and 5 polypeptide chains that form
these heterodimeric receptors each consist of a constant domain that anchors the
receptor to the T-cell membrane and a variable domain that participates in antigen
recognition. The variable domains are encoded by exons formed during T-cell
ontogeny by somatic recombination of variable (V), diversity (D - p and 5 chains
only) and joining (J) gene segments.
In humans and mice, the TCR genes are located in three chromosomal loci - TCRB
(TCRp chain genes), TCRG (TCRy chain genes) and TCRA/D (TCRa and 8 chain
genes). The complete sequencing of the human and murine TCR loci has been
pivotal in providing a better understanding of TCR genes in these species (Glusman
et al., 2001). Firstly, it has enabled a definitive catalogue of the TCR gene segments
to be obtained, thus enabling functional TCR studies to proceed without potential
complications arising from incomplete knowledge of the TCR gene repertoire.
Secondly, availability of genomic sequences of the TCR loci has allowed
identification and systematic analysis of the promoter and enhancer elements that
regulate TCR gene expression (Anderson et al., 1988; Krimpenfort et al., 1988;
Mathieu et al., 2000; Rowen et al., 1996; Ryu et al., 2004) and the effect that
recombination signal sequences (RSS) can have on utilization of particular TCR gene
segments (Probst et al., 2004; Wu et al., 2003). Thirdly, the ability to study the
genomic organisation of the TCR loci has provided insights and new perspectives on
the evolutionary history of this important group of genes (Glusman et al., 2001; Su
and Nei, 2001).
The TCRB locus is situated on chromosome 7q34 in humans and chromosome 6A-C
in mice (Barker et al., 1984; Caccia et al., 1984; Isobe et«/., 1985). The genomic
organisation of the locus is conserved between humans and mice; the 5' end contains
147
an array of V genes (65 in humans and 35 in mice), with the D, J and C genes
arranged into tandem clusters containing a single Dp gene, six or seven J(3 genes and
a single C(3 gene at the 3 "end of the locus. A solitary VP gene with an inverted
transcriptional orientation to the other TCRp genes lies at the extreme 3" end of the
locus. Within the VP array the relative order of human and murine orthologues
displays a striking level of conservation (Lai et al., 1988; Rowen et al., 1996), and
similarly the arrangement of orthologous genes in the DJC clusters is highly
conserved. The conservation of synteny also extends to non-TCRp genes in, and
adjacent to, the TCRB locus. In both species multiple trypsinogen genes flank the 5'
and 3' ends of the array of VP genes, the ephrin type-b receptor 6 precursor (EPHB6)
gene is situated at the extreme 3'end of the locus and a dopamine-P-hydroxylase-like
(DBH-like) gene is located immediately 5' to the locus (Glusman et al., 2001).
In humans, inter-chromosomal translocation has produced a cluster of VP
pseudogenes located on chromosome 9 (Glusman et al., 2001; Robinson et al., 1993;
Rowen et al., 1996). These VP genes are unable to undergo recombination because
no Dp, jp or CP genes were incorporated in this inter-chromosomal translocation,
and are described as 'orphan' genes.
Sequence data of TCR loci in other mammals such as cat, dog, sheep, pig, and cow is
currently being generated through efforts to sequence the entire genomes of these
species (http://www.ncbi.nih.gov/Genomes). The bovine genome project, an
international effort headed by Dr. Richard Gibbs, of the Baylor College ofMedicine
Human Genome Sequencing Centre (Houston, Texas, USA), began sequencing and
assembling the bovine genome in December 2003. The project is focused on a whole
genome shotgun (WGS) analysis of a female Hereford named LI Dominette 01449.
In October 2004 a first draft 3.3-fold WGS assembly was released, followed by a
second draft 6.2-fold WGS assembly in March 2005. Genomic sequencing of the
entire bovine TCRG loci (GenBank accession numbers AY644517 and AY644518)
has already proved useful in detailing the genomic organisation of the TCRy genes
and, in combination with cDNA analysis, in defining the full catalogue of TCRy gene
segments in cattle (Herzig et al., 2006a). The bovine genome has also be used
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recently to examine the TCR8 gene repertoire and organisation (Herzig et al.,
2006b).
Extensive cDNA analysis has achieved characterisation of a large number of bovine
TCRp gene segments (this study; Buitkamp et al., 1993; Houston 1997; Houston
and Morrison 1999; Tanake et al., 1990; Russell and MacHugh unpublished data) but
it is unlikely that the full complement of bovine TCRp genes has been described. In
contrast to the TCRG locus, only a small portion of the TCRB locus, incorporating
part of the DJC region, has been deposited (GenBank accession number AF453325).
It was therefore decided to examine the current bovine genome assembly to further
characterise the repertoire ofTCRp genes and the TCRB locus and compare the
repertoire of expressed TCRp genes described in the previous chapter with that
present in the genomic assembly. Although the genomic sequence of the TCRB locus
is incomplete, the results presented in this chapter reveal that (i) there is a massive
germline VP gene repertoire in the bovine, (ii) there are three DJC clusters, as had
been suggested previously (Conrad et al., 2002) and (iii) there is conserved synteny
in the organisation of the bovine and human TCRB loci.
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5.2 Materials and methods
5.2.1 Sequence data
Partial sequences of bovine V(3 and J(3 genes identified from cDNA analysis of
rearranged TCRp transcripts were derived from data collated in Chapter 4. Available
sequences of germline bovine Dp, jp and CP genes were derived from the annotated
sequence of part of the Dp, jp, CP region of the bovine TCRB locus (GenBank
accession number AF453325 - Conrad et al., 2002). Human germline sequence data
for VP, Dp, jp and CP genes was extracted from the annotated TCRB locus sequence
deposited in the GenBank database (U66059-U66061 - Rowen et al., 1996).
5.2.2 Bovine genome analysis
The bovine genome assembly and WGS 'trace' sequence archive were accessed
through the National Centre for Biotechnology Information (NCBI) BLAST facility
(http://www.ncbi.nlm.nih.gov/BLAST). Sequences were compared to genomic data
using the BLASTN algorithm under default conditions. Sequences were deemed to
show significant homology if the "expected' (E) value was below 0.001. The current
bovine chromosome map and annotation of genomic scaffolds were accessed through
the NCBI Map Viewer (http://www.ncbi.nlm.nih.gov/mapview).
Where possible, the entire VP gene from initiation codon of the leader (L) exon to
the end of the 3'flanking 23bp spacer recombination signal sequence (23bp-RSS)
was identified and extracted. Leader exons were identified from the limited data on
bovine L exon available from deposited sequences (section 2.5.1) or similarity to
orthologous human VP gene L exon sequence. The VP intron was defined by
identification of conventional GT/AG splice sites in conjunction with knowledge of
the predicted L exon and variable (V) exon boundaries. RSS sequences were defined
according to the conserved consensus heptamer-spacer-nonamer characteristics
(Hesse et al., 1989; Ramsden et al., 1994). jp gene sequence data extracted included
the 5' flanking 12bp-RSS and the 3' flanking guanine (G) residue that is donated to
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the C(3 gene during splicing. DP gene sequence included both 5' flanking 23-bp RSS
and 3' flanking 12bp-RSS sequences.
5.2.3 Sequence analysis
Some general details about sequence analysis are given in section 2.5. Using the
IMGT/V-QUEST software programme (Giudicelli et al., 2004 - http://imgt.cines.fr)
the human VP gene with the highest nucleotide similarity to each genomic VP gene
sequence was identified and the subfamily of the bovine VP genes thus determined.
Percentage nucleotide identities were calculated using the Lasergene software
(DNAstar, Madison, WI). Comparison of VP sequences included only the sequence
encoding the mature VP polypeptide.
Based on experimental data from human and murine systems, which have provided
information on sequence features that are essential for TCRP gene segments to be
functional, the following criteria were evaluated in determining the potential
functional integrity of genomic bovine TCRp genes: (i) The presence of an initiation
codon in the predicted L exon of VP genes, (ii) maintenance of an open reading
frame in the L and V exons of VP genes in the post-splicing configuration and in jp
genes in the same reading frame as encodes the conserved Phe-Gly-X-Gly motif, (iii)
the presence of sequence encoding the conserved residues at positions 23 (cysteine),
41 (tryptophan), 42 (tyrosine) and 104 (cysteine) of the mature Vp polypeptide, (iv)
the presence of correct GT/AG splice sites at the end of the L exon and beginning of
V exons of VP genes, (v) the presence of a RSS compatible with somatic
recombination at the 3'flank of Vp genes (23-bp spacer), 5'flank of jp genes (12-bp
spacer) and the 3' (23-bp spacer) and 5' (12-bp spacer) flank of Dp genes. The
consensus sequence of the human and murine RSS is CACAGTG-12/23bp-
ACAAAAACC although there is variation in the heptamer and the nonamer
sequence (Ramsden et al., 1994). In vitro studies have indicated that the initial three
CAC bases of the heptamer are critical for recombination (Akamatsu et al., 1994;
Hesse et al., 1989) as is a non-A base at the either of the two most distal (from the
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spacer) positions in the nonamer (Akamatsu et al., 1994); there are conflicting results
concerning the requirement for three consecutive As in the nonamer core (Akamatsu
et al., 1994; Hesse et al., 1989) and so in this study they have not been considered
necessary for recombination. RSSs with spacers varying in length by +/-1 bp have
been shown to be capable of undergoing recombination, whereas spacers that differ
in length by >lbp from the usual 12 or 23bp are unable to effect recombination
(Akamatsu et al., 1994; Hesse etal., 1989).
5.2.4 Generation and sequencing of VP11+ TCRp chain transcripts
5.2.4.1 Vpi 1+ subfamily-specific PCR amplification of cDNA
Naive PBMC from animal 641 were isolated (section 2.3.1) and cDNA generated as
described in sections 2.4.1-2.4.3. cDNA was amplified using a Vpi 1-specific
5'primer (CCCAAGATACTGTGTGATAGGGAT) and the CP specific 3'primer
BCext (Table 2.3). The reaction used 20 pmol of each primer, 1 unit BIOTAQ
(5units/pl Bioline, London, UK), 4 pi SM-0005 buffer (ABgene, Epsom, Surrey, UK
- Appendix C.7), 2 pi cDNA, and nuclease-free water to give a final volume of 40
pi. The programme used was as follows - 5 min at 94°C, 5 cycles of (1 min at 94°C,
1 min at 60°C, 1 min at 72°C), 25 cycles of (30 s at 94°C, 1 min at 60°C, 1 min at
72°C) and a final extension period of 5 min at 72°C.
5.2.4.2 Cloning and sequencing of Vpi1+ TCRP chain transcripts
Following confirmation of PCR products of the expected size by agarose gel
electrophoresis (section 2.4.5), the products were purified using the Wizard PCR
Preps DNA Purification System (section 2.4.6), sub-cloned into plasmid pGEM-T
Easy vectors and used to transform High Efficiency Competent JM109 cells (section
2.4.7). The presence of inserts of the anticipated size in selected sub-clones was
verified by PCR as described in section 2.4.7.1. The resulting PCR products were




5.3.1 Characterization of the Vp gene repertoire in the current
bovine genome assembly
5.3.1.1 Identification of 123 bovine VP genes
Sequences within the bovine genome showing significant sequence homology to the
84 known bovine V|3 genes defined from analyses of cDNA (Chapter 4), and/or the
65 human TCR|3V genes in the TCRB locus (Rowen et al., 1996) were identified
using the BLASTN algorithm: 138 sequences were found on 36 scaffolds/contigs.
The subfamily to which each sequence belonged was determined and, to avoid
confusion with the nomenclature used for the cDNA data, each sequence was
assigned a name composed of the subfamily and an alphabetic suffix (e.g. VB13a).
As commented on previously (section 4.3.1), there was high nucleotide sequence
similarity between genes belonging to Vpi and 5 subfamilies and between genes
belonging to the Vpi2 and VP 13 subfamilies (data not shown).
It was not possible to assign the severely mutated genes named Untitled 1 and
Untitled 2 to subfamilies. Both showed highest nucleotide identity with human Vpi2
genes (70% nucleotide identity between Untitled 1 and human Vpi2s2, 74%
nucleotide identity between Untitled 2 and human VP 12s 1) but neither had >75%
nucleotide identity with any of the members of the bovine VP 12 subfamily (data not
shown) and thus could not be described as Vpl2 genes.
Comparisons of percentage nucleotide sequence identities of genes within the same
subfamilies (data not shown) demonstrated that several genes shared >98%
nucleotide identity. Some of these segments were defined as distinct genes on the
basis that they were either (i) located on the same contig (e.g. VBlv and VBlw) or
(ii) were adjacent to different VP genes at equivalent positions in their respective
contigs (e.g. VBlp and VBlaa). Fifteen genes sharing >98% nucleotide sequence
similarity to other sequences could not be verified as either allelic variants or distinct
genes and were therefore left unclassified and not included in further analysis
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(Appendix G). Exclusion of these unclassified genes gave a total of 123 Vp genes,
located on 26 scaffolds/contigs, in the current bovine genome assembly (Table 5.1).
Genes belonging to several new subfamilies were found, including single members
of subfamilies Vpi 1 (80.1% nucleotide identity to human Vpi lsl), Vp21 (highest
identity with human Vp21sl - 75.9%), VP23 (75.6% nucleotide identity to human
Vp23sl) and three members ofVpi8 (76.6%, 76.3% and 76.4% nucleotide identity
to human Vpi8sl).
The most striking feature of the repertoire of Vp genes identified from the genome
was the massive numbers of genes belonging to subfamilies Vp 1 (29) and Vpi3 (36).
Extensive duplication of a cassette containing tandemly arranged Vpi/13 genes
accounts for the majority of this expansion, with several of the large
scaffolds/contigs containing up to five consecutive repeats of this cassette (e.g.
NW_931372.1/Bt4_WGA842_2 and NW_937104.1/BtUn_WGA12501_2 - Table
5.1).
Table 5.1 Bovine Vp genes in the current bovine genome assembly (overleaf). The name,
sequence orientation and length of the scaffolds/contigs on which Vp sequences have been
identified are shown in column 1. The location on the scaffolds/contigs of the Vp sequences from
initiation codon of the leader exon to the end of the RSS sequence is shown in column 2; the
lengths of the sequences are detailed in parentheses. The nine Vp sequences (VB2d, VBlOc, lOq,
lOu, VB13z, 13ab, VB17d, VB18c and Untitled 1) for which genomic sequence was incomplete
are marked by (*). The name and functional status for each Vp sequence is shown in columns 3
and 4; genes were classified as either functional (Func), pseudogenes (P), open-reading frame
pseudogenes (ORF), orphan pseudogenes (Orphan) or unknown, as described in section 5.3.1.3.
VP gene sequences derived from cDNA that displayed >98% nucleotide identity to genomic
sequences were considered to represent matches (section 5.3.1.4) and are shown in column 4. In
column 5 the number of matching base pairs is shown as a fraction of the total as well as a
percentage.
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Scaffold/Contig Location (size in bp) Name Functionality Matching Nucleotide identity
cDNA between genomic
sequence and cDNA sequences
NW_931372.1/ 1.942-1.429(514) VBla Func
Bt4_WGA842_2 4.108-3,638(471) VB13a P
(Rev) 397.044 7,249-6,781 (469) VB13b P
9,478-8.966(513) VBlb P
11,711-11.251 (461) VB13c P
13.421-12,906(516) VBlc Func Vpisll 257/259 (99%)
16,375-15,907(469) VB13d ORF
20,308-19,795 (514) VBld Func Vpls5 265/267 (99%)
24,183-23,715(469) VB13e Func Vpi3s4 240/244 (98%)
127,658-127,142(517) VBle Func Vpls8 271/271 (100%)
134,709-133,563 (517) VB5a P
144.067-143,573 (495) VB7a Func Vp7sl 270/273 (98%)
148,348-147.849(500) VB9a Func Vp9sl 214/214(100%)
224,480-223,797 (663) VBxa Func Vpxsl 234/234 (100%)
NW_931373.1/ 2,007-2,4174(468) VB13f ORF
Bt4_WGA843_2 3,730-4,238 (509) VBlf P
(For) 117,860 5,662-6,123 (462) VB13g ORF VP 13s 14 241/244(98%)
7.860-8.357 (498) VBlg Func
13,438-13,886(449) VB12a P
15,444-15,957(514) VB5b P
17,335-17,804(470) VBI3h Func Vpl3s5 241/244 (98%)
22,731-23,199(469) VB13i Func
24,934-25,431 (498) VBlh Func
26,786-27,255 (470) VB13J Func VP 13s 18 240/244 (98%)
29.030-29.545 (516) VBli Func
31,525-31,993 (469) VB13k Func VP 13s 12 243/244 (99%)
34,432-34.916(485) VB6a Func Vp6sl 239/240 (99%)
38,570-38.972 (403)* Untitled 1 P
49,381-49.887(507) VB5c Func Vp5sl 167/169(98%)
54,673-55,065 (623) VB6b Func Vp6s2 268/268(100%)
59,624-60.117(494) VB23a P
66,135-66.601 (467) Untitled 2 P
71,941-72,436(496) VB21a P
78.923-79,404 (482) VB8a Func Vp8sl 282/282 (100%)
93,732-94.016(481) VB8b Func VP8s2 275/276 (99%)
96.082-96,549 (468) VB16a Func VP 16s 1 267/270 (98%)
Table 5.1 Bovine Vp genes in the current bovine genome assembly (1 of 5 pages). Notes on page
154.
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Scaffold/Contig Location (size in bp) Name Functionality Matching Nucleotide identity
cDNA between genomic
sequence and cDNA sequences
NW_931373.1/ 98,381-98.884(504) VB24a Func Vp24sl 271/273 (99%)
Bt4_WGA843_2 103,112-103,610(489) VB25a P Vp25sl 238/240 (99%)
(For) 117.860. Cont. 114.007-114,671 (665) VB18a P
NW 931380.1/ 94,139-94,838(700) VB20a Func Vp20sl 272/273 (99%)
Bt4_WGA850_2 154,796-154,162(635) VB4a Func VP4s6 249/253 (98%)
(Rev) 175.468 157,271-156,634(638) VB4b Func Vp4s4 279/282 (98%)
159,755-159,122(633) VB4c Func Vp4s3 252/253 (99%)
162,835-162,156(680) VB4d P
168.549-167,838(712) VB3a Func Vp3sl 273/273 (100%)
173,797-173,289(509) VB14a Func VP 14s 1 272/273 (99%)
NW_931534.1/ 72,447-72,916(470) VB131 ORPHAN Vpl3s3 262/267 (98%)
Bt5_WGA944_2
(For) 437,222
NW_935493.1/ 5,820-6,318(499) VBlOa P
BtUn_WGA10890_2 10.098-10.588(491) VBlOb Func Vpi0s8 239/243 (98%)
(For) 45,197 19.101-19.593 (492)* VBlOc Unknown Vpi0s3 225/225 (100%)
23,860-24.366 (507) VB17s2a Func Vpl7s2 270/270(100%)
32,873-33,375 (503) VB15a Func
38.632-39.141 (510) VBlla Func Vpl lsl 249/251 (99%)
40.332-40.850(519) VB28a Func VP28sl 265/266 (99%)
NW_936628.1/ 1,796-2,264(469) VB13m P
BtUn_WGA12025_2 3,961-4,476(516) VBlj Func vpi s 13 169/169(100%)
(For) 37,581 8.419-8,932(514) VBlk Func Vpis3 272/273 (99%)
9,958-10,426 (469) VB13n ORF
11.793-12,300(508) VB11 P
13.776-14,245 (470) VB13o P
15,174-15.642(470) VB13p ORF
17,561-18.059(499) VBlm Func Vpis2 271/273 (99%)
22,269-22,782 (514) VBln P
24,133-24,585 (453) VB13q P
28.340-28,834 (495) VB7b Func Vp7sl 270/273 (98%)
NW_937104.1/ 347-816(470) VB13r Func VP 13s 10 243/244 (99%)
BtUn_WGA12501_2 4,077-4.589(513) VBlo Func
(For) 34,940 8.007-8,4375 (469) VB13s ORF
10,279-10,794(516) VBIp Func VplslO 224/227 (98%)
11,987-12.456(470) VB13t P
Table 5.1 (continued) Bovine Vp genes in the current bovine genome assembly (2 of 5 pages).
Notes on page 154.
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NW_937104.1/ 14.441-14,959(519) VBlq Func
BtUn_WGA12501_2 16,135-16.604 (470) VB13u ['









26,913-27,381 (469) VB13w Func Vpi3sl6 243/244 (99%)
28,763-29.271 (509) VBlt P
30,697-31,165 (469) VB13x Func Vpi3s7 244/244 (100%)
32,098-32,567 (470) VB13y Func VP 13s 19 242/244 (99%)
NW_937259.1/ 255-1(255)* VB13z P
BtUnWGA 12656_2 3,531-3,062(470) VB13aa ORF
(Rev) 34,012 5,393-4,896 (498) VBIu Func VP 1 s 12 216/218(99%)
7.474-7,185 (290)* VBI3ab Unknown Vpi 3s 18 117/117(100%)
9,348-8,834(515) VBIv P Vpis9 269/270 (99%)
11,993-11,524 (470) VB13ac ORF
15,676-15,161 (516) VBlw Func Vpls9 269/270 (99%)
17.894-17.425 (470) VB13ad ORF
25,787-25,291 (497) VBlx P
27,993-27,525 (469) VB13ae Func Vpi3s8 243/244 (99%)
29,900-29,390(511) VB5d P
31,605-31,137(469) VBI3af P
NW_939383.1/ 857-86(880) VB2a Func Vp2s2 279/281 (99%)







22,034-21.566(469) VBlOe Func Vpl0s4 239/240 (99%)
NW_939582.1/ 7,455-7.942 (488) VBlOf P
BtUn_WGA14979_2 13,260-13,749(490) VBlOg Func Vpi0s7 241/243 (99%)
(For) 23,220 16.749-17,249(501) VBlOh P




NW_940681.1/ 14,460-13,608(853) VB2b Func Vp2s5 280/282 (99%)
BtUn_WGA16078_2 18.998-18,935 (215)* VB18c P
(Rev) 19,041
Table 5.1 (continued) Bovine VP genes in the current bovine genome assembly (3 of 5 pages).
Notes on page 154.
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Table 5.1 (continued) Bovine Vp genes in the current bovine genome assembly (4 of 5 pages).
Notes on page 154.
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1,018-549 (470) VB13am Func Vp 13s 1 272/272(100%)
Table 5.1 (continued) Bovine Vp genes in the current bovine genome assembly (5 of 5 pages).
Notes on page 153.
5.3.1.2 All but one of the mapped Vp genes are located on
chromosome 4
The chromosomal locations of the contigs containing Vp genes were undetermined in
the available annotation of the genome sequence data, but 3 large scaffolds -
NW_931372. l/Bt4_WGA842_2, NW_931373. l/Bt4_WGA843_2,
NW_93l380.l/Bt4_WGA850_2 - which between them contained 46 VP genes were
mapped to chromosome 4.
One gene, VB131, was located on a scaffold - NW_93l534.l/Bt5 WGA944_2 -
mapped to chromosome 5, inferring that in cattle, as in humans (Robinson et al.,
1993; Rowen et al., 1996), there has been inter-chromosomal translocation of VP
gene(s). Consequently, VB131 has been tentatively designated an orphan pseudogene
as no Dp, jp or Cp have been identified on chromosome 5 (section 5.3.2-4).
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5.3.1.3 Functional integrity of the Vp genes identified in the genome
The sequence of the entire gene, from the initiation codon of the L exon to the end of
the recombination signal sequence (RSS), was available for 114 of the 123 V(3 genes
identified in the genome sequence data (the incomplete sequences were: VB2d,
VBlOc, lOq, lOu, VB13z, 13ab, VB17d, VB18c and Untitled 1). The leader
sequence, splice sites, translated Vp region and the RSS were all analysed for each of
these 114 sequences to assess their predicted functional status.
VP genes can be assigned to one of four functional classes: (i) Functional, (ii)
pseudogenes (P), which lack an initiation codon or contain a premature stop codon,
usually due to frameshifts within the coding regions, (iii) open-reading frame
pseudogenes (ORFs), which are non-functional due to defects in splice sites or RSSs
or loss of conserved residues vital for protein function, and (iv) orphan genes, which
are non-functional due to absence of adjacent D, J and C gene segments on the same
chromosome.
Using these criteria, only 65 of the 114 intact VP genes identified in the genome are
predicted to be functional. The remaining 49 genes are predicted to encode 35
pseudogenes, 13 ORFs pseudogenes and a single orphan gene. Of the 9 genes for
which incomplete sequence data was obtained 3 (Untitled 1, VB 18c and 13z) would
be predicted to encode pseudogenes whilst the functional status of the remaining 6
can not be determined (Table 5.1 and Table 5.3). A summary of the results obtained
from this analysis are presented in Appendix H.
5.3.1.4 Comparison of cDNA and genomic vp gene sequences
Of the 84 Vp genes identified from TCRp transcripts, 55 (65%) showed >98%
nucleotide identity to a genomic VP sequence and were considered to be matches;
corresponding cDNA and genomic Vp sequences are shown in Table 5.1. An
additional 3 VP genes identified from cDNA (Vp2sl, 2s3, 13s2) had matches in
'trace' sequences from the WGS analysis that have not been integrated into the
genomic assembly (Table 5.2). Of the 26 VP genes identified from cDNA that have
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no matches in the current genome assembly or 'trace' sequences, 21 come from the
large multi-member subfamilies (Vpisl, ls4, ls6, ls7; Vp2s4, 2s8, 2s9; Vp4sl, 4s2,
4s5, 4s7, 4s8; Vpl0s2, 10s5, 10s9; Vpl2sl, 12s2; Vpl3s6, 13s9, 13sl 1, 13sl3), with
Vp6s3, Vp7s2, VP 15s 1, 15s2 and Vpi7s3 also unmatched to any genomic sequence.
Vp gene WGS Trace Location Matches Sequence identity
2sl 382505214 538-257 1-282 281/282 (99%)
2s3 491324250 897-616 1-282 280/282 (99%)
13s2 648423488 802-536 1-267 267/267 (100%)
Table 5.2 Vp gene sequences identified from cDN A that display >98% nucleotide
identity with WGS 'trace' sequences.
Twelve of functional VP genes identified within the genome (VB la, lg, lk, li, lo,
lq, lr, Is: VBlOp; VB13i, 13v and 13ak) had no corresponding cDNA matches.
Notably, except for VB1 la, all of these genes belong to the large subfamilies Vpi,
10 and 13. A Vpi 1 subfamily-specific 5'primer was designed and used together with
the BCext primer to amplify Vpi 1 segments from cDNA prepared from PBMC.
Analysis of the sequences of 36 cDNA clones derived from the PCR product,
confirmed the presence of a Vpi 1 subfamily member (Vpi 1 s 1), the nucleotide and
amino acid sequences ofwhich are given in Figure 5.1. The nucleotide sequence
identity between the genomic and transcript consensus sequences for VP 11 s 1 was
99% (Table 5.1).
Two of the VP genes identified from rearranged TCRp transcripts matched genomic
genes predicted to be unable to undergo somatic recombination. Vpi3sl4 matched
VB13g and aj (Table 5.1), both of which had defects in the nonamer sequence of the
RSS which were considered to prohibit recombination (Appendix H). Vpi3s3
matched VB131 (Table 5.1), which has been designated as an orphan pseudogene
due to its location on chromosome 5 (section 5.3.1.2). A possible explanation for
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Figure 5.1 A) Nucleotide sequence and B) amino acid sequence of Vp 1 lsl, aligned and CDR1
and CDR2 (shaded regions) defined, according to the IMGT unique numbering system.
A
1 11 21 31 41 51
VBllSl CAAGATAC TGTGTGATAG GGATGGGAAA GAAGATTACT
CDR1
61 71 81 91 101 111
VBllSl CTAGAATGTT CTCAAACTAT GGGCCTTGAC AAC ATGTAC
CDR2
121 131 141 151 161 171
VBllSl TGGTATCAGC AAGACCCAGG AATGGAACTG CAGCTGATCC ATTATTCATA CGGGGTTAAT
181 191 201 211 221 231
VBllsl ACC ACGGA GAAAGGAGAG CGCTCG...T CTAGGTCGAC TGTCTCCAGA
241 251 261 271 281 2 91





1 11 21 31 41 51
VBllsl RY CVIGMGKKIT LECSQTMGLD N MY WYQQDPGMEL QLIHYSYGVN
61 71 81 91 101
VBllsl T....TEKGE RS.SRSTVSR T.SKEHFPLT LETANSSQTS SYFC
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these anomalous matches is that there are highly homologous but functional and as
yet unidentified VP genes within the bovine TCRB locus. As discussed in section
5.3.1, there are several examples of distinct genes sharing >98% nucleotide sequence
identity and, as already exemplified with V(31s9 and Vpi 7s 1, it is possible for Vp
genes identified from cDNA to match multiple genomic sequences (VBlv/VBlw
and VB17b/VB17c respectively), of which only one is functional (VBlw and VB17c
respectively). Alternative explanations include (i) errors in analysis of the genomic
data, e.g. in sequencing or chromosomal mapping, (ii) mis-classification of genes
with RSS defects that may not absolutely preclude recombination in cattle and (iii)
existence of functional allelic variants of either VB13g or aj which lack the RSS
defect.
Amalgamating data from the cDNA and genomic analysis gives a total repertoire of
152 bovine VP genes belonging to 25 different subfamilies (Table 5.3). Thirteen
subfamilies have multiple members, with subfamilies Vpi, 2, 4, 10, and 13
representing large subfamilies with> 9 members each. Most notable is the
exceptional numbers of genes within the VpiO (18 members), Vpi (33 members)
and Vpi3 (42 members) subfamilies.
Table 5.3 The repertoire of bovine VP genes identified from combined genomic and cDNA
analysis (overleaf). Numbers in parentheses identify the number of genes identified in both
cDNA and genomic DNA. Vp sequences identified only from cDNA are not classified into
functional and non-functional groups as functional status can not always be determined from
cDNA data.
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VP sub¬ Genomic Data cDNA Total
family Functional Pseudo-gene ORF Orphan Unknown
Data
1 20 8 1 13 (9) 33
2 3 1 1 9(4) 11
3 1 1(1) 1
4 3 1 8(3) 9
5 1 3 1 (1) 4
6 2 3(2) 3
7 2 2(1) 3
8 2 2(2) 2
9 1 1 (1) 1
10 6 6 1 3 11 (8) 18
11 1 1 (1) 1
12 1 2(0) 3
13 14 10 10 1 1 19 (14) 42
14 1 1 (1) 1
15 1 2(0) 3
16 1 1 (1) 1
17 2 1 1 3(2) 4
18 3 3
19




24 1 1(1) 1
25 1 1 (1) 1
26
27
28 1 1(1) 1
29
30
X 1 1 (1) 1
Untitled 2 2
Total 65 38 13 1 6 85 (56) 152
Table 5.3 The repertoire of bovine Vp genes identified from combined genomic and cDNA
analysis. Notes on previous page.
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5.3.2 Analysis of the jp gene repertoire in the current bovine
genome assembly.
Seventeen jp segments were identified in the bovine genome, based on significant
sequence homology to (i) the partial bovine jp gene sequences identified from
analysis of TCRP transcripts, (ii) the 13 available bovine germline jp sequences
and/or, (iii) human germline Jp gene sequences. These sequences were all located on
scaffold NW_931380. l/Bt4_WGA850_2 and organised into three clusters at
—131,000-133,000 (5 sequences), -122,000-123,000 (5 sequences) and -112,000-
114,000 (7 sequences). As the scaffold sequence was in reverse orientation, these
were referred to as bovine jpi, jp2 and jp3 clusters respectively. Assuming that all
of the bovine jp genes were identified, the conventional nomenclature system,
whereby jp genes are named according to genomic position was adopted
(Kazatchkine, 1995).
From the genomic data it was possible to identify the entire germline sequence of
each jp gene, including the 12bp-RSS (Table 5.4). Comparison of the human and
bovine germline jp sequences allowed orthologues to be identified (Appendix I,
Table 5.4) and, as had been indicated from cDNA analysis (section 4.4), the presence
of two bovine clusters (jp2 and jp3) orthologous to the human jp2 cluster was
confirmed; this will be discussed in more detail in section 5.3.5. Although none of
the bovine clusters contained orthologues to all of the genes in the orthologous
human jp cluster, there appears to be conservation of the genomic organisation of the
Jp genes within clusters (Figure 5.2).
Each of the jp sequences derived from cDNA analysis had exact identity with a
single sequence in the genome except for J10 and J2. The genomic segments jp2s2
and Jp3s2 both showed exact identity with the 30bp of J10 on which classification of
the cDNAs was based, but their germline sequence differed 3' to the conserved Phe-
Gly-X-Gly motif. Retrospective analysis suggests that both Jp2s2 and jp3s2 genes
were represented among the TCRp transcripts that had been defined as expressing
J10 (data not shown). The genomic segment jp 1 s2 differed from J2 by a single base
165















Figure5.2Comparativeenomicorganisationfthehum na dbovinj ecl sters.Sc mrepres ntation orderfjpgen sinthaligned(A)humanidb vic ust sBjp2eJ 3 clusters.Redlinesindicateorthologoushum nanbovinJpg e(App ixIT bl5.4).xr pre nting genes,andthedista c sbe w enrnotsh wcal .
pair deletion, which makes the genomic sequence non-functional. Jp 1 s2 also lacked a
consensual RSS nonamer, as did J(31s5 (Table 5.4), indicating that these germline
sequences are ORF pseudogenes, unable to undergo somatic recombination.
Assuming these are not due to sequencing errors in the genomic data, identification
of sequences with identity to these two genes in rearranged TCRP transcripts (J2 for
jpis2 and J9 for jpis5) infers that these genes have allelic forms, ofwhich at least
one is functional. A precedent for this exists with human jp2s7, which has two
alleles, one of which is functional and the other an ORF pseudogene (Folch and
Lefranc, 2000a). Thus all of the jp genes present in the current bovine genome have
been identified in TCRP transcripts and vice versa.
Table 5.4 Bovine Jp genes in the current bovine genome assembly (overleaf). The 17 jp genes
have been ascribed names (column 1) according to convention (Kazatchkine, 1995). For each
gene the corresponding temporary name given to matching sequences described from cDNA
analysis is shown in column 2 and the orthologous human gene in column 3. The position of each
gene in scaffold NW_931380.1/Bt4_WGA850_2. is detailed in column 4. The nucleotide sequence
of the RSS and the jp gene and the translated amino acid sequence of the jp gene are displayed
in columns 5 and 6 respectively. Genomic bovine Jpis2 and ls5 are ORF pseudogenes as they
have non-consensual nonamer RSS sequences (*), and jpis2 has a frameshift due a single base
pair deletion in the jp region. Based of the sequence of J2 derived from cDNA, a thymidine
(shown in parentheses) has been introduced in jpis2 (f).Conservation of heptamer sequence
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5.3.3 Analysis of Dp genes in the current bovine genome
Three sequences with significant homology to the available bovine germline Dp gene
sequences and/or the human DP genes were identified in the bovine genome. Due to
the small size of Dp genes and the potential for substantial modification of both the
3' and 5' ends during somatic recombination, no attempt had been made to identify
bovine Dp gene sequences during the analysis ofTCRp transcripts in Chapter 4.
Each of the Dp sequences identified was located 3' to one of the jp clusters on the
scaffold NW_931380.1/Bt4_WGA850_2 and was named accordingly. Bovine Dpi
shared 77% nucleotide identity with human Dpi and was of similar size (13bp in
bovine compared to 12bp in human Dpi). Bovine Dp2 and Dp3 shared 81% and
70% nucleotide sequence identity, respectively, with human DP2, and all three genes
were 16bp in length. This level of nucleotide identity is comparable to that seen
between human and porcine Dp genes (Baron et al., 2001). Therefore, it would
appear that in the bovine there is one orthologous gene to human Dpi and two
orthologous genes to human Dp2, reflecting the situation of the jp gene clusters. The
sequence details of the three Dp genes are given in Table 5.5. Interestingly Dpi does
not encode for a glycine (G) in the third reading frame; in other species studied all
Dp genes encode at least one glycine residue in each of the three reading frames
(McCormack et al., 1991).
5.3.4 Analysis of CP genes in the current bovine genome
Consistent with the report by Conrad et al (2002), 3 CP genes were identified in the
bovine genome. Each of the CP genes was located 5' to a Jp cluster on the scaffold
NW_931380. l/Bt4_WGA850_2 (Appendix J and section 5.3.5), and was named
accordingly. As in mice and humans, Cp genes comprise four exons, but it was not
possible to identify exon 2 for either Cp2 or Cp3, as the sequence in the regions
predicted to contain these exons was undetermined. The aligned sequences of the
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The bovine C|31 and C(32 genes are very closely related, sharing >99% nucleotide
sequence identity, whilst Cp3 is more divergent with approximately 96% identity to
the other two C|3 genes (Appendix J).The 3 bovine C|3 genes are more similar to each
other than to either of the human CP genes (Appendix J) suggesting that there has
been a process of intra-species homogenisation of the bovine CP gene sequences,
such has been reported previously from humans and mice following comparison of
their Cp gene sequences (Glusman et al., 2001).
5.3.5 Organisation of the bovine Dp, jp and Cp genes
The Dp, Jp and Cp genes identified in the bovine genome are located in three,
tandemly located DJC clusters on scaffold NW_931380.1/Bt4_WGA850_2.
Although each cluster has the orthodox arrangement of several (five or seven) jp
genes located between a 3' Dp and a 5' Cp gene, the presence of three instead of two
DJC clusters is unique amongst the mammalian TCRB loci that have so far been
characterised - human (Rowen et al., 1996), murine (GenBank accession number
AE000665), rat (Williams et al., 1991) and porcine (GenBank accession number
AB079894).
By describing human orthologues of the bovine jp (section 5.3.2) and Dp (section
5.3.3) genes and comparing the nucleotide sequences of the bovine CP genes to each
other (section 5.3.4) it would appear that the third DJC cluster has arisen from
duplication of ancestral Cpi, Dp2 and Jp2 cluster genes. The results of a dot-matrix
analysis of scaffold NW_931380.1/Bt4JWGA850_2 versus itself with the TCRp
genes masked, is consistent with a duplication of the region incorporating Cpi, Dp2
and the jp2 cluster (Dr. J. Aerts, Roslin Institute, personal communication).
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5.3.6 Regions of the bovine and human TCRB loci display
conserved synteny.
The current map of bovine chromosome 4 places 6 scaffolds - NW_931374.1/Bt4_
WGA844 2 to NW_931379.1/Bt4_WGA849_2 - none of which contain TCRP
genes, in between scaffolds NW_931373.1/Bt4_WGA843_2 and NW_931380.1/Bt4-
_WGA850_2. These 6 scaffolds have a combined length in excess of 2,000Kb and
the interposition of such a large insertion within the bovine TCRB locus would seem
unlikely. One of these scaffolds, NW_931377.1/Bt4_WGA847_2, contains the
muscle chloride channel 1 (CLCN1) gene, which is located outside of the TCRB
locus in both humans and sheep, in positions that display conserved synteny
(Antonacci et al., 2001; Di Meo et al., 2000). Additionally, as noted in Table 5.1, the
TCRp genes located on scaffolds NW_931372.1/Bt4_WGA842_2 and
NW_931380.1/Bt4_WGA850_2 (except VB20a) appear to be in the reverse
orientation whilst the TCRp genes located on NW_931373.1/Bt4_WGA843_2 are in
the forward orientation. In both the murine and human TCRB loci all of the TCRp
genes, with the exception of the orthologous human Vp20 and murine Vpi4, have
the same orientation (Rowen et al., 1996, GenBank accession numbers AE000663-
AE000665). These observations suggest that the order and orientation of scaffolds
mapped to this area of chromosome 4 may require modification.
If the orientation ofNW_931372.1/Bt4_WGA842_2 and NW_931380.1/Bt4-
_WGA850_2 are inverted so that all 3 scaffolds holding constituents of the bovine
TCRB locus are brought into the same orientation, the organisation of the genes on
these scaffolds (and contig NW_935493. l/BtUn_WGA10890_2) shows marked
conservation in synteny ofTCRp genes with corresponding regions of the human
TCRB locus, as shown in Figure 5.3.
There is a striking conservation of the order of orthologous Vp genes, including the
location of Vp20 3' to the DJC clusters and in the opposite transcriptional orientation
to the other TCRp genes (section 1.2.3.1) and although there is no human orthologue
of VpXsl, the position of this gene at the extreme 5' end of the VP cluster is
consistent with the position of its murine orthologue, Vp2 (GenBank accession
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number AE000663 - Figure 1.4). The large region (~100Kb) of undetermined
sequence in NW_931372.1/Bt4_ WGA842_2 prevents any conserved synteny that
may exist in this region from being demonstrated. As described in section 5.3.2 and
Figure 5.2 there is also substantially conserved synteny between the order of the
bovine and human Dpjpcp genes.
Synteny also extends to non-TCR genes in and adjacent to the TCRB locus.
Trypsinogen (T) genes, a dopamine-P-hydroxylase-like (DBH-like) gene and an
ephrin type-b receptor 6 precursor (EPHB6) gene are all located in positions on the
bovine scaffolds that correspond to their positions in the human TCRB locus (Figure
5.3).
Figure 5.3 Schematic representation of the human TCRB locus and components of the bovine
TCRB loci (overleaf). The human (upper) TCRB locus is displayed in three segments running
from the 5'end (upper panel) to the 3'end (lower panel). Bovine genome scaffolds
NW_931372.1/Bt4_WGA842_2, NW_931373.1/Bt4 WGA843 2, NW_931380.1/Bt4_WCA850_2
and contig NW_935493.1/BtUn_WGA10890_2 (Lopes et al.) are displayed against
corresponding regions of the human TCRB locus. Scaffolds NW_931372.1/Bt4_WGA842_2,
and NW_931380.1/Bt4_WGA850_2 have been inverted as discussed above. Genes within the loci
are shown according to the legend overleaf. Vp genes represented by two coloured boxes have
allelic forms of different functional status. Red lines indicate orthologous human and murine
TCRp genes as identified by nucleotide sequence identity (sections 5.3.1 - 5.3.4). The arrows
adjacent to human Vp20sl and bovine VB20a indicate the opposite transcriptional orientation
of these genes compared to the other TCRp genes in the TCRB loci. Non-TCR genes, dopamine-
P-hydroxylase like (DBH-like), ephrin type-b receptor 6 precursor (EPHB6) and trypsinogen
genes in and adjacent to the TCRB locus have been shown. The boxes representing genes, and
the distances between the genes are not shown to scale. Exons are not shown. The format of the
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5.4 Discussion
In this chapter the current (second) bovine genome assembly has been examined for
genomic sequence and organisation of the TCRB locus. At present the sequence of
the TCRB locus is incomplete and fragmentary, with TCRP gene sequences
distributed over twenty-one contigs and five scaffolds; these results therefore
represent a work 'in progress' and will require reviewing in the future as more
genomic sequence becomes available. The imminent release of a third assembly (Dr
Aerts, personal communication) is eagerly anticipated and will hopefully consolidate,
if not complete, the genomic sequence of the TCRB locus and allow more definitive
conclusions to be made.
The primary motivation for examining the genome assembly for TCRB locus
sequence was to further characterize the repertoire of bovine TCRP genes. Despite
the incomplete status of the TCRB locus sequence, 123 VP sequences were
identified, which represents a dramatic expansion compared to that of either the
human or murine repertoires which are composed of 65 and 34 Vp genes respectively
(Bosc and Lefranc, 2000; Folch and Lefranc, 2000b). Much of this expansion is
attributable to extensive duplication in certain subfamilies - most notably VpiO (16
genes), Vpl (29 genes) and Vpi3 (36 genes). Several novel bovine subfamilies were
identified in the genome including single members of the Vpi 1, VP21, VP23
subfamilies and 3 members of the Vpi 8 subfamily. Bovine orthologues of all human
Vp subfamilies except Vpi9, 22, 26, 27, 29 and 30 were identified, as was an
orthologue ofmurine Vp2, which is absent in humans.
Accurate description of the repertoire of functional genes is essential for
development of effective techniques to analyze TCR in functional studies.
Acquisition of the full genomic sequence ofmost (114) of the Vp genes identified
enabled their functional status to be predicted by analysis of the DNA sequence. Of
the genes identified 65 are predicted to be functional (56%), 35 are predicted to be
pseudogenes (33%), 13 are predicted to be open-reading frame pseudogenes (11%)
and 1 is an orphan pseudogene (1%). However, some caution must be exacted in
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these predictions as (i) there may be functional allelic forms of some of the non¬
functional VP genes described in the genome, (ii) single base pair errors in
sequencing are often sufficient to change the functional classification of VP genes
and (iii) although generally accurate, prediction of functional status from analysis of
DNA sequence is not always correct; there are two human VP genes (Vpl3s4 and
VP6s8) which at the DNA level are predicted to be functional but protein modelling
demonstrates are incapable of correct protein folding and are therefore non¬
functional (Rowen et al., 1996).
The percentage of predicted VP pseudogenes present in the current bovine genome
(44%) is higher but comparable to that in the murine (39%) or human (37% -
including the 7 orphan pseudogenes on chromosome 9 - Robinson et al. (1993),
Rowen et al (1996), GenBank accession number AF029308) VP germline
repertoires. As in humans and mice, there are some bovine subfamilies, Vpl8, 21, 23
and 25, that at present do not contain any known functional VP genes. In humans
these 4 families all have functional members, suggesting loss of function of the
bovine orthologues has occurred subsequent to human/artiodactyl divergence 65-80
MYA (Li et al., 1990). Although the VP 12 genes identified in the bovine genome are
also non-functional, analyses of cDNA have revealed two Vpi2 sequences with no
obvious sequence defects.
In the human TCRB locus 22 VP 'relics' (i.e. genes with major lesions) were
identified by application of a modified Smith-Waterman algorithm (Rowen et al.,
1996). The two severely mutated bovine VP genes named Untitled 1 and 2 probably
represent 'relics' of bovine Vpi2 subfamily members, and by applying the modified
Smith-Waterman algorithm in future work further 'relics' may be identified.
Approximately 35% (29 out of 84) of the VP genes identified from cDNA analysis
had no matching genomic sequence in the current assembly. Genomic sequences
matching 3 of these genes (Vp2sl, 2s3 and 13s2) were subsequently identified in the
WGS trace sequence archive. Conversely, approximately 19% (12 out 65) of the
functional Vp genes identified in the genome did not have matching cDNA
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sequences. Thus, at present it would appear that results from cDNA analysis provide
a more comprehensive coverage of the functional bovine TCR(3 repertoire than the
genomic data. Although this may simply reflect the current incomplete TCRB locus
sequence in the genome, a potential confounding factor may be the presence of
insertion-deletion related polymorphisms (IDRPs). TCRB locus IDRPs are known to
exist in both humans and mice (Behlke et al., 1986; Haqqi et al., 1989; Jouvin-
Marche et al., 1989; Noonan et al., 1986; Pullen et al., 1990; Seboun et al., 1989;
Zhao et al., 1994) and can result in deletion of up to 50% of the germline Vp
repertoire. It was notable that the majority (19 out of 26) of VP genes identified from
cDNA analysis that lacked a matching genomic sequence, were members of the large
multimember Vpi, 2, 4, 10 and 13 subfamilies, as were 10 out of II of the genomic
VP genes predicted to be functional that lacked a matching cDNA sequence. The
discordance in the representation of the members of these large subfamilies identified
from cDNA and genome analysis may indicate that the coverage of these subfamilies
is still incomplete and their membership may be considerably larger than already
appreciated.
Seventeen Jp genes, 3 Dp genes and 3 Cp genes were identified in the genome. In
contrast to the situation with the VP genes, all of the jp genes present in the genome
had been identified in cDNA analysis and vice versa, suggesting comprehensive
cDNA and genomic coverage of bovine jp has been achieved. Two of the genomic
jp sequences (jp 1 s2 and JJ31 s5) were classified as ORF pseudogenes, but as they
have been identified in cDNA it is assumed functional alleles of these genes must
exist. All of the Dp, jp and CP genes were present on a single scaffold -
NW_931380.1/Bt4_WGA850_2 - which also contained a trypsinogen gene and the
VP20 gene, which in humans and mice reside 5' and 3' to the DJC region. Thus,
apart from a few minor areas of undetermined sequence within the scaffold, the
entire DJC region of the bovine TCRB locus would appear to be present in the
current assembly. The observed organisation of the bovine DJC genes into 3 clusters
is unique amongst the mammals for which this region has been characterised; human
- Rowen et al (1996), rat - Williams et al (1991), pig - (GenBank accession number
AB079894) and mouse - (GenBank accession number AE000665).
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However, southern blot analysis of genomic DNA from 2 rabbits identified the
presence of 3 Cp genes in one individual, which was corroborated by subsequent
genomic sequencing (Komatsu et al., 1987). The existence of a third bovine Cp had
been indicated by Conrad et al (2002) from preliminary analysis of a BAC clone
containing TCRB locus genomic sequence. Analysis of TCRp chain transcripts in the
present study (Chapter 4) had also suggested the existence of two bovine Jp clusters
orthologous to the human jp2 cluster. The deposited genomic sequence (GenBank
accession number AF453325) analysed by Conrad and colleagues matched part of
the DJC region but did not contain the Dpi gene or the first four genes in the jpi
cluster; therefore the results presented here provide the first description of the entire
bovine Dpjpcp region. The extra DJC cluster appears to have arisen by duplication
of a region incorporating the Cpl gene, the DP2 gene and the jp2 cluster.
Interestingly, this region has been deleted in New Zealand White mice (NZW), with
an unequal cross-over event invoked as the most likely explanation (Kotzin et al.,
1985; Noonan et al., 1986). The absence of a third DJC cluster in the pig (GenBank
accession number AB079894) suggests that the duplication occurred after
suidae/ruminant divergence 60-65 MYA (Kumar and Hedges, 1998). It will be
interesting in the future to determine if the duplication is present in other ruminants
such as the sheep and goat or if it is unique to cattle.
Forty-six of the VP sequences and all of the Dp, jp and Cp sequences were located
on four scaffolds which have been mapped to chromosome 4. Location of the TCRB
locus on chromosome 4 is consistent with results from fluorescent in-situ
hybridisation (FISH) analysis (Antonacci et al., 2001) and, as in humans, places the
TCRB and TCRC loci on the same chromosome (Miccoli et al., 2003). The location
of one VP sequence (VB131) on a scaffold mapped to chromosome 5 is presumably
the result of an inter-chromosomal translocation event, as has occurred in humans
(Robinson et al., 1993; Rowen et al., 1996). In contrast to humans, where multiple
VP genes and a trypsinogen gene have been translocated from chromosome 7 to 9,
possibly in multiple translocation events (Rowen et al., 1996), only one VP gene has
been identified on bovine chromosome 5 although 2Kb downstream there is a 19Kb
region of undetermined sequence that may contain other VP elements.
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The remaining 76 Vp sequences identified were located on contigs that have yet to
be mapped onto chromosomes. If it is assumed that all of these contigs will
eventually map to the TCRB locus on chromosome 4, the locus would already be
~650Kb in length, equivalent in size to both the human and murine TCRB loci
(Rowen et al., 1996, GenBank accession numbers AE000663-AE000665). The
number of trypsinogen genes (8 in humans and 20 in mice) and VP genes present in
the murine and human TCRB locus are inversely proportional (Glusman et al.,
2001). This inverse proportionality would appear to extend to the bovine TCRB
locus in which only 4 trypsinogen genes have been identified; this is likely to
represent the full complement of trypsinogen genes within the bovine TCRB locus,
since sequence for the areas of the bovine TCRB locus corresponding to those in
which trypsinogen genes are located in mouse and man appears to be complete.
Conservation in synteny of the TCRB locus and adjacent gene loci between humans
and mouse is well established (Glusman et al., 2001; Lai et al., 1988). Previous
studies using FISH have described conserved arrangement of the TCRB locus
relative to adjacent gene loci between humans and ruminants (Antonacci et al., 2001;
Di Meo et al., 2000). The availability of genomic sequence data has permitted
analyses of synteny at a higher level of resolution and reveals a striking level of
conservation in the organisation of genes within the TCRB locus between cattle and
humans. Comparison of Figures 1.4 and 5.3 shows that the conserved synteny
between bovine and human TCRB loci exceeds that displayed between the human
and murine loci, consistent with the closer evolutionary relationship of cattle and
humans (Kumar and Hedges, 1998; Li et al., 1990). Direct interpretation of the
conserved synteny between the human and bovine VP gene regions (as shown in
Figure 5.3) would suggest that bovine Vpl9, 22, 26, 27 and 29 genes are absent from
the germline repertoire. However, duplications of VP genes can distort apparent
conserved synteny and such conclusions remain speculative in the absence of the
complete TCRB locus sequence.
Extensive duplication of portions of the 5'end Vp region and subsequent gene
divergence or conversion has made reconstruction of a convincing evolutionary
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history of the human TCRp locus difficult (Glusman et al., 2001; Rowen et al.,
1996). However, knowledge of the organisation and sequence of germline murine
and human V(3 genes has been useful in analysing the evolutionary dynamics of Vp
subfamilies (Su and Nei, 2001). Although incomplete, the genomic sequence of the
bovine TCRB locus provides insight into the evolutionary dynamics of bovine Vp
genes. A distinctive feature of the bovine VP genes is that the majority of the Vpi
and VP 13 genes are present in tandem (see Table 5.1 and Figure 5.3), suggesting that
much of the expansion of these two subfamilies is a consequence of duplication of a
VP1/VP13 cassette. Partial similarity of banding patterns in southern blots genomic
bovine DNA hybridised with Vp 1 and Vpi3 specific probes had indicated that the
members of these two subfamilies might be associated in the genome (Figure 4.10e).
The bovine genome also contains tandem arrangement ofVpi/Vpl2 and VP5/Vpl3
genes (Table 5.1). As discussed previously in Chapter 4, subfamilies Vpi and Vp5
are very closely related as are the Vpi2 and 13 subfamilies, and segregation of the
VP1/VP5 subfamilies and VP12/VP13 subfamilies may be an artificial consequence
of the assigned subfamily membership of bovine VP genes being based on
comparison to human VP sequence. Therefore, it is possible that tandemly arranged
VP1/VP12 and VP5/VP13 in the bovine genome are descendants of duplications of
the same cassette that have undergone subsequent divergence, more detailed
phylogenetic analyses will be required to shed light on this issue.
Interestingly, in humans there are five repeats of a cassette containing Vp5 and VP 13
genes; Vpi and Vpi2s2 are also tandemly organised in the genome (Rowen et al.,
1996). It could therefore be conjectured that an ancestral Vp 1 -5/Vp 12-13 cassette has
been duplicated and subsequent evolution has resulted in the various tandem
duplications evident in the cattle and human TCRB loci. Unlike the duplicated
bovine cassette, some of the human Vp5/Vpi3 duplications also contain a VP6 gene
(Rowen et al., 1996). These duplications have been estimated to have occurred 32-
24MYA (Su and Nei, 2001), subsequent to primate/artiodactyl divergence (65-80
MYA - Kumar and Hedges, 1998; Li et al., 1990). Thus duplication of the cassette in
the two species must have occurred independently. The occurrence of parallel but
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separate duplications in human and bovine VP repertoires raises fascinating
questions about the evolutionary pressures that influenced these duplications.
Identification of numerous pairs of bovine VP genes (10) which share >98%
nucleotide similarity (Appendix G) indicates that duplications of some bovine Vp
genes have occurred very recently. A large duplication in the murine TCRa, which
occurred only 4-8 MYA has created 40 pairs ofVa genes which share =97%
nucleotide identity (Glusman et al., 2001). An alternative for some of these pairs of
bovine VP genes may be homogenisation due to gene conversion events; evidence
for which has been presented to explain similarity between human Vpi3s2a and
13s2b and has also been recognised in murine Va and primate Vp genes (Funkhouser
et al., 1997; Glusman et al., 2001). The existence of distinct VP genes that share
>98% nucleotide sequence identity complicates cDNA and genome sequence
comparisons since allelic variants usually also show a similar low level of sequence
difference.
Although the genomic sequence of the TCRB locus is incomplete, the results
presented in this chapter reveal that (i) there is a massive germline VP gene
repertoire in the bovine, (ii) there are three DJC clusters, as had been suggested
previously (Conrad et al., 2002) and (iii) there is marked conserved synteny in the
organisation of the bovine and human TCRB loci.
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6 Chapter 6 - Immunodominance, clonality and TCRp
chain expression in the bovine CD8+ T-cell
response to Theileria parva
6.1 Introduction
Theileria parva is a tick-transmitted parasite that causes a severe and usually fatal
lymphoproliferative disease of cattle known as East Coast Fever (ECF) in eastern,
central and southern Africa. ECF has significant economic impact on livestock
agriculture in the affected region, causing annual losses estimated in 1989 to be
approximately $168 million (Mukhebi et al., 1992). These losses are due to a
combination of the deaths of >1 million cattle/year (Norval et al., 1992), reduced
production and the cost of acaricides for tick control, which is currently the principal
means of prevention. Due to issues of cost, availability, increasing resistance and
environmental concerns, continued use of acaricides is considered to be
unsustainable. An alternative control measure, immunisation by the infection and
treatment (I & T) protocol (Radley et al., 1975a), has had little impact because of the
lack of local infrastructure for the production and distribution of the live sporozoites,
which are required for immunisation. Therefore, current research efforts are directed
towards the development of an effective subunit vaccine (Graham et al., 2006;
McKeever et al., 1999; Musoke et al., 2005).
Cattle that recover naturally from infection or are immunized by the I & T protocol
are solidly immune to challenge with homologous and certain heterologous parasite
strains (Radley et al., 1975a). Kinetic and adoptive cell transfer studies have
demonstrated that MHC class I-restricted CD8+ CTL that target schizont-infected
lymphocytes are prominent in mediating this immunity (McKeever et al., 1994;
Morrison et al., 1987). Furthermore, there is a strong correlation between the
specificity of the CTL response and cross-strain protection (Taracha et al., 1995a).
Thus CD8+ T-cell antigens are obvious candidates for inclusion in a T. parva subunit
vaccine.
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The strain-specificity of the CTL response (Goddeeris et al., 1986; Goddeeris et al.,
1990; Morrison et al., 1987) together with evidence that there are hierarchies
amongst both MHC-haplotypes (Morrison, 1996a; Morrison et al., 1987) and
epitopes (Taracha et al., 1995b) in their ability to elicit CD8 T-cell responses
indicate that T. /?arwi-specific CTLs are focused on a limited number of
immunodominant epitopes that exhibit polymorphism between different strains.
Immunodominance has been described in the CD8+ T-cell responses against many
viruses, bacteria and tumours (Yewdell and Bennink, 1999) and appears to be the
result of numerous influences that operate concurrently (section 1.3). A thorough
understanding of immunodominance is fundamental to the rational design of
vaccines eliciting effective CD8" T-cell responses. In particular the inherent
focusing ofCTL against a limited number of epitopes, which is the defining
characteristic of immunodominance, is a significant impediment to vaccine
development where there is a need for broad CTL specificity to restrain emergence
of 'escape mutants' (e.g. HIV) or to facilitate recognition of strain polymorphism in
the immunodominant antigens (e.g. T. parva)
In several viral systems, including HCV and HIV, a diverse clonal composition and
TCR repertoire within CTL responses against individual epitopes has been correlated
with the ability to constrain 'escape mutants' that express epitope variants (Douek et
al., 2002; Lopes et al., 2003; Meyer-Olson et al., 2004; Turnbull et al., 2006).
Similarly, the clonality and heterogeneity in the TCR repertoire ofCTL responses
against defined T. parva epitopes may relate to their ability to recognise variant
forms expressed by heterologous parasite strains and hence confer protection against
these strains.
The recent identification of T. parva antigens recognised by CTL restricted by
defined MHC haplotypes (Graham et al., 2006) offers the opportunity to
quantitatively assess immunodominance within the T. parva system. CTL-epitope
mapping has identified two AlO-restricted epitopes from the Tp2 antigen (Tp2.1 and
Tp2.2) and a single A18-restricted epitope from the Tpl antigen (Tpl.l). Using the
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tools developed in Chapter 3, it is now also possible to analyze the diversity of the
expressed TCR[3 chains and clonal composition ofCTL induced by these defined
epitopes.
In this chapter is presented the analysis of immunodominance of CD8+ T-cell
responses to T.parva (Muguga) in animals homozygous for the A10 and A18 MHC
class I haplotypes. The results show that the Tp2.2 epitope is highly dominant and
the Tp2.1 epitope subdominant in the A10-restricted T. pcirva-specific CD8 T-cell
response, whilst the Tpl.l epitope is highly dominant in the A18-restricted response.
The CD8+ T-cell responses to both Tp2.2. and Tpl. 1 appear to be polyclonal and
express a diverse repertoire of TCRP chains, but are dominated by a small number of
large clonal expansions.
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6.2 Materials and methods
6.2.1 Animals, immunisation and challenge
Animals 468 (A18+ homozygous), 592 (A10+ homozygous), 641 (A 18" homozygous)
and 1011 (A10+ homozygous) were immunized using the CTVM Theileria parva
(Muguga) sporozoite stabilate 71 and challenged as described in section 2.2.
6.2.2 Generation of CD8+ T-cell enriched cell-lines and clones
CD8+ T-cell enriched cell-lines were generated from PBMC by stimulation in vitro
with irradiated autologous parasitized cells as described in section 2.3.3. Cell-lines
were generated from animals 641 and 1011 prior to immunisation and from animals
468, 641 and 1011 >2 months after immunisation. The cell-line derived from 592
was established with PBMC collected >2 months after a second homologous in vivo
challenge following the initial immunisation. By collecting PBMC at least 2 months
after immunization or challenge, it was hoped that the resultant cell-lines would be
representative of the CD8* T-cell memory pool. Approximately 90 clones were
derived from each of the 4 post-immunisation cell-lines by limiting dilution (section
2.3.4).
6.2.3 Immunofluorescence staining and flow cytometry
The constituent cell populations of cell-lines obtained pre- and post-immunisation
from animals 641 and 1011 were assessed as described in section 2.3.7 using the
monoclonal antibodies (mAb) listed in Table 6.1. The phenotypes of clones that did
not show specific cytotoxic activity for peptide-loaded MHC-matched Ta targets
were assessed using monoclonal antibodies specific for CD3, CD4, CD8, WC1 (a
gamma/delta T cell marker) and NKp46 (a marker for NK cells) . Any clones with a
phenotype inconsistent with that of a CD8+ T-cell were excluded from analysis.
Clones that demonstrated specific cytotoxic activity against the appropriate peptide
loaded MHC-matched targets were assumed to be CD8 T-cells.
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6.2.4 Cytotoxicity assays
Cytotoxicity assays were performed as described in section 2.3.8. All cell-
lines/clones were tested against autologous TpM. Cell-lines/clones from A18+
animals were also tested against (i) 592 TpM (MHC-mismatched (A10) TpM), (ii)
468 Ta (MHC-matched (A18+) Ta) and (iii) Tpl.l-loaded 468 Ta. Cell-lines/clones
from A10" animals were also tested against (i) 641 TpM (MHC-mismatched (A18+)
TpM) and (ii) 592 Ta (MHC-matched (A10+) Ta) peptide-loaded with either Tp2.1 or
Tp2.2. Cytotoxic activity of 592 clones against the MHC-mismatched TpM and 468
clones against MHC-matched Ta was not examined.
6.2.5 Sequencing of TCRp chains
cDNA from clones was generated as described in sections 2.4.1-2.4.3. The TCRp
chains were amplified using the VP subfamily-specific semi-nested PCR and/or the
'Pan-VP' semi-nested PCR protocols (section 2.4.4.2). The PCR products were
sequenced (sections 2.4.9.1-2.4.9.2) and the TCRp transcript sequences analysed as
described in sections 2.5 and 4.2.2. The sequences of TCRp chains have been
presented in the format of Chothia et al. (1988) - section 2.5.4.
6.2.6 TCRp chain CDR3 (CDR3P-HDA) heteroduplex assays
CDR3P-HDA was performed on cDNA from T-cell clones, cell-lines and PBMC
collected from animal 592 immediately prior to a third in vivo challenge (pre-
challenge) and at the peak of the response to this challenge (post-challenge) on day
10 (Morrison et al., 1987) (McKeever et al., 1994) as described in section 2.4.8.2.
The PBMC were enriched for CD8+ T-cells by lysis of CD4' yd T-cells with
antibody-directed complemented mediated lysis (section 2.3.2); the efficacy of this
depletion was assessed by FACS analysis with mAb specific for CD4, WC1, CD8
and CD3 (section 2.3.7) prior to processing for CDR3P-HDA.
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6.3 Results
6.3.1 CD8+T-cell lines obtained post-immunisation but not those
obtained pre-immunization are cytotoxic for targets
presenting defined T. parva (Muguga)-epitopes
PBMC taken from animals 641 (homozygous for the A18 MHCI haplotype) and
1011 (homozygous for the A10 MHCI phenotype) pre- and post-immunisation with
Theileria parva (Muguga) were stimulated in vitro with autologous T. parva
(Muguga)-infected cells (TpM) and depleted of CD4+ and y8 T-cells. The resulting
CD8+ enriched cell-lines were assessed for cytotoxic activity against (i) autologous
TpM, (ii) MHC-mismatched TpM, (iii) MHC-matched Theileria annulata-infected
cells (Ta) and (iv) MHC-matched Ta that had been pulsed with synthetic peptides
representing the AlO-restricted epitopes Tp2.1 or Tp2.2 or the A18-restricted epitope
Tpl.l.
The cell-line obtained from animal 1011 (A10+) prior to immunisation demonstrated
cytotoxicity approaching 50% against the autologous TpM at effector:target ratios of
40:1 and 20:1 but no significant cytotoxic activity against a MHC-mismatched TpM
(Figure 6.1a). In contrast, the cell-line obtained from the other naive animal, 641
(A18+), displayed equivalent levels of killing (approximately 30%) against both the
autologous and MHC-mismatched TpM (Figure 6.1b). Neither of the pre-
immunization cell-lines displayed any significant cytotoxic activity against the
MHC-matched Ta targets, either in their native state or when loaded with peptide
(Figure 6.1a and b).
The cell-lines derived from 641 and 1011 post-immunisation displayed maximum
levels of cytotoxicity on the autologous TpM targets (-30% and -50% respectively)
similar to those detected prior to immunisation (although the 1011 cell-line gave
higher levels of cytotoxicity at lower effecter:target ratios), but they did not kill
MHC-mismatched TpM or MHC-matched Ta lines (Figure 6.1). In contrast to the
pre-immunisation cell-lines, the post-immunisation cell lines from both animals
demonstrated high levels of cytotoxic activity against the MHC-matched Ta targets
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1011 Pre-im m unised
B 641 Pre-immunised
Figure 6.1 Cytotoxic activity of in vitro CD8+ T-cell enriched cell-lines derived from PBMC of
(a) 1011 pre-immunisation, (b) 641 pre-immunisation, (c) 1011 post-immunisation, (d) 641 post-
immunisation against: autologous TpM (dark blue line with diamonds), MHC-mismatched
TpM (pink line with squares), MHC-matched Ta (yellow line with diamonds), MHC-matched
Ta loaded with Tp2.1 (light blue line with crosses), MHC-matched Ta loaded with Tp2.2 (black
line with crosses), MHC-matched Ta loaded with Tpl.l (green line with crosses). The level of
cytotoxicity required to be considered significant (>10%) is represented by the dashed line.
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loaded with peptide epitopes. The post-immunisation cell line from the A10 animal
(1011) gave maximum levels of killing of 47% and 106% of targets incubated with
the Tp2.1 and Tp2.2 epitopes respectively (Figure 6.1c), while the line from the A18'
animal (641) gave a maximal level of killing of 119% of the Tp 1.1 -loaded target
(Figure 6.Id).
Thus, although both the pre- and post-immunisation cell-lines demonstrated
cytotoxic activity against the MHC-matched TpM targets, only the post-
immunisation cell-lines exhibited cytotoxicity against targets presenting the defined
T. pai-va (Muguga) epitopes. The failure of the post-immunisation cell-lines to lyse
the native MFIC-matched Ta indicates the cytotoxicity against the peptide loaded
targets was epitope-specific.
6.3.2 Phenotype pre- and post-immunisation cell-lines
The phenotype of the cell-lines derived from the pre- and post-immunisation PBMC
were examined using a panel of mono-clonal antibodies in single colour FACS
analysis (Table 6.1). Minor populations of B-cells and monocytes (MyD-1 cells)
were evident in all four cell-lines, as were remnant populations of CD4+ T-cells and
WC1 yS T-cells following depletion of these populations by antibody-directed
complement mediated lysis. The proportion of the populations that were CD8+ varied
between the cell lines, from 26.9% in the pre-immunisation 1011 cell-line to 84.6%
in the post-immunisation 1011 cell-line.
However, the most notable difference between the pre- and post-immunisation cell-
lines was the disparity in the number of T-cells (CD3+) and NK-like cells (NKp46+).
Cell-lines obtained pre-immunisation were dominated by NKp46^ cells (76.2% in
1011 and 64.6% in 641), with CD3+ cells representing <30% of the population. In
contrast, in both post-immunisation cell-lines CD3+ cells constituted >80% of the
cell population whilst NKp46+ cell populations were comparatively minor (13.8% in
1011 and 6% in 641).
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IL-A12 CD4 - CD4+ T-cells 9.2% 12.2% 7.2% 5.8%
CC15 WC1 - WC1+ y8T-cells 8.8% 2.2% 3.1% 7.9%
IL-A51 CDS - CD8+ T-cells
and NK.-T cells
26.9% 84.6% 59.9% 69.8%
MM1A CD3 - T-cells 30.5% 83.9% 29.0% 86.5%
NKp46-
AKSl'




<1% ND <1% <1%
IL-A30 IgM - B-cells 2.8% ND 2.2% 6.5%
Table 6.1 Phenotype of the in vitro cell-lines generated from pre- and post-immunisation PBIV1C
from animals 1011 and 641.
6.3.3 Cytotoxic activity of Theileria parva-specific CD8+ T-cell
clones
Approximately 90 clones were generated from bulk CD8 T-cell-enriched cell-lines
established from two immunised AlO-homozygous (1011 and 592) and two
immunised A18-homozygous animals (468 and 641), and their cytotoxic activity
analysed. The results from this analysis are detailed in Appendix K.
6.3.3.1 Tp2.2 is the immunodominant CD8+ T-cell epitope in A10+
animals immunised against Theileria parva (Muguga).
Over 80% of the clones generated from the two A10+ animals (76/89 for 592 and
73/89 for 1011) demonstrated significant cytotoxicity against the autologous TpM
targets (Figures 6.2a and 6.3a), with levels of killing ranging from 10.0% to 49.7%
for 592 (Figure 6.2a) and 10.2%-79.0% for 1011 (Figure 6.3a). None of the 1011
clones exhibited significant cytotoxicity when tested against an MHC-mismatched
(A18T) TpM target (Figure 6.3a).
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The majority of the clones from both 592 (71/89 - 80%) and 1011 (65/89 - 73%)
demonstrated significant cytotoxicity against the Tp2.2-loaded A10+Ta target,
whereas only 9/89 (10%) of clones from 592 and 2/89 (2%) of clones from 1011
exhibited significant cytotoxicity against the Tp2.1-loaded A101 Ta target (Figures
6.2b and 6.3b). As with the levels of cytotoxicity against the autologous TpM, there
was considerable variation in the levels of cytotoxicity displayed against the peptide
loaded Ta targets - e.g. amongst the 592 clones cytotoxic for the Tp2.2-loaded target
percentage lysis varied from 63.7% (592.30) to 121.4% (592.73). With the exception
of one clone from animal 592 (592.15), none of the clones exhibited significant
cytotoxicity against both Tp2.1 and Tp2.2 (Figure 6.2b), confirming that the
cytotoxic activity was epitope-specific (see section 6.3.4).
These findings indicate that Tp2.2 is highly dominant in the response of immunised
A10+ animals against Tlieilerict parva (Muguga) as measured in vitro, whilst Tp2.1 is
a subdominant epitope. The identification of clones not cytotoxic for either Tp2.1 or
Tp2.2 presenting targets, some of which exhibited cytotoxicity against the
autologous TpM target (e.g. 592.63), indicates the potential presence of additional
subdominant epitopes in the response.
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6.3.3.2 Tp1.1 is the immunodominant CD8+ T-cell epitope A18+ animals
immunised against Theileria parva (Muguga).
The level of cytotoxicity displayed by the clones derived from the two A18-
homozygous animals against the autologous TpM targets was generally low. In fact,
none of the 468 clones achieved the 10% lysis considered to indicate significant
cytotoxic activity and only 12 clones showed >5% cytotoxicity (Figure 6.4a). A
minority (39/87 - 44.8%) of the 641 clones demonstrated significant cytotoxic
activity against the autologous TpM target, but the maximum lysis achieved was only
33.3% (Figure 6.5a). None of the clones from either animal displayed any significant
cytotoxic activity against the MHC-mismatched TpM target (Figures 6.4a and 6.5a).
Despite the low levels of killing detected on TpM targets, the majority of the clones
from both 468 (72/90 - 80%) and 641 (64/87 - 74%) gave significant killing when
assayed against the A18+Ta target loaded with the Tpl.l epitope (Figures 6.4b and
6.5b). Again, the levels of killing varied markedly between clones - ranging from
13.9 to 125.2% for 468 clones and from 11.2 to 117.2% for 641 clones. None of the
641 clones showed any significant cytotoxic activity against the A18+ Ta target in
the absence ofTpl.l peptide (Figure 6.5b), confirming their epitope specificity.
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6.3.4 Examination of TCRp chain expression by clones
To determine the clonal composition of the T. pcirva-specific CD8+ T-cell response
represented in the in vitro cell-lines from these 4 animals, and the repertoire of TCRP
chains expressed by the responding clonotypes, the TCRP chains expressed by the T-
cell clones were sequenced following PCR amplification using the VP subfamily-
specific primers and/or the 'PanVP' primer (Appendix L). Sequences for a single
predicted functional TCRP chain was obtained for 310 of the 355 clones (87%)
(Table 6.2).
Animal 468 592 641 1011 Total
Number of clones 90 89 87 89 355
Single functional TCRP sequenced 67 78 84 81 310
No TCRP chain sequenced 16 3 2 4 25
Dual functional TCRp sequenced 7 8 1 4 20
Table 6.2 Summary of the results of sequencing the TCRp chain expression by clones
derived from animals 468, 592, 641 and 1011.
Some of these clones expressed additional TCRP chains that were predicted to be
non-functional (Appendix L - sequence in red script) due either to frameshifts in the
CDR3 region or the expression of non-functional VP genes (Vpi0s6 and Vpi3s6 -
section 4.3.1). For 25 clones (7%) no TCRP chain sequence was obtained, whilst for
the remaining 20 clones (6%) two predicted functional TCRP chains were identified.
In the majority of the latter clones, at least one of the TCRP chains expressed was
identical to a sequence identified among the clones expressing a single functional
TCRp chain (e.g. 592.41 expresses a Vpi+ chain identical to that in 592.75 and a
VP14 chain identical to that in 592.26 and other clones), indicating that the
expression of dual functional TCRP chains by these 'clones' is predominantly
attributable to their non-clonal nature. Analysis ofTCRp chain expression by clone
592.15 reveals that it expresses two predicted functional chains - a Vp2+ chain that is
also expressed by 6 other clones that all display Tp2.2-specific cytotoxic activity,
and a Vpi4' chain that is expressed by 8 other clones which all exhibit Tp2.1-
specific cytotoxicity. The bi-clonality of this clone, indicated by the dual TCRp
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expression, provides an explanation for its ability to recognise both Tp2.1 and Tp2.2
epitopes (section 6.3.3.1). Only sequences ofTCRP chains expressed by clones with
a single functional TCRp chain were included in subsequent analyses.
6.3.5 Clonal composition of the response to immunodominant
epitopes
The cytotoxicity results described in section 6.3.3 indicate that Tpl.l and Tp2.2 are
the immunodominant epitopes in the CD8+ T-cell responses to Theileria parva
(Muguga) in A18+ and A10+ animals respectively. Acquisition of the single predicted
functional TCR[3 chain sequence of 61 and 60 Tp2.2-specific CTL clones from
animals 592 and 1011 respectively and 55 and 64 Tpl.l-specific CTL clones from
animals 468 and 641 respectively, allowed characterisation of the clonality of the
responses as detected in these in vitro cell-lines.
For each of the animals, the clones were organised into clonotypes on the basis of
expression ofTCRP chains with identical sequence (Tables 6.3 and 6.4). The
epitope-specific clones from animals 468, 592, 641 and 1011 belonged to 12, 17, 12
and 10 clonotypes respectively. As can be seen in Figure 6.4, where the cumulative
percentage of clones is shown in relation to the number of clonotypes, for each
animal a majority of the clones belong to a few large clonotypes. This is most
pronounced in 641 and 1011, where >75% of the immunodominant epitope-specific
CTL clones belong to only 2 clonotypes. The trend is less pronounced for animal
592, where the accumulation of the 8 most abundant clonotypes constituted 75% of
the clones. The long 'tail' of the curves, particularly seen for 1011, 468 and 641,
illustrate the presence of numerous less abundant clonotypes. Therefore, the CTL
responses measured in vitro against the immunodominant epitopes appear to be
polyclonal but dominated by a small number of large clonal expansions.
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Figure 6.6 The response to the immunodominant A18-restricted (Tpl.l) and AlO-restrieted
(Tp2.2) epitopes measured in vitro are dominated by a limited number of clonotypes. The
cumulative percentages of Tpl.l specific-clones from 641 (light blue), 468 (yellow) and Tp2.2-
specific clones from 1011 (pink) and 592 (dark blue) are plotted against the number of
clonotypes represented. Clonotypes are arranged in descending order of frequency.
6.3.6 TCRp chain repertoires of Tp2.2 and Tp1.1-specific CTL
clones
6.3.6.1 Diverse VP subfamily gene usage by Tp1.1- and Tp2.2-specific
CTL clones
V(B genes from 11 subfamilies were used by the 27 different Tp2.2-specific CTL
clonotypes identified from 592 and 1011. As shown in Figure 6.7a, the profile of the
VP subfamily usage by clones from these two animals was markedly different. Genes
from VP subfamilies 6, 7 and 17 were expressed by clones from 592 but not 1011
and conversely Vp4 and X were used by 1011 but not 592 clones. Furthermore, for
VP subfamilies utilized by clones from both animals the frequency of expression was
often dissimilar (e.g. Vpi4 and 28).
Similarly, the 24 Tpl.l-specific CTL clonotypes identified from 468 and 641 utilized
VP genes from 11 subfamilies. Again, there was obvious discordance of VP
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subfamily gene usage between clones from the 2 animals (Figure 6.7b), with Vp2, 6,
20 and 24 genes used only by clones from 468 and Vp4 and 16 gene usage being
unique to clones from 641. Interestingly, due to the presence of single large
clonotypes in both 468 and 641 the single member VP3 subfamily was used at high
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Figure 6.7 Percentage of immunodominant epitope-specific CTL clones expressing different Vp
subfamily genes, (a) Tp2.2-specific clones from 592 (light blue bars) and 1011 (purple), (b) Tpl-
specific clones from 468 (Zhang et al.) and 641 (orange).
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6.3.6.2 Diverse CDR3(5 region sequences of Tp1.1 and Tp2.2-specific
CTL clones
The sequences of the TCRp chains expressed by the Tp2.2- and Tp 1.1-specific CTL
clonotypes are presented in Tables 6.3 and 6.4. There is generally little evidence of
conservation of the CDR3P either in terms of length or amino acid sequence within
the epitope-specific CTL populations. For example, the two Tp2.2-specific Vp8s2+
clonotypes show CDR3P with different lengths and no conserved sequence motifs
(Table 6.3) and similarly the two large Tpl.l-specific Vp3sl" clonotypes (Table 6.4)
show no conserved CDR3p features.
However, there are a limited number of examples of CDR3P conservation. Three
Tp2.2-specific Vp28sl+ clonotypes express identical CDR3P regions and jp genes
(Table 6.3). The two clonotypes in 592 were distinguished on the basis that (i) there
was a single nucleotide polymorphism in the sequence of the Vp28sl gene,
suggesting the expression of different alleles and more significantly (ii) one of the
clonotypes co-expressed a non-functional Vpi3s6r TCRp chain, which was not
expressed by the other clonotype (Appendix L). The expression of identical TCRP
chains by Tp2.2- specific 592 and 1011 clonotypes suggests that this particular
Vp28sl+ chain represents a 'public' TCRp. Similarly, an identical 'public' Tpl.l-
specific Vpis9+ TCRP chain was expressed by a single clonotype in both 468 and a
641 (Table 6.4).
Additionally, amongst the Tp 1.1-specific CTL clonotypes there were examples of
pairs of Vpis7+ and Vpi4sl+clonotypes that exhibited conservation of CDR3p length
and partial conservation of the sequence (Table 6.4). In some cases the non-
conserved amino acid residues in corresponding positions of these CDR3p regions
involved conservative substitutions. The aspartate (D) and glutamate (E) in the 3,d
positions of the Vpis7+ chains CDR3ps are both polar, hydrophilic and negative
residues; and the tryptophan (W) and phenylalanine (F) in the 5th positions of the








FR CDR3 FR JP
gene
lsl CAS SQGRGSGFEQ Y F G 3s7 2 592
ls6 CAS S P N S Y E Q Y F G 3s7 1 592
ls7 CAS SQVGGIYGEL H F G 3sl 3 1011
2s4 C S A QWGGSYEEQ H F G 2sl 6 592
2s4 C S A RFGPGGLSYEQ Y F G 3s7 1 1011
4s6 C S A GVGTRLSYEQ Y F G 3s7 4 1011
6s2 CAS SPILAWETL Y F G 2s4 2 592
8s2 CAS SKSLFEIQ Y F G 3s5 2 592
8s2 CAS SYETSGYGEL H F G 3sl 1 592
12sl CAS HIRGGLDTQPL Y F G 3s2 4 592
12sl CAS SLVGRETL Y F G 2s4 1 1011
12s2 CAS SYSPGGGSPL Y F G 3s3 2 1011
13sl CAS SNSRATAYDY H F G ls2 1 1011
13s2 CAS S H A G Y E Q Y F G J3 1 592
13s4 CAS SSSLLDTQ Y F G 3s4 2 592
13s7 CAS GHLVGGTREL H F G 3sl 5 592
13s8 CAS SQGQQGYVNNPL Y F G 3s3 1 592
13s9 CAS G E Q Y F G 3 s7 2 592
14sl CAS SESQGANYDY H F G ls2 4 592
14sl CAS SVGNSNYEQ Y F G 3s7 28 1011
17sl C A A SSVFGGDLKSYEQ Y F G 3 s7 6 592
28sl CAS GGRDS IYDY H F G ls2 6 592
28sl CAS AEYGGENTQPL Y F G 3s2 14 592
28sl CAS AEYGGENTQPL Y F G 3s2 2 592
28sl CAS AEYGGENTQPL Y F G 3s2 1 1011
Xsl C T C SKAAAEDGYEQ Y F G 3s7 18 1011
Xsl C T C SRGDNSYEQ Y F G 3s7 1 1011
Table 6.3 TCRp chain sequence of the Tp2.2-specific CTL clonotypes identified from 592 and
1011. The TCRp chain sequence is presented in the format of Chothia et al (1988). The number
of clones represented within each clonotype and the animal from which each clonotype was
derived are detailed. The TCRp chain sequence of the three clonotypes expressing the 'public'








FR CDR3 FR JP
gene
li?' C A S S D DFYSTDTQ Y F G 3s 4 2 468
Is7 CAS SHEWYSTDTQ Y F G 3s4 18 641
Is 9 CAS S Q D Y P T N D P L Y F G 3s 3 8 468
ls9 C AS S Q D Y P T N D P L Y F G 3s 3 1 641
2s7 C G V PSGTASDY H F G ls2 2 468
2s9 C G A HGPDYSTDTQ Y F G 3s4 1 468
3sl CAS SYFGVTQPL Y F G 3s2 19 468
3sl CAS REKGLRGSSNDPL Y F G 3s3 34 641
3sl CAS NKWGGGNNPL Y F G 3s3 1 641
4s5 C S A RPDFGGFNDPL Y F G 3s3 1 641
4s5 C S A R S G A W D Y H F G ls2 1 641
6s2 CAS SRSSGHVSNDPL Y F G 3s3 1 468
10s4 CAS RRAVMNDPL Y F G 3s3 17 468
10s7 CAS S Q R Y D E Q Y F G 3s7 1 641
13sl CAS RGGAGRNGEL H F G 3sl 1 468
13sl CAS R I T A G E Q H F G 2sl 1 468
14 s 1 CAS SATTAGLAGAAL T F G 3s6 1 468
14sl C A S S S S W E Q Y F G 3s7 3 641
14 s 1 C AS S E S W E L H F G 2sl 1 641
14 S1 CAS SGGQLSER Y F G 2s5 1 641
14 S1 CAS SDHRAGPWEQ Y F G 3s7 1 641
16sl CAS S L G A L E V F F G lsl 1 641
20sl CAW S R G N E Q Y F G 3s7 1 468
24sl CAS RARTPSNDPL Y F G 3s3 1 468
Table 6.4 TCRp chain sequence of the Tpl.l-specific CTL clonotypes identified from 468 and
641. The TCRp chain sequences are presented in the format of Chothia et al (1988). The number
of clones represented within each clonotype and the animal from which each clonotype was
derived are detailed. The TCRp chain sequence of the clonotypes expressing the 'public' Vpis9+
TCRp chain, or the partially conserved Vpis7+ TCRp chain/Vpi4sl+ TCRp chain are shaded.
The two 641 clonotypes sharing identical TCRp chain sequence with non-Tpl specific
clonotypes are shown in bold italicised script (compare with Table 6.7)
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6.3.7 TCRp chain sequence of Tp2.1-specific CTL clonotypes
Only three Tp2.1-specific CTL clonotypes were identified from the 592 and 1011
clones. As can be seen from Table 6.5 there was no conservation of either the V(3
genes or CDR3(3 regions expressed by these clonotypes. However, insufficient








FR CDR3 FR JP
gene
4s3 CSA PGQQGYEQ YFG 3s7 1 1011
13s5 CTS SRGGRIDGEL HFG 3sl 1 1011
14 si CAS SVSFGGAPYGEL HFG 3sl 8 592
Table 6.5 TCRp chain sequence of the Tp2.1-specific CTL clonotypes identified from 592 and
1011. The TCRp chain sequence is presented in the format of Chothia et al (1988). The number
of clones represented within each clonotype and the animal from which each clonotype was
derived are detailed.
6.3.8 Clonal composition of T-cell clones not cytotoxic for defined
epitopes.
The sequences of the non-Tp2.1/Tp2.2-specific CTL clonotypes identified from the
592 and 1011 clones are presented in Table 6.6. This population appears to be
extremely polyclonal, with only two clonotypes (a Vpis3+ and a Vpi5s2+ clonotype)
being represented by more than 1 clone. There is generally little conservation of
either Vp gene or CDR3P expression although there is a pair of Vp2s3+ clonotypes
and a set of four Vpl5s2+ clonotypes that show conserved CDR3P length and partial
conservation ofCDR3P sequence (Table 6.6 - shaded sequences).
The non-Tp 1.1-specific CTL clonotypes present amongst the 468 and 641 clones
display a more oligo-clonal nature, with over half (6/11) of the clonotypes being
composed of 2 or more clones (Table 6.7). There is no identifiable conservation of
VP gene or CDR3P region expression by the different non-Tp 1.1-specific CTL
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clonotypes (Table 6.6). Notably, two non-Tpl.l cytotoxic 641 clonotypes (the
Vpis7+ and a Vp3sl+ clonotype) expressed TCR[3 chain sequences identical to those
expressed by Tp 1.1 -cytotoxic 641 clonotypes (compare the bold italicised sequence







FR CDR3 FR JP
gene
ls3 CAS SQDRRDSYVQL YFG 2s2 2 592
ls3 CAS SQGRYNNPL YFG 3s3 1 592
ls3 CAS SPAGRDTQ YFG 3s4 1 1011
ls7 CAS SQDIGGSTQIQ YFG 3s5 1 592
lsll CAS SSGAANSNNPL YFG 3s3 1 1011
lsl3 CAS SESRGGGYEQ YFG 3s7 1 592
2s3 CSA SMGFRGQSTQ YFG 2s3 1 1011
2 s 3 CSA SWGVGGQSTQ YFG 2s3 1 1011
5sl CAS SPTSGPSNNPL YFG 3s3 1 1011
6s2 CAS LASRNTEV FFG lsl 1 592
6s2 CAS SLHGNTEV FFG lsl 1 1011
6s3 CAS SPTGGGSAHNNPL YFG 3s3 1 1011
8sl CAS SKSTDTEV FFG lsl 1 592
10s3 CAS SHRTASYDY HFG ls2 1 1011
12sl CAS SLVGRETL YFG 2s4 1 1011
13sl CAS SYQGPNPL YFG 3s3 1 1011
13s2 CAS SYQPINSPL HFG ls5 1 1011
13s4 CAR GLGYRETL YFG 2s4 1 1011
15s2 CAS NSGQQGGTQPL YFG 3s2 1 1011
15s2 CAS NPGQQGGTQPL YFG 3s2 1 1011
15s2 CAS NPGQQGGAVQL YFG 2s2 1 1011
15s2 CAS NRGQQGGSYEQ YFG 3s7 2 1011
16sl CAS SRGEANSETL YFG 2s4 1 1011
17s2 CSG ASGLDY HFG ls2 1 592
17,S3 CAA SRDMTGTEV FFG lsl 1 592
20sl CAL RAGGSSETL YFG 2s4 1 1011
Table 6.6 TCRp chain sequence of the non-Tp2.1/Tp2.2 specific CTL clonotypes identified from
592 and 1011. The TCRp chain sequences are presented in the format of Chothia et al (1988).
The number of clones represented within each clonotype and the animal from which each
clonotype was derived are detailed. The TCRp chain sequence of the clonotypes expressing








FR CDR3 FR JP
gene
ls7 CAS SHEWYSTDTQ YFG 3s4 4 641
ls9 CAS SPDIPTIGER YFG 2s5 2 641
2s7 CGA RAPRGPSRE YFG 3s3 2 468
3si CAS REKGLRGSSNDPL YFG 3s3 9 641
3sl CAS SAKAHGRVHAGAAL TFG 3s6 1 641
7sl CAS SREPQDREI LFG 2sl 1 641
13s2 CAS SYEEHGEQ YFG 3s7 7 468
13sl0 CAS RGESHNPL YFG 3s3 1 641
14sl CAS SRGWEQ YFG 3s7 2 641
14 S1 CAS SKDSVPERL YFG 3s3 1 468
20sl CAW ESEETL YFG 2s4 1 468
20sl CAW THQTESYDY HFG ls2 1 468
Table 6.7 TCRp chain sequence of the non-Tpl.l-specific CTL clonotypes identified from 468
and 641 clones. The TCRp chain sequences are presented in the format of Chothia et at. (1988).
The number of clones represented within each clonotype and the animal from which each
clonotype was derived are detailed. The two 641 clonotypes sharing identical TCRp chain
sequence with Tpl.l-specific CTL clonotypes are shown in bold italicised script (compare with
Table 6.4)
6.3.9 Clonality of the in vivo CD8+ T-cell response to T.parva
An important question raised by these findings is whether the responses measured in
vitro are representative of the response of the memory T-cell population following in
vivo antigenic challenge or reflect biases introduced by in vitro manipulation. In
Chapter 3, comparative analyses of CD8+ T-cell emiched cell-lines with clones
derived from them demonstrated that the CDR3(3-HDA technique provides accurate
descriptions of the clonal composition of complex T-cell populations (section
3.3.4.2). In order to determine whether the in vitro findings reflect the composition of
the memory CD8+ T-cell response in vivo, one animal (592) was challenged with
sporozoites and the clonal composition of CD8+ T-cells harvested at the peak of the
response was compared with that measured in vitro from PBMC isolated prior to the
challenge.
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The results ofCDR3P-HDA revealed a remarkably similar pattern of clonal
composition observed in the in vivo response and that measured in vitro (Figure 6.9a
and 6.9b, red arrows indicate some of the heteroduplex bands evident in both
CDR3p-HDA) and co-migration of heteroduplex bands from the in vivo response,
the response measured in vitro and selected representative clones derived from the in
vitro cell-line could be demonstrated (e.g. Vpl4 in Figure 6.9c and VP28 in Figure
6.9d). This result, albeit with one animal, suggests that the responses measured in
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6- V(328 probe + clone 592.29
7- V(328 probe + clone 592.13
8- VJ328 probe + clone 592.69
Figure 6.8 Comparison of CDR3p-HDA of the in vitro and in vivo responses of the 7. parva-
specific memory CD8+ T-cell population from animal 592. (A) CDR3P-HDA of the in vitro CD8+
T-cell enriched cell-line derived from PBMC of animal 592 taken >2 months after the second in
vivo challenge. (B) CDR3P-HDA of the ex vivo CD8 T-cell enriched PBMC of animal 592 taken
lOd following the third in vivo challenge post-immunisation. (C) Comparison of Vpi4+ CDR3p-
HDA migration patterns (D) Comparison of Vpl4+ CDR3P-HDA migration patterns.
Homoduplices are indicated by yellow asterisk/arrows and red arrows indicated heteroduplex
bands. Not all similarities in the CDR3P-HDA results presented in a and b have been indicated.
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6.4 Discussion
Results of previous studies have indicated that the protective CD8" T-cell response
against T. parvci is subject to the phenomenon of immunodominance (Morrison,
1996a; Taracha et al., 1995b), whereby CTL are focused on a limited number of
immunogenic epitopes. The results from this chapter, based largely on in vitro
studies, provide the first direct quantitative evidence of immunodominance in the
CD8* T-cell response to T. parva and have yielded detailed information on the clonal
composition and TCRp chain repertoires ofCTLs specific for dominant epitopes.
Based on analysis of approximately 90 CD8+ T-cell clones from each of 4 animals
immunised against T. parva (Muguga), >70% of the clones from each animal were
found to be specific for a single dominant epitope, Tpl.l in the two A18-
homozygous animals (468 and 641) and Tp2.2 in the two AlO-homozygous animals
(592 and 1011). Thus, these epitopes appear to be highly immunodominant in cattle
with these particular MHC genotypes immunised against the Muguga strain of T.
parva. An additional epitope, Tp2.1, recognised by 10% or less of clones from the
two AlO-homozygous animals appears to be a subdominant epitope.
In contrast to the CD8+ T-cell lines generated from animals 641 and 1011 post-
immunisation, those generated pre-immunisation were not cytotoxic for MHC-
matched targets presenting the Tpl.l, Tp2.1 or Tp2.2 epitopes(Figure 6.1), indicating
that the detectable response to these epitopes was attributable to immunisation.
However, both pre- and post- immunisation cell-lines from these 2 animals exhibited
cytotoxic activity for the MHC-matched TpM targets. The cytotoxicity displayed by
both post-immunisation cell-lines and the 1011 pre-immunisation cell-line appeared
to be MHC-restricted whereas the 641 pre-immunisation cell-line also exhibited lysis
of the MHC-mismatched TpM target. These findings contradict the reports from
previous studies that indicate that in vitro stimulated PBMC from naive animals have
cytotoxic activity against allogeneic but not autologous TpM (Eugui and Emery,
1981; Pearson et al., 1979). This discrepancy may be associated with differences
between the in vitro culture methods used in this study (3 stimulations of PBMC with
autologous TpM, the last following enrichment for CD8T T cells and
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supplementation with IL-2) and the studies reported in the literature (single
stimulation with autologous TpM, no IL-2 supplementation or enrichment ofCD8+
cells).
Phenotypic analysis identified a significant difference in the composition of the cell-
lines generated pre- and post- immunisation (Table 6.1). T-cells (CD3+) constituted
the majority of the post-immunisation cell-lines populations, whereas in the pre-
immunisation cell-lines NK-like cells (NKp46 +) were the predominant population.
Several NKp46+ clones were established from the pre-immunisation 641 cell-line by
limiting dilution and phenotyped as CD3~, CD4", CD810 by FACS analysis (data not
shown) - consistent with the phenotype of bovine NKp46+ NK-like cells reported in
the literature (Storset et al., 2004). Variation in the cytotoxic activity of different
bovine NKp46+ populations has been reported (Storset et al., 2004) and may account
for the difference between the cytotoxicity profiles of the 1011 and 641 pre-
immunisation cell-lines (assuming that the cytotoxicity is due to the NKp46+
populations). NK cells serve as a crucial first line defence against a diverse range of
pathogens, including other apicomplexan parasites such as Plasmodium falciparum
and Toxoplasma gondii (Korbel et al., 2004; Lodoen and Lanier, 2006). Although
NK-like cells have been identified from the PBMC of a T. pnrvn-immunised animal
(Goddeeris et al., 1991), the role of these cells is not yet defined and may make an
interesting area of investigation in the future.
Sequences for a single predicted functional TCRp chain were obtained for 310 out of
the 355 clones analysed (87%), no TCRp chains were obtained for 25 of the clones
examined (7%) and two predicted functional TCRp chains were sequenced in the
remaining 20 clones (6%). The failure to identify any TCRp sequence was mainly
attributable to loss ofmRNA during processing (lack of cDNA demonstrated by
failure to amplify the control gene glyceraldehyde-3-phosphate dehydrogenase by
PCR - data not shown). For most of the clones with dual functional TCRP chains, at
least one of the expressed chains was identical to a sequence from another clone
expressing a single TCRP, indicating that these clones were actually bi-clonal. As
clones selected from plates showing growth in less than 30% ofwells seeded by
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limiting dilution have only 83% probability of being truly clonal (Henry et al., 1980),
the detection ofmore than one clone in ~6% of the cultures is not unexpected.
Alternative explanations for the expression of dual predicted functional TCR(3
chains, such as loss of allelic exclusion at the TCRB locus, which has been reported
to occur in up to 1% of human peripheral ap T-cells (Davodeau et al., 1995; Padovan
et al., 1995), and the expression of TCRP chains that although predicted from
nucleotide sequence to be functional are in fact non-functional (Rowen et al., 1996)
may be applicable but are less likely to be numerically significant.
The response to the immunodominant-epitope in the CD8T T-cell enriched cell-lines
from all 4 animals was found to be polyclonal but dominated by a limited number of
large clonal expansions (Figure 6.6). This pattern of clonality has been described for
antigen-specific CD81 T-cell responses to dominant epitopes in numerous
immunodominant systems (Annels et al., 2000; Chen et al., 2001c; Maryanski et al.,
1999; Naumov et al., 1998). Both random, non-synchronous activation of different
antigen-specific clonotypes (Bousso et al., 1999) and the early entry into activation
of clonotypes bearing high affinity TCR for the cognate pMHC ligand (Maryanski et
al., 1999) have been proposed in other models for the presence of large oligo-clonal
expansions amongst the polyclonal response.
Of the 4 animals in this study, only 592 had undergone in vivo challenges following
immunisation before the response of PBMC was analysed in vitro. Interestingly, the
Tp2.2-specific CTL clones from 592 were more evenly distributed amongst a larger
number of clonotypes than in 468, 641 and 1011, causing a notable 'right-shift' of
the 592 curve comparative to the curves of the other 3 animals in Figure 6.6. This
may indicate that the number of in vivo exposures to T. parva has influenced the
clonality of the subsequent CTL responses measured in vitro, but in the absence of
comparative information on the response following the initial immunisation and
corroborative data from more animals, this remains speculative. Intriguingly, the
immunodominant epitope-specific CTL population of clones was composed ofmore
clonotypes for 592 than for any of the other 3 animals, in contrast to the immuno-
focusing of responses (reduction in the number of antigen-specific clonotypes) seen
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on repeated antigen exposure in other CD8+ T-cell responses (Busch and Pamer,
1999; Kedzierska et al., 2004; Maryanski et al., 1999; Trautmann et al., 2005; Zhong
and Reinherz, 2004). However, this observation may be an artefact based on the
number of clones examined from each animal in this study - examination of larger
numbers of clones and statistical analysis will be required to validate this.
The TCRP repertoires expressed by the 121 Tp2.2-specific CTL clones (27
clonotypes) and 119 Tp1.1-specific CTL clones (24 clonotypes) were highly diverse.
Within both epitope-specific populations VP genes from 11 different subfamilies
were used (Figure 6.7) - with 21 and 14 Vp genes expressed by the Tp2.2- and
Tp 1.1-specific CTL clonotypes respectively. The CDR3P regions were also
characterised by a high degree of diversity (Tables 6.3 and 6.4). Expression of highly
diverse TCR repertoires by CD8+ T-cells specific for other immunodominant
epitopes has been reported, for example in the responses to the HLA-A11 restricted
AVF epitope from EBV (Campos-Lima et al., 1997) and the H2-Kd restricted
epitopes LLO 91-99 and p60 217-225 from Listeria monocytogenes (Busch and
Pamer, 1998; Busch and Pamer, 1999). In both of these models, it has been
suggested that the immunodominance of the epitopes correlates with their capacity to
elicit a response from a diverse TCR repertoire and the results indicate this may
relate to an ability of these epitopes to form highly stable complexes with the
presenting MHC molecules (Busch and Pamer, 1998), thereby enabling them to
activate T-cells bearing high and low affinity TCR (Busch and Pamer, 1999;
Campos-Lima et al., 1997). Further work to analyse the stability of complexes
formed by Tp2.2 and Tpl.l with the respective presenting MHC elements and the
affinity of the different antigen-specific TCRs could be informative in this regard.
Another possible contributing factor to the ability ofTpl.l and Tp2.2 to select
diverse TCR repertoires is the conformation of the pMHC ligand they form when
bound to the presenting MHCI molecule. Both epitopes are 1 lmers, - and therefore
likely to have a bulged conformation within the MHCI groove. Recent
crystallographic studies have shown that immunodominant epitopes from influenza
presented by H2-Db (PA224-233) and H2-Kb (PBI703-711) have a bulged conformation
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(Meijers et al., 2005) and have presented evidence that this feature of the PA224-233-
Db complex is fundamental to the selection of a diverse epitope-specific TCR
repertoire (Turner et al., 2005).
Diverse TCR repertoire expression by epitope-specific CD8+ T-cells has been
correlated with the ability to recognise epitope variants (Campos-Lima et al., 1997;
Meyer-Olson et al., 2004) and has been cited as an important factor in the control of
'escape mutants' in viral infections such as HIV (Douek et al., 2002; Lopes et al.,
2003) where in many individuals immunodominance focuses the response on a
limited number of epitopes at any given time during the infection. Studies using
peptides with single amino acid substitutions have demonstrated that T-cell
clonotypes expressing different TCRP chains specific for the same epitope show
different patterns of cross-reactivity with substituted variant peptides (Ishikawa et
al., 1998; Kim and Kim, 2002; Valmori et al., 1998). Thus, an antigen specific T cell
population with a diverse TCR repertoire has an inherently greater potential to
recognise variant epitopes than a response with a narrow TCR repertoire. The diverse
TCR repertoires expressed by Tpl.l and Tp2.2-specific CTL would therefore be
anticipated to accommodate some degree of cross-recognition of the polymorphic
forms expressed by other strains of T. parva and so mediate cross-protection.
However, as can be seen in Table 6.8, polymorphic versions ofTpl.l and Tp2.2
show considerable variation, whilst in the studies by Campos-Lima et al. (1997),
Douek et al. (Douek et al., 2002), Lopes et al. (2003) and others, that demonstrated
cross-recognition of epitope variants, the variant epitopes differed by only one
residue. This quantative difference may prove crucial in the ability ofTpl.l- and
Tp2.2-specific CTL to recognise epitope variants and offers an interesting area for
further exploration.
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Table 6.8 Amino acid sequences of epitopes Tpl.l, Tp2.1 and Tp2.2.
The amino acid sequences of the epitopes expressed by T. parva (Muguga)
and other strains are presented in alignment. Dashes represent
conserved amino acid residues. Epitope sequence data provided by
Dr. E. Taracha and Dr. S. Graham (ILRI, Nairobi, Kenya).
Despite the diversity of the TCRp repertoires expressed amongst the Tp2.2-specific
and Tpl.l-specific CTL populations there were some instances of conservation,
including the expression of'public' TCR|3 chains (section 6.3.6.2). It has been
suggested that 'public' TCRs represent a 'best fit' for their cognate pMHC ligand
and due to their high affinity are preferentially selected from the naive repertoire and
assume progressively greater prominence in the antigen-specific TCR repertoire
during chronic antigen exposure or subsequent challenge (Kedzierska et al., 2004;
Trautmann et al., 2005). However, both large and small clonotypes expressed the
'public' Vp28sl+Tp2.2-specific TCRp chain and Vpis9+Tpl.l-specific TCRP chain
(Tables 6.3 and 6.4), indicating that expression of'public' TCRp chains was not
strictly correlated to large clonal expansion and clonal prominence. Other parameters
such as precursor frequencies (Attuil et al., 2000), stochastic selection (Bousso et al.,
1999; Kedzierska et al., 2004) and expression of different TCRa chains (Hamrouni et
al., 2003) are all likely to be factors in determining clonal abundance. It should be
noted that the designation of'public' TCRp chain has been applied somewhat
loosely in this study - evidence of identical TCRP chain expression by clonotypes of
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the same specificities from more individuals would be required to verify this
designation.
A notable feature of the cytotoxicity results obtained in this study was that, with the
exception of animal 1011, levels of cytotoxic activity displayed by the clones against
the TpM targets were low (Figures 6.2a-6.5a). By contrast, the epitope-loaded MHC-
matched Ta targets appeared more sensitive to lysis by CTL, and many clones that
demonstrated CTL activity against these targets appeared non-cytotoxic against the
TpM target. Thus, the absence of detectable cytotoxicity against the TpM targets in
this study is not indicative of a lack cytotoxic capacity of the cells. Since the epitope-
loaded Ta targets were pre-incubated with 1 pg/ml ofpeptide, it is likely that the
epitope density on the surface of these cells was considerably higher than on the
TpM cells. This would imply that the expression of cytotoxic activity is in part
dependent on the extent of ligation of TCRs on the T-cells. The generally lower
levels of cytotoxicity displayed on TpM targets and the variability between lines may
also reflect the inherent susceptibility of the cells to lysis. Different T. parva-
transformed cells are known to vary in the profiles of cytokines they express and this
may be associated with the variation in their susceptibility to CTL lysis (McKeever
et al., 1997).
Analyses ofTCRp expression identified a number ofVpis7+ (4) and Vp3sl+ (9)
clones that did not give detectable cytotoxicity on either TpM or Tpl.l-loaded A18+
Ta targets but had TCRp sequences identical to those identified in Tpl .1-specific
CTL clonotypes (compare Tables 6.4 and 6.8). The level of cytotoxicity against the
Tpl.l-loaded A18+ target exhibited by individual clones sharing either the Vpls7+
chain (Figure 6.9a) or the Vp3sl+ chain (Figure 6.9b) show a gradation ranging from
0.4% to 112.4% for the Vpis7+clones and from 15.6% to 96.9% for the Vp3sl +
clonotypes. This suggests that all of the Vpls7+ clones are members of a single
clonotype as are all of the Vp3sl+ clones and that despite the cytotoxicity results, all
of these clones are Tp 1.1-specific. This finding implies that other clones that were
defined as non-Tp2.1/2.2/1.1-specific CTL on the basis of the cytotoxicity results








































Figure 6.9 Cytotoxic activity against the Tpl-loaded A18+Ta target by 641 clones expressing the
(A) Vpis7+ TCRp chain (Vpis7-SHEWYSTDTQ-jp3s4) and (B) Vpis7+ TCRp chain (Vpis7-
REKGLRGSSNDPL-jp3s3).The level of activity considered to reflect significant cytotoxicity
(>10%) is represented by the dashed line - clones considered to be non-cytotoxic are presented
by yellow bars and clones considered to be cytotoxic by blue bars.
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epitope-specific CD8+ T-cells, including cytotoxic and non-cytotoxic subsets, has
been reported in responses to viral epitopes (Aandahl et al., 2003; Gillespie et al.,
2000; Sandberg et al., 2001). Thus, the percentage figures obtained for the
proportions of CD8+ T-cells that are specific for the defined T. parva epitopes
examined are likely to be underestimated and should be considered as minimum
estimates. In future experiments concurrent use of additional functional assays that
assess other parameters of T-cell activation such as IFN-y release, for example using
the technique developed by Ballingal et al. (2000) or immuno-screening antigen
presenting cells (APCs) transiently transfected with T. parva (Muguga) schizont
cDNA clones (Graham et al., 2006) using ELISpot assays, would provide a more
comprehensive analysis of the proportion of clones specific for the defined epitopes.
Amongst the population of T-cell clones that displayed no defined epitope-specific
cytotoxic activity were identified a substantial Vpi3s2+ clonotype (Table 6.7) in one
of the A18+ animals (468) and sets of Vp2s3+ and Vpi5s2+ clonotypes with semi-
conserved CDR3P regions (Table 6.6) in one of the A10+ animals (1011). This
suggests the presence of as yet undefined subdominant epitopes in both the Al 8- and
AlO-restricted responses to T. parva (Muguga) that are capable of eliciting
numerically significant CD8T T-cell responses. However, it must be noted that as
none of these clonotypes displayed cytotoxicity against any target they may be non-
cytotoxic cells specific for the already defined epitopes.
As in vitro culture of lymphocytes can introduce unknown biases into T-cell
responses with regard to the representation of both antigenic specificities (Yewdell
and Bennink, 1999) and ofTCR composition (Dietrich et al., 1997), results from in
vitro studies of the CD8+ T-cell response against T. parva may not be representative
of the in vivo response. In the absence of peptide-MHCI tetramers, it is difficult to
quantitatively analyse epitope immunodominance directly ex vivo. However,
comparison of the in vitro and in vivo responses of the memory CD8 T-cells in one
animal using CDR3P-HDA, demonstrated that the clonal composition of these
populations was remarkably similar (Figure 6.9). It could therefore be inferred that
the in vitro cultures provide a reasonable representation of the in vivo memory CD8+
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T-cell response and consequently of any immunodominance exhibited.
Unfortunately, due to time constraints it was not possible to compare the in vivo
memory CD8+ T-cell responses and the responses measure in vitro for the other
animals to corroborate this finding, but hopefully this work will be completed in the
future.
In summary the work presented in this study provides the first quantative evidence
for immunodominance in the CD8+ T-cell response to T. parva. The responses to
both the immunodominant A10- and A18-restricted epitopes measured in vitro are
polyclonal but dominated by a small number of large oligo-clonal expansions and
display diverse TCRP chain repertoires. Furthermore, there is evidence from one
animal that there is a high degree of correlation of the composition of the in vitro and
in vivo memory CD8+ T-cell responses, suggesting the immunodominance defined in
the in vitro studies can be extrapolated to the in vivo response. Demonstration of
marked immunodominance by polymorphic epitopes in the CD8~ T-cell response to
T. parva corroborates observations from previous studies and has important
implications for the future design of subunit vaccines.
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7 Chapter 7 - General discussion
Due to difficulties associated with the application and sustainability of current
control measures for Theileria parva, current research efforts are directed towards
the development of an effective subunit vaccine. As there is evidence that cytotoxic
CD8+ T-cell responses against parasitized lymphoblasts have an important role in
mediating immunological protection against T. parva, CTL target antigens are
obvious candidates for inclusion in such a vaccine. Previously described
characteristics of the T. parva-specific CTL response suggest it is focused on a
limited number of immunodominant epitopes that exhibit polymorphism between
parasite strains. This immunodominance potentially poses a major obstacle to the
development of a T. parva subunit vaccine that will effectively elicit CTL with the
ability to offer broad protection against the multiplicity of different T. parva strains
present in the 'field'. In viral systems in which immunodominance has been
documented, diversity in the clonality and TCR repertoire of the CTL response has
been associated with the ability to recognise epitope variants and thereby constrain
'escape mutants'. Consequently analysis of these two features is of interest when
considering potential candidate epitopes for inclusion in subunit vaccines.
The recent identification ofCTL target antigens offered the opportunity to study and
gain a more detailed understanding of immunodominance in responses to T. parva,
which will aid the future rational design of a subunit vaccine. The aim of this study
was to quantify immunodominance in the T. parva CD8+ T-cell response and
characterise the clonal composition and TCR repertoire of the responding epitope-
specific populations. The work completed in this study had three significant
outcomes:
1) Development ofmolecular tools for analysis of T-cell clonality and the TCRp
chain repertoire of bovine T-cell responses. To achieve the aim of this study it was
first necessary to develop the molecular tools to analyse bovine TCRP chain
expression. A panel of Vp subfamily-specific primers for use in snPCR reactions and
a 'Pan-VP' snPCR that allowed the amplification of all known bovine TCRp chains
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were developed and validated. Also designed was a CDR3P-HDA that could be used
to rapidly and accurately determine the clonal composition of complex bovine uPT-
cell populations.
These tools were subsequently used in this study to successfully analyse bovine T-
cell responses both in vitro and in vivo. However, they were designed on the basis of
the bovine TCRP gene sequence data available at the commencement of the study,
which has subsequently been expanded by the work within this project. In the light of
the expanded gene repertoire identified, some further studies are required to refine
and expand this set of tools; for example to accommodate the novel VP subfamilies
VP5, 11 and X and to confirm the specificity of the PCR reagents on the expanded
set of VP genes. Due to the generic nature of these tools they could be used in future
studies to analyze the bovine T-cell response to other pathogens.
2) Extension of the known bovine TCRp gene repertoire. The large volume of
TCRP chain sequencing completed in the course of this study has identified 38 novel
VP genes, including members of 4 novel bovine subfamilies (Vp 5, 12, 25 and X),
and substantial numbers of new VpiO and Vpl3 subfamily members. Also identified
were 4 novel jp genes. Examination of the incomplete second assembly of the bovine
genome identified a total of 123 VP genes, ofwhich 65 were predicted to be
functional. Members of five novel bovine subfamilies, Vpi 1, 18, 21, 23 and 25, were
identified from the genome, although only Vpi 1 was predicted to contain a
functional member. Although there was substantial similarity in the VP repertoires
identified from the genome and from cDNA analysis, several genomic genes had no
cDNA match and vice versa. From the combined cDNA and genomic analysis >90
bovine VP which are predicted to be functional have been identified. Partial
annotation of the bovine TCRB locus corroborates previous work (Conrad et al.,
2002) that suggested the existence of a third DJC cluster and has demonstrated
extensive duplication of a cassette containing tandemly located Vpi and 13 genes.
The bovine VP repertoire is now the largest characterised for any species, largely
attributable to the prodigious duplication of the Vpi/13 cassette.
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3) Characterisation of immunodominance in the CD8+ T-cell response to T.
parva. Analysis of the CD8+ T-cell response against T. parva (Muguga), utilising in
vitro derived CD8+ T cell-lines and clones, has shown that the Tp2.2 and Tpl.l
epitopes are highly dominant in animals homozygous for the A10 and A18 class I
MHC haplotypes, respectively, with >70% of the T-cell clones evaluated
demonstrating specific CTL activity. The responses to the immunodominant epitopes
were characterised by a polyclonal response which included a limited number of
large clonal expansions and expression of a diverse repertoire of TCRP chains. For
one animal it was possible to demonstrate remarkable similarity between the clonal
composition of the responses measured in vitro and that of the memory CD8" T-cell
population responding to parasite challenge in vivo, inferring that the in vitro results
give an accurate representation of the in vivo response and therefore that the
immunodominance noted in vitro can be extrapolated to the in vivo situation.
A review of the literature indicates that this is the first direct quantative evidence for
immunodominance in the CD8+ T-cell response to a parasite and furthermore that it
is also the first demonstration of immunodominance in the CD8+ T-cell response to
any pathogen in a non-murine/non-primate species. Due to the antigenic complexity
of parasites, it might have been predicted that immunodominance would not be an
important factor in the CD8+ T-cell responses to this group of pathogens. However,
the results described in this study indicate that immunodominance can operate to a
similar extent in an anti-parasite CD8+ T-cell response as does in the responses
against much less antigenically complex viral pathogens. Additionally, although the
TCR repertoires of T-cell response to parasites have been reported previously (e.g.
Casanova et al., 1991; Clarencio et a!., 2006), the work presented in this thesis
represents the most detailed description of such a response so far reported.
However, in many respects the results presented here represent a work in progress.
Some of the conclusions reached need to be confirmed and may need to be revised in
the light of data from further studies.
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The unprecedented expansion of the bovine TCRp gene repertoire identified from the
combined cDNA and genome analysis completed in this study raises many
interesting questions regarding the evolutionary history of this locus and the factors
that have driven extensive duplication of certain V(3 subfamilies. It is anticipated that
the imminent release of the third bovine genome assembly will permit a fuller
annotation of the TCRB locus and provide a more exhaustive description of the full
bovine TCRp gene repertoire. Once the sequence of the bovine TCRB locus is
complete, comparative analysis of the genomic structure of the bovine, murine and
human TCRB loci will offer interesting insights into the evolutionary dynamics of
this locus during mammalian speciation. Furthermore, the complete genomic
sequence will be useful in examining the enhancer and promoter elements contained
within the TCRB locus, that in humans and mice have been shown to influence the
naive TCR repertoire (Chen et al., 2001a; Ryu et al., 2004; Sieh and Chen, 2001) and
to be critical in directing the modifications of chromatin structure that control TCRP
rearrangement (Bouvier et al., 1996; Leduc et al., 2000; Oestreich et al., 2006; Sikes
et al., 1998). Recent work has made extensive use of cDNA and genomic data to
characterise the genomic organisation and repertoire of bovine TCRy (Herzig et al.,
2006a) and TCR8 (Herzig et al., 2006b) genes. However, the bovine TCRa gene
repertoire remains poorly characterised, which is unfortunate as knowledge of the
TCRa gene repertoire and the subsequent development of tools for analysis ofTCRa
chain expression would be helpful for unambiguously defining clonotypes within
antigen-specific apT-cell populations.
With evidence for at least 50 serologically defined bovine MHCI specificities
(Davies et al., 1994) and a multiplicity of genotypically different T. parva strains in
the 'field' (Oura et al., 2005), immunodominance of the CTL response by epitopes
that exhibit polymorphism between parasite strains may necessitate the incorporation
of a vast number ofCTL epitopes in the subunit vaccine in order to accommodate all
of the pertinent MHC haplotype/parasite strain permutations. In a parallel situation,
the combination of immunodominance and diversity ofHIV strains and human HLA
haplotypes has proved a major obstacle to the successful development of a subunit
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vaccine that elicits broadly effective CTL responses against HIV (Altfeld and Allen,
2006; Walker and Korber, 2001).
However, the ability to induce broad protection using relatively few parasite strains
in immunisation by infection and treatment (Radley et al., 1975b) suggests that
immunodominance may not be an insurmountable obstacle to the design of a broadly
effective T. parva subunit vaccine. To fully assess the consequences that
immunodominance in the CTL response will have on the design on subunit vaccines
for T. parva it will be necessary to design experiments to address questions such as:
(i) Within defined MHC-restrictions how many epitopes expressed by the global T.
parva population are capable of dominating the CTL responses? Given the
overlapping antigenic profiles of different parasite strains predicted by the mosaic
model (section 1.1.3.3), would inclusion of a limited number of immunodominant
epitopes sufficiently broaden the specificity of the CTL response on these defined
MHC backgrounds to induce protection against the majority of parasite strains?
(ii) Does the diverse clonal composition and TCRp repertoire of the CTL specific for
immunodominant epitopes influence the cross-reactivity of the CTL response and
therefore the capacity to offer protection against heterologous parasite strains? In
viral responses diverse clonal composition and TCR repertoires are associated with
recognition of epitope variants and constraint of the 'escape mutants' that express
them (Lopes et al., 2003; Meyer-Olson et al., 2004). There are now established broad
panels of Tp2.2 (Muguga)- and Tpl.l (Muguga)-specific clonotypes whose ability to
recognise the epitope variants expressed by other parasite strains could be directly
evaluated using in vitro assays. Results from such assays could begin to address this
question.
(iii) Does T. parva express conserved subdominant CTL epitopes which could serve
as targets for a subunit vaccine that will induce CTL against a broad spectrum of
parasite strains? In experimental murine viral systems subdominant epitope-specific
CTL have been shown to afford protection against in vivo challenge (Chen et al.,
1998; Oukka et al., 1996) and the ability to generate CTL responses to subdominant
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epitopes by vaccination has been shown in both primate and murine models (e.g.
Chen et al., 1998; Cole et al., 1997; Liu et al., 2006; Santra et al., 2002).
Furthermore, effective control ofHIV has been correlated to CD8+T-cell response
against subdominant rather than immunodominant epitopes (Frahm et al., 2006) and
consequently a current strategy being employed in HIV subunit vaccine design is the
identification and targeting of epitopes on the basis of their degree of conservation
rather than their position in the immunodominance hierarchy (Altfeld and Allen,
2006).
The results from studies answering these questions will provide significant
information that could have profound influence on future strategies employed in the
design of a 71 parva-specific subunit vaccine.
Studies extending the observations made in the A10- and A18- restricted responses
to T. parva (Muguga) to other combinations of bovine MHCI haplotypes and parasite
strains would confirm that immunodominance is a general feature of the CD8 ' T-cell
response against T. parva. Already, studies on immunodominance in the Aid-
restricted response to T. parva (Muguga) are being undertaken by other members of
the group. However, it would also be of interest to undertake further studies on the
responses described in this study. Application of the molecular tools developed in
this study could be used to address issues relating to (i) the stability of the repertoire
of epitope-specific CTL clonotypes and the persistence of individual clonal
expansions, (ii) the extent of immuno-focusing that occurs during repeated in vivo
parasite challenge and (iii) the kinetics of development of the CD8+ T-cell response
during primary immunisation or infection. The data from such studies would help
assess whether these features may impact on the strain-specificity of induced CTL
responses. Development and use of additional tools such as real-time CDR3P-
specific PCR amplification (Gallard et al., 2002; Hohlfeld, 2003) could add another
dimension by enabling examination of the kinetics of individual epitope-specific
clonotypes expansion/contraction during the response to T. parva, whilst the
generation and validation of relevant pMHC-tetramers (currently being completed)
will provide a means of directly quantifying immunodominance in the in vivo
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response to T. parvci and isolating ex vivo epitope-specific T-cells for analysis of
their function, clonal composition and expressed TCR repertoire.
The quantitative data on the immunodominance of the Tp2.2 and Tpl.l epitopes in
responses ofA10+ and A18+ animals provide a basis for further studies to examine
the mechanisms that establish the immunodominance of the Tp2.2 and Tpl.l
epitopes in these responses. Using materials generated in this study (e.g. epitope-
specific CTL clonotypes) and other available materials (e.g. the TAP"7" RMA-S cell
line transfected with A10+MHC products) it is now possible to devise experimental
assays to study factors known to influence immunodominance in other systems such
as, the stability of pMHC complexes (Busch and Pamer, 1998; Chen et al., 1994;
Gallimore et al., 1998) and the ability to elicit both high and low avidity CD8+ T-
cells (Busch and Pamer, 1998; Campos-Lima et al., 1997).
In summary, the results presented in this study have quantitatively demonstrated
immunodominance in the CD8+ T-cell response to T. parva and characterised the
clonal composition and TCRp repertoire of the responding T-cells. Evidence of
immunodominance against polymorphic epitopes in an outbred population poses
potential obstacles for the development of a subunit vaccine against this pathogen.
Further investigations will be necessary to evaluate the consequences this has on the




Appendix A - Correspondence between the IMGT and WHO-
IUIS nomenclature systems for human TCRpV
The following table showing the corresponding names of human TCR[3V genes
according to the IMGT and WHO-IUIS nomenclature systems is derived from the
IMGT website (http://imgt.cines.fr). Under the IMGT and WHO-IUIS systems these
genes would be prefixed with TRBV and TCRfSV respectively. The genes are













30 20sl 13 23sl 10-1 12s2
29-1 4s 1 7-9 6s4 9 lsl
28 3s 1 5-8 5a4 5-3 5s5
27 14s 1 7-8 6s2 8-2 30s2
26 28s 1 6-9 13s4 7-3 6s 1
25-1 Usl 5-7 5s7 6-4 13s5
24-1 15sl 7-7 6s6 5-2 5s8
23-1 19sl 6-8 13s7 8-1 30sl
22 29s 1 5-6 5s2 7-2 6s5
21-1 lOsl 7-6 6s3 6-3 13s2b
20-1 2s 1 6-7 13s8 4-3 7s2
19 17s 1 5-5 5s3 3-2 9s2
18 18s 1 7-5 6s9 6-2 13s2a
17 26sl 6-6 13s6 4-2 7s3
16 25sl 5-4 5s6 7-1 6s7
15 24s 1 7-4 6s8 6-1 13s3
14 16sl 6-5 13s 1 5-1 5s 1
12-5 8s3 12-2 8s5 4-1 7s 1
12-4 8s2 11-2 21 s3 3-1 9s 1
12-3 8s 1 10-2 12s3 2 22sl
11-3 21 s2 12-1 8s4 1 27sl
10-3 . Usl 11-1 21 s 1
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Appendix B - GenBank accession numbers
All deposited sequences can be obtained from the NCB1 nucleotide database
(http://www.ncbi.nlm.nih.gov)
(i) Genomic sequence ofHuman TCR Loci
AE000658-AE000662 Homo sapiens TCRA/D locus submitted by Koop et al.{ 1994)
U66059-U66061 Homo sapiens TCRB locus submitted by Rowen et al. (1996)
AF029308 Homo sapiens partial duplication ofTCRB locus on
chromosome 9 - direct submission by Rowen, L. et al.
AF159056 Homo sapiens TCRG locus - direct submission by Zhan, M.
et al.
(ii) Genomic Sequence ofMurine TCR Loci
AE007512 Mus musculus TCRA/D locus - direct submission by Lee, FY.
et al.
AE000663-AE000665 Mus musculus TCRB locus submitted by Chen et al. (2001a)
AF037352 Mus musculus TCRG locus - gamma 1 and 3 clusters - direct
submission by Zhou, Q. et al.
AF021335 Mus musculus TCRG locus - gamma 2 and 4 clusters - direct
submission by Parlee, M.J. et al.
(Hi) Genomic sequence of the bovine TCR loci
AF453325 Partial sequence of the TCRB locus Conrad et al. (2002)
AY644517 Bos taurus T cell receptor gamma cluster 1 (TCRG1) - direct
submission by Conrad M.L. et al.
AY644518 Bos taurus T cell receptor gamma cluster 2 (TCRG2) - direct
submission by Conrad M.L. et al.
II
(iv) Genomic sequence ofthe porcine TCR loci
AB079894 Partial sequence of the TCRB locus - direct submission by
Takagaki, Y. et al.
(v) Bovine TCR genes
D90121-D90130 Bovine TCRpV gene sequences submitted by Tanaka et al.
(1990)
LI 8951 Bovine Vp6s2 gene sequence submitted by Buitkamp et al.
(1993)
AJ006346-AJ006347 Bovine TCRpV gene sequences submitted by Houston et al.
(1997)
AJ006567-AJ006583 Bovine TCRpV gene sequences submitted by Houston et al.
(1997)
AJ235264-AJ235268 Bovine TCRpV gene sequences submitted by Houston et al.
(1997)
D90139-D90140 Bovine TCRpC gene sequences submitted by Tanaka et al.
(1990)
(vi) Human nesprin-1
AF495910 sequence submitted by Zhang et al. (2002)
(vii) Porcine TCR genes
AY690918 Porcine VpX gene sequence submitted by Butler et al. (2005)
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Appendix C - Solutions and media
All reagents were obtained from Sigma (Poole, Doreset, UK) unless otherwise stated.
Double-distilled water (DDW) was sourced from a Millipore-RO 60 Plus unit
(Millipore, Billerica, MA, USA).
C.l Alsever's Solution lOx stock
D-glucose 205.0 g (113.8mM)
Citric acid 5.5 g (2.9mM)
Sodium chloride 42.0 g (71.9mM)
Tris-sodium citrate Di-hydrate 80.0 g (27.2mM)
Made up to a volume of 1 L with DDW.
Made up to lx solution by filter sterilizing 0.1 L stock solution using 0.45 pm
Minisart single-use filter (Sartorius, Goettingen, Germany) and adding to 0.9 L of
sterile DDW.
C.2 RBC Lysis Buffer
Trizma base 10.6 g (0.175M)
0.175M TRIS pH adjusted to 7.4 with concentrated HC1 and made up to a volume of
0.5L with DDW
Ammonium chloride 8.55 g (0.16M)
Made up to a volume of 1L with DDW.
RBC lysis buffer consists of 1 part 0.175M TRIS pH 7.4 and 9 parts 0.16M
ammonium chloride. Filter sterilized using 0.45 pm Minisart single-use filter
(Sartorius, Goettingen, Germany)
C.3 Standard Culture Medium (SCM)
RPMI 1640 medium + 25mM HEPES + L-Glutamine (Gibco, Paisley, UK)
10% Foetal bovine serum (Gibco, Paisley, UK)
100 U/ml Penicillin, 100 pg/ml streptomycin, 292 pg/ml L-glutamine
(Penicillin-Streptomycin-Glutamine (lOOx) solution (Gibco, Paisley, UK)
2-Mercaptoethanol (2-ME) 5 xlO~4M
C.4 FACS Medium
RPMI 1640 medium + 25mM HEPES + L-Glutamine (Gibco, Paisley, UK)
2% Foetal bovine serum (Gibco, Paisley, UK)
0.2% Sodium Azide
C.5 Cytotoxicity Medium
RPMI 1640 medium + 25mM HEPES + L-Glutamine (Gibco, Paisley, UK)
5% Foetal bovine serum (Gibco, Paisley, UK)
C.6 Phosphate Buffered Saline (PBS)
Sodium chloride 170.0 mM
Potassium chloride 3.4 mM
Sodium phosphate, dibasic 9.2 mM
Potassium phosphate, monobasic 1.8mM
pH6.8
PBS tablets used according to manufacturer's instructions (Unipath LTD,
Basingstoke, Hampshire, UK)
C.7 SM-0005 PCR Buffer
45 mM Tris-HCl (pH 8.8 at 25°C)
11 mM Ammonium sulphate
4.5 mM Magnesium chloride
0.113 mg/ml Bovine serum albumin
4.4 pM EDTA
1.0 mM each of dATP, dCTP, dGTP and dTTP
Purchased from ABgene (Epsom, Surrey, UK)
C.8 Loading Buffer for Agarose Gel Electrophoresis
15% w/v Ficoll (Type 400) in DDW with bromophenol blue (0.25%v/v) and
xylene cyanol (0.25%) dyes
V
C.9 Tris-acetate/EDTA electrophoresis buffer (TAE) 50x stock
Trizmabase 242 g (2M)
Glacial acetic acid 57.1ml (2M)
EDTA 100 ml of 0.5M solution (50mM)
pH adjusted to 7.7-8.0 with glacial acetic acid if required, made up to a volume of 1
L with distilled water
C.10 SOC Media
Tryptone 20.00 g
Yeast extract 5.00 g
Sodium chloride 0.50 g
Potassium chloride 0.19 g
Glucose Oo
pH adjusted to 7.0 with 5M sodium hydroxide, made up to a volume of 1 L with
DDW and autoclaved
C.ll Luria-Bertani (LB) Agar plates with ampicillin




pH adjusted to 7.0 with 5M sodium hydroxide, made up to a volume of 1 L with
DDW and autoclaved
Upon use, LB agar was melted and ampicillin added to give a final concentration of
100 pg/ml. The required amount of media was poured into sterile Petri dishes and
allowed to set and dry. If LB/ampicillin/IPTG/X-Gal plates were required for
blue/white colony selection 100 pi of 24 mg/ml IPTG (Isopropyl p-D-1-
thiogalactopyranoside) and 50 pi of 50 mg/ml XGal (5-bromo-4-chloro-3-indolyl-P-
D-galactoside) in 50 pi of SOC media (Appendix C.10) was applied to the surface of
the media and allowed to dry before application of any culture.
VI
C.12 LB Media
Sodium chloride 10 g
Yeast Extract 5 g
Tryptone 10 g
Agar 15 g
pH adjusted to 7.0 with 5M sodium hydroxide, made up to a volume of 1 L with
DDW and autoclaved
C.13a Cell Re-suspension Solution for Plasmid Mini-Preparations (Method A)
Tris-HCl pH7.5 5mloflM solution (50mM)
EDTA 2 ml of 0.5M solution (lOOmM)
Made up to a volume of 0.1 L with DDW and autoclaved. RNAase added at 100
pg/ml prior to use.
C.13b Cell Lysis Solution for Plasmid Mini-Preparations (Method A)
Sodium hydroxide 50 ml of 0.4M solution (0.2M)
Sodium lauryl sulphate (SDS) 50 ml of 2% solution (l%w/v)
C.13c Neutralisation Solution for Plasmid Mini-Preparations (Method A)
Potassium acetate 12.55 g (1.32M)
pH adjusted to 4.8 with glacial acetic acid, made up to 0.1 L with DDW and
autoclaved.
C.14 Loading Buffer for Polyacrylamide Gel Electrophoresis
40% w/v sucrose in distilled water with bromophenol blue (0.25%v/v) and
xylene cyanol (0.25%) dyes
C.15 9% non-denaturing polvacrvlamide gel preparation
Enough for two Biorad Protean ® II xi system gels (80 mis)






96 pi TEMED (N, N,N', N-Tetramethylethylene-diamine), and 184 pi 25%
ammonium persulphate (1 g ammonium persulphate in 4 ml of DDW. 200 pi
aliquots stored at -20°C.) added for polymerisation.
C.16 Tris-borate/EDTA eletrophoresis buffer (TBE) lOx stock
Trizmabase 128 g (890mM)
Orthoboric acid 55 g (890mM)
EDTA 40 ml of 0.5M solution (20mM)
Made up to a volume of 1 L in distilled water.
C.17 20%w/v Polyethylene glycol (PEGV2.5M NaCl
Sodium chloride 58.44 g (2.5M)
PEG MW8000 100.00 g (20%w/v)
Made up to a volume of 0.5 L in DDW.
C.18 5 x CSA Buffer
Trizmabase 4.840 g (400mM)
Magnesium chloride 0.203 g (lOmM)
pH adjusted to 9.0 with concentrated HC1, made up to a volume of 0.1 L with DDW
and autoclaved.
C.19 3M Sodium Acetate pH 5.2
Sodium acetate.3H2O 40.81 g (3M)
pH adjusted to 5.2 with glacial acetic acid, made up to a final volume of 0.1 L in
DDW and autoclaved.
VIII
C.20 Supplemented D-MEM medium
D-MEM + 4500mg/L Glucose + L-glutamine + Pyruvate (Gibco, Paisley, UK)
10% Foetal bovine serum (Gibco, Paisley, UK)
lOOU/ml Penicillin, 100p.g/ml streptomycin, 292pg/ml L-glutamine (Penicillin-
Streptomycin-Glutamine (lOOx) solution (Gibco, Paisley, UK)
C.21 Depurination Solution - 0.125M HC1 (Southern Blot)
Hydrochloric acid 11 ml concentrated HC1 (11M) (0.125M)
Made up to a volume of 1L with distilled water.
C.22 Denaturation Solution - 1.5M Nad, 0.5N NaOH (Southern Blot)
Sodium chloride 87.66g (1.5M)
Sodium hydroxide 20.00g (0.5M)
Made up to a volume of 1L with distilled water.
C.23 Neutralization Solution - 1M Tris fpH7.4), 1.5M NaCl (Southern Blot)
Sodium chloride 87.66g (1.5M)
Trizmabase 60.50g (1M)
pH adjusted to 7.5 with concentrated HC1 and made up to a volume of 1L with
distilled water.
C.24 20 x SSC - 3M Nad, 0.3M Na^citrate (Southern Blot)
Tris-sodium citrate 88.23g (0.3M)
Sodium chloride 175.32g (3M)
Made up to a volume of IL with distilled water.
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Appendix D - Annealing sites of the 3' TCRpC-specific
primers
The annealing sites of the 5 different 3' TCRpC-specific primers used in this study
are shown on the 2 deposited bovine TCR(3C gene sequences (GenBank accession
numbers D90139 and D90140 - Appendix B)
3 ' 1 11 21 31 4 1 51




61 71 81 91 101 111
PVBrevl
4
D90139 ATCTCCCGGA CCCAGAAGGC CACGCTCGTG TGCCTGGCCA CGGGCTTCTA CCCCGACCAC
D90140 T
4
121 131 141 151 161 171
PVBrev2
4
D90139 GTGGAGCTGA CCTGGTGGGT GAACAGGAAG CAGGTCACGA CTGGGGTCAG CACGGACCCT
D90140 .......... . : . .
M
BCint BCext
181 191 201 211 221 2 31
D90139 GAACCCTATA AGGAGGACCC TGCACGGGAT GACTCCAGAT ACTGTCTGAG CAGCCGGCTG
D90140 . .G C. .G
241 251 261 271 281 2 91
D90139 AGGGTGACTG CTGCCTTCTG GCACAACCCC CGCAACCACT TCCGATGCCA AGTCCAGTTC
D90140 C
3 01 311 321 331 341 351
D90139 CACGGGCTCA CGGACCAGGA CCAGTGGGAG GAGCAGGACA GGGCCAAGCC CGTCACCCAG
D90140 A A A AT
X
361 371 381 391 401 411
D90139 AACATCAGCG CCGAGGCCTG GGGCAGAGCA GACTGTGGTG TCACCTCCGC ATCTTATCAG
D90140 C G
421 431 441 451 461 471
D90139 CAAGGCGTCC TGTCTGCCAC CCTCCTCTAT GAGATCCTGC TGGGGAAGGC CACCCTGTAC
D90140 G G
481 491 501 511 521 531 5 '
D90139 GCTGTGCTGG TCAGCGCCCT GGTGCTAATG GCCATGGTCA AGAGAAAAGA GTCCTGAAGC
D90140 G T. ...A...G.. T
XI
Appendix E - Additional bovine VP gene sequences
Sequence data for bovine V(3 genes V(31s8, VpislO, Vpisl 1, Vp2s2, Vp2s5, Vp2s7,
VP4s2, Vp6s3, Vp7s2, Vp9sl and Vpi7s2 were obtained from Houston (1997) and
for Vp4s3, Vp4s4, Vp8sl, Vp8s2 and Vpi7s2 from data made available by Russell
and MacHugh (unpublished). Sequences have been aligned and CDR1 and CDR2
(shaded regions) defined according to the IMGT unique numbering system
(Giudicelli et al., 2004). Identity is shown as dashes and gaps by dots.
E.l Nucleotide (A) and amino acid (B) sequence of VBls8, VBlslO and VBlsll




61 71 81 91 101 111
VBls8 CTGAGATGTT CCCCTAACTC TGGACACAGC TCT GTGAAC
VBlslO CG-A— C— --ATC-
VBlsll G-A— C— -A- T- -
CDR2
121 131 141 151 161 171
VBls8 TGGTACCAAC AGGCCCTGGG CCAGGGCCCC CAGTTCCTCG TTCAGTGTTA CCGCGGACAA
VBlslO - -A T -A A A—T -AA-A-G
VBlsll T - -A A A—T -AA-ACG
VBls8 GTT AGTAG AGGAGAAAAC ATGCCA. . .G ATCGATTCTC AGCAAAACAA
VBlslO CAG.. -A-GA GAA--G --AT--...- --G G
VBlsll -AG -A-GA GAA--G --AT--...- --G G
241 251 261
VB1S8 TTT...AGTG ACTTGCGCTC TGAGCTGAAT
VBlslO -C... CTA C









B 1 11 21 31 41 51
VBls8 SGVTQTPKY LIKSRKQQAT LRCSPNSGHS S . VN WYQQALGQGP QFLVQCYRGQ
VBlslO -E—V- E R Y ...-S T I-YFNR-
VBlsll -X VI E—-R ,-Y V I-YFNT-
61 71 81 91 101
VB1S8 V. . ..SRGEN MP.DRFSAKQ F.SDLRSELN LSSLELTDSA VYLC
VBlslO Q. . ..NEKG- IS . G-- - . — SS -T
VBlsll E . . ..NEKG- IS. G- - - . — SS -T
XIII
E.2 Nucleotide (A) and amino acid (B) sequence of VB2s2, VB2s5 and V|32s7




VB2s2 ATCGAGTGCC GTGCACTGGA CTTTCAAGCC TCAAGT ATGTTC
VB2s5 C- . G
VB2s7 G
CDR2
VB2s2 TGGTACCGTC AGTTCCCGAA ACGAGGCCTC GTGCTGATGG CAACTTCTAA TGTGGGCACT
VB2S5 —C G-
VB2S7 —A
181 191 201 211 221 231
VB2s2 AATGCC... ACATA CGAACAAGGT TATACCAAGG ACAAGTTTCC CATCAGTCAT
VB2s5 G —.2.2'..... A
VB2s7 G .... ..... A
241 251 261 271 281 291
VB2S2 CCA. . . GACC TAACATTTTC ATCTCTGACG GTGACACGTG TGGATCCTGC AGACAGCGGC
VB2S5 ... G T- A- -








VB2s2 GALVSQQPRR AVSKSGASVT IECRALDFQA SS MF WYRQFPKRGL VLMATSNVGT
VB2s5 -T V- A-S
VB2s7 — V.V- E—
VB2s2 NA...TYEQG YTKDKFPISH P.DLTFSSLT VTRVDPADSG LYFC
VB2s5 D- . . . -N R M S
VB2s7 D-..J -N S
XV
E.3 Nucleotide (A) and amino acid (B) sequence of VB4s2, VB4s3 and VB4s4
VB4s2 CGCGGGAC CTCCATGACG
VB4S3 GGTGCTCTCG TCTCTCAAAA GCCAAGCAGG GCCATCTGTC AA--T G T-
VB4S4 GCAGG GCCATCTGTC AA T-
CDR1
VB4s2 ATCGAGTGTC ...ATGTCGA TAGCCAAGTC ACCTGG.
VB4s3 GTC-G--T— 1—GC— G—A—.
VB4S4 ...-G : —-G -AT—C.
. ATGTAC
CDR2
VB4S2 TGGTACCGAC AGCTTCCAGG ACAGAGCTTG GTGTTGATGG CTACTGCCAA TCAGGGCTCC
181 191 201 211 221 231
VB4S2 AGGGCT ACTTA CGAGAGTGGG TTTACCGAGG ACAAGTTTCC CATTGACCGC
VB4S3 -A T--CA G
VB4s4 -A- . , . ; T--CA G
241 251 261 271 281 2 91
VB4 s2 CCG. . . AAAC TGGAGTTCTC AACTCTGACT GTGAGCAACG TGAGCTCCGA AGACAGTAGC
VB4s3 ... G A T- C T








VB4s2 RGTSMT IEC.HVDSQV TW MY WYRQLPGQSL VLMATANQGS
VB4S3 GLAVSQKPSR AICQ RQ--—L AM N-
VB4s4 R AICQ .Q— NF --










E.4 Nucleotide (A) and amino acid (B) sequence of V|38sl and VB8s2
VB8sl AACCTAGGAG TCACCCAGAC CCCTAGGCAT GAGGTGACAG AAAAGGGACA GGCAGTCACT
VB8S2 G
CDR1
VB8sl CTGAGTTGTG AGCTGATTAA AAGCCACACT GCC CTTTAT
VB8S2 --C- , T-
CDR2
VB8S1 TGGTACAGAC AGACCTCGGT GCGGGGACTG GAGTTTCTGG CTTACTTCAG CAACCAAGCT
VB8s2 C-G T T A
VB8sl CCT . .ATTGA TGAGTCGGGG ATGCCCAAGG ACCGATTCTC AGCTAAAATG
VB8s2 1 G
VB8sl CCT...AACT CGTCGTTCTC CACTCTGAAG ATCCAGCCCA CAGATCCTGG GGACTCGGCC





VB8sl NLGVTQTPRH EVTEKGQAVT LSCELIKSHT A LY WYRQTSVRGL EFLAYFSNQA
VB8s2 P A -A .. ...-F 1—N
VB8sl P.
VB8s2
.IDESG MPKDRFSAKM P.NSSFSTLK IQPTDPGDSA TYLC
A- H.-A
XVIII






GCAG TGTCCCAGTC CCCCAGGCAC AGGGTTGCAG GGAGGGGCCA GACTGTGAAT
--A-AAT-- CTA--CATG- -A-T-ACGG- C-AGAAATC-
AGAAC-TC
...GAT--T- AAAT-T-CCA GATA--ATTT CT-C-C--T- A-GCT -GA CC
CDR1
71 81 91 101 111
VB6s3 CTTAGGTGTG ACCCAATTTC TGGTCATGTT TCC CTTTAT
VB7s2 T-G-CA -A-A-CG-CT G—A AA- G-T A-G--C
VB9sl --AGAA -G-A--AGCT GAAC A- AGT A-G---
Si iiSis i:Si Mississ J i si s ;i
VB 17s2 --GGA A -A-AGCACCT G—CT-CAG- G-- A-G--C
CDR2
VB6s3 TGGTACCGAC AGACCCTGGG GCAGGGCCCA GAGTTTTTGA CTTACTTTCA AAACGACCAA
VB7S2 TAA- G-GCCCA -A--CCG C-CA--T TCAT-CACA- CT—C-GA—
VB9S1 TAAG- - -GA-TCCAA -A-ATTG-TG A--GC-A--T T-AG—ACA- T—TA-G-T-
VB17S2 G- --GA--CA-- T-TG A- -C-GA-TT A C-AC GGTT-TAA-G
VB6s3 GGA ATAGA CAAATCAGGG ATGCCTAAAA ACCGGTTTTC TGCTGAGAGG
VB7s2 CTC. . . . . -CT-G A- -TGAGA-T G-T--G...- GT--C--C-G GT AT-C
VB9s 1 CTC G-T-G A--TGA-AC- G A...- GT--T--C-- AC-G TCT
VB17s2 -AT .--TC- G-G-GG- -AC T-AT--...G -AG-C-ACAG - -TCTCTC-A
VB6S3 CCT...GAGA GCACATACTC CTATCTGAAG ATCCAGCCAG TGGAGCCCGG GGACTCAGCA
VB7s2 --A...--C- --T-TC-G-G -CGC G-C C-GA-CG-CC --A-A--ACA C--T
VB9S1 . ..--C- AAG-TC-T-T AA-C--TC-C G-CT-CC A-- C T--C
VB17s2 GAG...A--C AGGAGCTG-T TCC C-CT G-GA--T CTC- CA- -AA CC-AA C
VB6S3 GTGTATCTCT GT










.AVSQSPRH RVAGRGQTVN LRCDPISGHV S LY WYRQTLGQGP EFLTYFQNDQ
-KY L-M-MTDKKS -T-EQRL—N A M- --K-SAQKP- -LMFIHNYQK
NI -E-EQKLN-D - M- --K-DSKKLL KAMFSYN-KL
DAEIYQI -F LL-EA--D-T -E-KQHL-YS A M- DP L KLIY-STWK
VB6s3 G....IDKSG MPKNRFSAER P.ESTYSYLK IQPVEPGDSA VYLC
VB7s2 TGNES V-.S--WS-C -.D-SQCR-D LNALK-Q
VB9sl L....VGNET V-. S PES -.DKAHLN-H IDSL M-F-
VB17s2 D.... -QRGD LS.EGY-VS- E.KQELFP-T VKSAHTNQT-
XX
Appendix F - Artefactual band from Vp subfamily-specific
snPCR
Alignment of the nucleotide sequences of (A) the snPCR artefactual band, (B) locus
XM_595623 of bovine genome scaffold NW_932240.1/Bt9_WGA1710_2 and (C)
the human nesprin-1 gene (GenBank accession number AF495910 - Appendix B).
Identity is shown as dashes and gaps by dots. The potential binding sites of BCint at
the 5' end and BCint (reverse complement) at the 3' end of the artefactual band are
indicated by the shaded boxes
1 11 21 31 41 51
A GGTCAGCTC. ..CACGTGGT CAACAAATTG AGACTGGTGG AACAAAAGTT TCAGCAGGTA
B AC -T—T AA |
C AC T—T AA—I—■: G --G--AA -G A---
►
BCint
61 71 81 91 101 111
A GATGAGTGGC TGAAAACAAC GGAGGAGAAA GTGAGTCTCA GAACGGCACG TCAGTCTAGC
B
C A -C G- A --T C-- -G--CAG A-
121 131 141 151 161 171
A CGAGCCGCCA AGGAGATGCA GTTACATCAG ATGAAGAAGT GGCATGAAGA AATCACCGCA
B
C A-G--AA A- - A C -G-G--T
181 191 201 211 221 231
A TACAGAGATG AAGTTGAGGA AGTGGGAGCC AGAGCACAGG AGATCCTGGA CGAGAGCCAC
B
241 251 261 271 281 291
A GTGAGCAGCC GAATGGGCTG CCAGGCCACG CAGCTGACGT CCAAATACCA AGCGCTGCTC
B A -
C A A T- - C T- G G--C T
XXI
301 311 321 331 341 351
A CTCCAAGTGC TGGAACAAAT AAAATTCCTG GAAGAGGAGA TCCAGAGTTT GGAGGAATCA
B
c - -G -T
361 371 381 391 401 411






c A -G C-- C- -TA G--AT- T--
481 491 501 511 521 531
A GAGGGTTTGC TGAAAGACAT GGAGAAAGGC CAGAGCTTGC TCAAATCAGC CCGAGAGAAA
B
C T -C T --C--T -G G
541 551 561 571 58 1 591
A GGCGAGAGGG CTCTTAAATA CTTGGAAGAT GCTGAGGCAG AGACGTTAAG AAAAGAGATC
B C- -
c __A - -G G--A -GC G G T
601 611 621
A CACGACCACG TGGAGCGGTT G
B
C - -T—T A A
M
BCint (reverse complement)
431 441 451 461 471
AAATTGATAA AGTAGATAAA GCGATGATGG GGAAAAAGAT GAAGACGCTG
XXII
Appendix G - Sequence nucleotide identity between V3
sequences in the genome
VP genes sharing >98% nucleotide sequence homology are, by convention, assumed
to represent alleles of the same gene (Arden et al., 1995a, b). After editing to remove
the leader sequence, intron and the recombination signal sequence (RSS), all VP
genes identified in the genome were compared for percentage nucleotide sequence
identity to the other members of their subfamily (data not shown) and genes sharing
>98% nucleotide sequence identity noted. Unless genes sharing >98% were (i)
serially located on the same contig or (ii) adjacent to different VP genes at equivalent
positions in their respective contigs, it was not possible to classify whether the
sequences represent distinct gene loci or allelic variants. The results of this analysis
are summarized in Table G.l below. The status of fifteen gene sequences (VBlag,
ad, ae, af, VB2e, VB7c, VBlOj, s, k, 1, t VB13ah, ai, al and VB17a) were considered
to be unclassified and excluded from further analysis.
VP subfamily Genes Nucleotide
identity (%)
Comments
VB1 c/ag* 100 lag removed
d/z/ad 99-100 d/z not alleles - adjacent to different Vp genes
lad removed
e/y 99 Not alleles - adjacent to different VP genes
m/ae* 100 lae removed
p/aa 100 Not alleles - adjacent to different Vp genes
v/w 100 Not alleles - serially located on same contig
x/ab 99 Not alleles - adjacent to different Vp genes
ac/af 100 laf removed
VB2 a/e* 100 2e removed
VB7 a/c 99.7 7c removed
VB10 e/j 98.6 lOj removed
i/s 99.0 10s removed
Table G.l Combinations of VP genes identified in the bovine genome that share >98%
nucleotide sequence homology. (*) identified Vp genes of which the genomic sequence was
incomplete.
XXIII
VP subfamily Genes Nucleotide
identity (%)
Comments
VB10 k*/r 99.4 10k removed
k*/l* 98.9 10k removed
l*/q* 100 101 removed
l*/r 99.4 101 removed
m/t* 100 lOt removed
VB13 d/ah* 100 13ah removed
e/ai/ag 98.3-99.0 e/ag not alleles - adjacent to different Vp genes
13ai removed
j/ab* 100 Not alleles - adjacent to different VP genes
s/al* 100 13al removed
z*/af 100 Not alleles - serially located on same contig
g/aj 99.7 Not alleles - adjacent to different Vp genes
ac/ad 99.0 Not alleles - serially located on same contig
VB17 a*/b 98.6 17a removed
a*/c 100 17a removed
a*/d* 98.6 17a removed
Table G.l (continued) Combinations of Vp genes identified in the bovine genome that share
>98% nucleotide sequence homology. (*) identified V p genes of which the genomic sequence
was incomplete.
XXIV
Appendix H - Analysis of the functionality of Vp gene
sequences identified in the genome
Sequenced data for the entire V(3 genes identified from the genome from initiation
codon of the leader (L) exon to the end of the RSS was analysed to enable prediction
of the functional status of the genes according to the criteria described in section
5.2.3. Tables H. 1 and H.2 summarize the results of this analysis.
Table H.l (overleaf) Genomic Vp sequence analysis for assessment of functionality (excluding
the portion of the V exon encoding the mature Vp polypeptide).
(i) Bovine gene name. (*) denotes VB gene with incomplete sequence data.
(ii) Translation of the L exon. (*) denotes stop codon. Some of the L exons had
insertions/deletions that would cause a frameshift in the V exon after splicing and
consequent introduction of premature stop codons.
(iii) Splice site sequence. The splice sites flanking the intron were assessed for the presence
of the conventional GT/AG splice site motif. The 5'flanking splice site is shown above
the 3'flanking splice site
(iv) Translation of the portion of the V exon encoding leader sequence. This was predicted
following alignment of the genomic Vp sequences using the IMGT/V-QUEST software
programme (http://imgt.cines.fr - Giudicelli et a/., 2004)
(v) Intron length.
(vi) Length of sequence in the germline arrangement between the codon for the conserved
cysteine at position 104 in the VP gene and the start of the RSS.
(vii-ix) Sequence of the components of the RSS. Italicised, underlined text with an asterisk
indicates spacer sequences that vary by +/- 1 bp from the normal 23bp.
Shaded text indicates components of individual VB gene sequences which were considered to
render them non-functional. The full analysis of the portion of the V exon encoding the mature
VP polypeptide has not be included due to its volume - details of any V exon defects leading to
non-functional VB sequences have been summarised in Table H.2. The name of the all VB genes
considered to be non-functional (including those considered non-functional due to defects in the
V exon as detailed in Table H.2) are indicated by shading. The information contained in
columns (iv), (v) and (vi) are not directly related to functional status but were included in the
general analysis of VB gene sequence data and so are presented here.
XXV
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Table H.2 Summary of non-functional VB genes. This table summarises the justification
for the classification of VB gene sequences as either pseudogenes, ORF pseudogenes or
orphan pseudogenes.
VPsubfamily Gene Functionality Reason
1 b Pseudogene Frameshift in V exon, defect in acceptor splice
f Pseudogene Frameshift in L exon, Frameshift in V exon
1 Pseudogene Frameshift in L exon, Frameshift in V exon
n Pseudogene Stop codon in L exon
t Pseudogene Frameshift in L exon, Frameshift in V exon
V Pseudogene Stop codon in L exon
X Pseudogene Frameshift in V exon
ab Pseudogene Frameshift in V exon
ac ORF Defect in acceptor splice
2 c ORF Extra codons in V exon
4 d Pseudogene Frameshift in V exon
5 a Pseudogene Frameshift in V exon, defect in acceptor splice, defect in
RSS
b Pseudogene Stop codon in Vexon
d Pseudogene Frameshift in L exon, Frameshift in V exon, defect in
acceptor splice
10 a Pseudogene Frameshift in L exon
d Pseudogene Frameshift in L exon, Frameshift in V exon, defect in RSS
f Pseudogene Frameshift in V exon, defect in RSS
h Pseudogene Stop codon in V exon
n Pseudogene Frameshift in L exon, Frameshift in V exon
0 ORF Defect in RSS
r Pseudogene Frameshift in L
12 a Pseudogene Stop codons in V exon, defect in RSS
XXXVII
Table H.2 (continued) Summary of non-functional VB genes.
13 a Pseudogene Loss of initiation codon
b Pseudogene Frameshift in V exon, defect in acceptor splice
c Pseudogene Frameshift in V exon, defect in acceptor splice, defect in
RSS
d ORF Loss of conserved TRP@41
f ORF Loss of conserved Cys@104
g ORF Defect in RSS
1 Orphan Located on chromosome 5
m Pseudogene Loss of initiation codon, loss of conserved Cys@104
n ORF Defect in RSS
0 Pseudogene Frameshift in V exon
P ORF Defect in RSS
q Pseudogene Frameshift in V exon, defect in acceptor splice, defect in
RSS
s ORF Defect in RSS
t Pseudogene Stop codon in V, frameshift in V exon, defect in acceptor
splice
u Pseudogene Stop codon in V exon
z Pseudogene Stop codon in V exon
aa ORF Defect in RSS
ac ORF Defect in acceptor splice, defect in RSS
ad ORF Defect in acceptor splice
af Pseudogene Stop codon in V exon
aj ORF Defect in RSS
17 b Pseudogene Stop codon in L exon
18 a Pseudogene Frameshift in L exon, Frameshift in V exon, defect in RSS
b Pseudogene Frameshift in L exon, Frameshift in V exon, defect in RSS
c Pseudogene Frameshift in V exon, defect in RSS
21 a Pseudogene Frameshift in V exon, defect in RSS
23 a Pseudogene Loss of intiation codon, Frameshift in L exon, Frameshift in
V exon, defect in acceptor splice
25 a Pseudogene Loss of initiation codon, defect in acceptor splice
Untitled 1 Pseudogene Frameshift in V exon
2 Pseudogene Frameshift in L exon, Frameshift in V exon, defect in RSS
XXXVIII
Appendix I - Nucleotide sequence comparison of human and
bovine Jp gene orthoiogues
The percentage nucleotide sequence identity of the genomic sequences of each
bovine Jp gene and the human jp gene with which it displays highest identity (i.e. its
orthologue) is shown in Table 1.1.





jpis2 JP 1 s2 72.1
jpis3 JP1 s4 72.5
jpis4 Jp 1 s5 70.0













Table 1.1 Nucleotide sequence identity between bovine
jp genes and their human orthoiogues.
XXXIX
Appendix J - Genomic bovine CP gene data
J. 1 Location of the 3 bovine CB genes on scaffold NW 931380.1/Bt4 WGA850 2
CP Exon Length Location on NW 931380.1/Bt4 WGA850 2
1 1 390 127,946- 128,335
2 18 127,261 - 127,278
3 107 126,998- 127, 104
4 18 126,655 - 126,672
2 1 390 118,118-118,507
2 Region ofundetermined sequence
3 107 117,643 - 117,749
4 18 117,299- 117,316
3 1 390 109,509- 109,898
2 Region ofundetermined sequence
3 107 108,748- 108,854
4 18 108,457- 108,474
J.2 Alignment of the A) nucleotide and B) amino acid sequences of the genomic
sequences of the 3 bovine CB genes.
Identity is shown as dashes and gaps (due to absence of sequence for exon 2 of
bovine Cp2 and CP3) by dots.
A
1 11 21 31 41 51
C|31 ATGATCTGAG CCGGGTCCAC CCGCCCAAGG TGGCTGTGTT CGAACCCTCG GAAGCAGAGA
C(32
CP3 C T
61 71 81 91 101 111




121 131 141 151 161 171
C(J1 TGGAGCTGAC CTGGTGGGTG AACAGGAAGC AGGTCACAAC TGGGGTCAGC ACGGACCCTG
C(32
C(33 G- -
181 191 201 211 221 231
CP1 AGCCCTATAA GGAGGACCCT GCACGGGATG ACTCCAGATA CTGTCTGAGC AGCCGGCTGA
C(32
241 251 261 2 71 281 291
cpi GGGTGACCGC GGCCTTCTGG CACAACCCCC GCAACCACTT CCGATGCCAA GTCCAGTTCC
CP2
CP3
301 311 321 331 341 351
cpi ACGGGCTCAC AGACCAGGAC CAGTGGGAGG AGCAGGACAG GGCCAAGCCC GTCACCCAGA
CP2 A
361 371 381 39 1 401 411
CPI ACATCAGCGC CGAGGCCTGG GGCAGAGCAG ACTGTGGCGT CACCTCCGCA TCTTATCAGC
CP2 --
Cp3 -G
421 431 441 451 461 471
Cpi AAGGCGTCCT GTCTGCCACC CTCCTCTATG AGATCCTGCT GGGGAAGGCC ACCCTGTACG
Cp2
CP3 G -G
481 491 501 511 521 531
CPI CTGTGCTGGT CAGCGCCCTG GTGCTGATGG CCATGGTCAA GAGAAAAGAG TCCTGA
Cp2 A
CP3 T- - - -A G--T
XLI
B
1 11 21 31 41 51
CP1 DDLSRVHPPK VAVFEPSEAE ISRTQKATLV CLATGFYPDH VELTWWVNRK QVTTGVSTDP
CP2
C(33
61 71 81 91 101 111
Cpi EPYKEDPARD DSRYCLSSRL RVTAAFWHNP RNHFRCQVQF HGLTDQDQWE EQDRAKPVTQ
CP2
121 131 141 151 161 171
Cpi NISAEAWGRA DCGVTSASYQ QGVLSATLLY EILLGKATLY AVLVSALVLM AMVKRKES*
CP2
CP3 K-D-
J.3 Percentage nucleotide sequence identity comparisons of bovine and human
C(3 gene exons
A) CP gene exon 1 (upper right) and exon 2 (lower left). * No sequence
human Cpi human Cp2 bovine Cpi bovine Cp2 bovine Cp3
human Cpi 98.7 82.3 81.7 80.7
human Cp2 88.9 81.2 81.2 80.5
bovine Cpi 83.0 94.4 99.7 97.2
bovine Cp2* _ _ _ 96.9
bovine Cp3* . - . -
B) CP gene exon 3 (upper right) and exon 4 (lower left)
human Cpi human CP2 bovine Cpi bovine Cp2 bovine Cp3
human Cpi 92.5 90.6 89.7 91.5
human Cp2 90.4 88.8 87.8 88.8
bovine Cpi 80.9 85.7 99.1 97.2
bovine CP2 90.4 85.7 100 96.3
bovine Cp3 85.7 90.4 85.7 85.7
XLII
Appendix K - Cytotoxicity results
Results of cytotoxicity levels >10% are considered to represent significant cytotoxic
activity and are indicated by shading of the text. ND indicates cytotoxic assays for












1 7.0% ND 0.3% 81.2%
2 8.6% ND 0.2% 0.4%
3 9.2% ND 77.5% 0.7%
4 5.8% ND 102.3% 0.4%
5 16.3% ND 0.1% 93.2%
6 6.4% ND 0.4% 84.0%
7 10.6% ND -0.5% 81.8%
8 12.7% ND 77.4% 0.6%
9 25.1% ND 0.5% 105.4%
10 28.8% ND 0.3% 103.2%
11 30.5% ND -0.4% 79.4%
12 36.2% ND -0.3% 102.1%
13 46.7% ND 0.5% 100.9%
14 13.9% ND 0.1% 100.0%
15 31.6% ND 48.7% 84.4%
16 26.5% ND 0.0% 98.5%
17 31.1% ND 0.5% 94.6%
18 20.5% ND 0.3% 84.3%
19 10.6% ND -0.1% 68.7%
20 24.7% ND 0.2% 99.4%
21 14.4% ND 0.2% 83.4%
22 16.7% ND 0.1% 86.2%
23 17.5% ND -0.1% 85.9%
24 28.6% ND 0.2% 94.3%
25 16.3% ND 1.0% 100.1%
26 18.8% ND 0.0% 77.9%
27 10.0% ND 2.0% 0.8%
28 11.4% ND -0.2% 0.5%
29 24.8% ND 0.2% 95.5%
30 22.2% ND 0.5% 63.9%
31 ND ND ND ND












33 27.1% ND -0.1% 97.6%
34 22.9% ND 0.0% 91.7%
35 28.7% ND -0.1% 94.9%
36 32.4% ND 0.4% 86.8%
37 32.5% ND 0.1% 91.2%
38 2.2% ND -0.5% 0.4%
39 30.9% ND -0.4% 95.9%
40 31.7% ND 1.1% 101.1%
41 23.6% ND 0.0% 93.5%
42 7.0% ND 0.1% 0.0%
43 16.4% ND -0.2% 96.3%
44 13.3% ND 95.9% 0.2%
45 13.4% ND 0.5% 98.0%
46 9.2% ND 0.1% 6.1%
47 14.3% ND 0.1% 99.2%
48 14.8% ND -0.1% 94.8%
49 17.8% ND 108.4% 1.2%
50 4.3% ND 1.1% 0.9%
51 18.4% ND 0.2% 88.5%
52 10.7% ND -0.5% 93.7%
53 19.7% ND -0.1% 93.6%
54 4.9% ND -0.1% -0.2%
55 8.7% ND 0.9% 98.9%
56 28.1% ND 1.2% 101.7%
57 24.7% ND 0.2% 105.1%
58 22.3% ND 0.4% 94.7%
59 20.8% ND -0.3% 84.1%
60 20.5% ND 0.0% 83.4%
61 15.0% ND 99.1% 7.6%
62 30.1% ND 0.3% 99.6%
63 49.7% ND 0.3% 0.6%
64 14.4% ND 1.1% 101.0%
65 9.5% ND 101.2% 0.4%
66 14.4% ND 0.0% 85.8%
67 3.0% ND 0.2% 0.5%
68 28.1% ND 0.6% 95.5%
69 39.2% ND 0.0% 93.5%
70 20.6% ND 0.7% 92.0%
71 21.5% ND -0.3% 79.3%












72 37.6% ND 0.3% 94.8%
73 21.7% ND 0.2% 121.4%
74 24.0% ND -0.1% 100.0%
75 15.6% ND 0.2% 98.3%
76 30.5% ND 0.6% 98.0%
77 33.4% ND 0.5% 92.5%
78 10.9% ND 0.3% 92.4%
79 30.2% ND 0.1% 96.6%
80 15.4% ND 0.3% 99.7%
81 18.0% ND 90.1% 1.1%
82 25.1% ND 0.1% 86.6%
83 19.0% ND -0.5% 83.3%
84 33.0% ND -0.1% 79.8%
85 34.0% ND 0.1% 96.2%
86 15.3% ND -0.1% 97.0%
87 29.2% ND 0.5% 98.7%
88 20.0% ND 0.2% 101.0%
89 18.6% ND 1.0% 96.4%
90 10.4% ND 0.4% 86.9%
Spontaneous
release 1 0.3% ND 0.3% 0.2%
Spontaneous
release 2 0.1% ND -0.2% -0.3%
Spontaneous
release 3 -0.1% ND -0.1% 0.2%













1 25.4% -4.7% -5.7% 70.0%
2 74.1% -3.6% -5.6% 75.8%
3 62.3% -3.0% -4.9% 105.9%
4 27.7% -3.3% -5.7% 73.3%
5 69.0% -3.4% -5.2% 63.8%
6 65.3% -3.8% -5.7% 75.8%
7 15.0% -4.1% -5.9% -0.1%
8 49.6% -4.1% -5.5% 35.0%
9 8.8% -3.3% -4.9% 0.2%
10 40.4% -1.2% -5.2% 57.7%
11 71.7% -2.5% -4.5% 118.1%
12 38.1% -4.0% -5.2% 61.4%
13 67.4% -3.7% -5.4% 71.0%
14 49.9% -4.1% -5.1% 29.9%
15 71.3% -4.9% -3.6% 102.3%
16 59.2% -1.6% -5.0% 109.6%
17 50.7% -4.0% -5.7% 78.8%
18 6.6% -4.2% -5.0% 0.8%
19 7.1% -4.0% -5.1% -0.2%
20 15.9% -3.3% -5.5% 66.6%
21 8.3% -4.7% -5.0% -0.3%
22 52.9% -4.3% -5.1% 90.8%
23 8.4% -5.0% -5.4% 0.8%
24 14.0% -3.8% 75.1% -0.5%
25 38.2% -1.1% -4.9% 83.8%
26 44.2% -2.9% -5.7% 84.4%
27 54.8% -3.2% -5.4% 87.5%
28 54.3% -4.2% -5.4% 76.8%
29 42.9% 5.9% 3.3% 9.0%
30 69.1% -3.8% -2.6% 46.1%
31 43.4% -3.1% -5.5% 79.0%
32 44.3% -2.4% -4.9% 0.0%
33 56.3% -1.5% -4.8% 97.3%
34 42.5% -3.9% -5.0% 73.3%
35 0.8% -4.0% -5.2% 73.9%
36 42.1% -3.4% -4.6% 84.4%
37 68.7% -2.4% -5.1% 96.2%
38 49.7% -3.2% -4.5% 96.6%












40 37.4% -3.6% -5.2% 62.4%
41 18.5% -1.4% -5.2% 0.2%
42 72.6% -3.4% -4.6% 0.3%
43 59.1% -2.9% -5.2% 82.7%
44 45.2% -4.3% -5.6% 42.5%
45 32.2% -0.8% -3.7% 39.7%
46 54.1% -3.0% -5.6% 72.0%
47 45.3% -4.8% -5.8% 55.1%
48 50.6% -4.6% -5.4% 78.1%
49 47.9% 0.5% -4.9% 78.6%
50 3.8% -3.2% -5.5% 0.1%
51 46.0% -3.3% -4.2% 100.5%
52 4.5% -3.6% -4.5% 0.5%
53 42.4% -3.2% -5.3% 87.6%
54 72.2% 6.7% -3.2% 118.6%
55 8.9% -2.8% -4.7% 1.8%
56 7.5% -2.1% -4.9% 0.5%
57 10.2% -4.7% -4.1% 1.6%
58 32.1% -3.7% 73.3% -0.2%
59 78.6% -2.2% -3.1% 76.4%
60 66.6% -1.5% -5.1% 76.5%
61 60.3% -2.4% -0.3% 109.2%
62 71.4% -3.1% -4.5% 96.4%
63 19.1% -3.7% -3.0% 2.9%
64 18.4% -3.2% -5.1% 18.0%
65 2.6% -3.9% -5.0% -0.7%
66 15.9% -3.3% 5.7% 25.2%
67 36.0% -2.1% -4.1% 67.7%
68 9.4% -4.2% -4.1% 0.4%
69 60.7% -0.6% -4.5% 104.1%
70 ND ND ND ND
71 58.3% -3.1% -1.1% 96.4%
72 7.3% -3.9% -4.6% 0.6%
73 53.5% -3.9% -5.0% 66.8%
74 54.3% -4.3% -5.0% 76.1%
75 56.1% -3.8% -4.8% 79.1%
76 51.4% -4.3% -3.9% 91.3%
77 43.1% -3.2% -5.3% 61.5%
78 38.6% -3.9% -5.6% 70.3%












79 6.6% -1.9% -5.0% 0.9%
80 51.5% -3.8% -5.4% 59.7%
81 6.7% -3.2% -4.9% 1.3%
82 33.7% -3.1% -5.4% 38.4%
83 44.6% -1.5% -5.5% 20.1%
84 54.7% 5.2% -1.1% 97.1%
85 52.7% -1.1% -3.1% 116.6%
86 60.0% -1.9% -4.9% 78.6%
87 8.3% -2.8% -4.1% 1.6%
88 64.4% -2.3% -3.9% 87.1%
89 26.9% 1.7% -5.2% 49.7%
90 68.5% 1.8% -4.3% 94.9%
Spontaneous
release 1 0.5% 0.4% 3.8% 1.1%
Spontaneous
release 2 -0.1% 0.9% 0.3% 0.1%
Spontaneous
release 3 -0.3% -1.3% -4.1% -1.2%











1 3.5% 0.5% ND 64.2%
2 1.7% 0.6% ND 85.1%
3 4.4% 1.4% ND 38.8%
4 1.1% 0.3% ND 83.5%
5 1.1% 0.9% ND 0.8%
6 1.5% 0.9% ND 87.9%
7 1.6% 1.4% ND 84.9%
8 1.5% 0.6% ND 42.3%
9 2.9% 0.3% ND 56.9%
10 3.6% 1.2% ND 79.1%
11 3.0% 1.9% ND 93.1%
12 3.7% 1.1% ND 83.7%
13 2.2% -1.3% ND -0.2%
14 7.7% 2.4% ND 77.8%
15 1.0% 0.2% ND 53.1%
16 1.6% 0.3% ND -0.1%
17 5.7% 0.0% ND 0.0%
18 2.7% 0.8% ND 47.2%
19 3.7% 0.1% ND 44.9%
20 2.7% 0.3% ND 8.0%
21 0.8% 0.0% ND 23.6%
22 3.2% 0.6% ND 42.0%
23 5.4% 0.3% ND -0.1%
24 0.2% -0.2% ND -1.5%
25 2.8% -1.3% ND 56.8%
26 2.5% 0.6% ND 36.1%
27 1.6% -1.3% ND 85.8%
28 1.6% 0.7% ND 54.2%
29 7.5% -0.5% ND 125.2%
30 4.2% 0.4% ND -1.3%
31 0.2% -1.1% ND 0.3%
32 1.6% 0.0% ND 48.2%
33 2.6% -0.4% ND 64.2%
34 3.8% -0.1% ND 72.8%
35 0.1% -0.4% ND 32.5%
36 2.6% 0.3% ND 29.2%
37 4.4% 0.9% ND 84.5%
38 1.6% 0.4% ND 13.9%










40 1.4% 0.5% ND -1.2%
41 -0.5% 0.9% ND 52.9%
42 2.9% 1.6% ND 86.0%
43 1.8% 0.0% ND 45.7%
44 1.6% 0.6% ND 18.3%
45 3.2% 0.4% ND 64.5%
46 2.1% 0.8% ND 68.8%
47 1.5% 1.2% ND 51.6%
48 1.5% 0.7% ND 70.1%
49 2.8% -0.4% ND 80.3%
50 1.3% -0.2% ND 43.3%
51 2.2% 0.4% ND 58.2%
52 1.1% 0.0% ND 23.5%
53 8.0% -0.3% ND 84.5%
54 2.9% -0.1% ND 58.8%
55 1.3% 0.0% ND 87.2%
56 0.9% 0.0% ND 46.2%
57 1.9% 0.5% ND 54.2%
58 0.8% 0.9% ND 26.8%
59 1.4% 0.5% ND 71.9%
60 1.9% 1.3% ND 26.6%
61 2.2% -0.7% ND -2.7%
62 3.2% 0.6% ND 99.8%
63 0.5% 1.5% ND -0.3%
64 2.5% 0.1% ND 74.5%
65 1.0% 0.5% ND 59.8%
66 3.7% 0.7% ND 100.7%
67 1.8% 0.9% ND 105.5%
68 -0.3% 2.8% ND -0.5%
69 6.9% -0.9% ND 105.8%
70 1.7% -0.9% ND -0.6%
71 3.7% -1.0% ND 94.2%
72 8.2% 0.7% ND 101.1%
73 2.3% -0.3% ND 66.1%
74 3.3% -0.3% ND 57.7%
75 1.3% 0.4% ND 74.8%
76 5.4% 0.8% ND 86.2%
77 5.2% 0.7% ND 106.7%
78 2.6% 1.0% ND 1.0%










79 0.9% 0.5% ND 87.5%
80 5.9% 0.4% ND 1.9%
81 3.3% 0.3% ND 97.4%
82 6.1% 1.2% ND 101.1%
83 4.1% 0.5% ND 1.3%
84 -0.3% 0.2% ND 0.7%
85 1.2% 0.5% ND 58.8%
86 2.1% 0.6% ND 54.5%
87 4.3% 1.9% ND 78.2%
88 5.3% 2.0% ND 80.5%
89 2.1% 0.1% ND 94.5%
90 1.1% 0.0% ND 36.9%
Spontaneous
release 1 -0.3% 0.1% ND 0.8%
Spontaneous
release 2 0.1% -0.2% ND 0.1%
Spontaneous
release 3 0.2% 0.1% ND -0.9%











1 -14.1% -8.4% -13.7% -15.6%
2 19.9% -8.7% -10.7% 56.3%
3 14.3% -8.7% -14.5% 4.6%
4 8.3% -6.1% -11.9% 53.1%
5 4.8% -8.0% -14.3% 31.8%
6 -1.3% -10.0% -14.3% -4.3%
7 12.7% -7.7% -12.3% 92.7%
8 -2.2% -8.4% -14.2% 15.7%
9 -0.1% -8.2% -14.0% 9.8%
10 -8.1% -4.6% -13.3% -5.5%
11 33.3% -7.7% -6.1% 80.4%
12 12.9% -5.3% -10.9% 65.1%
13 20.7% -9.4% -12.6% 72.9%
14 -0.8% -8.2% -13.8% 88.6%
15 26.3% -5.4% -11.3% 110.6%
16 18.8% -7.1% -11.3% 96.0%
17 21.1% -6.9% -13.2% 91.6%
18 8.9% -9.9% -13.7% 112.4%
19 ND ND ND ND
20 -7.4% -8.7% -14.4% 11.2%
21 -1.6% -9.4% -13.7% 0.4%
22 8.9% -8.2% -13.1% 53.0%
23 12.9% -8.1% -14.4% 46.2%
24 -9.2% -5.4% -14.0% -3.2%
25 27.2% -7.6% -12.2% 117.2%
26 5.5% -9.1% -13.6% 72.7%
27 22.4% -3.2% -12.6% 86.6%
28 ND ND ND ND
29 -8.5% -8.1% -14.5% -13.2%
30 12.1% -8.6% -12.8% 45.2%
31 -3.9% -9.6% -14.3% 29.1%
32 -11.8% -10.4% -14.8% , -8.8%
33 1.5% -9.6% -14.3% 8.6%
34 2.2% -8.1% -14.7% 33.3%
35 -6.7% -9.5% -14.4% 5.4%
36 5.8% -6.8% -13.2% 4.6%
37 -11.3% -10.7% -14.4% -18.6%
38 -19.9% -8.7% -13.5% -18.0%
39 1.6% -9.2% -14.7% 15.7%
LII
Clone MHC-matched MHC-mismatched Tp1 presented by
Number TpM TpM A18+Ta A18+ Ta
40 14.5% -8.0% -14.0% 83.8%
41 26.1% -7.4% -13.7% 67.0%
42 -11.3% -9.8% -14.8% -10.9%
43 5.3% -6.6% -13.7% 62.4%
44 18.1% -8.3% -14.1% 43.3%
45 -6.9% -8.8% -13.5% 9.0%
46 18.3% -7.9% -12.5% 70.7%
47 -6.7% -9.8% -14.0% 21.2%
48 2.5% -5.2% -11.1% 54.7%
49 ND ND ND ND
50 14.7% -10.0% -12.4% 89.1%
51 15.9% -8.7% -14.1% 17.9%
52 13.8% -7.7% -13.3% 68.0%
53 16.4% -9.0% -12.5% 71.3%
54 17.0% -9.5% -11.2% 44.6%
55 14.7% -7.8% -11.1% 53.9%
56 14.3% -10.1% -12.9% 83.6%
57 22.3% -8.5% -12.3% 70.1%
58 20.7% -7.6% -8.3% 93.7%
59 5.8% -10.0% -14.8% 22.8%
60 8.9% -8.1% -13.3% 11.6%
61 2.6% -4.5% -13.8% 101.7%
62 -2.0% -9.2% -14.3% 4.6%
63 10.6% -7.7% -14.3% 9.6%
64 11.0% -4.4% -13.7% 83.4%
65 16.2% -7.7% -14.7% 73.5%
66 26.9% -8.6% -13.5% 90.6%
67 6.2% -9.8% -14.2% 42.0%
68 25.7% -6.3% -12.1% 78.4%
69 5.3% -8.6% -15.3% 59.5%
70 -3.9% -8.2% -15.4% 21.6%
71 -10.4% -10.0% -14.1% -10.3%
72 0.7% -9.1% -14.6% -2.9%
73 -2.7% -9.4% -14.3% 31.8%
74 -6.2% -9.8% -14.3% 16.2%
75 6.9% -7.2% -13.9% 19.4%
76 -12.9% -8.1% -13.3% -18.6%
77 29.3% -5.7% -12.5% 82.0%
78 17.4% -4.8% -13.3% 85.4%










79 9.2% -4.8% -13.8% 91.9%
80 -8.3% -9.4% -14.3% 6.6%
81 27.7% -6.5% -11.0% 31.6%
82 -2.7% -8.6% -12.8% -15.6%
83 15.0% 0.2% -12.4% 89.3%
84 9.5% -3.8% -12.3% 58.1%
85 -4.0% -6.9% -13.9% 55.2%
86 9.6% -8.1% -13.5% 71.6%
87 14.9% -6.7% -13.4% 41.7%
88 24.3% -6.7% -13.8% 59.4%
89 18.3% -6.2% -13.6% 96.9%
90 15.2% -8.2% -13.9% 88.8%
Spontaneous
release 1 0.2% 0.8% -0.8% -2.0%
Spontaneous
release 2 0.1% 1.4% 0.6% -2.1%
Spontaneous
release 3 -0.3% -2.2% 0.2% 4.1%
D) 641 clones cytotoxicity results (continued).
LIV
























































































































































































































592.18 592.51 592.70 592.78 592.87
+ + + + +



























































































































































592.12 592.43 592.48 592.55
+ + +












































































592.5 592.6 592.36 592.39 592.59
+ + + +








































592.3 592.4 592.8 592.15
+ +





















592.44 592.49 592.61 592.65 592.81
+ + + +




























592.11 592.22 592.30 592.32 592.62 592.71
+ + + + + +

































































































































































































































































































































































































































































































1011.22 1011.47 1011.49 1011.75 1011.88
+ + + + +



































































































































































































































































































































































































































































































































































1011.5 1011.8 1011.11 1011.15 1011.16 1011.17 1011.33 1011.38 1011.43 1011.54 1011.61 1011.62 1011.64 1011.69 1011.84 1011.85 1011.86 1011.90
+ + + + + + + + + + + + + + + + + +

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































641.72 641.75 641.77 641.78 641.84 641.87 641.89
+ + + +

















































































































































































































































































































D)Sequencesof641clo e(continued). CloneswithdualfunctionalTCRph insequenced(1)-64 .35 CloneswithnofunctionalTCRphainssequ nced(2)-641.24and45
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Abstract We investigated the repertoire of functional T-
cell receptor (3-chain variable genes (TRBVgenes) in cattle
by analysing the nucleotide sequences and predicted amino
acid sequences ofa set ofcDNA clones isolated from lymph
node T cells. Thirty-nine distinct TRBV sequences were
identified, bringing the tutal number of recognised bovine
TRBV gene segments to more than 40. Sixteen TRBV sub
groups were defined based on their sequence homology to
each other and to human TRBV genes. All of the main
phylogenetic lineages of BV gene subgroups described in
humans and mice were represented. Eight of the subgroups
were found to contain more than one member. The most
striking feature of the results was the large number of
sequences (more than half of the sequenced clones) in the
BV9 and BV20 subgroups, which were found to contain 12
and 8 distinct sequences, respectively. In contrast, the
corresponding human TRBV subfamilies contain a single
member. The results indicate that, as in humans, there has
been extensive gene duplication within the TRBV locus
during evolution. However, duplication of different BV
Subgiuups in cattle has icsulted in a TRBV gene repertoire
distinct from that found in other species.
Introduction
The generation of a repertoire of T lymphocytes with
unique receptors for antigenic recognition is a key feature
of the immune system of higher vertebrates which enables
them to mount highly specific T-cell-mediated immune
E. F. Houston ■ K. Parsons
Institute for Animal Health, Compton,
Newbury, Berkshire, RG20 7NN, UK
T. Connelley • N. D. MacHugh • W. I. Morrison (El)
Division of Animal Health and Welfare,
Royal (Dick) School of Veterinary Studies,
Easter Bush Veterinary Centre, Roshn,
Midlothian, EH25 9RG, UK
e-mail: ivan.morrison@ed.ac.uk
responses to a wide variety ofpathogenic organisms. The T-
cell receptor (TR) consists of a disulphide-linked hetero-
dimer that specifically recognises peptides associated with
major histocompatibility complex (MHC) proteins on the
surface of antigen-presenting cells. The diversity displayed
by the a and |3 (or y and 6) chains that make up the liet-
crodimcr is determined by multiple variable (10. diversity
(£>; (3- and 6-chains) and joining (J) genes that associate
more or lesc randomly during somatic recombination to
generate a variable exon immediately upstream of a
constant (C) gene segment (Davis 1990).
The TRBV genes that encode the variable region of the
TR (3-chain are classified into subgroups, the members of
which share >75% sequence homology at the nucleotide
level (Arden et al. 1995a,b). Comparison of the sequences
of TRV subgroups from different species reveals that most
sequences have a much higher degree of similarity to a
homologue in another species than to other subgroups in
the same species. For example, when the deduced protein
sequences of human and mouse TRBV genes were com¬
pared, 14 murine subgroups, which display <40% identity,
were found to have >60% identity to their human ho-
mologues (Clark et al. 1995). In addition, physical maps of
the TRB locus in mice and humans have demonstrated that
the relative order of the TRBV homologues is conserved
(Lai et a!. 1988; Rowen et al. 1996). However, both the
number of BV subgroups and the number of functional
gene segments within the BV subgroups have been shown
to differ between humans and mice. While most murine
subgroups comprise a single functional gene segment,
some human genes have undergone extensive duplication,
resulting in subgroups with multiple members. These ob¬
servations indicate that a set of ancestral V gene segments
has been retained through speciation and that different
duplication and deletion events have resulted in the
development of unique TRBV repertoires in different
species.
Information on the complement of TR variable genes in
humans and mice has allowed the development ofmethods
to determine TRBV gene usage of responding T cells and to
identify abundant T-cell clones based on unique features of
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the third complementarity determining region (CDR3)
(Akatsuka et al. 1999; Bernardin et al. 2003). Such studies
have provided useful information on the clonal composition
of T-cell responses and long-term fate of T-cell clones
(Cohen et al. 2002; Turner et al. 2003; Bernardin et al.
2004). However, these methodologies are not currently
applicable in farm animal species because of limited infor¬
mation on their TR genes. In the case of cattle, small num¬
bers ofcDNA clones encoding the bovine TR a-, (3-, y- and
6-chains have been isolated and sequenced (Ishiguro et al.
1990; Takeuchi et al. 1992; Tanaka et al. 1990). A series of
TRB sequences isolated from a lymphocyte cDNA library
contained 13 distinct TRBV gene segments representing
nine different subgroups (Tanaka et al. 1990). Based on
these findings and the results of Southern blotting of ge
nomic DNA, these workers suggested that the identified
subgroups contain relatively few members.
Herein, we report the results ofa more extensive analysis
of bovine TRBV sequences, which identifies 39 distinct
TRBV gene sequences, 20 of which fall within two multi¬
member subgroups, BV9 and BV20. These findings indicate
that there have been multiple gene duplication events with¬
in the bovine TRB locus, leading to marked expansion of
the BV9 and BV20 subgroups.
Materials and methods
Sources of RNA
RNA samples for analysis of TRBV gene sequences were
obtained from lymphocytes isolated from the peripheral
lymph nodes of two Holstein Friesian cattle (3327 and
5158). Three populations of cells were used: (i) unfraction-
atcd mononuclear cells isolated from a prencapular lymph
node removed surgically from animal 3327, (ii) activated
(CD3"1", class II MHCT) T cells isolated from the contra¬
lateral lymph node oflhe same animal 9 days after infection
with the protozoan parasite Theileria parva and (iii) a
CD2~CD8+ subset of T cells isolated from a prescapular
lymph node of animal 5158, also 9 days after infection
with T. parva. Infection with T. parva has been shown to
result in the appearance of large numbers of non-
parasitised CD2~, CDS', CD3+, y/6TR lymphoblasts in
the lymph node draining the sito of inoculation (Morrison
and McKeever 1998). Purification of the T-cell subsets
was achieved by two colour immunofluorescence staining
followed by separation with a FACStar Plus cell sorter
(Becton Dickinson).
Amplification of TRBV transcripts
Total RNA was extracted from lymph node cells using an
Ultraspec RNA isolation kit (Biotecx, AMS Biotechnology
UK Ltd., Witney, Oxon). cDNA containing TRB Vsequences
was derived by reverse transcription of RNA using Super
script RT II (Gibco BRL, Paisley, UK), with an anti-sense
primer, PBC1 (5'-GAGATCTCTGCTTCCGAGG-3'), com¬
plementary to a conserved region near the 5' end of the
bovine TRBC. First strand cDNA was purified using a
GLASSMax spin cartridge kit (Gibco), and a homopolymer
tail of cytosine bases was added to the 3' end using terminal
deoxynucleotidyl transferase. Tailed cDNA was amplified
by anchored polymerase chain reaction (PCP,) with primers
complementary to the homopolymer tail (5'-ACTACTACA
AGCTTGGGIIGGGIIGGGIIG-3') and the 5' end ofbovine
TRBC genes (PBC2; 5'-GTTCGAACACAGCCACCTTG-
3'). Amplification conditions were as follows: denaturing at
9/l°C for 1 min, annealing at 55°C for 1 min and extension
at 72°C for 1 min, for 35 cycles with a final extension step
of72°C for 10 min. PCR products ofapproximately 550 bp
were excised from agarose gels. DNA recovered using a
Geneclean II kit (BIO 101, Vista, CA, USA) was cloned
into pCRII plasmid vector using the TA cloning kit
(Invitrogen, R&D Systems, Abingdon, Oxon, UK) and
transformed into OneShot INVaF' competent E. coli
(Invitrogen), allowing blue/white selection of colonies
containing inserts.
Sequencing of TRBV inserts
Sequencing reactions were carried out by the chain ter¬
mination method (Sanger et al. 1977) using PRISM Dye
Terminator Cycle Sequencing Ready Reaction Kit (Applied
Biosystems Inc., Warrington, Cheshire, UK) and primers
complementary to vector sequences flanking the insert (5'-
AGCTCGGATCCACTAGTAAC-3' and 5'-TCTAGATGC
ATGCTCGAGCG-3'). Electrophoresis of the extension
products was performed on a 373A DNA Sequencer (Ap¬
plied Biosystems). All clones containing rearranged TRB
transcripts were sequenced at least twice.
Sequence analysis
Sequence data were analysed using the GAP, BESTFIT,
FASTA, PILEUP and LINEUP programs from the Uni¬
versity of Wisconsin Genetic Computing Group (GCG)
package (Devereux et al. 1984). The sequences were edited
to remove leader, BD, BJ and BC sequences. The 3' ends of
the Vgene segments were assigned as three codons after the
conserved cysteine residue at position 92, according to
convention. The sequences were classified into TRBV
subgroups by screening them for nucleotide sequence
homology to human and available bovine TRBV sequences
in the GenEMBL database, using the FASTA program.
Sequences sharing greater than 75% identity at the nucleo¬
tide level are defined as being members of the same sub¬
group. The nomenclature used for classification of the
TRBV sequences is based on the IMGT system established
for human and mouse BV subgroups (Lefranc et al. 1998;
Giudicelli and Lefranc 1999). Numbers assigned on the
basis ofprevious nomenclature (Arden et al. 1995a) are also
listed in parentheses in Table 1.
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Tabic 1 Classification of bovine TRBV sequences into subgroups Results
TRBV Number Number of Subgroup members
subgroup" of clones subgroup identified previously11
sequenced members Identical Different
BV3 (BV9) 1 I
BV4 (BV7) 2 1 1
BV6 (BV13) 7 3
BV7 (BV6) 5 1 2
BV9 (BV1) 38 12 t
BV14 (BV16) 1 1
BV15 (BV24) 5 I
BV19 (BV17) 2 1 1
BV20 (BV2) 23 8 2
BV21 (BV10) 8 3
BV24 (BV15) 3 2 1
BV26 (BV28f 2 1 1
BV27 (BV14) 3 1
BV28 (BV3) 2 1 1
BV29 (BV4) 1 1 1
BV30 (BV20) 4 1
Total 107 39 7 4
"Classification is based on the IMGT nomenclature described in
Giudicelli and Lefranc (1999). Numbers assigned on the basis of
previous nomenclature (Arden et al. 1995a) are given in
parentheses
bAll described in Tanaka et al. (1990) except one—BV7 (BV6 in
previous nomenclature) sequence reported by Buitkamp et al.
(1993)
Previously classified by Tanaka et al. (1990) as BV10 (BV12 in
previous nomenclature)
Southern blotting
Genomic DNA was extracted from primary cultures of
bovine skin fibroblasts using Wizard Genomic DNA Puri¬
fication Kit (Promcga, Madison, WI, USA), and aliquots
were incubated overnight at 37°C with the following
enzymes: Hindlll, Xbal (10 U/ug DNA), Sphl and Sspl
(2.5 U/pg DNA). The samples were run overnight on a
0.8% agarose slab gel, and the DNA fragments were
transferred to a nitrocellulose filter (Hybond-N+, Amer-
sham Biosciences, Chalfont St. Giles, UK), in 20* SSC
buffer as described in Maniatis (1992). BV9, BV20 and
BV27 gene segments amplified from cloned plasmids by
PCR were purified with Wizard PCR Preps DNA Puri¬
fication System (Promega, Madison, WI, USA) and
labelled with 32P-dCTP using a Random Primed DNA
labelling kit (Boehringer Mannheim, Lewes, East Sussex,
UK). The blots were hybridised with the radiolabelled
probes in Rapid-Hyb (Amersham Biosciences, Little
Chalfont, Bucks, UK), with an incubation period of 2 h al
65°C and final stringency washes in 0.1 x SSC, 0.1% (w/v)
SDS at 65°C. The blots were exposed to x ruy films for 16 h
at -70°C.
Sequence analysis of TRBV cDNA clones
Sequence infonnation was obtained from a total of 107
clones that contained rearranged V-D-J C transcripts with
a correct open reading frame. Forty-two of these clones
were derived from the resting lymph node cells, 13 from the
activated population from the samo animal and 22 from the
activated cells from the second animal. The 107 clones
included four sequences that reoccurred (i.e. they were
identical throughout the V D J region), including throo
copies of one sequence and three identical pairs. The du¬
plicated sequences were found only in the clones derived
from the activated T-ccll populations, which would be more
likely to include clonally expanded T cells and hence yield
more than one copy of the same V-D-J rearrangement.
Nevertheless, there was no obvious preferential usage of
particular gene segments by either of the activated T cell
populations (CD3+, class II+ or CD2~CD8+) from which
cDNA was isolated (data not shown).
Identification of 16 TRBV subfamilies
The 107 cDNA clones that were sequenced were classified
into 16 subgroups based on their nucleotide sequence
homology with human TRBV sequences (Table 1). Five of
these subgroups were found to contain more than one
member, resulting in a total of 39 distinct BV gene se¬
quences. The clones included sequences identical to the
members of six subgroups reported by Tanaka et al. (1990)
(clones referred to in the text below with the prefix BTB),
namely BVR BV9, BV10,BV20, BV24 and BV28. However,
the sequence reported as BV10 (BV12 in old nomenclature)
by Tanaka et al. (1990) has been reclassified as BV26 since
it displayed 80% similarity with human BV26 as compared
with 66% similarity with human BV10. New individual
subgroup members were identified for a further five
previously reported subgroups (BV7, BV9, BV19, BV20
and BV29) (Buitkamp et al. 1993; Tanaka et al. 1990).
Seven new TRBV subgroups (BV3, BV6, BV14, BV15,
BV21, BV27 and BV30), whose members showed closer
homology to human BV sequences than to previously
identified bovine sequences, were defined; detailed in¬
formation on the sequences of these genes is reported
elsewhere (Houston and Morrison 1999).
The BV9 and BV20 subgroups contain multiple
members
Sixty-one (57%) of the cloned TRBV sequences were found
to fall within two multi member subgroups, BV9 and BV20.
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The B V9 subgroup
Thirty eight clones (35%) were classified as belonging to the
bovine BV9 subgroup (Table 2). Twelve distinct sequences,
comprising ten groups of two or more clones that were
identical and two single clones, were identified (designated
BV9-1 to BV9-12). Two of the sequences, BV9-3 and BV9-4,
differed from each other by only four nucleotides, whereas
the remaining sequences all differed by at least 12 nucleo¬
tides. Although it is possible that BV9-3 and BV9-4 represent
alleles, in the absence of genetic data, they have tentatively
been classified, along with the other sequences, as subgroup
members. The four clones classified as BV9-1 were identical
to a BV9 clone (BTB18) identified previously by Tanaka et
al. (1990). However, the alignment of BTB18 with the
nucleotide sequences ofBV9 subgroup members results in a
frameshift in the BTB18 sequence between residues 165 and
191, which leads to a complete change in nine amino acids of
the deduced protein sequence in this region and elimination
ofthe residues Arg-64 and Phe-65, which are found in nearly
all other members of the BV9 subgroup and in homologous
human sequences. This suggests that the anomaly is due to
an error in the published sequence of BTB18. All 12 BV9
sequences were represented in the cDNA clones derived
from one of the animals in the study.
The BV20 subgroup
Twenty-three sequences were classified as belonging to the
bovine BV2Q subgroup (Table 3), including sequences with
close similarity to the BV20 sequences (BTB1, BTB4 and
BTB10) identified by Tanaka et al. (1990). Eight distinct
sequences, comprising seven groups of two or more clones
that were identical and an additional single clone, were
identified (designated BV20-1 to BV20-8). Two of the
sequences (BV20-3 and BV20-4) differed by only five
nucleotides, whereas all the remaining sequences differed
by at least nine nucleotides. Although BV20-3 and BV20-4
could be alleles, in the absence of genetic data, they have
tentatively been classified, along with the remaining se¬
quences, as subgroup members. Maximal alignment of the
nucleotide sequences with the previously published BV20
sequences requires a dinucleotide insertion near the 5' end
of the Fgcne in the published BTB1 and BTB1 sequences,
resulting in a change in the predicted protein sequences.
The predicted amino acid sequences for BTB1 and BTB4
do not contain valine or isoleucine at position 6 or proline at
position 8, residues that are found in the deduced protein
sequences ofevery BV9 subgroup member identified in the
present study and arc conserved in almost every TRBVgene
segment regardless of species. This suggests that the
deletion of two nucleotides near the 5' ends of BTB1 and
BTB4 has arisen from defective mRNA transcripts or from
errors in the sequencing of these clones. Taking this error
into account, the sequence of one of the subgroup members
(designated BV20-1) was found to be identical to the
published sequence of BTB4. Two of the six sequences
designated BV20-3 were identical to BTB10, apart from
one nucleotide difference leading to a coding substitution.
In addition, the sequence designated BV20-2 differed from
the published sequence BTBl by only five nucleotides. All
but one (BV20-4) of the BV20 sequences were represented
in the cDNA clones derived from one of the animals in the
study.
A feature of the BV20 sequences was the presence of
variability in the nucleotides that make up the three codons
towards the C terminus, after the cysteine at position 93. In
contrast to other subgroups, for which different clones of
the same gene segment exhibited identical sequences in this
region, variability was consistently observed between dif¬
ferent BV20 clones with otherwise identical sequences.
Consequently, a consensus sequence could not be derived
for the last three codons of the Vregion formost ofthe BV20
subgroup members. These three codons were therefore ex¬
cluded from the analyses of sequence differences between
the BV20 subgroup members discussed below.
Table 2 Comparison of se- Number Nucieotide identities (%) Human
quence identities of members
of the bovine BV9 subgroup
The human BV9 (BV1) sequence
used for comparison is con¬
tained in Concannon et al.
(1986) [GenBank accession
number Ml3836], Sequences
for BV9-1, BV9-2, BV9-3,
BV9-4, BV9-5, BV9-6, BV9-7,
BV9-8 and BV9-10 are also
available on the GenBank data¬
base, with accession numbers
AJ006568-76, respectively
of clones 9-2 9-3 9-4 9-5 9-6 9-7 9-5 9-9 9-10 9-11 9-12 BV9
BV9-1 4 95.0 79.9 78.7 82.4 89.5 80.3 83.7 84.9 81.6 80.8 81.6 78
BV9-2 4 78.3 78.3 80.8 89.1 79.1 83.7 84.1 78.3 80.3 81.6 78
BV9-3 4 98.3 84.1 82.4 87.0 90.4 82.4 87.0 91.2 93.3 79
BV9-4 2 82.9 81.2 86.4 90.0 82.0 87.4 91.6 93.7 79
BV9-5 4 85.4 93.7 89.1 86.2 88.7 87.0 84.5 79
BV9-6 3 83.7 85.8 87.0 84.7 82.8 84.9 77
BV9-7 6 92.5 81.6 87.0 87.9 89.1 77
BV9-8 3 86.6 89.5 88.7 92.1 81
BV9-9 2 82.8 82.8 84.5 76
BV9-10 4 86.2 86.6 77
BV9-11 1 95.0 77
BV9-12 1 76
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Table 3 Comparison of sequence identities of members of the bovine BV20 subgroup
Number of clones Nucleotide identities (%) Human BV20
20-2 20-3 20-4 20-5 20-6 20-7 20-8
BV20-1 4 94.6 96.0 95.7 94.6 94.2 93.5 96.8 79
BV20-2 4 96.8 95.7 93.9 96.0 96.0 95.7 77
BV20-3 4 98.2 93.5 96.4 95.7 95.3 78
BV20-4 2 92.8 96.8 95.0 95.3 78
BV20-5 3 95.3 96.0 95.3 78
BV20-6 2 96.4 97.1 78
BV20-7 3 95.0 79
BV20-8 1 78
The human BV20 (BV2) sequence human used for comparison is contained in Concannon et al. (1986) [GenBank accession number
M13842]. Sequences for BV20-I, BV20-3, BV20-5 and BV20-7 are available on the GenBank database, with accession numbers
AJ006581-83 and AJ006567, respectively
Sequence divergence within the BV9
and BV20 subgroups
The levels of identity in the nucleotide sequences between
the members of the BV9 and BV20 subgroups are shown
in Tables 2 and 3. The level of nucleotide identity between
the BV9 subgroup members (excluding BV9-4) ranged
from 78.3 to 95.0%, with the majority of sequences show¬
ing 80-90% identity. The amino acid identity between
these BV9 subgroup members ranged from 64.2 to 91.0%.
The BV20 subgroup members exhibited higher levels of
similarity than the members of the BV9 subgroup. The
percentage nucleotide identity between BV20 subgroup
members (excluding BV20-4) ranged from 92.8 to 97.1%,
while the amino acid identity ranged from 84.0 to 94.6%.
Divergence in amino acid sequence within the BV9
and BV20 subgroups
Alignments of the predicted protein sequences of the BV9
and BV20 gene segments are illustrated in Fig. 1. Compari¬
sons of the nucleotide sequences of the BV9 subgroup mem¬
bers with BV9-1 revealed that there was a preferential rate of
coding vs non-coding substitutions in both the framework
and predicted CDRs. The ratio of coding to non-coding
substitutions ranged from 1.8:1 to 4.6:1 in the framework
regions and from 3.5:1 to 9:1 in the CDR1 and CDR2
regions. In three of the sequences (BV9-6, BV9-11 and BV9-
12), all of the substitutions in CDR1 and CDR2 led to coding
changes. The BV20 subgroup members also showed a strong
bias towards nucleotide substitutions lhat resulted in coding








BV9-3 DSEVTQTPKYLIKSRKQQVILRCSPESGHRSVYWYQQALGQGLQFLIQYYNGAEYEKGNIS DRFSGKQF SDSSSELNLTSLELKDSAVYLCASS
BV9-4 g —V T
BV9-1 G-RGT V L—S PK—VE—RQEVSGEAQLP V —FR S T M —
BV9-2 A-G-RGT-G V L- PE—V-&-RQEVRGEAQLP —FH S T
BV9-5 Y-S P V—FD-KVRT MP E— R-QM—S T •
BV9-6 G N—AT H: F P V QKVRGESHLL R S T M
BV9-7 G LY-S P F—K-N MP L-E— QM—S T M |fl|
BV9-8 L-l P -K-N MP —FH S T
BV9-9 AT N S—N P V-C-R-QVSRGE-MP A —FR S T —
BV9-10 T L--F P V D-KV-Q —V —AA S—P T
BV9 — 11 -E T ——Y-S T P F—QQN T —f-
BV9-12 -I V P F-TQSN T
CDR1 CDR2 CDR3
10 20 30 40 50 60 66 70 80 90 100
BV2 0-1 LVSQQPRRAVSKSGASVTIECRALDFQATTVFWYRQFPKRGLMLMATSNVGSDATYEQGYNKDKIPISQPDLTFSSLTVTRVDPADSSLYFCGAX
BV20-2 SSM V TN- T F H G l-V
BV2 0-3 1 SSM H V ' -L~ N S-R
BV2 0-4 TSSM V |-A N -Xg
BV20-5 V E-T—: F R M G SFR
BV20-6 S V A F H—R M |j|§
BV2 0-7 H —-SNM V —E-T--;■ F R M—S T—G S—
BV2 0-8 V -E-T F H J~R
Fig. 1 Alignment of the amino acid sequences ofmembers of the bovine TCRBV9 (a) and TCRBV20 (b) subfamilies. Identical residues are
shown as dashes. Amino acid residues are numbered, and the CDRs are defined according to the IMGT system
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both the framework and CDRs resulted in similarly high
ratios ofcoding to non-coding changes, e.g. BV20-6—7:1 in
the framework and 6:1 in the CDRs.
Demonstration of multiple gene segments
in genomic DNA
To examine the complexity of the BV9 and BV20 sub¬
families at the genomic level, Southern blot analysis was
performed on non rearranged genomic DNA obtained from
primary bovine fibroblast cell lines. In addition to probes
specific for BV9 and BV20, a BV27 probe (representing a
putative single-member subgroup) was used in these
experiments. The four enzymes employed (Hin&lll, Sspl,
Xbal and Sphl) were selected on the basis that the
sequenced SFgene segments belonging to these subgroups
did not contain restriction sites for the enzymes. The results
are shown in Fig. 2. Hybridisation with the BV27 probe
revealed a single band (5.0-7.9 kb in size) in preparations
of genomic DNA digested with Hin&lll, Sspl and Sphl. At
the other extreme, the BV9 probe gave a highly complex
banding pattern, detecting at least 14 DNA fragments,
ranging in size from 1.7 to 13.1 kb, in DNA digested with
three of the four enzymes. The complexity of the banding
pattern obtained with the BV20 probe varied depending on
the restriction enzyme employed. Thus, while only two
prominent bands were detected in the ///udlll-digested
DNA, at least eight bands were discernible in the prepa¬
ration digested with Xbal. There was a marked variation in
the intensity of the bands detected with the BV2 probe,
suggesting that some of the bands may represent super-
imposition of more than one gene segment. Overall, the
results are consistent with the presence ofmultiple BV9 and







Fig. 2 Southern blot of bovine DNA digested with Hindlll (laneJ),
Sspl (lane 2), Xbal (lane 3) and Sphl (lane 4), hybridised with ~2P-
labelled probes for BV9 (a), BV20 (b) and BV27 (c)
Discussion
The results presented, for the first time, in this paper
provide an indication of the extent of the functional TRBV
gene repertoire in cattle. In a previous study, Tanaka et al.
(1990) identified members ofnine bovine TRBVsubgroups,
but the small numbers of sequences did not permit a
detailed classification. Thirty-nine distinct TRBVsequences
were identified in the present study, including many that
had previously been unreported, allowing an extended
classification for bovine TRBV genes to be established.
Sixteen TRBV subgroups were defined based on their
sequence homology to each other and to human TRBV
genes. These included the nine subgroups reported pre¬
viously (Tanaka et al. 1990) and the seven new subgroups,
BV3, BV6, BV14, BV15, BV21, BV27 and BV30; the
detailed sequences of which we have reported elsewhere
(Houston and Morrison 1999). The BV gene sequences
described in our study include subgroups in all of the
phylogenetic lineages ofSKgenes described in humans and
mice. Thus, our findings contradict proposals by Su et al.
(1999) that cattle and sheep may have a more restricted
repertoire of BV genes and that particular lineages of BV
genes may not be expressed in these species.
Unlike rearranged immunoglobulin genes, there is no
convincing evidence that TR variable genes undergo
somatic mutation during maturation of immune responses.
Thus, since the C-terminal codons, which are subject to
modification during rearrangement of BV genes, were
excluded from the analyses of the cDNA clones in this
study, the 39 sequences identified are considered to re¬
present distinct genomic BV gene segments. Two pairs of
sequences (BV9-3/BV9-4 and BV20-3/BV20-4) exhibited
only four and five nucleotide differences, respectively.
Based on experience with human BV genes, where se¬
quences with five or less nucleotide differences have been
shown to be alleles (Arden et al. 1995a,b), it is possible that
these pairs represent alleles rather than distinct genes.
However, in the absence of genetic data, their formal
classification as alleles is not possible; they have therefore
been tentatively designated as distinct subgroup members
pending further studies. Together with the additional four
sequences identified in previous studies (Table 1), this
brings the total number of bovine TRBV gene segments so
far identified to 41 (excluding the two potential allele
sequences). Given the number of clones sequenced, this is
unlikely to represent the full repertoire of functional BV
genes in cattle. Nevertheless, the results indicate that the
level of TRBVgene diversity in cattle is more similar to that
in humans than in mice.
Our sequence analyses identified five bovine subgroups
(BV6, BV9, BV20, BV21 and BV24) that contained more
than one member. Inclusion of previously published
sequences (Buitkamp et al. 1993; Tanaka et al. 1990)
revealed a further three subgroups (BV7, BV19 and BV29)
with more than one member. However, the most striking
feature of our results was the large number of sequences in
the BV9 and BV20 subgroups, both of which are single-
member subgroups in man. Twenty of the 39 BV gene
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sequences identified in the present study, including 61
(57%) of the cDNA clones examined, were classified with¬
in one of these two subgroups. The large number of BV9
and BV20 clones detected did not reflect over-representa¬
tion of these segments in the activated T-cell populations
since 10 of the 12 BV9 sequences and 5 of the 8 BV20
sequences (26 clones in total) were detected in the subset of
42 clones isolated from resting lymph node cells. That the
different sequences represent distinct gene segments was
supported by the finding that BV9 and BV20 probes
hybridised with multiple bands in restriction enzyme
digested genomic DNA. Variability in the complexity of
the BV20 banding patterns obtained with different enzymes
is likely to be due to conservation of the flanking regions
containing some of the restriction sites, reflecting the rel¬
atively recent duplication of these gene segments. Such a
phenomenon has been observed for some mouse TRAV
genes (Clark et al. 1995). This may also account for the
finding by Tanaka et al. (1990) of a single Pstl DNA
fragment in Southern blots of bovine DNA hybridised with
BV20 (BV2 in former nomenclature).
Comparisons of TRBV sequences between species have
provided convincing evidence that a set of ancestral V gene
segments, recognisable as distinct BVgene subgroups, has
been retained through speciation, forming the basis for the
TRBV repertoire of each species. The presence of identi¬
fiable BV genes in birds (Tjoelker et al. 1990) and car¬
tilaginous fish (Rast et al. 1997) indicates that the
appearance of such genes predates evolution of mammals.
Physical mapping studies of the TRB locus in mice and
humans indicate that the relative order of the TRSFhomo-
logues is conserved although internal duplications have
occurred in the human locus (Lai et al. 1988; Rowen et al.
1996). The results of the present study are consistent with
this view of TRBV evolution, in that all of the sequences
identified showed much greater sequence similarity to their
human homologues than to other bovine TRBV subgroup
members (data not shown). The level of sequence homol¬
ogy between the subgroups of different species varies, and
identification of homologues may not always be straight¬
forward. For example, the level of identity between mouse
and human TRBV subgroups at the amino acid level ranges
from greater than 70% for some subgroups to between 40
and 50% for others; this compares with identities below
40% at the amino acid level between different mouse TRBV
subgroups (Arden et al. 1995b; Clark et al. 1995). All but
one of the bovine TRBV subgroups showed greater than
60% identity to their human counterparts at the protein
level, the exception being members of BV21 (57%), while
the average amino acid similarity between the genes in
different bovine BV subgroups was less than 50%.
The number of TRBV gene segments encoded in the
germline varies between species and includes both func¬
tional and non-functional genes. The functional repertoire
is determined by both the number of subgroups that express
functional genes and the number of functional genes within
each subgroup. In humans, 32 subgroups have been de¬
fined, 23 of which contain a total of 47 functional gene
segments (Arden et al. 1995a; Rowen et al. 1996), while in
the mouse, 25 subgroups with 22 functional TRBV genes
have been identified at the genomic level (Arden et al.
1995a). An additional 19 non-functional genes have been
described in humans (Rowen et al. 1996). In contrast to
mice, in which the majority of TRBV subgroups contain a
single member, seven human TRBV subgroups are multi-
membered, the largest being BV5 (five functional and two
non-functional members), BV6 (seven functional and two
non-functional members) and BV7 (six functional and three
nonfunctional members) (Arden et al. 1995a; Rowen et al.
1996). In this respect, the bovine TRBV appears more
similar to human than mouse, in that our results together
with previously published data have identified eight multi¬
member subgroups. However, the subgroups in which there
has been amplification of gene segments differ between the
two species; six of the eight bovine subgroups that contain
more than one member are single-member subgroups in
man, and two of these subgroups, BV9 and BV20, have
undergone extensive amplification in cattle. A recent study
ofmore than 300 pig BVcDNA sequences identified 19 BV
subgroups (Butler et al. 2005), which included all but one of
the subgroups identified in cattle; clones within the
subgroups in this study were not subjected to further
classification. A more limited study in sheep identified 18
distinct BV sequences within 13 subgroups (Halsey et al.
1999), all but one of which (BVI2, reported as BV8 based
on previous nomenclature) were identified in cattle. Interest¬
ingly, these genes include five distinct BV9 sequences,
suggesting that duplication of this subgroup may be a feature
of ruminants.
Genomic sequencing of the human TRBV region has
clearly demonstrated that multi-member subgroups of BV
have arisen through gene duplication events (Rowen et al.
1996). The retention of duplications in particular BV
subgroups indicates that they are likely to convey an evo¬
lutionary advantage for survival of the species. The cd (3 TR
repertoire is generated in the thymus by production of T
lymphocytes expressing different combinations of rear¬
ranged a- and (3-chains that are subjected to sequential
positive and negative selection processes based on the
affinity with which they interact with different combina¬
tions of self MHC plus peptide (von Boehmer et al. 2003).
Diversity is determined not only by the repertoire of V
genes but also by various mechanisms that create diversity
at the V-D-J-C junction; in the case of the (3-chain, this
involves the use of large numbers of BJ segments,
imprecise joining of the segments, the cleavage and non-
templated addition of nucleotides at the junctions of the
gene segments (N region diversification) and the use of
alternative reading frames for the BD genes, which combine
to form the CDR3. Studies of the structure of the TR based
on x-ray crystallography suggest that the CDR3 within the
(3-chain is principally involved in peptide interactions,
whereas CDR1 and CDR2 predominantly form contacts
with the a-helices bordering the peptide-binding groove of
MHC molecules (Garboczi et al. 1996; Garcia et al. 1998;
Kjer-Nielsen et al. 2003). Within a species, particular BV
genes may either be ofspecific advantage because they give
rise to TR specificities that allow effective responses to
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prevalent life-threatening pathogens or convey more gen¬
eral benefits because of their ability to generate a diverse
repertoire of TR specificities that survives negative selec¬
tion in the thymus.
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